id	sid	tid	token	lemma	pos
ihlr-26084	1	1	reverse	reverse	VERB
ihlr-26084	1	2	payment	payment	NOUN
ihlr-26084	1	3	:	:	PUNCT
ihlr-26084	1	4	a	a	DET
ihlr-26084	1	5	comparative	comparative	ADJ
ihlr-26084	1	6	study	study	NOUN
ihlr-26084	1	7	garry	garry	PROPN
ihlr-26084	1	8	a.	a.	PROPN
ihlr-26084	1	9	gabison	gabison	PROPN
ihlr-26084	1	10	*	*	PROPN
ihlr-26084	1	11	and	and	CCONJ
ihlr-26084	1	12	zaakir	zaakir	PROPN
ihlr-26084	1	13	tameez	tameez	VERB
ihlr-26084	1	14	*	*	PROPN
ihlr-26084	1	15	*	*	NOUN
ihlr-26084	1	16	abstract	abstract	ADV
ihlr-26084	1	17	this	this	DET
ihlr-26084	1	18	article	article	NOUN
ihlr-26084	1	19	compares	compare	VERB
ihlr-26084	1	20	reverse	reverse	ADJ
ihlr-26084	1	21	payment	payment	NOUN
ihlr-26084	1	22	settlements	settlement	NOUN
ihlr-26084	1	23	,	,	PUNCT
ihlr-26084	1	24	also	also	ADV
ihlr-26084	1	25	known	know	VERB
ihlr-26084	1	26	as	as	ADP
ihlr-26084	1	27	pay	pay	NOUN
ihlr-26084	1	28	-	-	PUNCT
ihlr-26084	1	29	fordelay	fordelay	NOUN
ihlr-26084	1	30	deals	deal	NOUN
ihlr-26084	1	31	,	,	PUNCT
ihlr-26084	1	32	in	in	ADP
ihlr-26084	1	33	the	the	DET
ihlr-26084	1	34	united	united	PROPN
ihlr-26084	1	35	states	states	PROPN
ihlr-26084	1	36	and	and	CCONJ
ihlr-26084	1	37	europe	europe	PROPN
ihlr-26084	1	38	.	.	PUNCT
ihlr-26084	2	1	these	these	DET
ihlr-26084	2	2	deals	deal	NOUN
ihlr-26084	2	3	occur	occur	VERB
ihlr-26084	2	4	where	where	SCONJ
ihlr-26084	2	5	a	a	DET
ihlr-26084	2	6	branded	brand	VERB
ihlr-26084	2	7	drug	drug	NOUN
ihlr-26084	2	8	manufacturer	manufacturer	NOUN
ihlr-26084	2	9	sues	sue	NOUN
ihlr-26084	2	10	,	,	PUNCT
ihlr-26084	2	11	settles	settle	VERB
ihlr-26084	2	12	with	with	ADP
ihlr-26084	2	13	,	,	PUNCT
ihlr-26084	2	14	and	and	CCONJ
ihlr-26084	2	15	pays	pay	VERB
ihlr-26084	2	16	a	a	DET
ihlr-26084	2	17	generic	generic	ADJ
ihlr-26084	2	18	manufacturer	manufacturer	NOUN
ihlr-26084	2	19	to	to	PART
ihlr-26084	2	20	delay	delay	VERB
ihlr-26084	2	21	the	the	DET
ihlr-26084	2	22	entry	entry	NOUN
ihlr-26084	2	23	of	of	ADP
ihlr-26084	2	24	its	its	PRON
ihlr-26084	2	25	generic	generic	NOUN
ihlr-26084	2	26	.	.	PUNCT
ihlr-26084	3	1	unlike	unlike	ADP
ihlr-26084	3	2	the	the	DET
ihlr-26084	3	3	united	united	PROPN
ihlr-26084	3	4	states	states	PROPN
ihlr-26084	3	5	,	,	PUNCT
ihlr-26084	3	6	which	which	PRON
ihlr-26084	3	7	has	have	VERB
ihlr-26084	3	8	a	a	DET
ihlr-26084	3	9	decentralized	decentralize	VERB
ihlr-26084	3	10	drug	drug	NOUN
ihlr-26084	3	11	purchasing	purchasing	NOUN
ihlr-26084	3	12	system	system	NOUN
ihlr-26084	3	13	,	,	PUNCT
ihlr-26084	3	14	european	european	PROPN
ihlr-26084	3	15	healthcare	healthcare	PROPN
ihlr-26084	3	16	systems	system	NOUN
ihlr-26084	3	17	such	such	ADJ
ihlr-26084	3	18	as	as	ADP
ihlr-26084	3	19	those	those	PRON
ihlr-26084	3	20	in	in	ADP
ihlr-26084	3	21	france	france	PROPN
ihlr-26084	3	22	and	and	CCONJ
ihlr-26084	3	23	the	the	DET
ihlr-26084	3	24	united	united	PROPN
ihlr-26084	3	25	kingdom	kingdom	PROPN
ihlr-26084	3	26	wield	wield	NOUN
ihlr-26084	3	27	monopsony	monopsony	ADV
ihlr-26084	3	28	buying	buy	VERB
ihlr-26084	3	29	power	power	NOUN
ihlr-26084	3	30	over	over	ADP
ihlr-26084	3	31	drugs	drug	NOUN
ihlr-26084	3	32	.	.	PUNCT
ihlr-26084	4	1	we	we	PRON
ihlr-26084	4	2	investigate	investigate	VERB
ihlr-26084	4	3	whether	whether	SCONJ
ihlr-26084	4	4	regulator	regulator	NOUN
ihlr-26084	4	5	and	and	CCONJ
ihlr-26084	4	6	monopsony	monopsony	ADJ
ihlr-26084	4	7	power	power	NOUN
ihlr-26084	4	8	can	can	AUX
ihlr-26084	4	9	neutralize	neutralize	VERB
ihlr-26084	4	10	these	these	DET
ihlr-26084	4	11	anticompetitive	anticompetitive	ADJ
ihlr-26084	4	12	agreements	agreement	NOUN
ihlr-26084	4	13	.	.	PUNCT
ihlr-26084	5	1	we	we	PRON
ihlr-26084	5	2	conclude	conclude	VERB
ihlr-26084	5	3	that	that	SCONJ
ihlr-26084	5	4	while	while	SCONJ
ihlr-26084	5	5	the	the	DET
ihlr-26084	5	6	incentives	incentive	NOUN
ihlr-26084	5	7	to	to	PART
ihlr-26084	5	8	agree	agree	VERB
ihlr-26084	5	9	to	to	ADP
ihlr-26084	5	10	a	a	DET
ihlr-26084	5	11	reverse	reverse	ADJ
ihlr-26084	5	12	settlement	settlement	NOUN
ihlr-26084	5	13	are	be	AUX
ihlr-26084	5	14	more	more	ADV
ihlr-26084	5	15	limited	limited	ADJ
ihlr-26084	5	16	in	in	ADP
ihlr-26084	5	17	europe	europe	PROPN
ihlr-26084	5	18	,	,	PUNCT
ihlr-26084	5	19	they	they	PRON
ihlr-26084	5	20	do	do	AUX
ihlr-26084	5	21	not	not	PART
ihlr-26084	5	22	disappear	disappear	VERB
ihlr-26084	5	23	.	.	PUNCT
ihlr-26084	6	1	regulators	regulator	NOUN
ihlr-26084	6	2	should	should	AUX
ihlr-26084	6	3	do	do	VERB
ihlr-26084	6	4	more	more	ADJ
ihlr-26084	6	5	to	to	PART
ihlr-26084	6	6	encourage	encourage	VERB
ihlr-26084	6	7	the	the	DET
ihlr-26084	6	8	entry	entry	NOUN
ihlr-26084	6	9	of	of	ADP
ihlr-26084	6	10	generics	generic	NOUN
ihlr-26084	6	11	by	by	ADP
ihlr-26084	6	12	:	:	PUNCT
ihlr-26084	6	13	(	(	PUNCT
ihlr-26084	6	14	1	1	X
ihlr-26084	6	15	)	)	PUNCT
ihlr-26084	6	16	making	make	VERB
ihlr-26084	6	17	patents	patent	NOUN
ihlr-26084	6	18	protected	protect	VERB
ihlr-26084	6	19	by	by	ADP
ihlr-26084	6	20	anticompetitive	anticompetitive	ADJ
ihlr-26084	6	21	reserve	reserve	PROPN
ihlr-26084	6	22	settlement	settlement	NOUN
ihlr-26084	6	23	unenforceable	unenforceable	ADJ
ihlr-26084	6	24	and	and	CCONJ
ihlr-26084	6	25	(	(	PUNCT
ihlr-26084	6	26	2	2	X
ihlr-26084	6	27	)	)	PUNCT
ihlr-26084	6	28	linking	link	VERB
ihlr-26084	6	29	generic	generic	ADJ
ihlr-26084	6	30	entry	entry	NOUN
ihlr-26084	6	31	to	to	ADP
ihlr-26084	6	32	a	a	DET
ihlr-26084	6	33	clear	clear	ADJ
ihlr-26084	6	34	statutory	statutory	ADJ
ihlr-26084	6	35	entry	entry	NOUN
ihlr-26084	6	36	system	system	NOUN
ihlr-26084	6	37	instead	instead	ADV
ihlr-26084	6	38	of	of	ADP
ihlr-26084	6	39	an	an	DET
ihlr-26084	6	40	opaque	opaque	ADJ
ihlr-26084	6	41	patent	patent	NOUN
ihlr-26084	6	42	system	system	NOUN
ihlr-26084	6	43	.	.	PUNCT
ihlr-26084	7	1	i.	i.	PROPN
ihlr-26084	7	2	introduction	introduction	PROPN
ihlr-26084	7	3	most	most	ADJ
ihlr-26084	7	4	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	7	5	companies	company	NOUN
ihlr-26084	7	6	in	in	ADP
ihlr-26084	7	7	both	both	CCONJ
ihlr-26084	7	8	the	the	DET
ihlr-26084	7	9	united	united	PROPN
ihlr-26084	7	10	states	states	PROPN
ihlr-26084	7	11	(	(	PUNCT
ihlr-26084	7	12	“	"	PUNCT
ihlr-26084	7	13	us	us	PROPN
ihlr-26084	7	14	”	"	PUNCT
ihlr-26084	7	15	)	)	PUNCT
ihlr-26084	7	16	and	and	CCONJ
ihlr-26084	7	17	the	the	DET
ihlr-26084	7	18	european	european	PROPN
ihlr-26084	7	19	union	union	PROPN
ihlr-26084	7	20	(	(	PUNCT
ihlr-26084	7	21	“	"	PUNCT
ihlr-26084	7	22	eu	eu	NOUN
ihlr-26084	7	23	”	"	PUNCT
ihlr-26084	7	24	)	)	PUNCT
ihlr-26084	7	25	face	face	VERB
ihlr-26084	7	26	little	little	ADJ
ihlr-26084	7	27	competition	competition	NOUN
ihlr-26084	7	28	for	for	ADP
ihlr-26084	7	29	their	their	PRON
ihlr-26084	7	30	drugs	drug	NOUN
ihlr-26084	7	31	because	because	SCONJ
ihlr-26084	7	32	of	of	ADP
ihlr-26084	7	33	patent	patent	NOUN
ihlr-26084	7	34	and	and	CCONJ
ihlr-26084	7	35	statutory	statutory	ADJ
ihlr-26084	7	36	protections	protection	NOUN
ihlr-26084	7	37	.	.	PUNCT
ihlr-26084	8	1	first	first	ADV
ihlr-26084	8	2	,	,	PUNCT
ihlr-26084	8	3	both	both	CCONJ
ihlr-26084	8	4	us	we	PRON
ihlr-26084	8	5	and	and	CCONJ
ihlr-26084	8	6	eu	eu	PROPN
ihlr-26084	8	7	regulators	regulator	NOUN
ihlr-26084	8	8	delegate	delegate	VERB
ihlr-26084	8	9	to	to	ADP
ihlr-26084	8	10	the	the	DET
ihlr-26084	8	11	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	8	12	companies	company	NOUN
ihlr-26084	8	13	the	the	DET
ihlr-26084	8	14	task	task	NOUN
ihlr-26084	8	15	of	of	ADP
ihlr-26084	8	16	assessing	assess	VERB
ihlr-26084	8	17	whether	whether	SCONJ
ihlr-26084	8	18	patents	patent	NOUN
ihlr-26084	8	19	constitute	constitute	VERB
ihlr-26084	8	20	entry	entry	NOUN
ihlr-26084	8	21	barriers	barrier	NOUN
ihlr-26084	8	22	.	.	PUNCT
ihlr-26084	9	1	in	in	ADP
ihlr-26084	9	2	the	the	DET
ihlr-26084	9	3	us	us	PROPN
ihlr-26084	9	4	,	,	PUNCT
ihlr-26084	9	5	the	the	DET
ihlr-26084	9	6	federal	federal	ADJ
ihlr-26084	9	7	drug	drug	PROPN
ihlr-26084	9	8	administration	administration	PROPN
ihlr-26084	9	9	(	(	PUNCT
ihlr-26084	9	10	“	"	PUNCT
ihlr-26084	9	11	fda	fda	PROPN
ihlr-26084	9	12	”	"	PUNCT
ihlr-26084	9	13	)	)	PUNCT
ihlr-26084	9	14	requires	require	VERB
ihlr-26084	9	15	brand	brand	NOUN
ihlr-26084	9	16	-	-	PUNCT
ihlr-26084	9	17	name	name	NOUN
ihlr-26084	9	18	drug	drug	NOUN
ihlr-26084	9	19	manufacturers	manufacturer	NOUN
ihlr-26084	9	20	to	to	PART
ihlr-26084	9	21	declare	declare	VERB
ihlr-26084	9	22	which	which	PRON
ihlr-26084	9	23	patents	patent	NOUN
ihlr-26084	9	24	cover	cover	VERB
ihlr-26084	9	25	a	a	DET
ihlr-26084	9	26	drug	drug	NOUN
ihlr-26084	9	27	in	in	ADP
ihlr-26084	9	28	its	its	PRON
ihlr-26084	9	29	market	market	NOUN
ihlr-26084	9	30	authorization	authorization	NOUN
ihlr-26084	9	31	application	application	NOUN
ihlr-26084	9	32	.	.	PUNCT
ihlr-26084	10	1	but	but	CCONJ
ihlr-26084	10	2	the	the	DET
ihlr-26084	10	3	fda	fda	PROPN
ihlr-26084	10	4	does	do	AUX
ihlr-26084	10	5	not	not	PART
ihlr-26084	10	6	scrutinize	scrutinize	VERB
ihlr-26084	10	7	these	these	DET
ihlr-26084	10	8	patent	patent	NOUN
ihlr-26084	10	9	declarations	declaration	NOUN
ihlr-26084	10	10	.	.	PUNCT
ihlr-26084	11	1	instead	instead	ADV
ihlr-26084	11	2	,	,	PUNCT
ihlr-26084	11	3	the	the	DET
ihlr-26084	11	4	fda	fda	PROPN
ihlr-26084	11	5	relies	rely	VERB
ihlr-26084	11	6	on	on	ADP
ihlr-26084	11	7	generic	generic	ADJ
ihlr-26084	11	8	manufacturers	manufacturer	NOUN
ihlr-26084	11	9	to	to	PART
ihlr-26084	11	10	challenge	challenge	VERB
ihlr-26084	11	11	the	the	DET
ihlr-26084	11	12	patents	patent	NOUN
ihlr-26084	11	13	or	or	CCONJ
ihlr-26084	11	14	assert	assert	VERB
ihlr-26084	11	15	that	that	SCONJ
ihlr-26084	11	16	patents	patent	NOUN
ihlr-26084	11	17	are	be	AUX
ihlr-26084	11	18	invalid	invalid	ADJ
ihlr-26084	11	19	and/or	and/or	CCONJ
ihlr-26084	11	20	not	not	PART
ihlr-26084	11	21	infringed	infringe	VERB
ihlr-26084	11	22	if	if	SCONJ
ihlr-26084	11	23	they	they	PRON
ihlr-26084	11	24	want	want	VERB
ihlr-26084	11	25	to	to	PART
ihlr-26084	11	26	produce	produce	VERB
ihlr-26084	11	27	the	the	DET
ihlr-26084	11	28	same	same	ADJ
ihlr-26084	11	29	drug.1	drug.1	NOUN
ihlr-26084	11	30	in	in	ADP
ihlr-26084	11	31	the	the	DET
ihlr-26084	11	32	eu	eu	PROPN
ihlr-26084	11	33	,	,	PUNCT
ihlr-26084	11	34	the	the	DET
ihlr-26084	11	35	european	european	PROPN
ihlr-26084	11	36	medicines	medicine	NOUN
ihlr-26084	11	37	agency	agency	NOUN
ihlr-26084	11	38	(	(	PUNCT
ihlr-26084	11	39	“	"	PUNCT
ihlr-26084	11	40	ema	ema	X
ihlr-26084	11	41	”	"	PUNCT
ihlr-26084	11	42	)	)	PUNCT
ihlr-26084	11	43	ignores	ignore	VERB
ihlr-26084	11	44	patent	patent	NOUN
ihlr-26084	11	45	statuses	status	NOUN
ihlr-26084	11	46	*	*	PUNCT
ihlr-26084	11	47	j.d.-ph.d	j.d.-ph.d	PROPN
ihlr-26084	11	48	.	.	PROPN
ihlr-26084	12	1	,	,	PUNCT
ihlr-26084	12	2	senior	senior	ADJ
ihlr-26084	12	3	lecturer	lecturer	NOUN
ihlr-26084	12	4	of	of	ADP
ihlr-26084	12	5	law	law	NOUN
ihlr-26084	12	6	,	,	PUNCT
ihlr-26084	12	7	economics	economic	NOUN
ihlr-26084	12	8	&	&	CCONJ
ihlr-26084	12	9	regulation	regulation	NOUN
ihlr-26084	12	10	at	at	ADP
ihlr-26084	12	11	the	the	DET
ihlr-26084	12	12	centre	centre	NOUN
ihlr-26084	12	13	for	for	ADP
ihlr-26084	12	14	commercial	commercial	ADJ
ihlr-26084	12	15	law	law	NOUN
ihlr-26084	12	16	studies	study	NOUN
ihlr-26084	12	17	,	,	PUNCT
ihlr-26084	12	18	queen	queen	PROPN
ihlr-26084	12	19	mary	mary	PROPN
ihlr-26084	12	20	university	university	PROPN
ihlr-26084	12	21	of	of	ADP
ihlr-26084	12	22	london	london	PROPN
ihlr-26084	12	23	.	.	PUNCT
ihlr-26084	13	1	*	*	PUNCT
ihlr-26084	13	2	*	*	PUNCT
ihlr-26084	13	3	l.l.m	l.l.m	NOUN
ihlr-26084	13	4	.	.	PUNCT
ihlr-26084	13	5	candidate	candidate	NOUN
ihlr-26084	13	6	at	at	ADP
ihlr-26084	13	7	the	the	DET
ihlr-26084	13	8	centre	centre	NOUN
ihlr-26084	13	9	for	for	ADP
ihlr-26084	13	10	commercial	commercial	ADJ
ihlr-26084	13	11	law	law	NOUN
ihlr-26084	13	12	studies	study	NOUN
ihlr-26084	13	13	,	,	PUNCT
ihlr-26084	13	14	queen	queen	PROPN
ihlr-26084	13	15	mary	mary	PROPN
ihlr-26084	13	16	university	university	PROPN
ihlr-26084	13	17	of	of	ADP
ihlr-26084	13	18	london	london	PROPN
ihlr-26084	13	19	.	.	PUNCT
ihlr-26084	14	1	1	1	NUM
ihlr-26084	14	2	.	.	SYM
ihlr-26084	14	3	21	21	NUM
ihlr-26084	14	4	u.s.c	u.s.c	NOUN
ihlr-26084	14	5	.	.	PUNCT
ihlr-26084	15	1	§	§	PROPN
ihlr-26084	15	2	355(b)(2)(a	355(b)(2)(a	NUM
ihlr-26084	15	3	)	)	PUNCT
ihlr-26084	15	4	.	.	PUNCT
ihlr-26084	16	1	“	"	PUNCT
ihlr-26084	16	2	(	(	PUNCT
ihlr-26084	16	3	2	2	X
ihlr-26084	16	4	)	)	PUNCT
ihlr-26084	16	5	an	an	DET
ihlr-26084	16	6	application	application	NOUN
ihlr-26084	16	7	[	[	X
ihlr-26084	16	8	.	.	PUNCT
ihlr-26084	16	9	.	.	PUNCT
ihlr-26084	16	10	.	.	PUNCT
ihlr-26084	17	1	]	]	PUNCT
ihlr-26084	17	2	shall	shall	AUX
ihlr-26084	17	3	also	also	ADV
ihlr-26084	17	4	include	include	VERB
ihlr-26084	17	5	[	[	X
ihlr-26084	17	6	.	.	PUNCT
ihlr-26084	17	7	.	.	PUNCT
ihlr-26084	17	8	.	.	PUNCT
ihlr-26084	18	1	]	]	PUNCT
ihlr-26084	18	2	(	(	PUNCT
ihlr-26084	18	3	a	a	X
ihlr-26084	18	4	)	)	PUNCT
ihlr-26084	18	5	a	a	DET
ihlr-26084	18	6	certification	certification	NOUN
ihlr-26084	18	7	,	,	PUNCT
ihlr-26084	18	8	in	in	ADP
ihlr-26084	18	9	the	the	DET
ihlr-26084	18	10	opinion	opinion	NOUN
ihlr-26084	18	11	of	of	ADP
ihlr-26084	18	12	the	the	DET
ihlr-26084	18	13	applicant	applicant	NOUN
ihlr-26084	18	14	and	and	CCONJ
ihlr-26084	18	15	to	to	ADP
ihlr-26084	18	16	the	the	DET
ihlr-26084	18	17	best	good	ADJ
ihlr-26084	18	18	of	of	ADP
ihlr-26084	18	19	his	his	PRON
ihlr-26084	18	20	knowledge	knowledge	NOUN
ihlr-26084	18	21	,	,	PUNCT
ihlr-26084	18	22	with	with	ADP
ihlr-26084	18	23	respect	respect	NOUN
ihlr-26084	18	24	to	to	ADP
ihlr-26084	18	25	each	each	DET
ihlr-26084	18	26	patent	patent	NOUN
ihlr-26084	18	27	which	which	PRON
ihlr-26084	18	28	claims	claim	VERB
ihlr-26084	18	29	the	the	DET
ihlr-26084	18	30	drug	drug	NOUN
ihlr-26084	18	31	for	for	ADP
ihlr-26084	18	32	which	which	PRON
ihlr-26084	18	33	such	such	ADJ
ihlr-26084	18	34	investigations	investigation	NOUN
ihlr-26084	18	35	were	be	AUX
ihlr-26084	18	36	conducted	conduct	VERB
ihlr-26084	18	37	or	or	CCONJ
ihlr-26084	18	38	which	which	PRON
ihlr-26084	18	39	claims	claim	VERB
ihlr-26084	18	40	a	a	DET
ihlr-26084	18	41	use	use	NOUN
ihlr-26084	18	42	for	for	ADP
ihlr-26084	18	43	such	such	ADJ
ihlr-26084	18	44	drug	drug	NOUN
ihlr-26084	18	45	for	for	ADP
ihlr-26084	18	46	which	which	PRON
ihlr-26084	18	47	the	the	DET
ihlr-26084	18	48	applicant	applicant	NOUN
ihlr-26084	18	49	is	be	AUX
ihlr-26084	18	50	seeking	seek	VERB
ihlr-26084	18	51	approval	approval	NOUN
ihlr-26084	18	52	under	under	ADP
ihlr-26084	18	53	this	this	DET
ihlr-26084	18	54	subsection	subsection	NOUN
ihlr-26084	18	55	and	and	CCONJ
ihlr-26084	18	56	for	for	ADP
ihlr-26084	18	57	which	which	PRON
ihlr-26084	18	58	information	information	NOUN
ihlr-26084	18	59	is	be	AUX
ihlr-26084	18	60	required	require	VERB
ihlr-26084	18	61	to	to	PART
ihlr-26084	18	62	be	be	AUX
ihlr-26084	18	63	filed	file	VERB
ihlr-26084	18	64	under	under	ADP
ihlr-26084	18	65	paragraph	paragraph	NOUN
ihlr-26084	18	66	(	(	PUNCT
ihlr-26084	18	67	1	1	NUM
ihlr-26084	18	68	)	)	PUNCT
ihlr-26084	18	69	or	or	CCONJ
ihlr-26084	18	70	subsection	subsection	NOUN
ihlr-26084	18	71	(	(	PUNCT
ihlr-26084	18	72	c	c	NOUN
ihlr-26084	18	73	)	)	PUNCT
ihlr-26084	18	74	—	—	PUNCT
ihlr-26084	18	75	(	(	PUNCT
ihlr-26084	18	76	i	i	NOUN
ihlr-26084	18	77	)	)	PUNCT
ihlr-26084	18	78	that	that	SCONJ
ihlr-26084	18	79	such	such	ADJ
ihlr-26084	18	80	patent	patent	NOUN
ihlr-26084	18	81	information	information	NOUN
ihlr-26084	18	82	has	have	AUX
ihlr-26084	18	83	not	not	PART
ihlr-26084	18	84	been	be	AUX
ihlr-26084	18	85	filed	file	VERB
ihlr-26084	18	86	,	,	PUNCT
ihlr-26084	18	87	(	(	PUNCT
ihlr-26084	18	88	ii	ii	NOUN
ihlr-26084	18	89	)	)	PUNCT
ihlr-26084	18	90	that	that	SCONJ
ihlr-26084	18	91	such	such	ADJ
ihlr-26084	18	92	patent	patent	NOUN
ihlr-26084	18	93	has	have	AUX
ihlr-26084	18	94	expired	expire	VERB
ihlr-26084	18	95	,	,	PUNCT
ihlr-26084	18	96	(	(	PUNCT
ihlr-26084	18	97	iii	iii	NOUN
ihlr-26084	18	98	)	)	PUNCT
ihlr-26084	18	99	of	of	ADP
ihlr-26084	18	100	the	the	DET
ihlr-26084	18	101	date	date	NOUN
ihlr-26084	18	102	on	on	ADP
ihlr-26084	18	103	which	which	PRON
ihlr-26084	18	104	such	such	ADJ
ihlr-26084	18	105	patent	patent	NOUN
ihlr-26084	18	106	will	will	AUX
ihlr-26084	18	107	expire	expire	VERB
ihlr-26084	18	108	,	,	PUNCT
ihlr-26084	18	109	or	or	CCONJ
ihlr-26084	18	110	(	(	PUNCT
ihlr-26084	18	111	iv	iv	X
ihlr-26084	18	112	)	)	PUNCT
ihlr-26084	18	113	that	that	SCONJ
ihlr-26084	18	114	such	such	ADJ
ihlr-26084	18	115	patent	patent	NOUN
ihlr-26084	18	116	is	be	AUX
ihlr-26084	18	117	invalid	invalid	ADJ
ihlr-26084	18	118	or	or	CCONJ
ihlr-26084	18	119	will	will	AUX
ihlr-26084	18	120	not	not	PART
ihlr-26084	18	121	be	be	AUX
ihlr-26084	18	122	infringed	infringe	VERB
ihlr-26084	18	123	by	by	ADP
ihlr-26084	18	124	the	the	DET
ihlr-26084	18	125	manufacture	manufacture	NOUN
ihlr-26084	18	126	,	,	PUNCT
ihlr-26084	18	127	use	use	NOUN
ihlr-26084	18	128	,	,	PUNCT
ihlr-26084	18	129	or	or	CCONJ
ihlr-26084	18	130	sale	sale	NOUN
ihlr-26084	18	131	of	of	ADP
ihlr-26084	18	132	the	the	DET
ihlr-26084	18	133	new	new	ADJ
ihlr-26084	18	134	drug	drug	NOUN
ihlr-26084	18	135	for	for	ADP
ihlr-26084	18	136	which	which	PRON
ihlr-26084	18	137	the	the	DET
ihlr-26084	18	138	application	application	NOUN
ihlr-26084	18	139	is	be	AUX
ihlr-26084	18	140	submitted	submit	VERB
ihlr-26084	18	141	;	;	PUNCT
ihlr-26084	18	142	and	and	CCONJ
ihlr-26084	18	143	[	[	X
ihlr-26084	18	144	.	.	PUNCT
ihlr-26084	18	145	.	.	PUNCT
ihlr-26084	18	146	.	.	PUNCT
ihlr-26084	19	1	]	]	PUNCT
ihlr-26084	19	2	.	.	PUNCT
ihlr-26084	19	3	”	"	PUNCT
ihlr-26084	20	1	22	22	NUM
ihlr-26084	20	2	indiana	indiana	PROPN
ihlr-26084	20	3	health	health	PROPN
ihlr-26084	20	4	law	law	PROPN
ihlr-26084	20	5	review	review	NOUN
ihlr-26084	20	6	[	[	X
ihlr-26084	20	7	vol	vol	NOUN
ihlr-26084	20	8	.	.	PUNCT
ihlr-26084	20	9	19:21	19:21	NUM
ihlr-26084	20	10	for	for	ADP
ihlr-26084	20	11	the	the	DET
ihlr-26084	20	12	issuance	issuance	NOUN
ihlr-26084	20	13	of	of	ADP
ihlr-26084	20	14	market	market	NOUN
ihlr-26084	20	15	authorization.2	authorization.2	PROPN
ihlr-26084	20	16	most	most	ADV
ihlr-26084	20	17	european	european	ADJ
ihlr-26084	20	18	countries	country	NOUN
ihlr-26084	20	19	–	–	PUNCT
ihlr-26084	20	20	including	include	VERB
ihlr-26084	20	21	france	france	PROPN
ihlr-26084	20	22	and	and	CCONJ
ihlr-26084	20	23	the	the	DET
ihlr-26084	20	24	united	united	ADJ
ihlr-26084	20	25	kingdom	kingdom	PROPN
ihlr-26084	20	26	(	(	PUNCT
ihlr-26084	20	27	“	"	PUNCT
ihlr-26084	20	28	uk	uk	PROPN
ihlr-26084	20	29	”	"	PUNCT
ihlr-26084	20	30	)	)	PUNCT
ihlr-26084	20	31	–	–	PUNCT
ihlr-26084	20	32	do	do	AUX
ihlr-26084	20	33	not	not	PART
ihlr-26084	20	34	practice	practice	VERB
ihlr-26084	20	35	patent	patent	NOUN
ihlr-26084	20	36	linkage.3	linkage.3	PROPN
ihlr-26084	20	37	instead	instead	ADV
ihlr-26084	20	38	,	,	PUNCT
ihlr-26084	20	39	generic	generic	ADJ
ihlr-26084	20	40	manufacturers	manufacturer	NOUN
ihlr-26084	20	41	have	have	VERB
ihlr-26084	20	42	to	to	PART
ihlr-26084	20	43	perform	perform	VERB
ihlr-26084	20	44	their	their	PRON
ihlr-26084	20	45	own	own	ADJ
ihlr-26084	20	46	patent	patent	NOUN
ihlr-26084	20	47	clearance	clearance	NOUN
ihlr-26084	20	48	studies	study	NOUN
ihlr-26084	20	49	to	to	PART
ihlr-26084	20	50	decide	decide	VERB
ihlr-26084	20	51	whether	whether	SCONJ
ihlr-26084	20	52	a	a	DET
ihlr-26084	20	53	generic	generic	ADJ
ihlr-26084	20	54	drug	drug	NOUN
ihlr-26084	20	55	infringes	infringe	VERB
ihlr-26084	20	56	on	on	ADP
ihlr-26084	20	57	brand	brand	NOUN
ihlr-26084	20	58	-	-	PUNCT
ihlr-26084	20	59	name	name	NOUN
ihlr-26084	20	60	patents.4	patents.4	PROPN
ihlr-26084	20	61	therefore	therefore	ADV
ihlr-26084	20	62	,	,	PUNCT
ihlr-26084	20	63	generic	generic	ADJ
ihlr-26084	20	64	manufacturers	manufacturer	NOUN
ihlr-26084	20	65	must	must	AUX
ihlr-26084	20	66	exercise	exercise	VERB
ihlr-26084	20	67	more	more	ADJ
ihlr-26084	20	68	caution	caution	NOUN
ihlr-26084	20	69	than	than	ADP
ihlr-26084	20	70	in	in	ADP
ihlr-26084	20	71	the	the	DET
ihlr-26084	20	72	us	we	PRON
ihlr-26084	20	73	because	because	SCONJ
ihlr-26084	20	74	they	they	PRON
ihlr-26084	20	75	do	do	AUX
ihlr-26084	20	76	not	not	PART
ihlr-26084	20	77	benefit	benefit	VERB
ihlr-26084	20	78	from	from	ADP
ihlr-26084	20	79	the	the	DET
ihlr-26084	20	80	market	market	NOUN
ihlr-26084	20	81	authorization	authorization	NOUN
ihlr-26084	20	82	disclosure	disclosure	NOUN
ihlr-26084	20	83	.	.	PUNCT
ihlr-26084	21	1	second	second	ADJ
ihlr-26084	21	2	,	,	PUNCT
ihlr-26084	21	3	even	even	ADV
ihlr-26084	21	4	without	without	ADP
ihlr-26084	21	5	patent	patent	NOUN
ihlr-26084	21	6	protection	protection	NOUN
ihlr-26084	21	7	,	,	PUNCT
ihlr-26084	21	8	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	21	9	companies	company	NOUN
ihlr-26084	21	10	enjoy	enjoy	VERB
ihlr-26084	21	11	exclusivity	exclusivity	NOUN
ihlr-26084	21	12	periods	period	NOUN
ihlr-26084	21	13	in	in	ADP
ihlr-26084	21	14	the	the	DET
ihlr-26084	21	15	us	us	PROPN
ihlr-26084	21	16	and	and	CCONJ
ihlr-26084	21	17	eu	eu	PROPN
ihlr-26084	21	18	.	.	PUNCT
ihlr-26084	22	1	filing	file	VERB
ihlr-26084	22	2	a	a	DET
ihlr-26084	22	3	market	market	NOUN
ihlr-26084	22	4	authorization	authorization	NOUN
ihlr-26084	22	5	guarantees	guarantee	VERB
ihlr-26084	22	6	a	a	DET
ihlr-26084	22	7	market	market	NOUN
ihlr-26084	22	8	exclusivity	exclusivity	NOUN
ihlr-26084	22	9	of	of	ADP
ihlr-26084	22	10	five	five	NUM
ihlr-26084	22	11	years	year	NOUN
ihlr-26084	22	12	in	in	ADP
ihlr-26084	22	13	the	the	DET
ihlr-26084	22	14	us	us	PROPN
ihlr-26084	22	15	and	and	CCONJ
ihlr-26084	22	16	ten	ten	NUM
ihlr-26084	22	17	years	year	NOUN
ihlr-26084	22	18	in	in	ADP
ihlr-26084	22	19	the	the	DET
ihlr-26084	22	20	eu	eu	PROPN
ihlr-26084	22	21	for	for	ADP
ihlr-26084	22	22	most	most	ADJ
ihlr-26084	22	23	drugs.5	drugs.5	PROPN
ihlr-26084	22	24	many	many	ADJ
ihlr-26084	22	25	manufacturers	manufacturer	NOUN
ihlr-26084	22	26	use	use	VERB
ihlr-26084	22	27	different	different	ADJ
ihlr-26084	22	28	strategies	strategy	NOUN
ihlr-26084	22	29	to	to	PART
ihlr-26084	22	30	expend	expend	VERB
ihlr-26084	22	31	these	these	DET
ihlr-26084	22	32	exclusivity	exclusivity	NOUN
ihlr-26084	22	33	periods.6	periods.6	PROPN
ihlr-26084	22	34	the	the	DET
ihlr-26084	22	35	lack	lack	NOUN
ihlr-26084	22	36	of	of	ADP
ihlr-26084	22	37	competition	competition	NOUN
ihlr-26084	22	38	has	have	VERB
ihlr-26084	22	39	a	a	DET
ihlr-26084	22	40	larger	large	ADJ
ihlr-26084	22	41	effect	effect	NOUN
ihlr-26084	22	42	on	on	ADP
ihlr-26084	22	43	consumer	consumer	NOUN
ihlr-26084	22	44	surplus	surplus	NOUN
ihlr-26084	22	45	in	in	ADP
ihlr-26084	22	46	drug	drug	NOUN
ihlr-26084	22	47	markets	market	NOUN
ihlr-26084	22	48	than	than	ADP
ihlr-26084	22	49	other	other	ADJ
ihlr-26084	22	50	markets	market	NOUN
ihlr-26084	22	51	.	.	PUNCT
ihlr-26084	23	1	the	the	DET
ihlr-26084	23	2	demand	demand	NOUN
ihlr-26084	23	3	curves	curve	VERB
ihlr-26084	23	4	for	for	ADP
ihlr-26084	23	5	most	most	ADJ
ihlr-26084	23	6	medications	medication	NOUN
ihlr-26084	23	7	are	be	AUX
ihlr-26084	23	8	highly	highly	ADV
ihlr-26084	23	9	inelastic7	inelastic7	NOUN
ihlr-26084	23	10	because	because	SCONJ
ihlr-26084	23	11	they	they	PRON
ihlr-26084	23	12	are	be	AUX
ihlr-26084	23	13	necessities	necessity	NOUN
ihlr-26084	23	14	for	for	ADP
ihlr-26084	23	15	most	most	ADJ
ihlr-26084	23	16	consumers	consumer	NOUN
ihlr-26084	23	17	.	.	PUNCT
ihlr-26084	24	1	this	this	DET
ihlr-26084	24	2	inelasticity	inelasticity	NOUN
ihlr-26084	24	3	means	mean	VERB
ihlr-26084	24	4	that	that	SCONJ
ihlr-26084	24	5	even	even	ADV
ihlr-26084	24	6	a	a	DET
ihlr-26084	24	7	slight	slight	ADJ
ihlr-26084	24	8	decrease	decrease	NOUN
ihlr-26084	24	9	in	in	ADP
ihlr-26084	24	10	competition	competition	NOUN
ihlr-26084	24	11	can	can	AUX
ihlr-26084	24	12	lead	lead	VERB
ihlr-26084	24	13	to	to	ADP
ihlr-26084	24	14	large	large	ADJ
ihlr-26084	24	15	price	price	NOUN
ihlr-26084	24	16	increase	increase	NOUN
ihlr-26084	24	17	and	and	CCONJ
ihlr-26084	24	18	deadweight	deadweight	NOUN
ihlr-26084	24	19	loss	loss	NOUN
ihlr-26084	24	20	.	.	PUNCT
ihlr-26084	25	1	to	to	PART
ihlr-26084	25	2	countervail	countervail	VERB
ihlr-26084	25	3	these	these	DET
ihlr-26084	25	4	effects	effect	NOUN
ihlr-26084	25	5	,	,	PUNCT
ihlr-26084	25	6	many	many	ADJ
ihlr-26084	25	7	countries	country	NOUN
ihlr-26084	25	8	regulate	regulate	VERB
ihlr-26084	25	9	the	the	DET
ihlr-26084	25	10	price	price	NOUN
ihlr-26084	25	11	of	of	ADP
ihlr-26084	25	12	medications	medication	NOUN
ihlr-26084	25	13	.	.	PUNCT
ihlr-26084	26	1	direct	direct	ADJ
ihlr-26084	26	2	price	price	NOUN
ihlr-26084	26	3	regulation	regulation	NOUN
ihlr-26084	26	4	has	have	AUX
ihlr-26084	26	5	proven	prove	VERB
ihlr-26084	26	6	difficult	difficult	ADJ
ihlr-26084	26	7	because	because	SCONJ
ihlr-26084	26	8	costs	cost	NOUN
ihlr-26084	26	9	are	be	AUX
ihlr-26084	26	10	often	often	ADV
ihlr-26084	26	11	difficult	difficult	ADJ
ihlr-26084	26	12	to	to	ADP
ihlr-26084	26	13	assess.8	assess.8	PROPN
ihlr-26084	26	14	instead	instead	ADV
ihlr-26084	26	15	,	,	PUNCT
ihlr-26084	26	16	many	many	ADJ
ihlr-26084	26	17	countries	country	NOUN
ihlr-26084	26	18	like	like	ADP
ihlr-26084	26	19	france	france	PROPN
ihlr-26084	26	20	or	or	CCONJ
ihlr-26084	26	21	the	the	DET
ihlr-26084	26	22	uk	uk	PROPN
ihlr-26084	26	23	rely	rely	VERB
ihlr-26084	26	24	on	on	ADP
ihlr-26084	26	25	the	the	DET
ihlr-26084	26	26	monopsony	monopsony	ADJ
ihlr-26084	26	27	power	power	NOUN
ihlr-26084	26	28	of	of	ADP
ihlr-26084	26	29	the	the	DET
ihlr-26084	26	30	healthcare	healthcare	NOUN
ihlr-26084	26	31	system	system	NOUN
ihlr-26084	26	32	to	to	PART
ihlr-26084	26	33	negotiate	negotiate	VERB
ihlr-26084	26	34	prices	price	NOUN
ihlr-26084	26	35	against	against	ADP
ihlr-26084	26	36	the	the	DET
ihlr-26084	26	37	costs	cost	NOUN
ihlr-26084	26	38	2	2	NUM
ihlr-26084	26	39	.	.	PUNCT
ihlr-26084	27	1	article	article	NOUN
ihlr-26084	27	2	81	81	NUM
ihlr-26084	27	3	of	of	ADP
ihlr-26084	27	4	regulation	regulation	NOUN
ihlr-26084	27	5	(	(	PUNCT
ihlr-26084	27	6	ec	ec	PROPN
ihlr-26084	27	7	)	)	PUNCT
ihlr-26084	27	8	no	no	DET
ihlr-26084	27	9	726/2004	726/2004	NUM
ihlr-26084	27	10	of	of	ADP
ihlr-26084	27	11	the	the	DET
ihlr-26084	27	12	european	european	ADJ
ihlr-26084	27	13	parliament	parliament	NOUN
ihlr-26084	27	14	and	and	CCONJ
ihlr-26084	27	15	of	of	ADP
ihlr-26084	27	16	the	the	DET
ihlr-26084	27	17	council	council	NOUN
ihlr-26084	27	18	of	of	ADP
ihlr-26084	27	19	31	31	NUM
ihlr-26084	27	20	march	march	NOUN
ihlr-26084	27	21	2004	2004	NUM
ihlr-26084	27	22	laying	lay	VERB
ihlr-26084	27	23	down	down	ADP
ihlr-26084	27	24	community	community	NOUN
ihlr-26084	27	25	procedures	procedure	NOUN
ihlr-26084	27	26	for	for	ADP
ihlr-26084	27	27	the	the	DET
ihlr-26084	27	28	authorization	authorization	NOUN
ihlr-26084	27	29	and	and	CCONJ
ihlr-26084	27	30	supervision	supervision	NOUN
ihlr-26084	27	31	of	of	ADP
ihlr-26084	27	32	medicinal	medicinal	ADJ
ihlr-26084	27	33	products	product	NOUN
ihlr-26084	27	34	for	for	ADP
ihlr-26084	27	35	human	human	ADJ
ihlr-26084	27	36	and	and	CCONJ
ihlr-26084	27	37	veterinary	veterinary	ADJ
ihlr-26084	27	38	use	use	NOUN
ihlr-26084	27	39	and	and	CCONJ
ihlr-26084	27	40	establishing	establish	VERB
ihlr-26084	27	41	a	a	DET
ihlr-26084	27	42	european	european	ADJ
ihlr-26084	27	43	medicines	medicine	NOUN
ihlr-26084	27	44	agency	agency	NOUN
ihlr-26084	27	45	and	and	CCONJ
ihlr-26084	27	46	article	article	NOUN
ihlr-26084	27	47	126	126	NUM
ihlr-26084	27	48	of	of	ADP
ihlr-26084	27	49	directive	directive	NOUN
ihlr-26084	27	50	2001/83	2001/83	NUM
ihlr-26084	27	51	/	/	SYM
ihlr-26084	27	52	ec	ec	PROPN
ihlr-26084	27	53	of	of	ADP
ihlr-26084	27	54	the	the	DET
ihlr-26084	27	55	european	european	ADJ
ihlr-26084	27	56	parliament	parliament	NOUN
ihlr-26084	27	57	and	and	CCONJ
ihlr-26084	27	58	of	of	ADP
ihlr-26084	27	59	the	the	DET
ihlr-26084	27	60	council	council	NOUN
ihlr-26084	27	61	of	of	ADP
ihlr-26084	27	62	6	6	NUM
ihlr-26084	27	63	november	november	PROPN
ihlr-26084	27	64	2001	2001	NUM
ihlr-26084	27	65	on	on	ADP
ihlr-26084	27	66	the	the	DET
ihlr-26084	27	67	community	community	NOUN
ihlr-26084	27	68	code	code	NOUN
ihlr-26084	27	69	relating	relate	VERB
ihlr-26084	27	70	to	to	ADP
ihlr-26084	27	71	medicinal	medicinal	ADJ
ihlr-26084	27	72	products	product	NOUN
ihlr-26084	27	73	for	for	ADP
ihlr-26084	27	74	human	human	ADJ
ihlr-26084	27	75	use	use	NOUN
ihlr-26084	27	76	.	.	PUNCT
ihlr-26084	28	1	3	3	X
ihlr-26084	28	2	.	.	X
ihlr-26084	28	3	global	global	ADJ
ihlr-26084	28	4	guide	guide	NOUN
ihlr-26084	28	5	to	to	ADP
ihlr-26084	28	6	patent	patent	NOUN
ihlr-26084	28	7	linkage	linkage	NOUN
ihlr-26084	28	8	,	,	PUNCT
ihlr-26084	28	9	baker	baker	PROPN
ihlr-26084	28	10	mckenzie	mckenzie	PROPN
ihlr-26084	28	11	(	(	PUNCT
ihlr-26084	28	12	nov	nov	PROPN
ihlr-26084	28	13	.	.	PROPN
ihlr-26084	28	14	4	4	NUM
ihlr-26084	28	15	,	,	PUNCT
ihlr-26084	28	16	2019	2019	NUM
ihlr-26084	28	17	)	)	PUNCT
ihlr-26084	28	18	,	,	PUNCT
ihlr-26084	28	19	https://www	https://www	PROPN
ihlr-26084	28	20	.	.	PROPN
ihlr-26084	29	1	bakermckenzie.com/en/insight/publications/guides/global-gu	bakermckenzie.com/en/insight/publications/guides/global-gu	PROPN
ihlr-26084	29	2	ide	ide	PROPN
ihlr-26084	29	3	-	-	PUNCT
ihlr-26084	29	4	to	to	AUX
ihlr-26084	29	5	-	-	PUNCT
ihlr-26084	29	6	paten	paten	NOUN
ihlr-26084	29	7	t	t	PROPN
ihlr-26084	29	8	-	-	PUNCT
ihlr-26084	29	9	linkage	linkage	NOUN
ihlr-26084	29	10	[	[	X
ihlr-26084	29	11	https://perma.cc/n237-u74	https://perma.cc/n237-u74	X
ihlr-26084	29	12	t	t	X
ihlr-26084	29	13	]	]	PUNCT
ihlr-26084	29	14	(	(	PUNCT
ihlr-26084	29	15	“	"	PUNCT
ihlr-26084	29	16	patent	patent	NOUN
ihlr-26084	29	17	linkage	linkage	NOUN
ihlr-26084	29	18	is	be	AUX
ihlr-26084	29	19	generally	generally	ADV
ihlr-26084	29	20	understood	understand	VERB
ihlr-26084	29	21	to	to	PART
ihlr-26084	29	22	be	be	AUX
ihlr-26084	29	23	the	the	DET
ihlr-26084	29	24	practice	practice	NOUN
ihlr-26084	29	25	of	of	ADP
ihlr-26084	29	26	linking	link	VERB
ihlr-26084	29	27	the	the	DET
ihlr-26084	29	28	granting	granting	NOUN
ihlr-26084	29	29	of	of	ADP
ihlr-26084	29	30	marketing	marketing	NOUN
ihlr-26084	29	31	approval	approval	NOUN
ihlr-26084	29	32	or	or	CCONJ
ihlr-26084	29	33	any	any	DET
ihlr-26084	29	34	other	other	ADJ
ihlr-26084	29	35	regulatory	regulatory	ADJ
ihlr-26084	29	36	approval	approval	NOUN
ihlr-26084	29	37	for	for	ADP
ihlr-26084	29	38	a	a	DET
ihlr-26084	29	39	generic	generic	ADJ
ihlr-26084	29	40	or	or	CCONJ
ihlr-26084	29	41	biosimilar	biosimilar	ADJ
ihlr-26084	29	42	medicinal	medicinal	ADJ
ihlr-26084	29	43	product	product	NOUN
ihlr-26084	29	44	to	to	ADP
ihlr-26084	29	45	the	the	DET
ihlr-26084	29	46	status	status	NOUN
ihlr-26084	29	47	of	of	ADP
ihlr-26084	29	48	a	a	DET
ihlr-26084	29	49	patent	patent	NOUN
ihlr-26084	29	50	for	for	ADP
ihlr-26084	29	51	the	the	DET
ihlr-26084	29	52	originator	originator	NOUN
ihlr-26084	29	53	reference	reference	NOUN
ihlr-26084	29	54	product	product	NOUN
ihlr-26084	29	55	.	.	PUNCT
ihlr-26084	29	56	”	"	PUNCT
ihlr-26084	29	57	)	)	PUNCT
ihlr-26084	29	58	.	.	PUNCT
ihlr-26084	30	1	4	4	X
ihlr-26084	30	2	.	.	X
ihlr-26084	30	3	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	30	4	sector	sector	NOUN
ihlr-26084	30	5	inquiry	inquiry	NOUN
ihlr-26084	30	6	final	final	ADJ
ihlr-26084	30	7	report	report	NOUN
ihlr-26084	30	8	,	,	PUNCT
ihlr-26084	30	9	eur	eur	PROPN
ihlr-26084	30	10	.	.	PUNCT
ihlr-26084	31	1	comm'n	comm'n	VERB
ihlr-26084	31	2	¶¶	¶¶	PROPN
ihlr-26084	31	3	1100	1100	NUM
ihlr-26084	31	4	-	-	SYM
ihlr-26084	31	5	04	04	NUM
ihlr-26084	31	6	(	(	PUNCT
ihlr-26084	31	7	2009	2009	NUM
ihlr-26084	31	8	)	)	PUNCT
ihlr-26084	32	1	[	[	X
ihlr-26084	32	2	hereinafter	hereinafter	NOUN
ihlr-26084	32	3	ec	ec	PROPN
ihlr-26084	32	4	report	report	PROPN
ihlr-26084	32	5	]	]	X
ihlr-26084	32	6	.	.	PUNCT
ihlr-26084	33	1	5	5	X
ihlr-26084	33	2	.	.	X
ihlr-26084	33	3	valérie	valérie	ADJ
ihlr-26084	33	4	junod	junod	PROPN
ihlr-26084	33	5	,	,	PUNCT
ihlr-26084	33	6	droit	droit	PROPN
ihlr-26084	33	7	pharmaceutique	pharmaceutique	PROPN
ihlr-26084	33	8	:	:	PUNCT
ihlr-26084	33	9	un	un	PROPN
ihlr-26084	33	10	aperçu	aperçu	PROPN
ihlr-26084	33	11	global	global	ADJ
ihlr-26084	33	12	,	,	PUNCT
ihlr-26084	33	13	4	4	NUM
ihlr-26084	33	14	eur	eur	NOUN
ihlr-26084	33	15	.	.	PUNCT
ihlr-26084	34	1	l.j	l.j	PROPN
ihlr-26084	34	2	.	.	PROPN
ihlr-26084	34	3	23	23	NUM
ihlr-26084	34	4	,	,	PUNCT
ihlr-26084	34	5	26	26	NUM
ihlr-26084	34	6	(	(	PUNCT
ihlr-26084	34	7	2006	2006	NUM
ihlr-26084	34	8	)	)	PUNCT
ihlr-26084	34	9	.	.	PUNCT
ihlr-26084	35	1	some	some	DET
ihlr-26084	35	2	medications	medication	NOUN
ihlr-26084	35	3	,	,	PUNCT
ihlr-26084	35	4	such	such	ADJ
ihlr-26084	35	5	as	as	ADP
ihlr-26084	35	6	drugs	drug	NOUN
ihlr-26084	35	7	for	for	ADP
ihlr-26084	35	8	rare	rare	ADJ
ihlr-26084	35	9	diseases	disease	NOUN
ihlr-26084	35	10	(	(	PUNCT
ihlr-26084	35	11	orphan	orphan	NOUN
ihlr-26084	35	12	drugs	drug	NOUN
ihlr-26084	35	13	)	)	PUNCT
ihlr-26084	35	14	,	,	PUNCT
ihlr-26084	35	15	have	have	VERB
ihlr-26084	35	16	longer	long	ADJ
ihlr-26084	35	17	exclusivity	exclusivity	NOUN
ihlr-26084	35	18	periods	period	NOUN
ihlr-26084	35	19	in	in	ADP
ihlr-26084	35	20	both	both	CCONJ
ihlr-26084	35	21	the	the	DET
ihlr-26084	35	22	us	us	PROPN
ihlr-26084	35	23	and	and	CCONJ
ihlr-26084	35	24	eu	eu	PROPN
ihlr-26084	35	25	.	.	PROPN
ihlr-26084	35	26	see	see	VERB
ihlr-26084	35	27	21	21	NUM
ihlr-26084	35	28	u.s.c	u.s.c	ADJ
ihlr-26084	35	29	.	.	PUNCT
ihlr-26084	36	1	§	§	PROPN
ihlr-26084	36	2	360cc	360cc	PROPN
ihlr-26084	36	3	;	;	PUNCT
ihlr-26084	36	4	article	article	NOUN
ihlr-26084	36	5	8(1	8(1	NOUN
ihlr-26084	36	6	)	)	PUNCT
ihlr-26084	36	7	of	of	ADP
ihlr-26084	36	8	regulation	regulation	NOUN
ihlr-26084	36	9	(	(	PUNCT
ihlr-26084	36	10	ec	ec	PROPN
ihlr-26084	36	11	)	)	PUNCT
ihlr-26084	36	12	no	no	INTJ
ihlr-26084	36	13	.	.	NOUN
ihlr-26084	36	14	141/2000	141/2000	NUM
ihlr-26084	36	15	of	of	ADP
ihlr-26084	36	16	the	the	DET
ihlr-26084	36	17	european	european	ADJ
ihlr-26084	36	18	parliament	parliament	NOUN
ihlr-26084	36	19	.	.	PUNCT
ihlr-26084	37	1	6	6	X
ihlr-26084	37	2	.	.	X
ihlr-26084	37	3	see	see	VERB
ihlr-26084	37	4	,	,	PUNCT
ihlr-26084	37	5	e.g.	e.g.	ADV
ihlr-26084	37	6	,	,	PUNCT
ihlr-26084	37	7	ec	ec	PROPN
ihlr-26084	37	8	report	report	NOUN
ihlr-26084	37	9	,	,	PUNCT
ihlr-26084	37	10	supra	supra	PROPN
ihlr-26084	37	11	note	note	NOUN
ihlr-26084	37	12	4	4	NUM
ihlr-26084	37	13	,	,	PUNCT
ihlr-26084	37	14	at	at	ADP
ihlr-26084	37	15	¶	¶	PROPN
ihlr-26084	37	16	1558	1558	NUM
ihlr-26084	37	17	(	(	PUNCT
ihlr-26084	37	18	identifying	identify	VERB
ihlr-26084	37	19	many	many	ADJ
ihlr-26084	37	20	strategies	strategy	NOUN
ihlr-26084	37	21	such	such	ADJ
ihlr-26084	37	22	as	as	ADP
ihlr-26084	37	23	patent	patent	NOUN
ihlr-26084	37	24	clusters	cluster	NOUN
ihlr-26084	37	25	around	around	ADP
ihlr-26084	37	26	a	a	DET
ihlr-26084	37	27	medication	medication	NOUN
ihlr-26084	37	28	,	,	PUNCT
ihlr-26084	37	29	litigation	litigation	NOUN
ihlr-26084	37	30	against	against	ADP
ihlr-26084	37	31	competitors	competitor	NOUN
ihlr-26084	37	32	,	,	PUNCT
ihlr-26084	37	33	challenging	challenge	VERB
ihlr-26084	37	34	market	market	NOUN
ihlr-26084	37	35	approvals	approval	NOUN
ihlr-26084	37	36	,	,	PUNCT
ihlr-26084	37	37	etc	etc	X
ihlr-26084	37	38	.	.	X
ihlr-26084	37	39	)	)	PUNCT
ihlr-26084	37	40	.	.	PUNCT
ihlr-26084	38	1	7	7	X
ihlr-26084	38	2	.	.	X
ihlr-26084	38	3	see	see	VERB
ihlr-26084	38	4	e.g.	e.g.	ADV
ihlr-26084	38	5	,	,	PUNCT
ihlr-26084	38	6	justin	justin	PROPN
ihlr-26084	38	7	gatwood	gatwood	PROPN
ihlr-26084	38	8	et	et	PROPN
ihlr-26084	38	9	al	al	PROPN
ihlr-26084	38	10	.	.	PROPN
ihlr-26084	38	11	,	,	PUNCT
ihlr-26084	38	12	price	price	NOUN
ihlr-26084	38	13	elasticity	elasticity	NOUN
ihlr-26084	38	14	and	and	CCONJ
ihlr-26084	38	15	medication	medication	NOUN
ihlr-26084	38	16	use	use	NOUN
ihlr-26084	38	17	:	:	PUNCT
ihlr-26084	38	18	cost	cost	NOUN
ihlr-26084	38	19	sharing	sharing	NOUN
ihlr-26084	38	20	across	across	ADP
ihlr-26084	38	21	multiple	multiple	ADJ
ihlr-26084	38	22	clinical	clinical	ADJ
ihlr-26084	38	23	conditions	condition	NOUN
ihlr-26084	38	24	,	,	PUNCT
ihlr-26084	38	25	20	20	NUM
ihlr-26084	38	26	j.	j.	PROPN
ihlr-26084	38	27	managed	manage	VERB
ihlr-26084	38	28	care	care	NOUN
ihlr-26084	38	29	pharmacy	pharmacy	NOUN
ihlr-26084	38	30	1102	1102	NUM
ihlr-26084	38	31	(	(	PUNCT
ihlr-26084	38	32	2014	2014	NUM
ihlr-26084	38	33	)	)	PUNCT
ihlr-26084	38	34	.	.	PUNCT
ihlr-26084	39	1	8	8	X
ihlr-26084	39	2	.	.	X
ihlr-26084	39	3	see	see	VERB
ihlr-26084	39	4	,	,	PUNCT
ihlr-26084	39	5	e.g.	e.g.	ADV
ihlr-26084	39	6	,	,	PUNCT
ihlr-26084	39	7	patricia	patricia	PROPN
ihlr-26084	39	8	m.	m.	PROPN
ihlr-26084	39	9	danzon	danzon	PROPN
ihlr-26084	39	10	,	,	PUNCT
ihlr-26084	39	11	regulation	regulation	NOUN
ihlr-26084	39	12	of	of	ADP
ihlr-26084	39	13	price	price	NOUN
ihlr-26084	39	14	and	and	CCONJ
ihlr-26084	39	15	reimbursement	reimbursement	NOUN
ihlr-26084	39	16	for	for	ADP
ihlr-26084	39	17	pharmaceuticals	pharmaceutical	NOUN
ihlr-26084	39	18	,	,	PUNCT
ihlr-26084	39	19	oxford	oxford	PROPN
ihlr-26084	39	20	univ	univ	PROPN
ihlr-26084	39	21	.	.	PUNCT
ihlr-26084	40	1	press	press	NOUN
ihlr-26084	40	2	286	286	NUM
ihlr-26084	40	3	(	(	PUNCT
ihlr-26084	40	4	2012	2012	NUM
ihlr-26084	40	5	)	)	PUNCT
ihlr-26084	40	6	(	(	PUNCT
ihlr-26084	40	7	discussing	discuss	VERB
ihlr-26084	40	8	the	the	DET
ihlr-26084	40	9	different	different	ADJ
ihlr-26084	40	10	regulatory	regulatory	ADJ
ihlr-26084	40	11	approaches	approach	NOUN
ihlr-26084	40	12	including	include	VERB
ihlr-26084	40	13	cost	cost	NOUN
ihlr-26084	40	14	of	of	ADP
ihlr-26084	40	15	production	production	NOUN
ihlr-26084	40	16	pricing	pricing	NOUN
ihlr-26084	40	17	)	)	PUNCT
ihlr-26084	40	18	.	.	PUNCT
ihlr-26084	41	1	2022	2022	NUM
ihlr-26084	41	2	]	]	PUNCT
ihlr-26084	41	3	reverse	reverse	ADJ
ihlr-26084	41	4	payment	payment	NOUN
ihlr-26084	41	5	:	:	PUNCT
ihlr-26084	41	6	a	a	DET
ihlr-26084	41	7	comparative	comparative	ADJ
ihlr-26084	41	8	study	study	NOUN
ihlr-26084	41	9	23	23	NUM
ihlr-26084	41	10	of	of	ADP
ihlr-26084	41	11	other	other	ADJ
ihlr-26084	41	12	existing	exist	VERB
ihlr-26084	41	13	treatments	treatment	NOUN
ihlr-26084	41	14	.	.	PUNCT
ihlr-26084	42	1	monopsony	monopsony	ADJ
ihlr-26084	42	2	power	power	NOUN
ihlr-26084	42	3	plays	play	VERB
ihlr-26084	42	4	a	a	DET
ihlr-26084	42	5	central	central	ADJ
ihlr-26084	42	6	role9	role9	NOUN
ihlr-26084	42	7	in	in	ADP
ihlr-26084	42	8	reducing	reduce	VERB
ihlr-26084	42	9	prices	price	NOUN
ihlr-26084	42	10	of	of	ADP
ihlr-26084	42	11	healthcare	healthcare	NOUN
ihlr-26084	42	12	during	during	ADP
ihlr-26084	42	13	negotiations	negotiation	NOUN
ihlr-26084	42	14	between	between	ADP
ihlr-26084	42	15	the	the	DET
ihlr-26084	42	16	purchasing	purchase	VERB
ihlr-26084	42	17	governmental	governmental	ADJ
ihlr-26084	42	18	agency	agency	NOUN
ihlr-26084	42	19	and	and	CCONJ
ihlr-26084	42	20	the	the	DET
ihlr-26084	42	21	drug	drug	NOUN
ihlr-26084	42	22	manufacturers	manufacturer	NOUN
ihlr-26084	42	23	.	.	PUNCT
ihlr-26084	43	1	this	this	DET
ihlr-26084	43	2	negotiation	negotiation	NOUN
ihlr-26084	43	3	approach	approach	NOUN
ihlr-26084	43	4	has	have	AUX
ihlr-26084	43	5	had	have	VERB
ihlr-26084	43	6	some	some	DET
ihlr-26084	43	7	success.10	success.10	NOUN
ihlr-26084	43	8	nonetheless	nonetheless	ADV
ihlr-26084	43	9	,	,	PUNCT
ihlr-26084	43	10	medication	medication	NOUN
ihlr-26084	43	11	spending	spending	NOUN
ihlr-26084	43	12	remains	remain	VERB
ihlr-26084	43	13	a	a	DET
ihlr-26084	43	14	substantial	substantial	ADJ
ihlr-26084	43	15	portion	portion	NOUN
ihlr-26084	43	16	of	of	ADP
ihlr-26084	43	17	total	total	ADJ
ihlr-26084	43	18	healthcare	healthcare	NOUN
ihlr-26084	43	19	spending	spending	NOUN
ihlr-26084	43	20	in	in	ADP
ihlr-26084	43	21	france	france	PROPN
ihlr-26084	43	22	,	,	PUNCT
ihlr-26084	43	23	the	the	DET
ihlr-26084	43	24	uk	uk	PROPN
ihlr-26084	43	25	,	,	PUNCT
ihlr-26084	43	26	and	and	CCONJ
ihlr-26084	43	27	the	the	DET
ihlr-26084	43	28	us.11	us.11	ADJ
ihlr-26084	43	29	competition	competition	NOUN
ihlr-26084	43	30	authorities	authority	NOUN
ihlr-26084	43	31	in	in	ADP
ihlr-26084	43	32	the	the	DET
ihlr-26084	43	33	us	us	PROPN
ihlr-26084	43	34	and	and	CCONJ
ihlr-26084	43	35	the	the	DET
ihlr-26084	43	36	eu	eu	PROPN
ihlr-26084	43	37	have	have	AUX
ihlr-26084	43	38	cracked	crack	VERB
ihlr-26084	43	39	down	down	ADP
ihlr-26084	43	40	on	on	ADP
ihlr-26084	43	41	some	some	DET
ihlr-26084	43	42	practices	practice	NOUN
ihlr-26084	43	43	that	that	PRON
ihlr-26084	43	44	enable	enable	VERB
ihlr-26084	43	45	drug	drug	NOUN
ihlr-26084	43	46	manufacturers	manufacturer	NOUN
ihlr-26084	43	47	to	to	PART
ihlr-26084	43	48	extend	extend	VERB
ihlr-26084	43	49	their	their	PRON
ihlr-26084	43	50	monopoly	monopoly	NOUN
ihlr-26084	43	51	power	power	NOUN
ihlr-26084	43	52	and	and	CCONJ
ihlr-26084	43	53	add	add	VERB
ihlr-26084	43	54	to	to	ADP
ihlr-26084	43	55	healthcare	healthcare	NOUN
ihlr-26084	43	56	costs	cost	NOUN
ihlr-26084	43	57	.	.	PUNCT
ihlr-26084	44	1	this	this	DET
ihlr-26084	44	2	article	article	NOUN
ihlr-26084	44	3	focuses	focus	VERB
ihlr-26084	44	4	on	on	ADP
ihlr-26084	44	5	one	one	NUM
ihlr-26084	44	6	such	such	ADJ
ihlr-26084	44	7	practice	practice	NOUN
ihlr-26084	44	8	:	:	PUNCT
ihlr-26084	44	9	reverse	reverse	VERB
ihlr-26084	44	10	payment	payment	NOUN
ihlr-26084	44	11	settlements	settlement	NOUN
ihlr-26084	44	12	.	.	PUNCT
ihlr-26084	45	1	it	it	PRON
ihlr-26084	45	2	attempts	attempt	VERB
ihlr-26084	45	3	to	to	PART
ihlr-26084	45	4	answer	answer	VERB
ihlr-26084	45	5	whether	whether	SCONJ
ihlr-26084	45	6	the	the	DET
ihlr-26084	45	7	centralized	centralized	ADJ
ihlr-26084	45	8	monopsony	monopsony	NOUN
ihlr-26084	45	9	system	system	NOUN
ihlr-26084	45	10	common	common	ADJ
ihlr-26084	45	11	in	in	ADP
ihlr-26084	45	12	the	the	DET
ihlr-26084	45	13	eu	eu	PROPN
ihlr-26084	45	14	has	have	AUX
ihlr-26084	45	15	decreased	decrease	VERB
ihlr-26084	45	16	the	the	DET
ihlr-26084	45	17	incentives	incentive	NOUN
ihlr-26084	45	18	of	of	ADP
ihlr-26084	45	19	drug	drug	NOUN
ihlr-26084	45	20	manufacturers	manufacturer	NOUN
ihlr-26084	45	21	to	to	PART
ihlr-26084	45	22	carry	carry	VERB
ihlr-26084	45	23	out	out	ADP
ihlr-26084	45	24	reverse	reverse	ADJ
ihlr-26084	45	25	payment	payment	NOUN
ihlr-26084	45	26	settlements	settlement	NOUN
ihlr-26084	45	27	as	as	SCONJ
ihlr-26084	45	28	compared	compare	VERB
ihlr-26084	45	29	to	to	ADP
ihlr-26084	45	30	the	the	DET
ihlr-26084	45	31	us	us	PROPN
ihlr-26084	45	32	drug	drug	NOUN
ihlr-26084	45	33	pricing	pricing	NOUN
ihlr-26084	45	34	system	system	NOUN
ihlr-26084	45	35	.	.	PUNCT
ihlr-26084	46	1	section	section	NOUN
ihlr-26084	46	2	2	2	NUM
ihlr-26084	46	3	focuses	focus	VERB
ihlr-26084	46	4	on	on	ADP
ihlr-26084	46	5	drug	drug	NOUN
ihlr-26084	46	6	pricing	pricing	NOUN
ihlr-26084	46	7	mechanisms	mechanism	NOUN
ihlr-26084	46	8	in	in	ADP
ihlr-26084	46	9	the	the	DET
ihlr-26084	46	10	us	us	PROPN
ihlr-26084	46	11	.	.	PUNCT
ihlr-26084	47	1	these	these	DET
ihlr-26084	47	2	mechanisms	mechanism	NOUN
ihlr-26084	47	3	remain	remain	VERB
ihlr-26084	47	4	opaque	opaque	ADJ
ihlr-26084	47	5	and	and	CCONJ
ihlr-26084	47	6	do	do	AUX
ihlr-26084	47	7	not	not	PART
ihlr-26084	47	8	provide	provide	VERB
ihlr-26084	47	9	many	many	ADJ
ihlr-26084	47	10	constraints	constraint	NOUN
ihlr-26084	47	11	on	on	ADP
ihlr-26084	47	12	what	what	PRON
ihlr-26084	47	13	drug	drug	NOUN
ihlr-26084	47	14	manufacturers	manufacturer	NOUN
ihlr-26084	47	15	can	can	AUX
ihlr-26084	47	16	charge	charge	VERB
ihlr-26084	47	17	.	.	PUNCT
ihlr-26084	48	1	in	in	ADP
ihlr-26084	48	2	this	this	DET
ihlr-26084	48	3	context	context	NOUN
ihlr-26084	48	4	,	,	PUNCT
ihlr-26084	48	5	stopping	stop	VERB
ihlr-26084	48	6	competition	competition	NOUN
ihlr-26084	48	7	becomes	become	VERB
ihlr-26084	48	8	lucrative	lucrative	ADJ
ihlr-26084	48	9	.	.	PUNCT
ihlr-26084	49	1	courts	court	NOUN
ihlr-26084	49	2	have	have	AUX
ihlr-26084	49	3	failed	fail	VERB
ihlr-26084	49	4	to	to	PART
ihlr-26084	49	5	provide	provide	VERB
ihlr-26084	49	6	plaintiffs	plaintiff	NOUN
ihlr-26084	49	7	with	with	ADP
ihlr-26084	49	8	the	the	DET
ihlr-26084	49	9	tools	tool	NOUN
ihlr-26084	49	10	that	that	PRON
ihlr-26084	49	11	drug	drug	NOUN
ihlr-26084	49	12	consumers	consumer	NOUN
ihlr-26084	49	13	need	need	VERB
ihlr-26084	49	14	to	to	PART
ihlr-26084	49	15	increase	increase	VERB
ihlr-26084	49	16	competition	competition	NOUN
ihlr-26084	49	17	and	and	CCONJ
ihlr-26084	49	18	lower	low	ADJ
ihlr-26084	49	19	prices	price	NOUN
ihlr-26084	49	20	.	.	PUNCT
ihlr-26084	50	1	section	section	NOUN
ihlr-26084	50	2	3	3	NUM
ihlr-26084	50	3	discusses	discuss	VERB
ihlr-26084	50	4	pricing	pricing	NOUN
ihlr-26084	50	5	strategies	strategy	NOUN
ihlr-26084	50	6	in	in	ADP
ihlr-26084	50	7	the	the	DET
ihlr-26084	50	8	uk	uk	PROPN
ihlr-26084	50	9	and	and	CCONJ
ihlr-26084	50	10	france	france	PROPN
ihlr-26084	50	11	.	.	PUNCT
ihlr-26084	51	1	drug	drug	NOUN
ihlr-26084	51	2	manufacturers	manufacturer	NOUN
ihlr-26084	51	3	must	must	AUX
ihlr-26084	51	4	negotiate	negotiate	VERB
ihlr-26084	51	5	with	with	ADP
ihlr-26084	51	6	the	the	DET
ihlr-26084	51	7	agencies	agency	NOUN
ihlr-26084	51	8	in	in	ADP
ihlr-26084	51	9	charge	charge	NOUN
ihlr-26084	51	10	of	of	ADP
ihlr-26084	51	11	healthcare	healthcare	NOUN
ihlr-26084	51	12	expenditure	expenditure	NOUN
ihlr-26084	51	13	.	.	PUNCT
ihlr-26084	52	1	these	these	DET
ihlr-26084	52	2	agencies	agency	NOUN
ihlr-26084	52	3	wield	wield	VERB
ihlr-26084	52	4	a	a	DET
ihlr-26084	52	5	stronger	strong	ADJ
ihlr-26084	52	6	bargaining	bargaining	NOUN
ihlr-26084	52	7	position	position	NOUN
ihlr-26084	52	8	than	than	ADP
ihlr-26084	52	9	private	private	ADJ
ihlr-26084	52	10	insurers	insurer	NOUN
ihlr-26084	52	11	in	in	ADP
ihlr-26084	52	12	the	the	DET
ihlr-26084	52	13	us	we	PRON
ihlr-26084	52	14	because	because	SCONJ
ihlr-26084	52	15	of	of	ADP
ihlr-26084	52	16	their	their	PRON
ihlr-26084	52	17	monopsony	monopsony	ADJ
ihlr-26084	52	18	power	power	NOUN
ihlr-26084	52	19	.	.	PUNCT
ihlr-26084	53	1	however	however	ADV
ihlr-26084	53	2	,	,	PUNCT
ihlr-26084	53	3	reverse	reverse	ADJ
ihlr-26084	53	4	payments	payment	NOUN
ihlr-26084	53	5	still	still	ADV
ihlr-26084	53	6	occur	occur	VERB
ihlr-26084	53	7	,	,	PUNCT
ihlr-26084	53	8	and	and	CCONJ
ihlr-26084	53	9	the	the	DET
ihlr-26084	53	10	competition	competition	NOUN
ihlr-26084	53	11	authorities	authority	NOUN
ihlr-26084	53	12	still	still	ADV
ihlr-26084	53	13	need	need	VERB
ihlr-26084	53	14	to	to	PART
ihlr-26084	53	15	oversee	oversee	VERB
ihlr-26084	53	16	drug	drug	NOUN
ihlr-26084	53	17	settlements	settlement	NOUN
ihlr-26084	53	18	.	.	PUNCT
ihlr-26084	54	1	section	section	NOUN
ihlr-26084	54	2	4	4	NUM
ihlr-26084	54	3	provides	provide	VERB
ihlr-26084	54	4	some	some	DET
ihlr-26084	54	5	recommendations	recommendation	NOUN
ihlr-26084	54	6	.	.	PUNCT
ihlr-26084	55	1	first	first	ADV
ihlr-26084	55	2	,	,	PUNCT
ihlr-26084	55	3	the	the	DET
ihlr-26084	55	4	finding	finding	NOUN
ihlr-26084	55	5	of	of	ADP
ihlr-26084	55	6	an	an	DET
ihlr-26084	55	7	anticompetitive	anticompetitive	ADJ
ihlr-26084	55	8	reverse	reverse	ADJ
ihlr-26084	55	9	payment	payment	NOUN
ihlr-26084	55	10	should	should	AUX
ihlr-26084	55	11	be	be	AUX
ihlr-26084	55	12	coupled	couple	VERB
ihlr-26084	55	13	with	with	ADP
ihlr-26084	55	14	a	a	DET
ihlr-26084	55	15	suspension	suspension	NOUN
ihlr-26084	55	16	of	of	ADP
ihlr-26084	55	17	entry	entry	NOUN
ihlr-26084	55	18	barrier	barrier	NOUN
ihlr-26084	55	19	—	—	PUNCT
ihlr-26084	55	20	whether	whether	SCONJ
ihlr-26084	55	21	through	through	ADP
ihlr-26084	55	22	compulsory	compulsory	ADJ
ihlr-26084	55	23	licensing	licensing	NOUN
ihlr-26084	55	24	,	,	PUNCT
ihlr-26084	55	25	rendering	render	VERB
ihlr-26084	55	26	the	the	DET
ihlr-26084	55	27	patent	patent	NOUN
ihlr-26084	55	28	unenforceable	unenforceable	ADJ
ihlr-26084	55	29	,	,	PUNCT
ihlr-26084	55	30	or	or	CCONJ
ihlr-26084	55	31	a	a	DET
ihlr-26084	55	32	price	price	NOUN
ihlr-26084	55	33	reduction	reduction	NOUN
ihlr-26084	55	34	of	of	ADP
ihlr-26084	55	35	the	the	DET
ihlr-26084	55	36	branded	brand	VERB
ihlr-26084	55	37	drug	drug	NOUN
ihlr-26084	55	38	.	.	PUNCT
ihlr-26084	56	1	second	second	ADJ
ihlr-26084	56	2	,	,	PUNCT
ihlr-26084	56	3	the	the	DET
ihlr-26084	56	4	market	market	NOUN
ihlr-26084	56	5	exclusivity	exclusivity	NOUN
ihlr-26084	56	6	period	period	NOUN
ihlr-26084	56	7	and	and	CCONJ
ihlr-26084	56	8	the	the	DET
ihlr-26084	56	9	pricing	pricing	NOUN
ihlr-26084	56	10	mechanism	mechanism	NOUN
ihlr-26084	56	11	of	of	ADP
ihlr-26084	56	12	branded	brand	VERB
ihlr-26084	56	13	drugs	drug	NOUN
ihlr-26084	56	14	should	should	AUX
ihlr-26084	56	15	be	be	AUX
ihlr-26084	56	16	linked	link	VERB
ihlr-26084	56	17	to	to	ADP
ihlr-26084	56	18	market	market	NOUN
ihlr-26084	56	19	authorization	authorization	NOUN
ihlr-26084	56	20	instead	instead	ADV
ihlr-26084	56	21	of	of	ADP
ihlr-26084	56	22	patent	patent	NOUN
ihlr-26084	56	23	protection	protection	NOUN
ihlr-26084	56	24	.	.	PUNCT
ihlr-26084	57	1	this	this	DET
ihlr-26084	57	2	approach	approach	NOUN
ihlr-26084	57	3	would	would	AUX
ihlr-26084	57	4	nullify	nullify	VERB
ihlr-26084	57	5	the	the	DET
ihlr-26084	57	6	need	need	NOUN
ihlr-26084	57	7	to	to	PART
ihlr-26084	57	8	regulate	regulate	VERB
ihlr-26084	57	9	pay	pay	NOUN
ihlr-26084	57	10	-	-	PUNCT
ihlr-26084	57	11	for	for	ADP
ihlr-26084	57	12	-	-	PUNCT
ihlr-26084	57	13	delay	delay	NOUN
ihlr-26084	57	14	settlements	settlement	NOUN
ihlr-26084	57	15	and	and	CCONJ
ihlr-26084	57	16	streamline	streamline	VERB
ihlr-26084	57	17	generic	generic	ADJ
ihlr-26084	57	18	entry	entry	NOUN
ihlr-26084	57	19	.	.	PUNCT
ihlr-26084	58	1	ii	ii	PROPN
ihlr-26084	58	2	.	.	PUNCT
ihlr-26084	59	1	reverse	reverse	ADJ
ihlr-26084	59	2	payments	payment	NOUN
ihlr-26084	59	3	in	in	ADP
ihlr-26084	59	4	the	the	DET
ihlr-26084	59	5	us	we	PRON
ihlr-26084	59	6	this	this	DET
ihlr-26084	59	7	section	section	NOUN
ihlr-26084	59	8	highlights	highlight	VERB
ihlr-26084	59	9	the	the	DET
ihlr-26084	59	10	complexity	complexity	NOUN
ihlr-26084	59	11	of	of	ADP
ihlr-26084	59	12	the	the	DET
ihlr-26084	59	13	drug	drug	NOUN
ihlr-26084	59	14	market	market	NOUN
ihlr-26084	59	15	in	in	ADP
ihlr-26084	59	16	the	the	DET
ihlr-26084	59	17	us	us	PROPN
ihlr-26084	59	18	and	and	CCONJ
ihlr-26084	59	19	the	the	DET
ihlr-26084	59	20	9	9	NUM
ihlr-26084	59	21	.	.	PUNCT
ihlr-26084	59	22	see	see	VERB
ihlr-26084	59	23	e.g.	e.g.	ADV
ihlr-26084	59	24	,	,	PUNCT
ihlr-26084	59	25	zack	zack	PROPN
ihlr-26084	59	26	cooper	cooper	PROPN
ihlr-26084	59	27	et	et	PROPN
ihlr-26084	59	28	al	al	PROPN
ihlr-26084	59	29	.	.	PROPN
ihlr-26084	59	30	,	,	PUNCT
ihlr-26084	59	31	the	the	DET
ihlr-26084	59	32	price	price	NOUN
ihlr-26084	59	33	ai	ai	VERB
ihlr-26084	59	34	n’t	not	PART
ihlr-26084	59	35	right	right	ADJ
ihlr-26084	59	36	?	?	PUNCT
ihlr-26084	60	1	hospital	hospital	NOUN
ihlr-26084	60	2	prices	price	NOUN
ihlr-26084	60	3	and	and	CCONJ
ihlr-26084	60	4	health	health	NOUN
ihlr-26084	60	5	spending	spending	NOUN
ihlr-26084	60	6	on	on	ADP
ihlr-26084	60	7	the	the	DET
ihlr-26084	60	8	privately	privately	ADV
ihlr-26084	60	9	insured	insure	VERB
ihlr-26084	60	10	,	,	PUNCT
ihlr-26084	60	11	134	134	NUM
ihlr-26084	60	12	q.	q.	PROPN
ihlr-26084	60	13	j.	j.	PROPN
ihlr-26084	60	14	econ	econ	PROPN
ihlr-26084	60	15	.	.	PUNCT
ihlr-26084	61	1	51	51	NUM
ihlr-26084	61	2	(	(	PUNCT
ihlr-26084	61	3	2019	2019	NUM
ihlr-26084	61	4	)	)	PUNCT
ihlr-26084	61	5	(	(	PUNCT
ihlr-26084	61	6	finding	find	VERB
ihlr-26084	61	7	concentration	concentration	NOUN
ihlr-26084	61	8	of	of	ADP
ihlr-26084	61	9	us	us	PROPN
ihlr-26084	61	10	insurers	insurer	NOUN
ihlr-26084	61	11	lead	lead	VERB
ihlr-26084	61	12	to	to	ADP
ihlr-26084	61	13	lower	low	ADJ
ihlr-26084	61	14	prices	price	NOUN
ihlr-26084	61	15	in	in	ADP
ihlr-26084	61	16	local	local	ADJ
ihlr-26084	61	17	markets	market	NOUN
ihlr-26084	61	18	)	)	PUNCT
ihlr-26084	61	19	.	.	PUNCT
ihlr-26084	62	1	10	10	NUM
ihlr-26084	62	2	.	.	X
ihlr-26084	62	3	pierre	pierre	PROPN
ihlr-26084	62	4	dubois	dubois	PROPN
ihlr-26084	62	5	&	&	CCONJ
ihlr-26084	62	6	laura	laura	PROPN
ihlr-26084	62	7	lasio	lasio	PROPN
ihlr-26084	62	8	,	,	PUNCT
ihlr-26084	62	9	identifying	identify	VERB
ihlr-26084	62	10	industry	industry	NOUN
ihlr-26084	62	11	margins	margin	NOUN
ihlr-26084	62	12	with	with	ADP
ihlr-26084	62	13	price	price	NOUN
ihlr-26084	62	14	constraints	constraint	NOUN
ihlr-26084	62	15	:	:	PUNCT
ihlr-26084	62	16	structural	structural	ADJ
ihlr-26084	62	17	estimation	estimation	NOUN
ihlr-26084	62	18	on	on	ADP
ihlr-26084	62	19	pharmaceuticals	pharmaceutical	NOUN
ihlr-26084	62	20	,	,	PUNCT
ihlr-26084	62	21	108	108	NUM
ihlr-26084	62	22	am	am	NOUN
ihlr-26084	62	23	.	.	PUNCT
ihlr-26084	63	1	econ	econ	PROPN
ihlr-26084	63	2	.	.	PUNCT
ihlr-26084	64	1	rev	rev	PROPN
ihlr-26084	64	2	.	.	PROPN
ihlr-26084	64	3	3685	3685	NUM
ihlr-26084	64	4	(	(	PUNCT
ihlr-26084	64	5	2018	2018	NUM
ihlr-26084	64	6	)	)	PUNCT
ihlr-26084	64	7	(	(	PUNCT
ihlr-26084	64	8	discussing	discuss	VERB
ihlr-26084	64	9	how	how	SCONJ
ihlr-26084	64	10	the	the	DET
ihlr-26084	64	11	switch	switch	NOUN
ihlr-26084	64	12	in	in	ADP
ihlr-26084	64	13	regulatory	regulatory	ADJ
ihlr-26084	64	14	setting	setting	NOUN
ihlr-26084	64	15	leads	lead	VERB
ihlr-26084	64	16	to	to	ADP
ihlr-26084	64	17	a	a	DET
ihlr-26084	64	18	2	2	NUM
ihlr-26084	64	19	%	%	NOUN
ihlr-26084	64	20	price	price	NOUN
ihlr-26084	64	21	decrease	decrease	NOUN
ihlr-26084	64	22	for	for	ADP
ihlr-26084	64	23	anti	anti	ADJ
ihlr-26084	64	24	-	-	ADJ
ihlr-26084	64	25	ulcer	ulcer	ADJ
ihlr-26084	64	26	drugs	drug	NOUN
ihlr-26084	64	27	)	)	PUNCT
ihlr-26084	64	28	.	.	PUNCT
ihlr-26084	65	1	11	11	NUM
ihlr-26084	65	2	.	.	PUNCT
ihlr-26084	66	1	according	accord	VERB
ihlr-26084	66	2	to	to	ADP
ihlr-26084	66	3	the	the	DET
ihlr-26084	66	4	organization	organization	NOUN
ihlr-26084	66	5	for	for	ADP
ihlr-26084	66	6	economic	economic	ADJ
ihlr-26084	66	7	co	co	NOUN
ihlr-26084	66	8	-	-	NOUN
ihlr-26084	66	9	operation	operation	NOUN
ihlr-26084	66	10	and	and	CCONJ
ihlr-26084	66	11	development	development	NOUN
ihlr-26084	66	12	,	,	PUNCT
ihlr-26084	66	13	medication	medication	NOUN
ihlr-26084	66	14	expenditure	expenditure	NOUN
ihlr-26084	66	15	constituted	constitute	VERB
ihlr-26084	66	16	13.03	13.03	NUM
ihlr-26084	66	17	%	%	NOUN
ihlr-26084	66	18	,	,	PUNCT
ihlr-26084	66	19	12.27	12.27	NUM
ihlr-26084	66	20	%	%	NOUN
ihlr-26084	66	21	,	,	PUNCT
ihlr-26084	66	22	and	and	CCONJ
ihlr-26084	66	23	11.55	11.55	NUM
ihlr-26084	66	24	%	%	NOUN
ihlr-26084	66	25	of	of	ADP
ihlr-26084	66	26	total	total	ADJ
ihlr-26084	66	27	healthcare	healthcare	NOUN
ihlr-26084	66	28	expenditure	expenditure	NOUN
ihlr-26084	66	29	in	in	ADP
ihlr-26084	66	30	france	france	PROPN
ihlr-26084	66	31	,	,	PUNCT
ihlr-26084	66	32	the	the	DET
ihlr-26084	66	33	uk	uk	PROPN
ihlr-26084	66	34	,	,	PUNCT
ihlr-26084	66	35	and	and	CCONJ
ihlr-26084	66	36	the	the	DET
ihlr-26084	66	37	us	us	PROPN
ihlr-26084	66	38	in	in	ADP
ihlr-26084	66	39	2018	2018	NUM
ihlr-26084	66	40	respectively	respectively	ADV
ihlr-26084	66	41	.	.	PUNCT
ihlr-26084	67	1	medication	medication	NOUN
ihlr-26084	67	2	expenditure	expenditure	NOUN
ihlr-26084	67	3	includes	include	VERB
ihlr-26084	67	4	over	over	ADP
ihlr-26084	67	5	-	-	PUNCT
ihlr-26084	67	6	the	the	DET
ihlr-26084	67	7	-	-	PUNCT
ihlr-26084	67	8	counter	counter	NOUN
ihlr-26084	67	9	and	and	CCONJ
ihlr-26084	67	10	prescription	prescription	NOUN
ihlr-26084	67	11	drugs	drug	NOUN
ihlr-26084	67	12	,	,	PUNCT
ihlr-26084	67	13	but	but	CCONJ
ihlr-26084	67	14	ignores	ignore	VERB
ihlr-26084	67	15	drugs	drug	NOUN
ihlr-26084	67	16	provided	provide	VERB
ihlr-26084	67	17	to	to	ADP
ihlr-26084	67	18	patients	patient	NOUN
ihlr-26084	67	19	“	"	PUNCT
ihlr-26084	67	20	in	in	ADP
ihlr-26084	67	21	hospitals	hospital	NOUN
ihlr-26084	67	22	and	and	CCONJ
ihlr-26084	67	23	other	other	ADJ
ihlr-26084	67	24	health	health	NOUN
ihlr-26084	67	25	care	care	NOUN
ihlr-26084	67	26	settings	setting	NOUN
ihlr-26084	67	27	.	.	PUNCT
ihlr-26084	67	28	”	"	PUNCT
ihlr-26084	68	1	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	68	2	spending	spending	NOUN
ihlr-26084	68	3	,	,	PUNCT
ihlr-26084	68	4	org	org	PROPN
ihlr-26084	68	5	.	.	PUNCT
ihlr-26084	68	6	econ	econ	PROPN
ihlr-26084	68	7	.	.	PUNCT
ihlr-26084	68	8	coop	coop	PROPN
ihlr-26084	68	9	.	.	PUNCT
ihlr-26084	68	10	&	&	CCONJ
ihlr-26084	68	11	dev	dev	PROPN
ihlr-26084	68	12	.	.	PROPN
ihlr-26084	68	13	1	1	NUM
ihlr-26084	68	14	(	(	PUNCT
ihlr-26084	68	15	2021	2021	NUM
ihlr-26084	68	16	)	)	PUNCT
ihlr-26084	68	17	,	,	PUNCT
ihlr-26084	68	18	https://data.oecd.org/	https://data.oecd.org/	NOUN
ihlr-26084	68	19	healthres	healthre	NOUN
ihlr-26084	68	20	/	/	SYM
ihlr-26084	68	21	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	68	22	-	-	PUNCT
ihlr-26084	68	23	spending.htm	spending.htm	X
ihlr-26084	68	24	[	[	X
ihlr-26084	68	25	https://perma.cc/nmp8-5jxv	https://perma.cc/nmp8-5jxv	X
ihlr-26084	68	26	]	]	X
ihlr-26084	68	27	.	.	PUNCT
ihlr-26084	69	1	24	24	NUM
ihlr-26084	69	2	indiana	indiana	PROPN
ihlr-26084	69	3	health	health	PROPN
ihlr-26084	69	4	law	law	PROPN
ihlr-26084	69	5	review	review	NOUN
ihlr-26084	69	6	[	[	X
ihlr-26084	69	7	vol	vol	NOUN
ihlr-26084	69	8	.	.	PUNCT
ihlr-26084	70	1	19:21	19:21	NUM
ihlr-26084	70	2	distorted	distort	VERB
ihlr-26084	70	3	incentives	incentive	NOUN
ihlr-26084	70	4	of	of	ADP
ihlr-26084	70	5	market	market	NOUN
ihlr-26084	70	6	participants	participant	NOUN
ihlr-26084	70	7	.	.	PUNCT
ihlr-26084	71	1	case	case	NOUN
ihlr-26084	71	2	law	law	NOUN
ihlr-26084	71	3	shows	show	VERB
ihlr-26084	71	4	that	that	SCONJ
ihlr-26084	71	5	many	many	ADJ
ihlr-26084	71	6	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	71	7	companies	company	NOUN
ihlr-26084	71	8	have	have	AUX
ihlr-26084	71	9	delayed	delay	VERB
ihlr-26084	71	10	generic	generic	ADJ
ihlr-26084	71	11	entry	entry	NOUN
ihlr-26084	71	12	.	.	PUNCT
ihlr-26084	72	1	the	the	DET
ihlr-26084	72	2	supreme	supreme	PROPN
ihlr-26084	72	3	court	court	PROPN
ihlr-26084	72	4	decision	decision	NOUN
ihlr-26084	72	5	on	on	ADP
ihlr-26084	72	6	the	the	DET
ihlr-26084	72	7	topic	topic	NOUN
ihlr-26084	72	8	has	have	AUX
ihlr-26084	72	9	left	leave	VERB
ihlr-26084	72	10	much	much	ADJ
ihlr-26084	72	11	to	to	ADP
ihlr-26084	72	12	interpretation	interpretation	NOUN
ihlr-26084	72	13	.	.	PUNCT
ihlr-26084	73	1	public	public	ADJ
ihlr-26084	73	2	and	and	CCONJ
ihlr-26084	73	3	private	private	ADJ
ihlr-26084	73	4	enforcers	enforcer	NOUN
ihlr-26084	73	5	have	have	AUX
ihlr-26084	73	6	faced	face	VERB
ihlr-26084	73	7	problems	problem	NOUN
ihlr-26084	73	8	proving	prove	VERB
ihlr-26084	73	9	payment	payment	NOUN
ihlr-26084	73	10	amounts	amount	NOUN
ihlr-26084	73	11	to	to	ADP
ihlr-26084	73	12	pay	pay	VERB
ihlr-26084	73	13	-	-	PUNCT
ihlr-26084	73	14	for	for	ADP
ihlr-26084	73	15	-	-	PUNCT
ihlr-26084	73	16	delay	delay	NOUN
ihlr-26084	73	17	.	.	PUNCT
ihlr-26084	74	1	a.	a.	NOUN
ihlr-26084	74	2	opaque	opaque	PROPN
ihlr-26084	74	3	drug	drug	NOUN
ihlr-26084	74	4	pricing	pricing	NOUN
ihlr-26084	74	5	:	:	PUNCT
ihlr-26084	74	6	opportunities	opportunity	NOUN
ihlr-26084	74	7	for	for	ADP
ihlr-26084	74	8	pay	pay	NOUN
ihlr-26084	74	9	-	-	PUNCT
ihlr-26084	74	10	for	for	ADP
ihlr-26084	74	11	-	-	PUNCT
ihlr-26084	74	12	delay	delay	NOUN
ihlr-26084	74	13	the	the	DET
ihlr-26084	74	14	us	us	PROPN
ihlr-26084	74	15	drug	drug	NOUN
ihlr-26084	74	16	supply	supply	NOUN
ihlr-26084	74	17	chain	chain	NOUN
ihlr-26084	74	18	has	have	AUX
ihlr-26084	74	19	been	be	AUX
ihlr-26084	74	20	described	describe	VERB
ihlr-26084	74	21	as	as	ADP
ihlr-26084	74	22	a	a	DET
ihlr-26084	74	23	“	"	PUNCT
ihlr-26084	74	24	complex,”12	complex,”12	X
ihlr-26084	74	25	“	"	PUNCT
ihlr-26084	74	26	nonintuitive,”13	nonintuitive,”13	X
ihlr-26084	74	27	and	and	CCONJ
ihlr-26084	74	28	“	"	PUNCT
ihlr-26084	74	29	gordian”14	gordian”14	NOUN
ihlr-26084	74	30	system	system	NOUN
ihlr-26084	74	31	that	that	PRON
ihlr-26084	74	32	is	be	AUX
ihlr-26084	74	33	growing	grow	VERB
ihlr-26084	74	34	“	"	PUNCT
ihlr-26084	74	35	curiouser	curiouser	NOUN
ihlr-26084	74	36	and	and	CCONJ
ihlr-26084	74	37	curiouser	curiouser	NOUN
ihlr-26084	74	38	.	.	PUNCT
ihlr-26084	75	1	”15	”15	PROPN
ihlr-26084	75	2	a	a	DET
ihlr-26084	75	3	traditional	traditional	ADJ
ihlr-26084	75	4	supply	supply	NOUN
ihlr-26084	75	5	chain	chain	NOUN
ihlr-26084	75	6	has	have	VERB
ihlr-26084	75	7	manufacturers	manufacturer	NOUN
ihlr-26084	75	8	,	,	PUNCT
ihlr-26084	75	9	wholesalers	wholesaler	NOUN
ihlr-26084	75	10	,	,	PUNCT
ihlr-26084	75	11	and	and	CCONJ
ihlr-26084	75	12	retailers	retailer	NOUN
ihlr-26084	75	13	distributing	distribute	VERB
ihlr-26084	75	14	products	product	NOUN
ihlr-26084	75	15	and	and	CCONJ
ihlr-26084	75	16	negotiating	negotiate	VERB
ihlr-26084	75	17	prices	price	NOUN
ihlr-26084	75	18	.	.	PUNCT
ihlr-26084	76	1	but	but	CCONJ
ihlr-26084	76	2	the	the	DET
ihlr-26084	76	3	us	us	PROPN
ihlr-26084	76	4	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	76	5	industry	industry	NOUN
ihlr-26084	76	6	has	have	VERB
ihlr-26084	76	7	two	two	NUM
ihlr-26084	76	8	parallel	parallel	ADJ
ihlr-26084	76	9	chains	chain	NOUN
ihlr-26084	76	10	that	that	PRON
ihlr-26084	76	11	distribute	distribute	VERB
ihlr-26084	76	12	and	and	CCONJ
ihlr-26084	76	13	negotiate	negotiate	VERB
ihlr-26084	76	14	separately	separately	ADV
ihlr-26084	76	15	.	.	PUNCT
ihlr-26084	77	1	figure	figure	NOUN
ihlr-26084	77	2	1	1	NUM
ihlr-26084	77	3	is	be	AUX
ihlr-26084	77	4	a	a	DET
ihlr-26084	77	5	simplified	simplified	ADJ
ihlr-26084	77	6	model	model	NOUN
ihlr-26084	77	7	of	of	ADP
ihlr-26084	77	8	the	the	DET
ihlr-26084	77	9	distributing	distribute	VERB
ihlr-26084	77	10	and	and	CCONJ
ihlr-26084	77	11	pricing	pricing	NOUN
ihlr-26084	77	12	chains	chain	NOUN
ihlr-26084	77	13	.	.	PUNCT
ihlr-26084	78	1	the	the	DET
ihlr-26084	78	2	distribution	distribution	NOUN
ihlr-26084	78	3	chain	chain	NOUN
ihlr-26084	78	4	runs	run	VERB
ihlr-26084	78	5	from	from	ADP
ihlr-26084	78	6	drug	drug	NOUN
ihlr-26084	78	7	manufacturers	manufacturer	NOUN
ihlr-26084	78	8	,	,	PUNCT
ihlr-26084	78	9	which	which	PRON
ihlr-26084	78	10	sell	sell	VERB
ihlr-26084	78	11	products	product	NOUN
ihlr-26084	78	12	to	to	ADP
ihlr-26084	78	13	wholesalers	wholesaler	NOUN
ihlr-26084	78	14	,	,	PUNCT
ihlr-26084	78	15	which	which	PRON
ihlr-26084	78	16	distribute	distribute	VERB
ihlr-26084	78	17	them	they	PRON
ihlr-26084	78	18	to	to	ADP
ihlr-26084	78	19	retailers	retailer	NOUN
ihlr-26084	78	20	(	(	PUNCT
ihlr-26084	78	21	pharmacies	pharmacy	NOUN
ihlr-26084	78	22	)	)	PUNCT
ihlr-26084	78	23	,	,	PUNCT
ihlr-26084	78	24	which	which	PRON
ihlr-26084	78	25	sell	sell	VERB
ihlr-26084	78	26	to	to	ADP
ihlr-26084	78	27	consumers.16	consumers.16	PROPN
ihlr-26084	78	28	each	each	DET
ihlr-26084	78	29	participant	participant	NOUN
ihlr-26084	78	30	in	in	ADP
ihlr-26084	78	31	the	the	DET
ihlr-26084	78	32	distribution	distribution	NOUN
ihlr-26084	78	33	chain	chain	NOUN
ihlr-26084	78	34	buys	buy	VERB
ihlr-26084	78	35	and	and	CCONJ
ihlr-26084	78	36	sells	sell	VERB
ihlr-26084	78	37	drugs	drug	NOUN
ihlr-26084	78	38	at	at	ADP
ihlr-26084	78	39	close	close	ADV
ihlr-26084	78	40	to	to	PART
ihlr-26084	78	41	list	list	VERB
ihlr-26084	78	42	price	price	NOUN
ihlr-26084	78	43	.	.	PUNCT
ihlr-26084	79	1	however	however	ADV
ihlr-26084	79	2	,	,	PUNCT
ihlr-26084	79	3	list	list	NOUN
ihlr-26084	79	4	price	price	NOUN
ihlr-26084	79	5	is	be	AUX
ihlr-26084	79	6	misleading	misleading	ADJ
ihlr-26084	79	7	.	.	PUNCT
ihlr-26084	80	1	a	a	DET
ihlr-26084	80	2	parallel	parallel	ADJ
ihlr-26084	80	3	pricing	pricing	NOUN
ihlr-26084	80	4	chain	chain	NOUN
ihlr-26084	80	5	negotiates	negotiate	NOUN
ihlr-26084	80	6	(	(	PUNCT
ihlr-26084	80	7	usually	usually	ADV
ihlr-26084	80	8	in	in	ADP
ihlr-26084	80	9	secret	secret	ADJ
ihlr-26084	80	10	)	)	PUNCT
ihlr-26084	80	11	rebates	rebate	NOUN
ihlr-26084	80	12	and	and	CCONJ
ihlr-26084	80	13	other	other	ADJ
ihlr-26084	80	14	discounts.17	discounts.17	PROPN
ihlr-26084	80	15	thus	thus	ADV
ihlr-26084	80	16	,	,	PUNCT
ihlr-26084	80	17	no	no	DET
ihlr-26084	80	18	public	public	ADJ
ihlr-26084	80	19	data	data	NOUN
ihlr-26084	80	20	exists	exist	VERB
ihlr-26084	80	21	on	on	ADP
ihlr-26084	80	22	how	how	SCONJ
ihlr-26084	80	23	much	much	ADJ
ihlr-26084	80	24	manufacturers	manufacturer	NOUN
ihlr-26084	80	25	receive	receive	VERB
ihlr-26084	80	26	for	for	ADP
ihlr-26084	80	27	their	their	PRON
ihlr-26084	80	28	drugs	drug	NOUN
ihlr-26084	80	29	in	in	ADP
ihlr-26084	80	30	the	the	DET
ihlr-26084	80	31	us.18	us.18	NOUN
ihlr-26084	80	32	12	12	NUM
ihlr-26084	80	33	.	.	PUNCT
ihlr-26084	81	1	the	the	DET
ihlr-26084	81	2	prescription	prescription	NOUN
ihlr-26084	81	3	drug	drug	NOUN
ihlr-26084	81	4	landscape	landscape	NOUN
ihlr-26084	81	5	,	,	PUNCT
ihlr-26084	81	6	explored	explore	VERB
ihlr-26084	81	7	,	,	PUNCT
ihlr-26084	81	8	pew	pew	NOUN
ihlr-26084	81	9	trusts	trust	NOUN
ihlr-26084	81	10	(	(	PUNCT
ihlr-26084	81	11	mar	mar	PROPN
ihlr-26084	81	12	.	.	PROPN
ihlr-26084	81	13	8	8	NUM
ihlr-26084	81	14	,	,	PUNCT
ihlr-26084	81	15	2019	2019	NUM
ihlr-26084	81	16	)	)	PUNCT
ihlr-26084	81	17	,	,	PUNCT
ihlr-26084	81	18	https://www	https://www	PROPN
ihlr-26084	81	19	.	.	PUNCT
ihlr-26084	81	20	pewtrusts.org/en/research-and-analysis/reports/2019/03/08/the-prescription-drug-landscapeexplored	pewtrusts.org/en/research-and-analysis/reports/2019/03/08/the-prescription-drug-landscapeexplore	VERB
ihlr-26084	82	1	[	[	X
ihlr-26084	82	2	https://perma.cc/xc7z-93yk	https://perma.cc/xc7z-93yk	NOUN
ihlr-26084	82	3	]	]	X
ihlr-26084	82	4	.	.	PUNCT
ihlr-26084	83	1	13	13	NUM
ihlr-26084	83	2	.	.	PUNCT
ihlr-26084	84	1	see	see	VERB
ihlr-26084	84	2	gary	gary	PROPN
ihlr-26084	84	3	novack	novack	PROPN
ihlr-26084	84	4	,	,	PUNCT
ihlr-26084	84	5	what	what	PRON
ihlr-26084	84	6	determines	determine	VERB
ihlr-26084	84	7	how	how	SCONJ
ihlr-26084	84	8	much	much	ADJ
ihlr-26084	84	9	your	your	PRON
ihlr-26084	84	10	patient	patient	NOUN
ihlr-26084	84	11	pays	pay	VERB
ihlr-26084	84	12	for	for	ADP
ihlr-26084	84	13	their	their	PRON
ihlr-26084	84	14	medication	medication	NOUN
ihlr-26084	84	15	in	in	ADP
ihlr-26084	84	16	the	the	DET
ihlr-26084	84	17	united	united	PROPN
ihlr-26084	84	18	states	states	PROPN
ihlr-26084	84	19	?	?	PUNCT
ihlr-26084	85	1	,	,	PUNCT
ihlr-26084	85	2	167	167	NUM
ihlr-26084	85	3	am	am	NOUN
ihlr-26084	85	4	.	.	PUNCT
ihlr-26084	86	1	j.	j.	PROPN
ihlr-26084	86	2	ophthalmology	ophthalmology	PROPN
ihlr-26084	86	3	48	48	NUM
ihlr-26084	86	4	(	(	PUNCT
ihlr-26084	86	5	2016	2016	NUM
ihlr-26084	86	6	)	)	PUNCT
ihlr-26084	86	7	.	.	PUNCT
ihlr-26084	87	1	14	14	NUM
ihlr-26084	87	2	.	.	PUNCT
ihlr-26084	87	3	see	see	VERB
ihlr-26084	87	4	national	national	ADJ
ihlr-26084	87	5	academies	academy	NOUN
ihlr-26084	87	6	of	of	ADP
ihlr-26084	87	7	sciences	science	NOUN
ihlr-26084	87	8	,	,	PUNCT
ihlr-26084	87	9	engineering	engineering	NOUN
ihlr-26084	87	10	,	,	PUNCT
ihlr-26084	87	11	and	and	CCONJ
ihlr-26084	87	12	medicine	medicine	NOUN
ihlr-26084	87	13	,	,	PUNCT
ihlr-26084	87	14	making	make	VERB
ihlr-26084	87	15	medicines	medicine	NOUN
ihlr-26084	87	16	affordable	affordable	ADJ
ihlr-26084	87	17	:	:	PUNCT
ihlr-26084	87	18	a	a	DET
ihlr-26084	87	19	national	national	ADJ
ihlr-26084	87	20	imperative	imperative	NOUN
ihlr-26084	87	21	(	(	PUNCT
ihlr-26084	87	22	2018	2018	NUM
ihlr-26084	87	23	)	)	PUNCT
ihlr-26084	88	1	[	[	X
ihlr-26084	88	2	hereinafter	hereinafter	NOUN
ihlr-26084	88	3	“	"	PUNCT
ihlr-26084	88	4	national	national	ADJ
ihlr-26084	88	5	academies	academy	NOUN
ihlr-26084	88	6	”	"	PUNCT
ihlr-26084	88	7	]	]	PUNCT
ihlr-26084	88	8	.	.	PUNCT
ihlr-26084	89	1	15	15	NUM
ihlr-26084	89	2	.	.	PUNCT
ihlr-26084	90	1	wayne	wayne	PROPN
ihlr-26084	90	2	winegarden	winegarden	PROPN
ihlr-26084	90	3	,	,	PUNCT
ihlr-26084	90	4	the	the	DET
ihlr-26084	90	5	economist	economist	NOUN
ihlr-26084	90	6	costs	cost	NOUN
ihlr-26084	90	7	of	of	ADP
ihlr-26084	90	8	pharmacy	pharmacy	NOUN
ihlr-26084	90	9	benefit	benefit	NOUN
ihlr-26084	90	10	managers	manager	NOUN
ihlr-26084	90	11	:	:	PUNCT
ihlr-26084	90	12	a	a	DET
ihlr-26084	90	13	review	review	NOUN
ihlr-26084	90	14	of	of	ADP
ihlr-26084	90	15	the	the	DET
ihlr-26084	90	16	literature	literature	NOUN
ihlr-26084	90	17	,	,	PUNCT
ihlr-26084	90	18	pac	pac	PROPN
ihlr-26084	90	19	.	.	PUNCT
ihlr-26084	91	1	rsch	rsch	PROPN
ihlr-26084	91	2	.	.	PUNCT
ihlr-26084	92	1	inst	inst	PROPN
ihlr-26084	92	2	.	.	PROPN
ihlr-26084	93	1	1	1	NUM
ihlr-26084	93	2	,	,	PUNCT
ihlr-26084	93	3	3	3	NUM
ihlr-26084	93	4	(	(	PUNCT
ihlr-26084	93	5	2017	2017	NUM
ihlr-26084	93	6	)	)	PUNCT
ihlr-26084	93	7	.	.	PUNCT
ihlr-26084	94	1	16	16	NUM
ihlr-26084	94	2	.	.	PUNCT
ihlr-26084	95	1	national	national	ADJ
ihlr-26084	95	2	academies	academy	NOUN
ihlr-26084	95	3	,	,	PUNCT
ihlr-26084	95	4	supra	supra	PROPN
ihlr-26084	95	5	note	note	PROPN
ihlr-26084	95	6	14	14	NUM
ihlr-26084	95	7	,	,	PUNCT
ihlr-26084	95	8	at	at	ADP
ihlr-26084	95	9	41	41	NUM
ihlr-26084	95	10	-	-	SYM
ihlr-26084	95	11	47	47	NUM
ihlr-26084	95	12	.	.	PUNCT
ihlr-26084	96	1	17	17	NUM
ihlr-26084	96	2	.	.	PUNCT
ihlr-26084	97	1	i	i	PRON
ihlr-26084	97	2	d.	d.	PROPN
ihlr-26084	97	3	18	18	NUM
ihlr-26084	97	4	.	.	PUNCT
ihlr-26084	98	1	i	i	PRON
ihlr-26084	98	2	d.	d.	PROPN
ihlr-26084	98	3	2022	2022	NUM
ihlr-26084	98	4	]	]	PUNCT
ihlr-26084	98	5	reverse	reverse	ADJ
ihlr-26084	98	6	payment	payment	NOUN
ihlr-26084	98	7	:	:	PUNCT
ihlr-26084	98	8	a	a	DET
ihlr-26084	98	9	comparative	comparative	ADJ
ihlr-26084	98	10	study	study	NOUN
ihlr-26084	98	11	25	25	NUM
ihlr-26084	98	12	insurance	insurance	NOUN
ihlr-26084	98	13	companies	company	NOUN
ihlr-26084	98	14	sit	sit	VERB
ihlr-26084	98	15	at	at	ADP
ihlr-26084	98	16	the	the	DET
ihlr-26084	98	17	bottom	bottom	NOUN
ihlr-26084	98	18	of	of	ADP
ihlr-26084	98	19	the	the	DET
ihlr-26084	98	20	pricing	pricing	NOUN
ihlr-26084	98	21	chain	chain	NOUN
ihlr-26084	98	22	.	.	PUNCT
ihlr-26084	99	1	insurance	insurance	NOUN
ihlr-26084	99	2	covered	cover	VERB
ihlr-26084	99	3	about	about	ADP
ihlr-26084	99	4	86	86	NUM
ihlr-26084	99	5	%	%	NOUN
ihlr-26084	99	6	of	of	ADP
ihlr-26084	99	7	drug	drug	NOUN
ihlr-26084	99	8	spending	spending	NOUN
ihlr-26084	99	9	in	in	ADP
ihlr-26084	99	10	the	the	DET
ihlr-26084	99	11	united	united	PROPN
ihlr-26084	99	12	states	states	PROPN
ihlr-26084	99	13	in	in	ADP
ihlr-26084	99	14	2016.19	2016.19	NUM
ihlr-26084	99	15	the	the	DET
ihlr-26084	99	16	largest	large	ADJ
ihlr-26084	99	17	payors	payor	NOUN
ihlr-26084	99	18	are	be	AUX
ihlr-26084	99	19	private	private	ADJ
ihlr-26084	99	20	insurance	insurance	NOUN
ihlr-26084	99	21	(	(	PUNCT
ihlr-26084	99	22	43	43	NUM
ihlr-26084	99	23	%	%	NOUN
ihlr-26084	99	24	)	)	PUNCT
ihlr-26084	99	25	followed	follow	VERB
ihlr-26084	99	26	by	by	ADP
ihlr-26084	99	27	medicare	medicare	PROPN
ihlr-26084	99	28	(	(	PUNCT
ihlr-26084	99	29	29	29	NUM
ihlr-26084	99	30	%	%	NOUN
ihlr-26084	99	31	)	)	PUNCT
ihlr-26084	99	32	and	and	CCONJ
ihlr-26084	99	33	medicaid	medicaid	PROPN
ihlr-26084	99	34	(	(	PUNCT
ihlr-26084	99	35	10%).20	10%).20	NUM
ihlr-26084	99	36	medicare	medicare	PROPN
ihlr-26084	99	37	is	be	AUX
ihlr-26084	99	38	a	a	DET
ihlr-26084	99	39	federal	federal	ADJ
ihlr-26084	99	40	program	program	NOUN
ihlr-26084	99	41	that	that	PRON
ihlr-26084	99	42	primarily	primarily	ADV
ihlr-26084	99	43	supports	support	VERB
ihlr-26084	99	44	the	the	DET
ihlr-26084	99	45	elderly	elderly	ADJ
ihlr-26084	99	46	and	and	CCONJ
ihlr-26084	99	47	disabled	disabled	ADJ
ihlr-26084	99	48	.	.	PUNCT
ihlr-26084	100	1	in	in	ADP
ihlr-26084	100	2	theory	theory	NOUN
ihlr-26084	100	3	,	,	PUNCT
ihlr-26084	100	4	the	the	DET
ihlr-26084	100	5	federal	federal	ADJ
ihlr-26084	100	6	government	government	NOUN
ihlr-26084	100	7	has	have	VERB
ihlr-26084	100	8	significant	significant	ADJ
ihlr-26084	100	9	buying	buying	NOUN
ihlr-26084	100	10	power	power	NOUN
ihlr-26084	100	11	to	to	PART
ihlr-26084	100	12	negotiate	negotiate	VERB
ihlr-26084	100	13	rates	rate	NOUN
ihlr-26084	100	14	and	and	CCONJ
ihlr-26084	100	15	determine	determine	VERB
ihlr-26084	100	16	which	which	DET
ihlr-26084	100	17	drugs	drug	NOUN
ihlr-26084	100	18	to	to	PART
ihlr-26084	100	19	cover	cover	VERB
ihlr-26084	100	20	.	.	PUNCT
ihlr-26084	101	1	however	however	ADV
ihlr-26084	101	2	,	,	PUNCT
ihlr-26084	101	3	federal	federal	ADJ
ihlr-26084	101	4	law	law	NOUN
ihlr-26084	101	5	prohibits	prohibit	VERB
ihlr-26084	101	6	the	the	DET
ihlr-26084	101	7	government	government	NOUN
ihlr-26084	101	8	from	from	ADP
ihlr-26084	101	9	negotiating	negotiate	VERB
ihlr-26084	101	10	rates	rate	NOUN
ihlr-26084	101	11	for	for	ADP
ihlr-26084	101	12	most	most	ADJ
ihlr-26084	101	13	medicare	medicare	PROPN
ihlr-26084	101	14	drugs.21	drugs.21	PROPN
ihlr-26084	101	15	the	the	DET
ihlr-26084	101	16	law	law	NOUN
ihlr-26084	101	17	also	also	ADV
ihlr-26084	101	18	limits	limit	VERB
ihlr-26084	101	19	the	the	DET
ihlr-26084	101	20	ability	ability	NOUN
ihlr-26084	101	21	of	of	ADP
ihlr-26084	101	22	the	the	DET
ihlr-26084	101	23	government	government	NOUN
ihlr-26084	101	24	to	to	PART
ihlr-26084	101	25	use	use	VERB
ihlr-26084	101	26	benchmarks	benchmark	NOUN
ihlr-26084	101	27	,	,	PUNCT
ihlr-26084	101	28	such	such	ADJ
ihlr-26084	101	29	as	as	ADP
ihlr-26084	101	30	costeffectiveness	costeffectiveness	NOUN
ihlr-26084	101	31	,	,	PUNCT
ihlr-26084	101	32	to	to	PART
ihlr-26084	101	33	decide	decide	VERB
ihlr-26084	101	34	which	which	DET
ihlr-26084	101	35	drugs	drug	NOUN
ihlr-26084	101	36	to	to	PART
ihlr-26084	101	37	cover.22	cover.22	VERB
ihlr-26084	101	38	so	so	ADV
ihlr-26084	101	39	,	,	PUNCT
ihlr-26084	101	40	medicare	medicare	PROPN
ihlr-26084	101	41	’s	’s	PART
ihlr-26084	101	42	prescription	prescription	NOUN
ihlr-26084	101	43	drug	drug	NOUN
ihlr-26084	101	44	program	program	NOUN
ihlr-26084	101	45	covers	cover	VERB
ihlr-26084	101	46	nearly	nearly	ADV
ihlr-26084	101	47	all	all	PRON
ihlr-26084	101	48	drugs	drug	NOUN
ihlr-26084	101	49	that	that	PRON
ihlr-26084	101	50	are	be	AUX
ihlr-26084	101	51	approved	approve	VERB
ihlr-26084	101	52	by	by	ADP
ihlr-26084	101	53	the	the	DET
ihlr-26084	101	54	fda.23	fda.23	PROPN
ihlr-26084	101	55	19	19	NUM
ihlr-26084	101	56	.	.	PUNCT
ihlr-26084	101	57	centers	center	NOUN
ihlr-26084	101	58	for	for	ADP
ihlr-26084	101	59	medicare	medicare	PROPN
ihlr-26084	101	60	and	and	CCONJ
ihlr-26084	101	61	medicaid	medicaid	PROPN
ihlr-26084	101	62	services	services	PROPN
ihlr-26084	101	63	,	,	PUNCT
ihlr-26084	101	64	national	national	ADJ
ihlr-26084	101	65	health	health	NOUN
ihlr-26084	101	66	expenditure	expenditure	NOUN
ihlr-26084	101	67	projections	projection	NOUN
ihlr-26084	101	68	2017	2017	NUM
ihlr-26084	101	69	-	-	SYM
ihlr-26084	101	70	2026	2026	NUM
ihlr-26084	101	71	,	,	PUNCT
ihlr-26084	101	72	table	table	NOUN
ihlr-26084	101	73	11	11	NUM
ihlr-26084	101	74	prescription	prescription	NOUN
ihlr-26084	101	75	drug	drug	NOUN
ihlr-26084	101	76	expenditures	expenditure	NOUN
ihlr-26084	101	77	;	;	PUNCT
ihlr-26084	101	78	aggregate	aggregate	ADJ
ihlr-26084	101	79	and	and	CCONJ
ihlr-26084	101	80	per	per	ADP
ihlr-26084	101	81	capita	capita	NOUN
ihlr-26084	101	82	amounts	amount	NOUN
ihlr-26084	101	83	,	,	PUNCT
ihlr-26084	101	84	percent	percent	NOUN
ihlr-26084	101	85	distribution	distribution	NOUN
ihlr-26084	101	86	and	and	CCONJ
ihlr-26084	101	87	annual	annual	ADJ
ihlr-26084	101	88	percent	percent	NOUN
ihlr-26084	101	89	change	change	NOUN
ihlr-26084	101	90	by	by	ADP
ihlr-26084	101	91	source	source	NOUN
ihlr-26084	101	92	of	of	ADP
ihlr-26084	101	93	funds	fund	NOUN
ihlr-26084	101	94	(	(	PUNCT
ihlr-26084	101	95	feb	feb	PROPN
ihlr-26084	101	96	.	.	PROPN
ihlr-26084	101	97	16	16	NUM
ihlr-26084	101	98	,	,	PUNCT
ihlr-26084	101	99	2018	2018	NUM
ihlr-26084	101	100	)	)	PUNCT
ihlr-26084	101	101	(	(	PUNCT
ihlr-26084	101	102	on	on	ADP
ihlr-26084	101	103	file	file	NOUN
ihlr-26084	101	104	with	with	ADP
ihlr-26084	101	105	the	the	DET
ihlr-26084	101	106	author	author	NOUN
ihlr-26084	101	107	)	)	PUNCT
ihlr-26084	101	108	.	.	PUNCT
ihlr-26084	102	1	20	20	NUM
ihlr-26084	102	2	.	.	PUNCT
ihlr-26084	103	1	i	i	PRON
ihlr-26084	103	2	d.	d.	PROPN
ihlr-26084	103	3	21	21	NUM
ihlr-26084	103	4	.	.	PUNCT
ihlr-26084	104	1	section	section	NOUN
ihlr-26084	104	2	1860d-11(i	1860d-11(i	NUM
ihlr-26084	104	3	)	)	PUNCT
ihlr-26084	104	4	of	of	ADP
ihlr-26084	104	5	the	the	DET
ihlr-26084	104	6	social	social	ADJ
ihlr-26084	104	7	security	security	NOUN
ihlr-26084	104	8	act	act	NOUN
ihlr-26084	104	9	,	,	PUNCT
ihlr-26084	104	10	42	42	NUM
ihlr-26084	104	11	u.s.c	u.s.c	ADJ
ihlr-26084	104	12	.	.	PUNCT
ihlr-26084	105	1	§	§	PROPN
ihlr-26084	105	2	1395w-111(i	1395w-111(i	NUM
ihlr-26084	105	3	)	)	PUNCT
ihlr-26084	105	4	.	.	PUNCT
ihlr-26084	106	1	22	22	NUM
ihlr-26084	106	2	.	.	PUNCT
ihlr-26084	107	1	for	for	ADP
ihlr-26084	107	2	a	a	DET
ihlr-26084	107	3	good	good	ADJ
ihlr-26084	107	4	discussion	discussion	NOUN
ihlr-26084	107	5	of	of	ADP
ihlr-26084	107	6	the	the	DET
ihlr-26084	107	7	many	many	ADJ
ihlr-26084	107	8	relevant	relevant	ADJ
ihlr-26084	107	9	statutes	statute	NOUN
ihlr-26084	107	10	,	,	PUNCT
ihlr-26084	107	11	see	see	VERB
ihlr-26084	107	12	national	national	ADJ
ihlr-26084	107	13	academies	academy	NOUN
ihlr-26084	107	14	,	,	PUNCT
ihlr-26084	107	15	supra	supra	PROPN
ihlr-26084	107	16	note	note	PROPN
ihlr-26084	107	17	14	14	NUM
ihlr-26084	107	18	,	,	PUNCT
ihlr-26084	107	19	at	at	ADP
ihlr-26084	107	20	49	49	NUM
ihlr-26084	107	21	.	.	PUNCT
ihlr-26084	108	1	23	23	NUM
ihlr-26084	108	2	.	.	PUNCT
ihlr-26084	109	1	i	i	PRON
ihlr-26084	109	2	d.	d.	PROPN
ihlr-26084	109	3	(	(	PUNCT
ihlr-26084	109	4	“	"	PUNCT
ihlr-26084	109	5	historically	historically	ADV
ihlr-26084	109	6	,	,	PUNCT
ihlr-26084	109	7	cms	cms	NOUN
ihlr-26084	109	8	and	and	CCONJ
ihlr-26084	109	9	its	its	PRON
ihlr-26084	109	10	predecessor	predecessor	NOUN
ihlr-26084	109	11	organizations	organization	NOUN
ihlr-26084	109	12	have	have	AUX
ihlr-26084	109	13	relied	rely	VERB
ihlr-26084	109	14	on	on	ADP
ihlr-26084	109	15	approval	approval	NOUN
ihlr-26084	109	16	by	by	ADP
ihlr-26084	109	17	the	the	DET
ihlr-26084	109	18	fda	fda	PROPN
ihlr-26084	109	19	for	for	ADP
ihlr-26084	109	20	those	those	DET
ihlr-26084	109	21	determinations	determination	NOUN
ihlr-26084	109	22	,	,	PUNCT
ihlr-26084	109	23	and	and	CCONJ
ihlr-26084	109	24	have	have	AUX
ihlr-26084	109	25	not	not	PART
ihlr-26084	109	26	used	use	VERB
ihlr-26084	109	27	cost	cost	NOUN
ihlr-26084	109	28	as	as	ADP
ihlr-26084	109	29	a	a	DET
ihlr-26084	109	30	component	component	NOUN
ihlr-26084	109	31	of	of	ADP
ihlr-26084	109	32	coverage	coverage	NOUN
ihlr-26084	109	33	26	26	NUM
ihlr-26084	109	34	indiana	indiana	PROPN
ihlr-26084	109	35	health	health	PROPN
ihlr-26084	109	36	law	law	PROPN
ihlr-26084	109	37	review	review	NOUN
ihlr-26084	110	1	[	[	X
ihlr-26084	110	2	vol	vol	NOUN
ihlr-26084	110	3	.	.	PUNCT
ihlr-26084	111	1	19:21	19:21	NUM
ihlr-26084	111	2	medicaid	medicaid	PROPN
ihlr-26084	111	3	is	be	AUX
ihlr-26084	111	4	a	a	DET
ihlr-26084	111	5	federally	federally	ADV
ihlr-26084	111	6	financed	finance	VERB
ihlr-26084	111	7	program	program	NOUN
ihlr-26084	111	8	run	run	VERB
ihlr-26084	111	9	by	by	ADP
ihlr-26084	111	10	states	state	NOUN
ihlr-26084	111	11	that	that	SCONJ
ihlr-26084	111	12	primarily	primarily	ADV
ihlr-26084	111	13	covers	cover	VERB
ihlr-26084	111	14	the	the	DET
ihlr-26084	111	15	poor	poor	ADJ
ihlr-26084	111	16	.	.	PUNCT
ihlr-26084	112	1	medicaid	medicaid	PROPN
ihlr-26084	112	2	has	have	VERB
ihlr-26084	112	3	rebates	rebate	NOUN
ihlr-26084	112	4	set	set	VERB
ihlr-26084	112	5	by	by	ADP
ihlr-26084	112	6	law	law	NOUN
ihlr-26084	112	7	that	that	PRON
ihlr-26084	112	8	ensure	ensure	VERB
ihlr-26084	112	9	states	state	NOUN
ihlr-26084	112	10	receive	receive	VERB
ihlr-26084	112	11	rates	rate	NOUN
ihlr-26084	112	12	at	at	ADP
ihlr-26084	112	13	lower	low	ADJ
ihlr-26084	112	14	costs	cost	NOUN
ihlr-26084	112	15	than	than	ADP
ihlr-26084	112	16	either	either	CCONJ
ihlr-26084	112	17	medicare	medicare	PROPN
ihlr-26084	112	18	or	or	CCONJ
ihlr-26084	112	19	private	private	ADJ
ihlr-26084	112	20	insurers.24	insurers.24	NOUN
ihlr-26084	112	21	these	these	DET
ihlr-26084	112	22	rates	rate	NOUN
ihlr-26084	112	23	are	be	AUX
ihlr-26084	112	24	pegged	peg	VERB
ihlr-26084	112	25	to	to	ADP
ihlr-26084	112	26	either	either	CCONJ
ihlr-26084	112	27	a	a	DET
ihlr-26084	112	28	fraction	fraction	NOUN
ihlr-26084	112	29	of	of	ADP
ihlr-26084	112	30	the	the	DET
ihlr-26084	112	31	average	average	ADJ
ihlr-26084	112	32	manufacturer	manufacturer	NOUN
ihlr-26084	112	33	price	price	NOUN
ihlr-26084	112	34	or	or	CCONJ
ihlr-26084	112	35	the	the	DET
ihlr-26084	112	36	best	good	ADJ
ihlr-26084	112	37	price	price	NOUN
ihlr-26084	112	38	that	that	PRON
ihlr-26084	112	39	a	a	DET
ihlr-26084	112	40	manufacturer	manufacturer	NOUN
ihlr-26084	112	41	charges	charge	NOUN
ihlr-26084	112	42	wholesalers.25	wholesalers.25	VERB
ihlr-26084	112	43	while	while	SCONJ
ihlr-26084	112	44	regulating	regulate	VERB
ihlr-26084	112	45	medicaid	medicaid	PROPN
ihlr-26084	112	46	prices	price	NOUN
ihlr-26084	112	47	ensures	ensure	VERB
ihlr-26084	112	48	that	that	SCONJ
ihlr-26084	112	49	states	state	NOUN
ihlr-26084	112	50	pay	pay	VERB
ihlr-26084	112	51	less	less	ADJ
ihlr-26084	112	52	,	,	PUNCT
ihlr-26084	112	53	it	it	PRON
ihlr-26084	112	54	also	also	ADV
ihlr-26084	112	55	disincentivizes	disincentivize	VERB
ihlr-26084	112	56	manufacturers	manufacturer	NOUN
ihlr-26084	112	57	to	to	PART
ihlr-26084	112	58	compete	compete	VERB
ihlr-26084	112	59	.	.	PUNCT
ihlr-26084	113	1	manufacturers	manufacturer	NOUN
ihlr-26084	113	2	that	that	PRON
ihlr-26084	113	3	compete	compete	VERB
ihlr-26084	113	4	by	by	ADP
ihlr-26084	113	5	lowering	lower	VERB
ihlr-26084	113	6	rates	rate	NOUN
ihlr-26084	113	7	for	for	ADP
ihlr-26084	113	8	other	other	ADJ
ihlr-26084	113	9	insurers	insurer	NOUN
ihlr-26084	113	10	risk	risk	VERB
ihlr-26084	113	11	reducing	reduce	VERB
ihlr-26084	113	12	the	the	DET
ihlr-26084	113	13	prices	price	NOUN
ihlr-26084	113	14	used	use	VERB
ihlr-26084	113	15	to	to	PART
ihlr-26084	113	16	calculate	calculate	VERB
ihlr-26084	113	17	medicaid	medicaid	PROPN
ihlr-26084	113	18	rates	rate	NOUN
ihlr-26084	113	19	.	.	PUNCT
ihlr-26084	114	1	most	most	ADJ
ihlr-26084	114	2	medicare	medicare	PROPN
ihlr-26084	114	3	and	and	CCONJ
ihlr-26084	114	4	medicaid	medicaid	PROPN
ihlr-26084	114	5	plans	plan	NOUN
ihlr-26084	114	6	,	,	PUNCT
ihlr-26084	114	7	while	while	SCONJ
ihlr-26084	114	8	publicly	publicly	ADV
ihlr-26084	114	9	funded	fund	VERB
ihlr-26084	114	10	,	,	PUNCT
ihlr-26084	114	11	are	be	AUX
ihlr-26084	114	12	administered	administer	VERB
ihlr-26084	114	13	by	by	ADP
ihlr-26084	114	14	private	private	ADJ
ihlr-26084	114	15	insurance	insurance	NOUN
ihlr-26084	114	16	companies	company	NOUN
ihlr-26084	114	17	.	.	PUNCT
ihlr-26084	115	1	these	these	DET
ihlr-26084	115	2	private	private	ADJ
ihlr-26084	115	3	insurers	insurer	NOUN
ihlr-26084	115	4	can	can	AUX
ihlr-26084	115	5	negotiate	negotiate	VERB
ihlr-26084	115	6	rates	rate	NOUN
ihlr-26084	115	7	directly	directly	ADV
ihlr-26084	115	8	with	with	ADP
ihlr-26084	115	9	drug	drug	NOUN
ihlr-26084	115	10	manufacturers	manufacturer	NOUN
ihlr-26084	115	11	.	.	PUNCT
ihlr-26084	116	1	however	however	ADV
ihlr-26084	116	2	,	,	PUNCT
ihlr-26084	116	3	they	they	PRON
ihlr-26084	116	4	usually	usually	ADV
ihlr-26084	116	5	opt	opt	VERB
ihlr-26084	116	6	not	not	PART
ihlr-26084	116	7	to	to	PART
ihlr-26084	116	8	because	because	SCONJ
ihlr-26084	116	9	of	of	ADP
ihlr-26084	116	10	their	their	PRON
ihlr-26084	116	11	weak	weak	ADJ
ihlr-26084	116	12	bargaining	bargaining	NOUN
ihlr-26084	116	13	power	power	NOUN
ihlr-26084	116	14	.	.	PUNCT
ihlr-26084	117	1	the	the	DET
ihlr-26084	117	2	insurance	insurance	NOUN
ihlr-26084	117	3	market	market	NOUN
ihlr-26084	117	4	is	be	AUX
ihlr-26084	117	5	decentralized	decentralize	VERB
ihlr-26084	117	6	.	.	PUNCT
ihlr-26084	118	1	in	in	ADP
ihlr-26084	118	2	2016	2016	NUM
ihlr-26084	118	3	,	,	PUNCT
ihlr-26084	118	4	the	the	DET
ihlr-26084	118	5	share	share	NOUN
ihlr-26084	118	6	of	of	ADP
ihlr-26084	118	7	the	the	DET
ihlr-26084	118	8	largest	large	ADJ
ihlr-26084	118	9	five	five	NUM
ihlr-26084	118	10	insurance	insurance	NOUN
ihlr-26084	118	11	companies	company	NOUN
ihlr-26084	118	12	was	be	AUX
ihlr-26084	118	13	39.4	39.4	NUM
ihlr-26084	118	14	%	%	NOUN
ihlr-26084	118	15	based	base	VERB
ihlr-26084	118	16	on	on	ADP
ihlr-26084	118	17	market	market	NOUN
ihlr-26084	118	18	capitalization	capitalization	NOUN
ihlr-26084	118	19	;	;	PUNCT
ihlr-26084	118	20	the	the	DET
ihlr-26084	118	21	share	share	NOUN
ihlr-26084	118	22	of	of	ADP
ihlr-26084	118	23	the	the	DET
ihlr-26084	118	24	next	next	ADJ
ihlr-26084	118	25	twenty	twenty	NUM
ihlr-26084	118	26	was	be	AUX
ihlr-26084	118	27	only	only	ADV
ihlr-26084	118	28	33%.26	33%.26	NUM
ihlr-26084	118	29	the	the	DET
ihlr-26084	118	30	rest	rest	NOUN
ihlr-26084	118	31	of	of	ADP
ihlr-26084	118	32	the	the	DET
ihlr-26084	118	33	market	market	NOUN
ihlr-26084	118	34	is	be	AUX
ihlr-26084	118	35	covered	cover	VERB
ihlr-26084	118	36	by	by	ADP
ihlr-26084	118	37	around	around	ADV
ihlr-26084	118	38	700	700	NUM
ihlr-26084	118	39	additional	additional	ADJ
ihlr-26084	118	40	insurance	insurance	NOUN
ihlr-26084	118	41	companies.27	companies.27	NOUN
ihlr-26084	118	42	to	to	PART
ihlr-26084	118	43	make	make	VERB
ihlr-26084	118	44	up	up	ADP
ihlr-26084	118	45	for	for	ADP
ihlr-26084	118	46	their	their	PRON
ihlr-26084	118	47	limited	limit	VERB
ihlr-26084	118	48	buying	buying	NOUN
ihlr-26084	118	49	power	power	NOUN
ihlr-26084	118	50	,	,	PUNCT
ihlr-26084	118	51	insurers	insurer	NOUN
ihlr-26084	118	52	enlist	enlist	VERB
ihlr-26084	118	53	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	118	54	benefits	benefit	NOUN
ihlr-26084	118	55	managers	manager	NOUN
ihlr-26084	118	56	(	(	PUNCT
ihlr-26084	118	57	“	"	PUNCT
ihlr-26084	118	58	pbms”).28	pbms”).28	X
ihlr-26084	118	59	pbms	pbm	NOUN
ihlr-26084	118	60	are	be	AUX
ihlr-26084	118	61	third	third	ADJ
ihlr-26084	118	62	-	-	PUNCT
ihlr-26084	118	63	party	party	NOUN
ihlr-26084	118	64	administrators	administrator	NOUN
ihlr-26084	118	65	of	of	ADP
ihlr-26084	118	66	prescription	prescription	NOUN
ihlr-26084	118	67	drug	drug	NOUN
ihlr-26084	118	68	plans	plan	NOUN
ihlr-26084	118	69	and	and	CCONJ
ihlr-26084	118	70	formularies	formulary	NOUN
ihlr-26084	118	71	.	.	PUNCT
ihlr-26084	119	1	they	they	PRON
ihlr-26084	119	2	use	use	VERB
ihlr-26084	119	3	their	their	PRON
ihlr-26084	119	4	market	market	NOUN
ihlr-26084	119	5	power	power	NOUN
ihlr-26084	119	6	to	to	PART
ihlr-26084	119	7	negotiate	negotiate	VERB
ihlr-26084	119	8	drug	drug	NOUN
ihlr-26084	119	9	rates	rate	NOUN
ihlr-26084	119	10	with	with	ADP
ihlr-26084	119	11	pharmacies	pharmacy	NOUN
ihlr-26084	119	12	and	and	CCONJ
ihlr-26084	119	13	rebates	rebate	NOUN
ihlr-26084	119	14	with	with	ADP
ihlr-26084	119	15	manufacturers	manufacturer	NOUN
ihlr-26084	119	16	on	on	ADP
ihlr-26084	119	17	behalf	behalf	NOUN
ihlr-26084	119	18	of	of	ADP
ihlr-26084	119	19	insurers	insurer	NOUN
ihlr-26084	119	20	.	.	PUNCT
ihlr-26084	120	1	to	to	PART
ihlr-26084	120	2	do	do	VERB
ihlr-26084	120	3	so	so	ADV
ihlr-26084	120	4	,	,	PUNCT
ihlr-26084	120	5	they	they	PRON
ihlr-26084	120	6	often	often	ADV
ihlr-26084	120	7	manage	manage	VERB
ihlr-26084	120	8	tiered	tiered	ADJ
ihlr-26084	120	9	formularies	formulary	NOUN
ihlr-26084	120	10	for	for	ADP
ihlr-26084	120	11	insurance	insurance	NOUN
ihlr-26084	120	12	plans	plan	NOUN
ihlr-26084	120	13	.	.	PUNCT
ihlr-26084	121	1	in	in	ADP
ihlr-26084	121	2	a	a	DET
ihlr-26084	121	3	tiered	tiere	VERB
ihlr-26084	121	4	formulary	formulary	NOUN
ihlr-26084	121	5	,	,	PUNCT
ihlr-26084	121	6	drugs	drug	NOUN
ihlr-26084	121	7	that	that	PRON
ihlr-26084	121	8	are	be	AUX
ihlr-26084	121	9	assigned	assign	VERB
ihlr-26084	121	10	to	to	ADP
ihlr-26084	121	11	higher	high	ADJ
ihlr-26084	121	12	tiers	tier	NOUN
ihlr-26084	121	13	have	have	VERB
ihlr-26084	121	14	higher	high	ADJ
ihlr-26084	121	15	copayments	copayment	NOUN
ihlr-26084	121	16	for	for	ADP
ihlr-26084	121	17	patients	patient	NOUN
ihlr-26084	121	18	.	.	PUNCT
ihlr-26084	122	1	pbms	pbms	ADJ
ihlr-26084	122	2	use	use	VERB
ihlr-26084	122	3	tier	tier	NOUN
ihlr-26084	122	4	placement	placement	NOUN
ihlr-26084	122	5	as	as	ADP
ihlr-26084	122	6	a	a	DET
ihlr-26084	122	7	bargaining	bargaining	NOUN
ihlr-26084	122	8	chip	chip	NOUN
ihlr-26084	122	9	to	to	PART
ihlr-26084	122	10	reduce	reduce	VERB
ihlr-26084	122	11	rates	rate	NOUN
ihlr-26084	122	12	and	and	CCONJ
ihlr-26084	122	13	increase	increase	VERB
ihlr-26084	122	14	rates	rate	NOUN
ihlr-26084	122	15	.	.	PUNCT
ihlr-26084	123	1	these	these	DET
ihlr-26084	123	2	negotiations	negotiation	NOUN
ihlr-26084	123	3	typically	typically	ADV
ihlr-26084	123	4	occur	occur	VERB
ihlr-26084	123	5	in	in	ADP
ihlr-26084	123	6	secret	secret	ADJ
ihlr-26084	123	7	.	.	PUNCT
ihlr-26084	124	1	pbms	pbms	PROPN
ihlr-26084	124	2	could	could	AUX
ihlr-26084	124	3	use	use	VERB
ihlr-26084	124	4	their	their	PRON
ihlr-26084	124	5	bargaining	bargaining	NOUN
ihlr-26084	124	6	power	power	NOUN
ihlr-26084	124	7	to	to	PART
ihlr-26084	124	8	reduce	reduce	VERB
ihlr-26084	124	9	drug	drug	NOUN
ihlr-26084	124	10	costs	cost	NOUN
ihlr-26084	124	11	for	for	ADP
ihlr-26084	124	12	consumers	consumer	NOUN
ihlr-26084	124	13	;	;	PUNCT
ihlr-26084	124	14	they	they	PRON
ihlr-26084	124	15	have	have	VERB
ihlr-26084	124	16	however	however	ADV
ihlr-26084	124	17	mixed	mixed	ADJ
ihlr-26084	124	18	incentives	incentive	NOUN
ihlr-26084	124	19	.	.	PUNCT
ihlr-26084	125	1	unlike	unlike	ADP
ihlr-26084	125	2	insurance	insurance	NOUN
ihlr-26084	125	3	,	,	PUNCT
ihlr-26084	125	4	the	the	DET
ihlr-26084	125	5	pbm	pbm	NOUN
ihlr-26084	125	6	market	market	NOUN
ihlr-26084	125	7	is	be	AUX
ihlr-26084	125	8	highly	highly	ADV
ihlr-26084	125	9	concentrated	concentrated	ADJ
ihlr-26084	125	10	.	.	PUNCT
ihlr-26084	126	1	the	the	DET
ihlr-26084	126	2	three	three	NUM
ihlr-26084	126	3	largest	large	ADJ
ihlr-26084	126	4	pbms	pbms	ADJ
ihlr-26084	126	5	negotiate	negotiate	NOUN
ihlr-26084	126	6	rates	rate	NOUN
ihlr-26084	126	7	and	and	CCONJ
ihlr-26084	126	8	rebates	rebate	NOUN
ihlr-26084	126	9	for	for	ADP
ihlr-26084	126	10	nearly	nearly	ADV
ihlr-26084	126	11	75	75	NUM
ihlr-26084	126	12	%	%	NOUN
ihlr-26084	126	13	of	of	ADP
ihlr-26084	126	14	the	the	DET
ihlr-26084	126	15	drug	drug	NOUN
ihlr-26084	126	16	purchasing	purchasing	NOUN
ihlr-26084	126	17	market.29	market.29	NOUN
ihlr-26084	126	18	pbms	pbm	NOUN
ihlr-26084	126	19	not	not	PART
ihlr-26084	126	20	only	only	ADV
ihlr-26084	126	21	have	have	VERB
ihlr-26084	126	22	market	market	NOUN
ihlr-26084	126	23	power	power	NOUN
ihlr-26084	126	24	against	against	ADP
ihlr-26084	126	25	manufacturers	manufacturer	NOUN
ihlr-26084	126	26	,	,	PUNCT
ihlr-26084	126	27	but	but	CCONJ
ihlr-26084	126	28	also	also	ADV
ihlr-26084	126	29	against	against	ADP
ihlr-26084	126	30	insurers	insurer	NOUN
ihlr-26084	126	31	.	.	PUNCT
ihlr-26084	127	1	these	these	DET
ihlr-26084	127	2	insurers	insurer	NOUN
ihlr-26084	127	3	are	be	AUX
ihlr-26084	127	4	not	not	PART
ihlr-26084	127	5	privy	privy	ADJ
ihlr-26084	127	6	to	to	ADP
ihlr-26084	127	7	the	the	DET
ihlr-26084	127	8	confidential	confidential	ADJ
ihlr-26084	127	9	rates	rate	NOUN
ihlr-26084	127	10	and	and	CCONJ
ihlr-26084	127	11	rebates	rebate	NOUN
ihlr-26084	127	12	that	that	SCONJ
ihlr-26084	127	13	pbms	pbms	ADJ
ihlr-26084	127	14	negotiate.30	negotiate.30	PROPN
ihlr-26084	127	15	so	so	ADV
ihlr-26084	127	16	,	,	PUNCT
ihlr-26084	127	17	a	a	DET
ihlr-26084	127	18	pbm	pbm	NOUN
ihlr-26084	127	19	could	could	AUX
ihlr-26084	127	20	encourage	encourage	VERB
ihlr-26084	127	21	manufacturers	manufacturer	NOUN
ihlr-26084	127	22	to	to	PART
ihlr-26084	127	23	increase	increase	VERB
ihlr-26084	127	24	public	public	ADJ
ihlr-26084	127	25	list	list	NOUN
ihlr-26084	127	26	prices	price	NOUN
ihlr-26084	127	27	while	while	SCONJ
ihlr-26084	127	28	decreasing	decrease	VERB
ihlr-26084	127	29	private	private	ADJ
ihlr-26084	127	30	rebates	rebate	NOUN
ihlr-26084	127	31	and	and	CCONJ
ihlr-26084	127	32	pocket	pocket	VERB
ihlr-26084	127	33	the	the	DET
ihlr-26084	127	34	difference.31	difference.31	NOUN
ihlr-26084	127	35	then	then	ADV
ihlr-26084	127	36	,	,	PUNCT
ihlr-26084	127	37	manufacturers	manufacturer	NOUN
ihlr-26084	127	38	can	can	AUX
ihlr-26084	127	39	use	use	VERB
ihlr-26084	127	40	these	these	DET
ihlr-26084	127	41	higher	high	ADJ
ihlr-26084	127	42	list	list	NOUN
ihlr-26084	127	43	prices	price	NOUN
ihlr-26084	127	44	as	as	ADP
ihlr-26084	127	45	the	the	DET
ihlr-26084	127	46	baseline	baseline	NOUN
ihlr-26084	127	47	for	for	ADP
ihlr-26084	127	48	determining	determine	VERB
ihlr-26084	127	49	rebates	rebate	NOUN
ihlr-26084	127	50	for	for	ADP
ihlr-26084	127	51	medicaid	medicaid	PROPN
ihlr-26084	127	52	plans	plan	NOUN
ihlr-26084	127	53	and	and	CCONJ
ihlr-26084	127	54	leverage	leverage	NOUN
ihlr-26084	127	55	determinations	determination	NOUN
ihlr-26084	127	56	.	.	PUNCT
ihlr-26084	127	57	”	"	PUNCT
ihlr-26084	127	58	)	)	PUNCT
ihlr-26084	127	59	.	.	PUNCT
ihlr-26084	128	1	24	24	NUM
ihlr-26084	128	2	.	.	PUNCT
ihlr-26084	129	1	for	for	ADP
ihlr-26084	129	2	a	a	DET
ihlr-26084	129	3	good	good	ADJ
ihlr-26084	129	4	discussion	discussion	NOUN
ihlr-26084	129	5	of	of	ADP
ihlr-26084	129	6	the	the	DET
ihlr-26084	129	7	many	many	ADJ
ihlr-26084	129	8	relevant	relevant	ADJ
ihlr-26084	129	9	statutes	statute	NOUN
ihlr-26084	129	10	,	,	PUNCT
ihlr-26084	129	11	see	see	VERB
ihlr-26084	129	12	i	i	PRON
ihlr-26084	129	13	d.	d.	PROPN
ihlr-26084	129	14	at	at	ADP
ihlr-26084	129	15	107	107	NUM
ihlr-26084	129	16	-	-	SYM
ihlr-26084	129	17	08	08	NUM
ihlr-26084	129	18	.	.	PUNCT
ihlr-26084	130	1	25	25	NUM
ihlr-26084	130	2	.	.	PUNCT
ihlr-26084	131	1	i	i	PRON
ihlr-26084	131	2	d.	d.	PROPN
ihlr-26084	131	3	26	26	NUM
ihlr-26084	131	4	.	.	PUNCT
ihlr-26084	132	1	see	see	VERB
ihlr-26084	132	2	mitchell	mitchell	PROPN
ihlr-26084	133	1	k.	k.	PROPN
ihlr-26084	133	2	ng	ng	PROPN
ihlr-26084	133	3	et	et	PROPN
ihlr-26084	133	4	al	al	PROPN
ihlr-26084	133	5	.	.	PROPN
ihlr-26084	133	6	,	,	PUNCT
ihlr-26084	133	7	u.s	u.s	PROPN
ihlr-26084	133	8	.	.	PROPN
ihlr-26084	133	9	healthcare	healthcare	PROPN
ihlr-26084	133	10	insurance	insurance	NOUN
ihlr-26084	133	11	market	market	NOUN
ihlr-26084	133	12	concentration	concentration	NOUN
ihlr-26084	133	13	from	from	ADP
ihlr-26084	133	14	2001	2001	NUM
ihlr-26084	133	15	to	to	ADP
ihlr-26084	133	16	2016	2016	NUM
ihlr-26084	133	17	:	:	PUNCT
ihlr-26084	133	18	increased	increase	VERB
ihlr-26084	133	19	growth	growth	NOUN
ihlr-26084	133	20	in	in	ADP
ihlr-26084	133	21	direct	direct	ADJ
ihlr-26084	133	22	written	write	VERB
ihlr-26084	133	23	premiums	premium	NOUN
ihlr-26084	133	24	and	and	CCONJ
ihlr-26084	133	25	overall	overall	ADJ
ihlr-26084	133	26	decreased	decrease	VERB
ihlr-26084	133	27	market	market	NOUN
ihlr-26084	133	28	consolidation	consolidation	NOUN
ihlr-26084	133	29	,	,	PUNCT
ihlr-26084	133	30	12	12	NUM
ihlr-26084	133	31	cureus	cureus	NOUN
ihlr-26084	133	32	1	1	NUM
ihlr-26084	133	33	(	(	PUNCT
ihlr-26084	133	34	2020	2020	NUM
ihlr-26084	133	35	)	)	PUNCT
ihlr-26084	133	36	.	.	PUNCT
ihlr-26084	134	1	27	27	NUM
ihlr-26084	134	2	.	.	PUNCT
ihlr-26084	135	1	i	i	PRON
ihlr-26084	135	2	d.	d.	PROPN
ihlr-26084	135	3	28	28	NUM
ihlr-26084	135	4	.	.	PUNCT
ihlr-26084	136	1	see	see	VERB
ihlr-26084	136	2	generally	generally	ADV
ihlr-26084	136	3	,	,	PUNCT
ihlr-26084	136	4	national	national	ADJ
ihlr-26084	136	5	academies	academy	NOUN
ihlr-26084	136	6	,	,	PUNCT
ihlr-26084	136	7	supra	supra	PROPN
ihlr-26084	136	8	note	note	NOUN
ihlr-26084	136	9	14	14	NUM
ihlr-26084	136	10	,	,	PUNCT
ihlr-26084	136	11	at	at	ADP
ihlr-26084	136	12	47	47	NUM
ihlr-26084	136	13	-	-	SYM
ihlr-26084	136	14	53	53	NUM
ihlr-26084	136	15	.	.	NOUN
ihlr-26084	136	16	29	29	NUM
ihlr-26084	136	17	.	.	PUNCT
ihlr-26084	137	1	pharmacy	pharmacy	NOUN
ihlr-26084	137	2	benefit	benefit	NOUN
ihlr-26084	137	3	managers	manager	NOUN
ihlr-26084	137	4	:	:	PUNCT
ihlr-26084	137	5	as	as	SCONJ
ihlr-26084	137	6	drug	drug	NOUN
ihlr-26084	137	7	prices	price	NOUN
ihlr-26084	137	8	soar	soar	VERB
ihlr-26084	137	9	,	,	PUNCT
ihlr-26084	137	10	policymakers	policymaker	NOUN
ihlr-26084	137	11	take	take	VERB
ihlr-26084	137	12	aim	aim	NOUN
ihlr-26084	137	13	,	,	PUNCT
ihlr-26084	137	14	colo	colo	PROPN
ihlr-26084	137	15	.	.	PUNCT
ihlr-26084	138	1	health	health	PROPN
ihlr-26084	138	2	inst	inst	PROPN
ihlr-26084	138	3	.	.	PROPN
ihlr-26084	139	1	1	1	NUM
ihlr-26084	139	2	,	,	PUNCT
ihlr-26084	139	3	5	5	NUM
ihlr-26084	139	4	(	(	PUNCT
ihlr-26084	139	5	2018	2018	NUM
ihlr-26084	139	6	)	)	PUNCT
ihlr-26084	139	7	.	.	PUNCT
ihlr-26084	140	1	30	30	NUM
ihlr-26084	140	2	.	.	PUNCT
ihlr-26084	141	1	i	i	PRON
ihlr-26084	141	2	d.	d.	PROPN
ihlr-26084	141	3	31	31	NUM
ihlr-26084	141	4	.	.	PUNCT
ihlr-26084	142	1	i	i	PRON
ihlr-26084	142	2	d.	d.	PROPN
ihlr-26084	142	3	because	because	SCONJ
ihlr-26084	142	4	rebates	rebate	NOUN
ihlr-26084	142	5	are	be	AUX
ihlr-26084	142	6	generally	generally	ADV
ihlr-26084	142	7	negotiated	negotiate	VERB
ihlr-26084	142	8	in	in	ADP
ihlr-26084	142	9	secret	secret	ADJ
ihlr-26084	142	10	,	,	PUNCT
ihlr-26084	142	11	while	while	SCONJ
ihlr-26084	142	12	list	list	NOUN
ihlr-26084	142	13	prices	price	NOUN
ihlr-26084	142	14	are	be	AUX
ihlr-26084	142	15	often	often	ADV
ihlr-26084	142	16	public	public	ADJ
ihlr-26084	142	17	,	,	PUNCT
ihlr-26084	142	18	pbms	pbm	NOUN
ihlr-26084	142	19	can	can	AUX
ihlr-26084	142	20	theoretically	theoretically	ADV
ihlr-26084	142	21	pocket	pocket	VERB
ihlr-26084	142	22	the	the	DET
ihlr-26084	142	23	rebate	rebate	NOUN
ihlr-26084	142	24	savings	saving	NOUN
ihlr-26084	142	25	and	and	CCONJ
ihlr-26084	142	26	charge	charge	NOUN
ihlr-26084	142	27	insurers	insurer	NOUN
ihlr-26084	142	28	prices	price	NOUN
ihlr-26084	142	29	close	close	ADJ
ihlr-26084	142	30	to	to	ADP
ihlr-26084	142	31	the	the	DET
ihlr-26084	142	32	list	list	NOUN
ihlr-26084	142	33	price	price	NOUN
ihlr-26084	142	34	.	.	PUNCT
ihlr-26084	143	1	2022	2022	NUM
ihlr-26084	143	2	]	]	PUNCT
ihlr-26084	143	3	reverse	reverse	ADJ
ihlr-26084	143	4	payment	payment	NOUN
ihlr-26084	143	5	:	:	PUNCT
ihlr-26084	143	6	a	a	DET
ihlr-26084	143	7	comparative	comparative	ADJ
ihlr-26084	143	8	study	study	NOUN
ihlr-26084	143	9	27	27	NUM
ihlr-26084	143	10	these	these	DET
ihlr-26084	143	11	prices	price	NOUN
ihlr-26084	143	12	to	to	PART
ihlr-26084	143	13	negotiate	negotiate	VERB
ihlr-26084	143	14	rates	rate	NOUN
ihlr-26084	143	15	for	for	ADP
ihlr-26084	143	16	other	other	ADJ
ihlr-26084	143	17	insurers	insurer	NOUN
ihlr-26084	143	18	and	and	CCONJ
ihlr-26084	143	19	out	out	ADP
ihlr-26084	143	20	-	-	PUNCT
ihlr-26084	143	21	of	of	ADP
ihlr-26084	143	22	-	-	PUNCT
ihlr-26084	143	23	pocket	pocket	NOUN
ihlr-26084	143	24	payors	payor	NOUN
ihlr-26084	143	25	that	that	PRON
ihlr-26084	143	26	lack	lack	VERB
ihlr-26084	143	27	buying	buy	VERB
ihlr-26084	143	28	power	power	NOUN
ihlr-26084	143	29	.	.	PUNCT
ihlr-26084	144	1	in	in	ADP
ihlr-26084	144	2	conclusion	conclusion	NOUN
ihlr-26084	144	3	,	,	PUNCT
ihlr-26084	144	4	no	no	DET
ihlr-26084	144	5	major	major	ADJ
ihlr-26084	144	6	payor	payor	NOUN
ihlr-26084	144	7	of	of	ADP
ihlr-26084	144	8	pharmaceuticals	pharmaceutical	NOUN
ihlr-26084	144	9	in	in	ADP
ihlr-26084	144	10	the	the	DET
ihlr-26084	144	11	us	us	PROPN
ihlr-26084	144	12	has	have	VERB
ihlr-26084	144	13	both	both	CCONJ
ihlr-26084	144	14	significant	significant	ADJ
ihlr-26084	144	15	buying	buying	NOUN
ihlr-26084	144	16	power	power	NOUN
ihlr-26084	144	17	and	and	CCONJ
ihlr-26084	144	18	the	the	DET
ihlr-26084	144	19	incentive	incentive	NOUN
ihlr-26084	144	20	to	to	PART
ihlr-26084	144	21	lower	lower	VERB
ihlr-26084	144	22	effective	effective	ADJ
ihlr-26084	144	23	prices	price	NOUN
ihlr-26084	144	24	.	.	PUNCT
ihlr-26084	145	1	this	this	DET
ihlr-26084	145	2	distorted	distort	VERB
ihlr-26084	145	3	pricing	pricing	NOUN
ihlr-26084	145	4	model	model	NOUN
ihlr-26084	145	5	contributes	contribute	VERB
ihlr-26084	145	6	to	to	ADP
ihlr-26084	145	7	significantly	significantly	ADV
ihlr-26084	145	8	higher	high	ADJ
ihlr-26084	145	9	prices	price	NOUN
ihlr-26084	145	10	for	for	ADP
ihlr-26084	145	11	brand	brand	NOUN
ihlr-26084	145	12	-	-	PUNCT
ihlr-26084	145	13	name	name	NOUN
ihlr-26084	145	14	drugs	drug	NOUN
ihlr-26084	145	15	compared	compare	VERB
ihlr-26084	145	16	to	to	ADP
ihlr-26084	145	17	other	other	ADJ
ihlr-26084	145	18	countries	country	NOUN
ihlr-26084	145	19	.	.	PUNCT
ihlr-26084	146	1	for	for	ADP
ihlr-26084	146	2	example	example	NOUN
ihlr-26084	146	3	,	,	PUNCT
ihlr-26084	146	4	a	a	DET
ihlr-26084	146	5	2021	2021	NUM
ihlr-26084	146	6	study	study	NOUN
ihlr-26084	146	7	by	by	ADP
ihlr-26084	146	8	the	the	DET
ihlr-26084	146	9	government	government	NOUN
ihlr-26084	146	10	accountability	accountability	NOUN
ihlr-26084	146	11	office	office	NOUN
ihlr-26084	146	12	determined	determine	VERB
ihlr-26084	146	13	that	that	SCONJ
ihlr-26084	146	14	gross	gross	ADJ
ihlr-26084	146	15	retail	retail	ADJ
ihlr-26084	146	16	drug	drug	NOUN
ihlr-26084	146	17	prices	price	NOUN
ihlr-26084	146	18	are	be	AUX
ihlr-26084	146	19	4.36	4.36	NUM
ihlr-26084	146	20	times	time	NOUN
ihlr-26084	146	21	higher	high	ADJ
ihlr-26084	146	22	in	in	ADP
ihlr-26084	146	23	the	the	DET
ihlr-26084	146	24	us	us	PROPN
ihlr-26084	146	25	compared	compare	VERB
ihlr-26084	146	26	to	to	ADP
ihlr-26084	146	27	france.32	france.32	VERB
ihlr-26084	146	28	another	another	DET
ihlr-26084	146	29	study	study	NOUN
ihlr-26084	146	30	estimates	estimate	VERB
ihlr-26084	146	31	that	that	SCONJ
ihlr-26084	146	32	retail	retail	ADJ
ihlr-26084	146	33	drug	drug	NOUN
ihlr-26084	146	34	prices	price	NOUN
ihlr-26084	146	35	are	be	AUX
ihlr-26084	146	36	2.56	2.56	NUM
ihlr-26084	146	37	times	time	NOUN
ihlr-26084	146	38	higher	high	ADJ
ihlr-26084	146	39	in	in	ADP
ihlr-26084	146	40	the	the	DET
ihlr-26084	146	41	us	us	PROPN
ihlr-26084	146	42	compared	compare	VERB
ihlr-26084	146	43	to	to	ADP
ihlr-26084	146	44	all	all	DET
ihlr-26084	146	45	oecd	oecd	PROPN
ihlr-26084	146	46	countries.33	countries.33	PROPN
ihlr-26084	146	47	b.	b.	PROPN
ihlr-26084	146	48	pay	pay	PROPN
ihlr-26084	146	49	-	-	PUNCT
ihlr-26084	146	50	for	for	ADP
ihlr-26084	146	51	-	-	PUNCT
ihlr-26084	146	52	delay	delay	NOUN
ihlr-26084	146	53	tests	test	VERB
ihlr-26084	146	54	the	the	DET
ihlr-26084	146	55	gap	gap	NOUN
ihlr-26084	146	56	between	between	ADP
ihlr-26084	146	57	brand	brand	NOUN
ihlr-26084	146	58	-	-	PUNCT
ihlr-26084	146	59	name	name	NOUN
ihlr-26084	146	60	and	and	CCONJ
ihlr-26084	146	61	generic	generic	ADJ
ihlr-26084	146	62	prices	price	NOUN
ihlr-26084	146	63	is	be	AUX
ihlr-26084	146	64	also	also	ADV
ihlr-26084	146	65	much	much	ADV
ihlr-26084	146	66	higher	high	ADJ
ihlr-26084	146	67	in	in	ADP
ihlr-26084	146	68	the	the	DET
ihlr-26084	146	69	us	us	PROPN
ihlr-26084	146	70	than	than	ADP
ihlr-26084	146	71	in	in	ADP
ihlr-26084	146	72	other	other	ADJ
ihlr-26084	146	73	countries	country	NOUN
ihlr-26084	146	74	.	.	PUNCT
ihlr-26084	147	1	one	one	NUM
ihlr-26084	147	2	study	study	NOUN
ihlr-26084	147	3	estimates	estimate	VERB
ihlr-26084	147	4	that	that	SCONJ
ihlr-26084	147	5	the	the	DET
ihlr-26084	147	6	average	average	ADJ
ihlr-26084	147	7	annual	annual	ADJ
ihlr-26084	147	8	retail	retail	ADJ
ihlr-26084	147	9	price	price	NOUN
ihlr-26084	147	10	of	of	ADP
ihlr-26084	147	11	therapy	therapy	NOUN
ihlr-26084	147	12	for	for	ADP
ihlr-26084	147	13	brand	brand	NOUN
ihlr-26084	147	14	-	-	PUNCT
ihlr-26084	147	15	name	name	NOUN
ihlr-26084	147	16	drugs	drug	NOUN
ihlr-26084	147	17	is	be	AUX
ihlr-26084	147	18	eighteen	eighteen	NUM
ihlr-26084	147	19	times	time	NOUN
ihlr-26084	147	20	higher	high	ADJ
ihlr-26084	147	21	than	than	ADP
ihlr-26084	147	22	that	that	PRON
ihlr-26084	147	23	of	of	ADP
ihlr-26084	147	24	generics.34	generics.34	NOUN
ihlr-26084	147	25	another	another	DET
ihlr-26084	147	26	study	study	NOUN
ihlr-26084	147	27	concludes	conclude	VERB
ihlr-26084	147	28	that	that	SCONJ
ihlr-26084	147	29	brand	brand	NOUN
ihlr-26084	147	30	-	-	PUNCT
ihlr-26084	147	31	name	name	NOUN
ihlr-26084	147	32	drugs	drug	NOUN
ihlr-26084	147	33	are	be	AUX
ihlr-26084	147	34	more	more	ADV
ihlr-26084	147	35	expensive	expensive	ADJ
ihlr-26084	147	36	,	,	PUNCT
ihlr-26084	147	37	while	while	SCONJ
ihlr-26084	147	38	generics	generic	NOUN
ihlr-26084	147	39	are	be	AUX
ihlr-26084	147	40	less	less	ADV
ihlr-26084	147	41	expensive	expensive	ADJ
ihlr-26084	147	42	,	,	PUNCT
ihlr-26084	147	43	in	in	ADP
ihlr-26084	147	44	the	the	DET
ihlr-26084	147	45	us	us	PROPN
ihlr-26084	147	46	than	than	ADP
ihlr-26084	147	47	in	in	ADP
ihlr-26084	147	48	other	other	ADJ
ihlr-26084	147	49	oecd	oecd	PROPN
ihlr-26084	147	50	countries.35	countries.35	NOUN
ihlr-26084	147	51	generic	generic	ADJ
ihlr-26084	147	52	drugs	drug	NOUN
ihlr-26084	147	53	save	save	VERB
ihlr-26084	147	54	patients	patient	NOUN
ihlr-26084	147	55	money	money	NOUN
ihlr-26084	147	56	while	while	SCONJ
ihlr-26084	147	57	giving	give	VERB
ihlr-26084	147	58	them	they	PRON
ihlr-26084	147	59	a	a	DET
ihlr-26084	147	60	nearly	nearly	ADV
ihlr-26084	147	61	identical	identical	ADJ
ihlr-26084	147	62	drug	drug	NOUN
ihlr-26084	147	63	to	to	ADP
ihlr-26084	147	64	the	the	DET
ihlr-26084	147	65	brand	brand	NOUN
ihlr-26084	147	66	-	-	PUNCT
ihlr-26084	147	67	name	name	NOUN
ihlr-26084	147	68	medication	medication	NOUN
ihlr-26084	147	69	.	.	PUNCT
ihlr-26084	148	1	nearly	nearly	ADV
ihlr-26084	148	2	every	every	DET
ihlr-26084	148	3	state	state	NOUN
ihlr-26084	148	4	in	in	ADP
ihlr-26084	148	5	the	the	DET
ihlr-26084	148	6	us	us	PROPN
ihlr-26084	148	7	permits	permit	VERB
ihlr-26084	148	8	pharmacies	pharmacy	NOUN
ihlr-26084	148	9	to	to	PART
ihlr-26084	148	10	substitute	substitute	VERB
ihlr-26084	148	11	brand	brand	NOUN
ihlr-26084	148	12	-	-	PUNCT
ihlr-26084	148	13	name	name	NOUN
ihlr-26084	148	14	drugs	drug	NOUN
ihlr-26084	148	15	with	with	ADP
ihlr-26084	148	16	generic	generic	ADJ
ihlr-26084	148	17	drugs.36	drugs.36	NOUN
ihlr-26084	148	18	some	some	DET
ihlr-26084	148	19	states	state	NOUN
ihlr-26084	148	20	require	require	VERB
ihlr-26084	148	21	patient	patient	ADJ
ihlr-26084	148	22	consent	consent	NOUN
ihlr-26084	148	23	before	before	SCONJ
ihlr-26084	148	24	pharmacists	pharmacist	NOUN
ihlr-26084	148	25	make	make	VERB
ihlr-26084	148	26	substitutions	substitution	NOUN
ihlr-26084	148	27	,	,	PUNCT
ihlr-26084	148	28	while	while	SCONJ
ihlr-26084	148	29	other	other	ADJ
ihlr-26084	148	30	states	state	NOUN
ihlr-26084	148	31	require	require	VERB
ihlr-26084	148	32	pharmacists	pharmacist	NOUN
ihlr-26084	148	33	to	to	PART
ihlr-26084	148	34	substitute	substitute	VERB
ihlr-26084	148	35	in	in	ADP
ihlr-26084	148	36	nearly	nearly	ADV
ihlr-26084	148	37	all	all	PRON
ihlr-26084	148	38	cases.37	cases.37	NOUN
ihlr-26084	148	39	brand	brand	NOUN
ihlr-26084	148	40	manufacturers	manufacturer	NOUN
ihlr-26084	148	41	a	a	DET
ihlr-26084	148	42	strong	strong	ADJ
ihlr-26084	148	43	incentive	incentive	NOUN
ihlr-26084	148	44	to	to	PART
ihlr-26084	148	45	delay	delay	VERB
ihlr-26084	148	46	the	the	DET
ihlr-26084	148	47	entry	entry	NOUN
ihlr-26084	148	48	of	of	ADP
ihlr-26084	148	49	cheaper	cheap	ADJ
ihlr-26084	148	50	,	,	PUNCT
ihlr-26084	148	51	substitutable	substitutable	ADJ
ihlr-26084	148	52	generic	generic	ADJ
ihlr-26084	148	53	drugs	drug	NOUN
ihlr-26084	148	54	.	.	PUNCT
ihlr-26084	149	1	brand	brand	NOUN
ihlr-26084	149	2	manufacturers	manufacturer	NOUN
ihlr-26084	149	3	can	can	AUX
ihlr-26084	149	4	do	do	VERB
ihlr-26084	149	5	so	so	ADV
ihlr-26084	149	6	by	by	ADP
ihlr-26084	149	7	suing	sue	VERB
ihlr-26084	149	8	generics	generic	NOUN
ihlr-26084	149	9	alleging	allege	VERB
ihlr-26084	149	10	patent	patent	NOUN
ihlr-26084	149	11	infringement	infringement	NOUN
ihlr-26084	149	12	—	—	PUNCT
ihlr-26084	149	13	even	even	ADV
ihlr-26084	149	14	when	when	SCONJ
ihlr-26084	149	15	infringement	infringement	NOUN
ihlr-26084	149	16	was	be	AUX
ihlr-26084	149	17	unlikely	unlikely	ADJ
ihlr-26084	149	18	to	to	PART
ihlr-26084	149	19	have	have	AUX
ihlr-26084	149	20	occurred	occur	VERB
ihlr-26084	149	21	.	.	PUNCT
ihlr-26084	150	1	then	then	ADV
ihlr-26084	150	2	,	,	PUNCT
ihlr-26084	150	3	the	the	DET
ihlr-26084	150	4	brand	brand	NOUN
ihlr-26084	150	5	offers	offer	VERB
ihlr-26084	150	6	to	to	PART
ihlr-26084	150	7	settle	settle	VERB
ihlr-26084	150	8	with	with	ADP
ihlr-26084	150	9	the	the	DET
ihlr-26084	150	10	generic	generic	NOUN
ihlr-26084	150	11	for	for	ADP
ihlr-26084	150	12	the	the	DET
ihlr-26084	150	13	lawsuit	lawsuit	NOUN
ihlr-26084	150	14	it	it	PRON
ihlr-26084	150	15	initiated	initiate	VERB
ihlr-26084	150	16	.	.	PUNCT
ihlr-26084	151	1	in	in	ADP
ihlr-26084	151	2	these	these	DET
ihlr-26084	151	3	reverse	reverse	ADJ
ihlr-26084	151	4	payment	payment	NOUN
ihlr-26084	151	5	settlement	settlement	NOUN
ihlr-26084	151	6	schemes	scheme	NOUN
ihlr-26084	151	7	,	,	PUNCT
ihlr-26084	151	8	brand	brand	NOUN
ihlr-26084	151	9	companies	company	NOUN
ihlr-26084	151	10	often	often	ADV
ihlr-26084	151	11	pay	pay	VERB
ihlr-26084	151	12	generics	generic	NOUN
ihlr-26084	151	13	hundreds	hundred	NOUN
ihlr-26084	151	14	of	of	ADP
ihlr-26084	151	15	millions	million	NOUN
ihlr-26084	151	16	of	of	ADP
ihlr-26084	151	17	dollars	dollar	NOUN
ihlr-26084	151	18	to	to	PART
ihlr-26084	151	19	not	not	PART
ihlr-26084	151	20	enter	enter	VERB
ihlr-26084	151	21	the	the	DET
ihlr-26084	151	22	market	market	NOUN
ihlr-26084	151	23	.	.	PUNCT
ihlr-26084	152	1	the	the	DET
ihlr-26084	152	2	cartel	cartel	NOUN
ihlr-26084	152	3	schemes	scheme	NOUN
ihlr-26084	152	4	draw	draw	VERB
ihlr-26084	152	5	antitrust	antitrust	ADJ
ihlr-26084	152	6	scrutiny	scrutiny	NOUN
ihlr-26084	152	7	because	because	SCONJ
ihlr-26084	152	8	the	the	DET
ihlr-26084	152	9	parties	party	NOUN
ihlr-26084	152	10	are	be	AUX
ihlr-26084	152	11	sharing	share	VERB
ihlr-26084	152	12	monopoly	monopoly	NOUN
ihlr-26084	152	13	profits	profit	NOUN
ihlr-26084	152	14	rather	rather	ADV
ihlr-26084	152	15	than	than	ADP
ihlr-26084	152	16	competing	compete	VERB
ihlr-26084	152	17	.	.	PUNCT
ihlr-26084	153	1	they	they	PRON
ihlr-26084	153	2	are	be	AUX
ihlr-26084	153	3	also	also	ADV
ihlr-26084	153	4	known	know	VERB
ihlr-26084	153	5	as	as	ADP
ihlr-26084	153	6	pay	pay	NOUN
ihlr-26084	153	7	-	-	PUNCT
ihlr-26084	153	8	for	for	ADP
ihlr-26084	153	9	-	-	PUNCT
ihlr-26084	153	10	delay	delay	NOUN
ihlr-26084	153	11	agreements	agreement	NOUN
ihlr-26084	153	12	.	.	PUNCT
ihlr-26084	154	1	the	the	DET
ihlr-26084	154	2	us	us	PROPN
ihlr-26084	154	3	regulatory	regulatory	ADJ
ihlr-26084	154	4	framework	framework	NOUN
ihlr-26084	154	5	incentivizes	incentivize	VERB
ihlr-26084	154	6	patent	patent	NOUN
ihlr-26084	154	7	litigation	litigation	NOUN
ihlr-26084	154	8	that	that	PRON
ihlr-26084	154	9	can	can	AUX
ihlr-26084	154	10	lead	lead	VERB
ihlr-26084	154	11	to	to	PART
ihlr-26084	154	12	pay	pay	VERB
ihlr-26084	154	13	-	-	PUNCT
ihlr-26084	154	14	for	for	ADP
ihlr-26084	154	15	-	-	PUNCT
ihlr-26084	154	16	delay	delay	NOUN
ihlr-26084	154	17	settlements	settlement	NOUN
ihlr-26084	154	18	.	.	PUNCT
ihlr-26084	155	1	passed	pass	VERB
ihlr-26084	155	2	in	in	ADP
ihlr-26084	155	3	1984	1984	NUM
ihlr-26084	155	4	,	,	PUNCT
ihlr-26084	155	5	the	the	DET
ihlr-26084	155	6	hatch	hatch	NOUN
ihlr-26084	155	7	-	-	PUNCT
ihlr-26084	155	8	waxman	waxman	PROPN
ihlr-26084	155	9	act	act	NOUN
ihlr-26084	155	10	offers	offer	VERB
ihlr-26084	155	11	generic	generic	ADJ
ihlr-26084	155	12	companies	company	NOUN
ihlr-26084	155	13	an	an	DET
ihlr-26084	155	14	expedited	expedite	VERB
ihlr-26084	155	15	approval	approval	NOUN
ihlr-26084	155	16	process	process	NOUN
ihlr-26084	155	17	if	if	SCONJ
ihlr-26084	155	18	they	they	PRON
ihlr-26084	155	19	can	can	AUX
ihlr-26084	155	20	show	show	VERB
ihlr-26084	155	21	their	their	PRON
ihlr-26084	155	22	generic	generic	ADJ
ihlr-26084	155	23	is	be	AUX
ihlr-26084	155	24	32	32	NUM
ihlr-26084	155	25	.	.	PUNCT
ihlr-26084	156	1	prescription	prescription	NOUN
ihlr-26084	156	2	drugs	drug	NOUN
ihlr-26084	156	3	:	:	PUNCT
ihlr-26084	156	4	u.s	u.s	PROPN
ihlr-26084	156	5	.	.	PROPN
ihlr-26084	156	6	prices	price	NOUN
ihlr-26084	156	7	for	for	ADP
ihlr-26084	156	8	selected	select	VERB
ihlr-26084	156	9	brand	brand	NOUN
ihlr-26084	156	10	drugs	drug	NOUN
ihlr-26084	156	11	were	be	AUX
ihlr-26084	156	12	higher	high	ADJ
ihlr-26084	156	13	on	on	ADP
ihlr-26084	156	14	average	average	ADJ
ihlr-26084	156	15	than	than	ADP
ihlr-26084	156	16	prices	price	NOUN
ihlr-26084	156	17	in	in	ADP
ihlr-26084	156	18	australia	australia	PROPN
ihlr-26084	156	19	,	,	PUNCT
ihlr-26084	156	20	canada	canada	PROPN
ihlr-26084	156	21	,	,	PUNCT
ihlr-26084	156	22	and	and	CCONJ
ihlr-26084	156	23	france	france	PROPN
ihlr-26084	156	24	,	,	PUNCT
ihlr-26084	156	25	u.s	u.s	PROPN
ihlr-26084	156	26	.	.	PROPN
ihlr-26084	156	27	gov’t	gov’t	PROPN
ihlr-26084	156	28	accountability	accountability	NOUN
ihlr-26084	156	29	office	office	NOUN
ihlr-26084	156	30	1	1	NUM
ihlr-26084	156	31	,	,	PUNCT
ihlr-26084	156	32	15	15	NUM
ihlr-26084	156	33	(	(	PUNCT
ihlr-26084	156	34	2021	2021	NUM
ihlr-26084	156	35	)	)	PUNCT
ihlr-26084	156	36	.	.	PUNCT
ihlr-26084	157	1	33	33	NUM
ihlr-26084	157	2	.	.	PUNCT
ihlr-26084	158	1	andrew	andrew	PROPN
ihlr-26084	158	2	w.	w.	PROPN
ihlr-26084	158	3	mulcahy	mulcahy	PROPN
ihlr-26084	158	4	et	et	PROPN
ihlr-26084	158	5	al	al	PROPN
ihlr-26084	158	6	.	.	PROPN
ihlr-26084	158	7	,	,	PUNCT
ihlr-26084	158	8	international	international	ADJ
ihlr-26084	158	9	prescription	prescription	NOUN
ihlr-26084	158	10	drug	drug	NOUN
ihlr-26084	158	11	price	price	NOUN
ihlr-26084	158	12	comparisons	comparison	NOUN
ihlr-26084	158	13	:	:	PUNCT
ihlr-26084	158	14	current	current	ADJ
ihlr-26084	158	15	empirical	empirical	ADJ
ihlr-26084	158	16	estimates	estimate	NOUN
ihlr-26084	158	17	and	and	CCONJ
ihlr-26084	158	18	comparisons	comparison	NOUN
ihlr-26084	158	19	with	with	ADP
ihlr-26084	158	20	previous	previous	ADJ
ihlr-26084	158	21	studies	study	NOUN
ihlr-26084	158	22	,	,	PUNCT
ihlr-26084	158	23	rand	rand	PROPN
ihlr-26084	158	24	corp	corp	PROPN
ihlr-26084	158	25	.	.	PROPN
ihlr-26084	158	26	1	1	NUM
ihlr-26084	158	27	,	,	PUNCT
ihlr-26084	158	28	12	12	NUM
ihlr-26084	158	29	(	(	PUNCT
ihlr-26084	158	30	2021	2021	NUM
ihlr-26084	158	31	)	)	PUNCT
ihlr-26084	158	32	.	.	PUNCT
ihlr-26084	159	1	34	34	NUM
ihlr-26084	159	2	.	.	PUNCT
ihlr-26084	160	1	see	see	VERB
ihlr-26084	160	2	stephen	stephen	PROPN
ihlr-26084	160	3	w.	w.	PROPN
ihlr-26084	160	4	schondelmeyer	schondelmeyer	PROPN
ihlr-26084	160	5	&	&	CCONJ
ihlr-26084	160	6	leigh	leigh	PROPN
ihlr-26084	160	7	purvis	purvis	PROPN
ihlr-26084	160	8	,	,	PUNCT
ihlr-26084	160	9	price	price	NOUN
ihlr-26084	160	10	decreases	decrease	NOUN
ihlr-26084	160	11	for	for	ADP
ihlr-26084	160	12	widely	widely	ADV
ihlr-26084	160	13	used	use	VERB
ihlr-26084	160	14	generic	generic	ADJ
ihlr-26084	160	15	drugs	drug	NOUN
ihlr-26084	160	16	slow	slow	ADJ
ihlr-26084	160	17	in	in	ADP
ihlr-26084	160	18	2017	2017	NUM
ihlr-26084	160	19	after	after	ADP
ihlr-26084	160	20	two	two	NUM
ihlr-26084	160	21	years	year	NOUN
ihlr-26084	160	22	of	of	ADP
ihlr-26084	160	23	substantial	substantial	ADJ
ihlr-26084	160	24	price	price	NOUN
ihlr-26084	160	25	drops	drop	NOUN
ihlr-26084	160	26	,	,	PUNCT
ihlr-26084	160	27	aarp	aarp	PROPN
ihlr-26084	160	28	pub	pub	NOUN
ihlr-26084	160	29	.	.	PUNCT
ihlr-26084	161	1	pol’y	pol’y	NOUN
ihlr-26084	161	2	inst	inst	NOUN
ihlr-26084	161	3	.	.	PROPN
ihlr-26084	161	4	1	1	NUM
ihlr-26084	161	5	(	(	PUNCT
ihlr-26084	161	6	2019	2019	NUM
ihlr-26084	161	7	)	)	PUNCT
ihlr-26084	161	8	.	.	PUNCT
ihlr-26084	162	1	35	35	NUM
ihlr-26084	162	2	.	.	PUNCT
ihlr-26084	163	1	mulcahy	mulcahy	PROPN
ihlr-26084	163	2	,	,	PUNCT
ihlr-26084	163	3	et	et	PROPN
ihlr-26084	163	4	al	al	PROPN
ihlr-26084	163	5	.	.	PROPN
ihlr-26084	163	6	,	,	PUNCT
ihlr-26084	163	7	supra	supra	PROPN
ihlr-26084	163	8	note	note	VERB
ihlr-26084	163	9	33	33	NUM
ihlr-26084	163	10	,	,	PUNCT
ihlr-26084	163	11	at	at	ADP
ihlr-26084	163	12	xii	xii	PROPN
ihlr-26084	163	13	.	.	PUNCT
ihlr-26084	164	1	36	36	NUM
ihlr-26084	164	2	.	.	PUNCT
ihlr-26084	165	1	see	see	VERB
ihlr-26084	165	2	yan	yan	PROPN
ihlr-26084	165	3	song	song	PROPN
ihlr-26084	165	4	&	&	CCONJ
ihlr-26084	165	5	douglas	douglas	PROPN
ihlr-26084	165	6	barthold	barthold	PROPN
ihlr-26084	165	7	,	,	PUNCT
ihlr-26084	165	8	the	the	DET
ihlr-26084	165	9	effects	effect	NOUN
ihlr-26084	165	10	of	of	ADP
ihlr-26084	165	11	state	state	NOUN
ihlr-26084	165	12	-	-	PUNCT
ihlr-26084	165	13	level	level	NOUN
ihlr-26084	165	14	pharmacist	pharmacist	NOUN
ihlr-26084	165	15	regulations	regulation	NOUN
ihlr-26084	165	16	on	on	ADP
ihlr-26084	165	17	generic	generic	ADJ
ihlr-26084	165	18	substitution	substitution	NOUN
ihlr-26084	165	19	of	of	ADP
ihlr-26084	165	20	prescription	prescription	NOUN
ihlr-26084	165	21	drugs	drug	NOUN
ihlr-26084	165	22	,	,	PUNCT
ihlr-26084	165	23	27	27	NUM
ihlr-26084	165	24	health	health	NOUN
ihlr-26084	165	25	econ	econ	NOUN
ihlr-26084	165	26	.	.	PUNCT
ihlr-26084	166	1	1717	1717	NUM
ihlr-26084	166	2	(	(	PUNCT
ihlr-26084	166	3	2018	2018	NUM
ihlr-26084	166	4	)	)	PUNCT
ihlr-26084	166	5	.	.	PUNCT
ihlr-26084	167	1	37	37	NUM
ihlr-26084	167	2	.	.	PUNCT
ihlr-26084	168	1	i	i	PRON
ihlr-26084	168	2	d.	d.	PROPN
ihlr-26084	168	3	28	28	NUM
ihlr-26084	169	1	indiana	indiana	PROPN
ihlr-26084	169	2	health	health	PROPN
ihlr-26084	169	3	law	law	PROPN
ihlr-26084	169	4	review	review	NOUN
ihlr-26084	169	5	[	[	X
ihlr-26084	169	6	vol	vol	NOUN
ihlr-26084	169	7	.	.	PUNCT
ihlr-26084	170	1	19:21	19:21	NUM
ihlr-26084	170	2	chemically	chemically	ADV
ihlr-26084	170	3	similar	similar	ADJ
ihlr-26084	170	4	to	to	ADP
ihlr-26084	170	5	the	the	DET
ihlr-26084	170	6	brand	brand	NOUN
ihlr-26084	170	7	-	-	PUNCT
ihlr-26084	170	8	name	name	NOUN
ihlr-26084	170	9	drug	drug	NOUN
ihlr-26084	170	10	and	and	CCONJ
ihlr-26084	170	11	does	do	AUX
ihlr-26084	170	12	not	not	PART
ihlr-26084	170	13	violate	violate	VERB
ihlr-26084	170	14	any	any	DET
ihlr-26084	170	15	brand	brand	NOUN
ihlr-26084	170	16	-	-	PUNCT
ihlr-26084	170	17	name	name	NOUN
ihlr-26084	170	18	patents.38	patents.38	NOUN
ihlr-26084	170	19	it	it	PRON
ihlr-26084	170	20	encourages	encourage	VERB
ihlr-26084	170	21	generic	generic	ADJ
ihlr-26084	170	22	companies	company	NOUN
ihlr-26084	170	23	to	to	PART
ihlr-26084	170	24	more	more	ADV
ihlr-26084	170	25	quickly	quickly	ADV
ihlr-26084	170	26	introduce	introduce	VERB
ihlr-26084	170	27	generics	generic	NOUN
ihlr-26084	170	28	for	for	ADP
ihlr-26084	170	29	drugs	drug	NOUN
ihlr-26084	170	30	protected	protect	VERB
ihlr-26084	170	31	by	by	ADP
ihlr-26084	170	32	weak	weak	ADJ
ihlr-26084	170	33	patents	patent	NOUN
ihlr-26084	170	34	.	.	PUNCT
ihlr-26084	171	1	however	however	ADV
ihlr-26084	171	2	,	,	PUNCT
ihlr-26084	171	3	brand	brand	NOUN
ihlr-26084	171	4	-	-	PUNCT
ihlr-26084	171	5	name	name	NOUN
ihlr-26084	171	6	companies	company	NOUN
ihlr-26084	171	7	can	can	AUX
ihlr-26084	171	8	delay	delay	VERB
ihlr-26084	171	9	the	the	DET
ihlr-26084	171	10	approval	approval	NOUN
ihlr-26084	171	11	process	process	NOUN
ihlr-26084	171	12	for	for	ADP
ihlr-26084	171	13	up	up	ADP
ihlr-26084	171	14	to	to	PART
ihlr-26084	171	15	thirty	thirty	NUM
ihlr-26084	171	16	months	month	NOUN
ihlr-26084	171	17	by	by	ADP
ihlr-26084	171	18	timely	timely	ADJ
ihlr-26084	171	19	filing	file	VERB
ihlr-26084	171	20	a	a	DET
ihlr-26084	171	21	lawsuit	lawsuit	NOUN
ihlr-26084	171	22	against	against	ADP
ihlr-26084	171	23	the	the	DET
ihlr-26084	171	24	generic	generic	ADJ
ihlr-26084	171	25	alleging	alleging	NOUN
ihlr-26084	171	26	patent	patent	NOUN
ihlr-26084	171	27	infringement.39	infringement.39	NOUN
ihlr-26084	171	28	thus	thus	ADV
ihlr-26084	171	29	,	,	PUNCT
ihlr-26084	171	30	brand	brand	NOUN
ihlr-26084	171	31	-	-	PUNCT
ihlr-26084	171	32	name	name	NOUN
ihlr-26084	171	33	manufacturers	manufacturer	NOUN
ihlr-26084	171	34	were	be	AUX
ihlr-26084	171	35	incentivized	incentivize	VERB
ihlr-26084	171	36	to	to	PART
ihlr-26084	171	37	sue	sue	VERB
ihlr-26084	171	38	generic	generic	ADJ
ihlr-26084	171	39	entrants	entrant	NOUN
ihlr-26084	171	40	irrespective	irrespective	ADV
ihlr-26084	171	41	of	of	ADP
ihlr-26084	171	42	patent	patent	NOUN
ihlr-26084	171	43	strength	strength	NOUN
ihlr-26084	171	44	to	to	PART
ihlr-26084	171	45	delay	delay	VERB
ihlr-26084	171	46	the	the	DET
ihlr-26084	171	47	review	review	NOUN
ihlr-26084	171	48	process	process	NOUN
ihlr-26084	171	49	.	.	PUNCT
ihlr-26084	172	1	as	as	SCONJ
ihlr-26084	172	2	one	one	NUM
ihlr-26084	172	3	court	court	NOUN
ihlr-26084	172	4	put	put	VERB
ihlr-26084	172	5	it	it	PRON
ihlr-26084	172	6	,	,	PUNCT
ihlr-26084	172	7	“	"	PUNCT
ihlr-26084	172	8	litigiousness	litigiousness	PROPN
ihlr-26084	172	9	was	be	AUX
ihlr-26084	172	10	a	a	DET
ihlr-26084	172	11	product	product	NOUN
ihlr-26084	172	12	of	of	ADP
ihlr-26084	172	13	hatchwaxman	hatchwaxman	NOUN
ihlr-26084	172	14	.	.	PUNCT
ihlr-26084	173	1	’’40	’’40	AUX
ihlr-26084	173	2	reverse	reverse	VERB
ihlr-26084	173	3	payment	payment	NOUN
ihlr-26084	173	4	settlements	settlement	NOUN
ihlr-26084	173	5	that	that	PRON
ihlr-26084	173	6	resolved	resolve	VERB
ihlr-26084	173	7	patent	patent	NOUN
ihlr-26084	173	8	infringement	infringement	NOUN
ihlr-26084	173	9	litigation	litigation	NOUN
ihlr-26084	173	10	thus	thus	ADV
ihlr-26084	173	11	became	become	VERB
ihlr-26084	173	12	ubiquitous	ubiquitous	ADJ
ihlr-26084	173	13	.	.	PUNCT
ihlr-26084	174	1	in	in	ADP
ihlr-26084	174	2	2003	2003	NUM
ihlr-26084	174	3	,	,	PUNCT
ihlr-26084	174	4	congress	congress	PROPN
ihlr-26084	174	5	responded	respond	VERB
ihlr-26084	174	6	by	by	ADP
ihlr-26084	174	7	passing	pass	VERB
ihlr-26084	174	8	a	a	DET
ihlr-26084	174	9	law41	law41	NOUN
ihlr-26084	174	10	that	that	PRON
ihlr-26084	174	11	required	require	VERB
ihlr-26084	174	12	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	174	13	companies	company	NOUN
ihlr-26084	174	14	to	to	PART
ihlr-26084	174	15	report	report	VERB
ihlr-26084	174	16	these	these	DET
ihlr-26084	174	17	settlements	settlement	NOUN
ihlr-26084	174	18	to	to	ADP
ihlr-26084	174	19	the	the	DET
ihlr-26084	174	20	federal	federal	PROPN
ihlr-26084	174	21	trade	trade	PROPN
ihlr-26084	174	22	commission	commission	PROPN
ihlr-26084	174	23	(	(	PUNCT
ihlr-26084	174	24	“	"	PUNCT
ihlr-26084	174	25	ftc”).42	ftc”).42	NOUN
ihlr-26084	174	26	the	the	DET
ihlr-26084	174	27	ftc	ftc	PROPN
ihlr-26084	174	28	would	would	AUX
ihlr-26084	174	29	then	then	ADV
ihlr-26084	174	30	investigate	investigate	VERB
ihlr-26084	174	31	these	these	DET
ihlr-26084	174	32	settlements	settlement	NOUN
ihlr-26084	174	33	,	,	PUNCT
ihlr-26084	174	34	challenge	challenge	VERB
ihlr-26084	174	35	some	some	PRON
ihlr-26084	174	36	in	in	ADP
ihlr-26084	174	37	court	court	NOUN
ihlr-26084	174	38	,	,	PUNCT
ihlr-26084	174	39	and	and	CCONJ
ihlr-26084	174	40	publish	publish	VERB
ihlr-26084	174	41	annual	annual	ADJ
ihlr-26084	174	42	reports	report	NOUN
ihlr-26084	174	43	that	that	PRON
ihlr-26084	174	44	summarize	summarize	VERB
ihlr-26084	174	45	the	the	DET
ihlr-26084	174	46	agreements	agreement	NOUN
ihlr-26084	174	47	formed	form	VERB
ihlr-26084	174	48	each	each	DET
ihlr-26084	174	49	year.43	year.43	NOUN
ihlr-26084	174	50	the	the	DET
ihlr-26084	174	51	ftc	ftc	PROPN
ihlr-26084	174	52	argued	argue	VERB
ihlr-26084	174	53	that	that	SCONJ
ihlr-26084	174	54	these	these	DET
ihlr-26084	174	55	agreements	agreement	NOUN
ihlr-26084	174	56	violated	violate	VERB
ihlr-26084	174	57	section	section	NOUN
ihlr-26084	174	58	1	1	NUM
ihlr-26084	174	59	of	of	ADP
ihlr-26084	174	60	the	the	DET
ihlr-26084	174	61	sherman	sherman	PROPN
ihlr-26084	174	62	act	act	NOUN
ihlr-26084	174	63	by	by	ADP
ihlr-26084	174	64	foreclosing	foreclose	VERB
ihlr-26084	174	65	competition	competition	NOUN
ihlr-26084	174	66	between	between	ADP
ihlr-26084	174	67	generic	generic	ADJ
ihlr-26084	174	68	and	and	CCONJ
ihlr-26084	174	69	brand	brand	NOUN
ihlr-26084	174	70	-	-	PUNCT
ihlr-26084	174	71	name	name	NOUN
ihlr-26084	174	72	drugs.44	drugs.44	NOUN
ihlr-26084	174	73	circuit	circuit	NOUN
ihlr-26084	174	74	courts	court	NOUN
ihlr-26084	174	75	agreed	agree	VERB
ihlr-26084	174	76	that	that	SCONJ
ihlr-26084	174	77	manufacturers	manufacturer	NOUN
ihlr-26084	174	78	who	who	PRON
ihlr-26084	174	79	engaged	engage	VERB
ihlr-26084	174	80	in	in	ADP
ihlr-26084	174	81	reverse	reverse	ADJ
ihlr-26084	174	82	payment	payment	NOUN
ihlr-26084	174	83	settlements	settlement	NOUN
ihlr-26084	174	84	were	be	AUX
ihlr-26084	174	85	maintaining	maintain	VERB
ihlr-26084	174	86	monopolies	monopoly	NOUN
ihlr-26084	174	87	over	over	ADP
ihlr-26084	174	88	their	their	PRON
ihlr-26084	174	89	brand	brand	NOUN
ihlr-26084	174	90	-	-	PUNCT
ihlr-26084	174	91	name	name	NOUN
ihlr-26084	174	92	drugs.45	drugs.45	NOUN
ihlr-26084	174	93	but	but	CCONJ
ihlr-26084	174	94	some	some	DET
ihlr-26084	174	95	circuits	circuit	NOUN
ihlr-26084	174	96	held	hold	VERB
ihlr-26084	174	97	that	that	SCONJ
ihlr-26084	174	98	these	these	DET
ihlr-26084	174	99	monopolies	monopoly	NOUN
ihlr-26084	174	100	are	be	AUX
ihlr-26084	174	101	lawful	lawful	ADJ
ihlr-26084	174	102	because	because	SCONJ
ihlr-26084	174	103	they	they	PRON
ihlr-26084	174	104	are	be	AUX
ihlr-26084	174	105	granted	grant	VERB
ihlr-26084	174	106	by	by	ADP
ihlr-26084	174	107	patents	patent	NOUN
ihlr-26084	174	108	.	.	PUNCT
ihlr-26084	175	1	in	in	ADP
ihlr-26084	175	2	schering	schering	NOUN
ihlr-26084	175	3	-	-	PUNCT
ihlr-26084	175	4	plough	plough	NOUN
ihlr-26084	175	5	v.	v.	ADP
ihlr-26084	175	6	ftc	ftc	PROPN
ihlr-26084	175	7	,	,	PUNCT
ihlr-26084	175	8	the	the	DET
ihlr-26084	175	9	eleventh	eleventh	ADJ
ihlr-26084	175	10	circuit	circuit	NOUN
ihlr-26084	175	11	adopted	adopt	VERB
ihlr-26084	175	12	a	a	DET
ihlr-26084	175	13	patent	patent	NOUN
ihlr-26084	175	14	validity	validity	NOUN
ihlr-26084	175	15	test.46	test.46	NOUN
ihlr-26084	175	16	this	this	DET
ihlr-26084	175	17	test	test	NOUN
ihlr-26084	175	18	holds	hold	VERB
ihlr-26084	175	19	that	that	SCONJ
ihlr-26084	175	20	a	a	DET
ihlr-26084	175	21	“	"	PUNCT
ihlr-26084	175	22	reverse	reverse	ADJ
ihlr-26084	175	23	payment	payment	NOUN
ihlr-26084	175	24	settlement	settlement	NOUN
ihlr-26084	175	25	is	be	AUX
ihlr-26084	175	26	immune	immune	ADJ
ihlr-26084	175	27	from	from	ADP
ihlr-26084	175	28	antitrust	antitrust	ADJ
ihlr-26084	175	29	attack	attack	NOUN
ihlr-26084	175	30	so	so	ADV
ihlr-26084	175	31	long	long	ADV
ihlr-26084	175	32	as	as	SCONJ
ihlr-26084	175	33	its	its	PRON
ihlr-26084	175	34	anticompetitive	anticompetitive	ADJ
ihlr-26084	175	35	effects	effect	NOUN
ihlr-26084	175	36	fall	fall	VERB
ihlr-26084	175	37	within	within	ADP
ihlr-26084	175	38	the	the	DET
ihlr-26084	175	39	scope	scope	NOUN
ihlr-26084	175	40	of	of	ADP
ihlr-26084	175	41	the	the	DET
ihlr-26084	175	42	38	38	NUM
ihlr-26084	175	43	.	.	PUNCT
ihlr-26084	176	1	drug	drug	NOUN
ihlr-26084	176	2	price	price	NOUN
ihlr-26084	176	3	competition	competition	NOUN
ihlr-26084	176	4	and	and	CCONJ
ihlr-26084	176	5	patent	patent	NOUN
ihlr-26084	176	6	term	term	NOUN
ihlr-26084	176	7	restoration	restoration	NOUN
ihlr-26084	176	8	act	act	NOUN
ihlr-26084	176	9	of	of	ADP
ihlr-26084	176	10	1984	1984	NUM
ihlr-26084	176	11	,	,	PUNCT
ihlr-26084	176	12	21	21	NUM
ihlr-26084	176	13	u.s.c	u.s.c	NOUN
ihlr-26084	176	14	.	.	PUNCT
ihlr-26084	177	1	§	§	PROPN
ihlr-26084	177	2	§	§	PROPN
ihlr-26084	177	3	301	301	NUM
ihlr-26084	177	4	,	,	PUNCT
ihlr-26084	177	5	355	355	NUM
ihlr-26084	177	6	,	,	PUNCT
ihlr-26084	177	7	360cc	360cc	PROPN
ihlr-26084	177	8	.	.	PUNCT
ihlr-26084	178	1	39	39	NUM
ihlr-26084	178	2	.	.	PUNCT
ihlr-26084	179	1	21	21	NUM
ihlr-26084	179	2	u.s.c	u.s.c	NOUN
ihlr-26084	179	3	.	.	PUNCT
ihlr-26084	180	1	§	§	PROPN
ihlr-26084	180	2	355(c)(3)(c	355(c)(3)(c	PROPN
ihlr-26084	180	3	)	)	PUNCT
ihlr-26084	180	4	.	.	PUNCT
ihlr-26084	181	1	40	40	NUM
ihlr-26084	181	2	.	.	PUNCT
ihlr-26084	182	1	in	in	ADP
ihlr-26084	182	2	re	re	PROPN
ihlr-26084	182	3	wellbutrin	wellbutrin	PROPN
ihlr-26084	182	4	xl	xl	PROPN
ihlr-26084	182	5	antitrust	antitrust	ADJ
ihlr-26084	182	6	litigation	litigation	NOUN
ihlr-26084	182	7	,	,	PUNCT
ihlr-26084	182	8	868	868	NUM
ihlr-26084	182	9	f.3d	f.3d	NUM
ihlr-26084	182	10	132	132	NUM
ihlr-26084	182	11	,	,	PUNCT
ihlr-26084	182	12	158	158	NUM
ihlr-26084	182	13	(	(	PUNCT
ihlr-26084	182	14	3d	3d	NUM
ihlr-26084	182	15	cir	cir	NOUN
ihlr-26084	182	16	.	.	PROPN
ihlr-26084	182	17	2017	2017	NUM
ihlr-26084	182	18	)	)	PUNCT
ihlr-26084	182	19	(	(	PUNCT
ihlr-26084	182	20	internal	internal	ADJ
ihlr-26084	182	21	quotation	quotation	NOUN
ihlr-26084	182	22	marks	mark	NOUN
ihlr-26084	182	23	and	and	CCONJ
ihlr-26084	182	24	citations	citation	NOUN
ihlr-26084	182	25	omitted	omit	VERB
ihlr-26084	182	26	)	)	PUNCT
ihlr-26084	182	27	.	.	PUNCT
ihlr-26084	183	1	41	41	NUM
ihlr-26084	183	2	.	.	PUNCT
ihlr-26084	184	1	medicare	medicare	PROPN
ihlr-26084	184	2	prescription	prescription	NOUN
ihlr-26084	184	3	drug	drug	NOUN
ihlr-26084	184	4	,	,	PUNCT
ihlr-26084	184	5	improvement	improvement	NOUN
ihlr-26084	184	6	,	,	PUNCT
ihlr-26084	184	7	and	and	CCONJ
ihlr-26084	184	8	modernization	modernization	NOUN
ihlr-26084	184	9	act	act	NOUN
ihlr-26084	184	10	of	of	ADP
ihlr-26084	184	11	2003	2003	NUM
ihlr-26084	184	12	,	,	PUNCT
ihlr-26084	184	13	h.r	h.r	PROPN
ihlr-26084	184	14	.	.	PROPN
ihlr-26084	184	15	1	1	NUM
ihlr-26084	184	16	,	,	PUNCT
ihlr-26084	184	17	108th	108th	ADJ
ihlr-26084	184	18	cong	cong	NOUN
ihlr-26084	184	19	.	.	PUNCT
ihlr-26084	185	1	(	(	PUNCT
ihlr-26084	185	2	2003	2003	NUM
ihlr-26084	185	3	)	)	PUNCT
ihlr-26084	185	4	.	.	PUNCT
ihlr-26084	186	1	42	42	NUM
ihlr-26084	186	2	.	.	PUNCT
ihlr-26084	186	3	21	21	NUM
ihlr-26084	186	4	u.s.c	u.s.c	NOUN
ihlr-26084	186	5	.	.	PUNCT
ihlr-26084	187	1	§	§	PROPN
ihlr-26084	187	2	§	§	PROPN
ihlr-26084	187	3	1112	1112	NUM
ihlr-26084	187	4	-	-	SYM
ihlr-26084	187	5	13	13	NUM
ihlr-26084	187	6	(	(	PUNCT
ihlr-26084	187	7	2011	2011	NUM
ihlr-26084	187	8	)	)	PUNCT
ihlr-26084	187	9	.	.	PUNCT
ihlr-26084	188	1	43	43	NUM
ihlr-26084	188	2	.	.	PUNCT
ihlr-26084	188	3	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	188	4	agreement	agreement	NOUN
ihlr-26084	188	5	filings	filing	NOUN
ihlr-26084	188	6	,	,	PUNCT
ihlr-26084	188	7	fed	fed	PROPN
ihlr-26084	188	8	.	.	PUNCT
ihlr-26084	189	1	trade	trade	PROPN
ihlr-26084	189	2	comm’n	comm’n	NOUN
ihlr-26084	189	3	,	,	PUNCT
ihlr-26084	189	4	https://www.ftc.gov/tipsadvice/competition-guidance/industry-guidance/health-care/pharmaceutical-agreement-filings	https://www.ftc.gov/tipsadvice/competition-guidance/industry-guidance/health-care/pharmaceutical-agreement-filing	NOUN
ihlr-26084	189	5	[	[	X
ihlr-26084	189	6	https://perma.cc/9f2f-b26	https://perma.cc/9f2f-b26	NOUN
ihlr-26084	189	7	m	m	VERB
ihlr-26084	189	8	]	]	X
ihlr-26084	189	9	(	(	PUNCT
ihlr-26084	189	10	last	last	ADV
ihlr-26084	189	11	visited	visit	VERB
ihlr-26084	189	12	april	april	PROPN
ihlr-26084	189	13	5	5	NUM
ihlr-26084	189	14	,	,	PUNCT
ihlr-26084	189	15	2021	2021	NUM
ihlr-26084	189	16	)	)	PUNCT
ihlr-26084	189	17	.	.	PUNCT
ihlr-26084	190	1	44	44	NUM
ihlr-26084	190	2	.	.	PUNCT
ihlr-26084	191	1	i	i	PRON
ihlr-26084	191	2	d.	d.	PROPN
ihlr-26084	191	3	45	45	NUM
ihlr-26084	191	4	.	.	PUNCT
ihlr-26084	191	5	see	see	VERB
ihlr-26084	191	6	generally	generally	ADV
ihlr-26084	191	7	andrx	andrx	ADJ
ihlr-26084	191	8	pharms	pharm	NOUN
ihlr-26084	191	9	.	.	PUNCT
ihlr-26084	191	10	,	,	PUNCT
ihlr-26084	191	11	inc	inc	PROPN
ihlr-26084	191	12	.	.	PROPN
ihlr-26084	191	13	v.	v.	PROPN
ihlr-26084	191	14	biovail	biovail	PROPN
ihlr-26084	191	15	corp	corp	PROPN
ihlr-26084	191	16	.	.	PROPN
ihlr-26084	191	17	int’l	int’l	NUM
ihlr-26084	191	18	,	,	PUNCT
ihlr-26084	191	19	256	256	NUM
ihlr-26084	191	20	f.3d	f.3d	NUM
ihlr-26084	191	21	799	799	NUM
ihlr-26084	191	22	(	(	PUNCT
ihlr-26084	191	23	8th	8th	ADJ
ihlr-26084	191	24	cir	cir	NOUN
ihlr-26084	191	25	.	.	PUNCT
ihlr-26084	191	26	2001	2001	NUM
ihlr-26084	191	27	)	)	PUNCT
ihlr-26084	191	28	;	;	PUNCT
ihlr-26084	191	29	louisiana	louisiana	PROPN
ihlr-26084	191	30	wholesale	wholesale	PROPN
ihlr-26084	191	31	drug	drug	PROPN
ihlr-26084	191	32	co.	co.	PROPN
ihlr-26084	191	33	v.	v.	ADP
ihlr-26084	191	34	hoechst	hoechst	PROPN
ihlr-26084	191	35	marion	marion	PROPN
ihlr-26084	191	36	roussel	roussel	PROPN
ihlr-26084	191	37	,	,	PUNCT
ihlr-26084	191	38	inc	inc	PROPN
ihlr-26084	191	39	.	.	PROPN
ihlr-26084	191	40	(	(	PUNCT
ihlr-26084	191	41	in	in	ADP
ihlr-26084	191	42	re	re	PROPN
ihlr-26084	191	43	cardizem	cardizem	PROPN
ihlr-26084	191	44	cd	cd	PROPN
ihlr-26084	191	45	antitrust	antitrust	ADJ
ihlr-26084	191	46	litig	litig	NOUN
ihlr-26084	191	47	.	.	PUNCT
ihlr-26084	191	48	)	)	PUNCT
ihlr-26084	192	1	,	,	PUNCT
ihlr-26084	192	2	332	332	NUM
ihlr-26084	192	3	f.3d	f.3d	NUM
ihlr-26084	192	4	896	896	NUM
ihlr-26084	192	5	(	(	PUNCT
ihlr-26084	192	6	6th	6th	ADJ
ihlr-26084	192	7	cir	cir	NOUN
ihlr-26084	192	8	.	.	PROPN
ihlr-26084	192	9	2003	2003	NUM
ihlr-26084	192	10	)	)	PUNCT
ihlr-26084	192	11	;	;	PUNCT
ihlr-26084	192	12	valley	valley	NOUN
ihlr-26084	192	13	drug	drug	PROPN
ihlr-26084	192	14	co.	co.	PROPN
ihlr-26084	192	15	v.	v.	ADP
ihlr-26084	192	16	geneva	geneva	PROPN
ihlr-26084	192	17	pharms	pharms	PROPN
ihlr-26084	192	18	.	.	PUNCT
ihlr-26084	192	19	,	,	PUNCT
ihlr-26084	192	20	inc	inc	PROPN
ihlr-26084	192	21	.	.	PROPN
ihlr-26084	192	22	,	,	PUNCT
ihlr-26084	192	23	344	344	NUM
ihlr-26084	192	24	f.3d	f.3d	NUM
ihlr-26084	192	25	1294	1294	NUM
ihlr-26084	192	26	(	(	PUNCT
ihlr-26084	192	27	11th	11th	ADJ
ihlr-26084	192	28	cir	cir	NOUN
ihlr-26084	192	29	.	.	PROPN
ihlr-26084	192	30	2003	2003	NUM
ihlr-26084	192	31	)	)	PUNCT
ihlr-26084	192	32	;	;	PUNCT
ihlr-26084	192	33	schering	schering	NOUN
ihlr-26084	192	34	-	-	PUNCT
ihlr-26084	192	35	plough	plough	PROPN
ihlr-26084	192	36	corp	corp	PROPN
ihlr-26084	192	37	.	.	PROPN
ihlr-26084	192	38	v.	v.	PROPN
ihlr-26084	192	39	ftc	ftc	PROPN
ihlr-26084	192	40	,	,	PUNCT
ihlr-26084	192	41	402	402	NUM
ihlr-26084	192	42	f.3d	f.3d	NUM
ihlr-26084	192	43	1056	1056	NUM
ihlr-26084	192	44	(	(	PUNCT
ihlr-26084	192	45	11th	11th	ADJ
ihlr-26084	192	46	cir	cir	NOUN
ihlr-26084	192	47	.	.	PROPN
ihlr-26084	192	48	2005	2005	NUM
ihlr-26084	192	49	)	)	PUNCT
ihlr-26084	192	50	;	;	PUNCT
ihlr-26084	192	51	joblove	joblove	PROPN
ihlr-26084	192	52	v.	v.	PROPN
ihlr-26084	192	53	barr	barr	PROPN
ihlr-26084	192	54	labs	labs	PROPN
ihlr-26084	192	55	.	.	PUNCT
ihlr-26084	192	56	,	,	PUNCT
ihlr-26084	192	57	inc	inc	PROPN
ihlr-26084	192	58	.	.	PROPN
ihlr-26084	192	59	(	(	PUNCT
ihlr-26084	192	60	in	in	ADP
ihlr-26084	192	61	re	re	ADP
ihlr-26084	192	62	tamoxifen	tamoxifen	NOUN
ihlr-26084	192	63	citrate	citrate	NOUN
ihlr-26084	192	64	antitrust	antitrust	ADJ
ihlr-26084	192	65	litig	litig	NOUN
ihlr-26084	192	66	.	.	PUNCT
ihlr-26084	192	67	)	)	PUNCT
ihlr-26084	192	68	,	,	PUNCT
ihlr-26084	192	69	466	466	NUM
ihlr-26084	192	70	f.3d	f.3d	NUM
ihlr-26084	192	71	187	187	NUM
ihlr-26084	192	72	(	(	PUNCT
ihlr-26084	192	73	2d	2d	NUM
ihlr-26084	192	74	cir	cir	NOUN
ihlr-26084	192	75	.	.	PUNCT
ihlr-26084	192	76	2006	2006	NUM
ihlr-26084	192	77	)	)	PUNCT
ihlr-26084	192	78	;	;	PUNCT
ihlr-26084	192	79	ark	ark	PROPN
ihlr-26084	192	80	.	.	PUNCT
ihlr-26084	193	1	carpenters	carpenters	PROPN
ihlr-26084	193	2	health	health	PROPN
ihlr-26084	193	3	&	&	CCONJ
ihlr-26084	193	4	welfare	welfare	PROPN
ihlr-26084	193	5	fund	fund	PROPN
ihlr-26084	193	6	v.	v.	ADP
ihlr-26084	193	7	bayer	bayer	PROPN
ihlr-26084	193	8	ag	ag	PROPN
ihlr-26084	193	9	(	(	PUNCT
ihlr-26084	193	10	in	in	ADP
ihlr-26084	193	11	re	re	ADP
ihlr-26084	193	12	ciprofloxacin	ciprofloxacin	NOUN
ihlr-26084	193	13	hydrochloride	hydrochloride	ADJ
ihlr-26084	193	14	antitrust	antitrust	ADJ
ihlr-26084	193	15	litig	litig	NOUN
ihlr-26084	193	16	.	.	PUNCT
ihlr-26084	193	17	)	)	PUNCT
ihlr-26084	194	1	,	,	PUNCT
ihlr-26084	194	2	544	544	NUM
ihlr-26084	194	3	f.3d	f.3d	NUM
ihlr-26084	194	4	1323	1323	NUM
ihlr-26084	194	5	(	(	PUNCT
ihlr-26084	194	6	fed	fed	PROPN
ihlr-26084	194	7	.	.	PUNCT
ihlr-26084	194	8	cir	cir	PROPN
ihlr-26084	194	9	.	.	PROPN
ihlr-26084	194	10	2008	2008	NUM
ihlr-26084	194	11	)	)	PUNCT
ihlr-26084	194	12	;	;	PUNCT
ihlr-26084	194	13	arkansas	arkansas	PROPN
ihlr-26084	194	14	carpenters	carpenters	PROPN
ihlr-26084	194	15	health	health	PROPN
ihlr-26084	194	16	&	&	CCONJ
ihlr-26084	194	17	welfare	welfare	PROPN
ihlr-26084	194	18	fund	fund	PROPN
ihlr-26084	194	19	v.	v.	PROPN
ihlr-26084	194	20	bayer	bayer	PROPN
ihlr-26084	194	21	ag	ag	PROPN
ihlr-26084	194	22	,	,	PUNCT
ihlr-26084	194	23	604	604	NUM
ihlr-26084	194	24	f.3d	f.3d	NUM
ihlr-26084	194	25	98	98	NUM
ihlr-26084	194	26	(	(	PUNCT
ihlr-26084	194	27	2d	2d	NUM
ihlr-26084	194	28	cir	cir	NOUN
ihlr-26084	194	29	.	.	PUNCT
ihlr-26084	194	30	2010	2010	NUM
ihlr-26084	194	31	)	)	PUNCT
ihlr-26084	194	32	;	;	PUNCT
ihlr-26084	194	33	in	in	ADP
ihlr-26084	194	34	re	re	NOUN
ihlr-26084	194	35	k	k	X
ihlr-26084	194	36	-	-	ADJ
ihlr-26084	194	37	dur	dur	ADJ
ihlr-26084	194	38	antitrust	antitrust	ADJ
ihlr-26084	194	39	litig	litig	NOUN
ihlr-26084	194	40	.	.	PUNCT
ihlr-26084	195	1	,	,	PUNCT
ihlr-26084	195	2	686	686	NUM
ihlr-26084	195	3	f.3d	f.3d	NUM
ihlr-26084	195	4	197	197	NUM
ihlr-26084	195	5	(	(	PUNCT
ihlr-26084	195	6	3d	3d	NUM
ihlr-26084	195	7	cir	cir	NOUN
ihlr-26084	195	8	.	.	PROPN
ihlr-26084	195	9	2012	2012	NUM
ihlr-26084	195	10	)	)	PUNCT
ihlr-26084	195	11	;	;	PUNCT
ihlr-26084	195	12	ftc	ftc	PROPN
ihlr-26084	195	13	v.	v.	PROPN
ihlr-26084	195	14	watson	watson	PROPN
ihlr-26084	195	15	pharms	pharms	PROPN
ihlr-26084	195	16	.	.	PUNCT
ihlr-26084	195	17	,	,	PUNCT
ihlr-26084	195	18	inc	inc	PROPN
ihlr-26084	195	19	.	.	PROPN
ihlr-26084	195	20	,	,	PUNCT
ihlr-26084	195	21	677	677	NUM
ihlr-26084	195	22	f.3d	f.3d	NUM
ihlr-26084	195	23	1298	1298	NUM
ihlr-26084	195	24	(	(	PUNCT
ihlr-26084	195	25	11th	11th	ADJ
ihlr-26084	195	26	cir	cir	NOUN
ihlr-26084	195	27	.	.	PROPN
ihlr-26084	195	28	2012	2012	NUM
ihlr-26084	195	29	)	)	PUNCT
ihlr-26084	195	30	.	.	PUNCT
ihlr-26084	196	1	46	46	NUM
ihlr-26084	196	2	.	.	PUNCT
ihlr-26084	196	3	schering	schering	NOUN
ihlr-26084	196	4	-	-	PUNCT
ihlr-26084	196	5	plough	plough	PROPN
ihlr-26084	196	6	corp	corp	PROPN
ihlr-26084	196	7	.	.	PROPN
ihlr-26084	196	8	,	,	PUNCT
ihlr-26084	196	9	402	402	NUM
ihlr-26084	196	10	f.3d	f.3d	NUM
ihlr-26084	196	11	at	at	ADP
ihlr-26084	196	12	1064	1064	NUM
ihlr-26084	196	13	.	.	PUNCT
ihlr-26084	197	1	2022	2022	NUM
ihlr-26084	197	2	]	]	PUNCT
ihlr-26084	197	3	reverse	reverse	ADJ
ihlr-26084	197	4	payment	payment	NOUN
ihlr-26084	197	5	:	:	PUNCT
ihlr-26084	197	6	a	a	DET
ihlr-26084	197	7	comparative	comparative	ADJ
ihlr-26084	197	8	study	study	NOUN
ihlr-26084	197	9	29	29	NUM
ihlr-26084	197	10	exclusionary	exclusionary	ADJ
ihlr-26084	197	11	potential	potential	NOUN
ihlr-26084	197	12	of	of	ADP
ihlr-26084	197	13	the	the	DET
ihlr-26084	197	14	patent	patent	NOUN
ihlr-26084	197	15	.	.	PUNCT
ihlr-26084	198	1	”47	”47	PROPN
ihlr-26084	198	2	because	because	SCONJ
ihlr-26084	198	3	a	a	DET
ihlr-26084	198	4	valid	valid	ADJ
ihlr-26084	198	5	patent	patent	NOUN
ihlr-26084	198	6	grants	grant	VERB
ihlr-26084	198	7	a	a	DET
ihlr-26084	198	8	legal	legal	ADJ
ihlr-26084	198	9	right	right	NOUN
ihlr-26084	198	10	to	to	PART
ihlr-26084	198	11	exclude	exclude	VERB
ihlr-26084	198	12	,	,	PUNCT
ihlr-26084	198	13	a	a	DET
ihlr-26084	198	14	brand	brand	NOUN
ihlr-26084	198	15	manufacturer	manufacturer	NOUN
ihlr-26084	198	16	suing	sue	VERB
ihlr-26084	198	17	for	for	ADP
ihlr-26084	198	18	patent	patent	NOUN
ihlr-26084	198	19	infringement	infringement	NOUN
ihlr-26084	198	20	can	can	AUX
ihlr-26084	198	21	not	not	PART
ihlr-26084	198	22	be	be	AUX
ihlr-26084	198	23	violating	violate	VERB
ihlr-26084	198	24	antitrust	antitrust	ADJ
ihlr-26084	198	25	law	law	NOUN
ihlr-26084	198	26	.	.	PUNCT
ihlr-26084	199	1	so	so	ADV
ihlr-26084	199	2	,	,	PUNCT
ihlr-26084	199	3	a	a	DET
ihlr-26084	199	4	pay	pay	NOUN
ihlr-26084	199	5	-	-	PUNCT
ihlr-26084	199	6	for	for	ADP
ihlr-26084	199	7	-	-	PUNCT
ihlr-26084	199	8	delay	delay	NOUN
ihlr-26084	199	9	agreement	agreement	NOUN
ihlr-26084	199	10	could	could	AUX
ihlr-26084	199	11	only	only	ADV
ihlr-26084	199	12	be	be	AUX
ihlr-26084	199	13	illegal	illegal	ADJ
ihlr-26084	199	14	if	if	SCONJ
ihlr-26084	199	15	the	the	DET
ihlr-26084	199	16	patent	patent	NOUN
ihlr-26084	199	17	was	be	AUX
ihlr-26084	199	18	invalid.48	invalid.48	ADJ
ihlr-26084	199	19	this	this	PRON
ihlr-26084	199	20	created	create	VERB
ihlr-26084	199	21	a	a	DET
ihlr-26084	199	22	significant	significant	ADJ
ihlr-26084	199	23	hurdle	hurdle	NOUN
ihlr-26084	199	24	for	for	ADP
ihlr-26084	199	25	the	the	DET
ihlr-26084	199	26	ftc	ftc	PROPN
ihlr-26084	199	27	and	and	CCONJ
ihlr-26084	199	28	private	private	ADJ
ihlr-26084	199	29	plaintiffs	plaintiff	NOUN
ihlr-26084	199	30	,	,	PUNCT
ihlr-26084	199	31	who	who	PRON
ihlr-26084	199	32	were	be	AUX
ihlr-26084	199	33	expected	expect	VERB
ihlr-26084	199	34	to	to	PART
ihlr-26084	199	35	show	show	VERB
ihlr-26084	199	36	a	a	DET
ihlr-26084	199	37	patent	patent	NOUN
ihlr-26084	199	38	was	be	AUX
ihlr-26084	199	39	invalid	invalid	ADJ
ihlr-26084	199	40	when	when	SCONJ
ihlr-26084	199	41	its	its	PRON
ihlr-26084	199	42	infringement	infringement	NOUN
ihlr-26084	199	43	lawsuit	lawsuit	NOUN
ihlr-26084	199	44	had	have	AUX
ihlr-26084	199	45	already	already	ADV
ihlr-26084	199	46	been	be	AUX
ihlr-26084	199	47	settled	settle	VERB
ihlr-26084	199	48	.	.	PUNCT
ihlr-26084	200	1	in	in	ADP
ihlr-26084	200	2	k	k	ADJ
ihlr-26084	200	3	-	-	ADJ
ihlr-26084	200	4	dur	dur	ADJ
ihlr-26084	200	5	antitrust	antitrust	NOUN
ihlr-26084	200	6	litigation,49	litigation,49	VERB
ihlr-26084	200	7	the	the	DET
ihlr-26084	200	8	third	third	ADJ
ihlr-26084	200	9	circuit	circuit	NOUN
ihlr-26084	200	10	disagreed	disagree	VERB
ihlr-26084	200	11	with	with	ADP
ihlr-26084	200	12	the	the	DET
ihlr-26084	200	13	eleventh	eleventh	ADJ
ihlr-26084	200	14	circuit	circuit	NOUN
ihlr-26084	200	15	in	in	ADP
ihlr-26084	200	16	a	a	DET
ihlr-26084	200	17	case	case	NOUN
ihlr-26084	200	18	that	that	SCONJ
ihlr-26084	200	19	concerned	concern	VERB
ihlr-26084	200	20	the	the	DET
ihlr-26084	200	21	same	same	ADJ
ihlr-26084	200	22	agreement	agreement	NOUN
ihlr-26084	200	23	as	as	ADP
ihlr-26084	200	24	schering	schering	NOUN
ihlr-26084	200	25	-	-	PUNCT
ihlr-26084	200	26	plough	plough	NOUN
ihlr-26084	200	27	.	.	PUNCT
ihlr-26084	201	1	the	the	DET
ihlr-26084	201	2	court	court	NOUN
ihlr-26084	201	3	held	hold	VERB
ihlr-26084	201	4	that	that	SCONJ
ihlr-26084	201	5	the	the	DET
ihlr-26084	201	6	manufacturer	manufacturer	NOUN
ihlr-26084	201	7	’s	’s	PART
ihlr-26084	201	8	monopoly	monopoly	NOUN
ihlr-26084	201	9	over	over	ADP
ihlr-26084	201	10	its	its	PRON
ihlr-26084	201	11	brand	brand	NOUN
ihlr-26084	201	12	-	-	PUNCT
ihlr-26084	201	13	name	name	NOUN
ihlr-26084	201	14	drug	drug	NOUN
ihlr-26084	201	15	is	be	AUX
ihlr-26084	201	16	only	only	ADV
ihlr-26084	201	17	lawful	lawful	ADJ
ihlr-26084	201	18	if	if	SCONJ
ihlr-26084	201	19	its	its	PRON
ihlr-26084	201	20	patents	patent	NOUN
ihlr-26084	201	21	are	be	AUX
ihlr-26084	201	22	valid	valid	ADJ
ihlr-26084	201	23	.	.	PUNCT
ihlr-26084	202	1	because	because	SCONJ
ihlr-26084	202	2	the	the	DET
ihlr-26084	202	3	parties	party	NOUN
ihlr-26084	202	4	settled	settle	VERB
ihlr-26084	202	5	out	out	ADP
ihlr-26084	202	6	of	of	ADP
ihlr-26084	202	7	court	court	NOUN
ihlr-26084	202	8	with	with	ADP
ihlr-26084	202	9	a	a	DET
ihlr-26084	202	10	large	large	ADJ
ihlr-26084	202	11	payment	payment	NOUN
ihlr-26084	202	12	,	,	PUNCT
ihlr-26084	202	13	the	the	DET
ihlr-26084	202	14	court	court	NOUN
ihlr-26084	202	15	reasoned	reason	VERB
ihlr-26084	202	16	that	that	SCONJ
ihlr-26084	202	17	the	the	DET
ihlr-26084	202	18	contested	contest	VERB
ihlr-26084	202	19	patents	patent	NOUN
ihlr-26084	202	20	were	be	AUX
ihlr-26084	202	21	probably	probably	ADV
ihlr-26084	202	22	weak.50	weak.50	VERB
ihlr-26084	202	23	thus	thus	ADV
ihlr-26084	202	24	,	,	PUNCT
ihlr-26084	202	25	the	the	DET
ihlr-26084	202	26	payment	payment	NOUN
ihlr-26084	202	27	could	could	AUX
ihlr-26084	202	28	reveal	reveal	VERB
ihlr-26084	202	29	that	that	SCONJ
ihlr-26084	202	30	the	the	DET
ihlr-26084	202	31	generic	generic	ADJ
ihlr-26084	202	32	was	be	AUX
ihlr-26084	202	33	likely	likely	ADJ
ihlr-26084	202	34	to	to	PART
ihlr-26084	202	35	win	win	VERB
ihlr-26084	202	36	the	the	DET
ihlr-26084	202	37	case	case	NOUN
ihlr-26084	202	38	if	if	SCONJ
ihlr-26084	202	39	it	it	PRON
ihlr-26084	202	40	did	do	AUX
ihlr-26084	202	41	not	not	PART
ihlr-26084	202	42	settle	settle	VERB
ihlr-26084	202	43	.	.	PUNCT
ihlr-26084	203	1	so	so	ADV
ihlr-26084	203	2	,	,	PUNCT
ihlr-26084	203	3	the	the	DET
ihlr-26084	203	4	court	court	NOUN
ihlr-26084	203	5	ruled	rule	VERB
ihlr-26084	203	6	that	that	SCONJ
ihlr-26084	203	7	the	the	DET
ihlr-26084	203	8	reverse	reverse	ADJ
ihlr-26084	203	9	payment	payment	NOUN
ihlr-26084	203	10	settlement	settlement	NOUN
ihlr-26084	203	11	violated	violate	VERB
ihlr-26084	203	12	antitrust	antitrust	ADJ
ihlr-26084	203	13	law	law	NOUN
ihlr-26084	203	14	even	even	ADV
ihlr-26084	203	15	though	though	SCONJ
ihlr-26084	203	16	the	the	DET
ihlr-26084	203	17	underlying	underlie	VERB
ihlr-26084	203	18	patent	patent	NOUN
ihlr-26084	203	19	validity	validity	NOUN
ihlr-26084	203	20	was	be	AUX
ihlr-26084	203	21	unknown	unknown	ADJ
ihlr-26084	203	22	because	because	SCONJ
ihlr-26084	203	23	it	it	PRON
ihlr-26084	203	24	eliminated	eliminate	VERB
ihlr-26084	203	25	the	the	DET
ihlr-26084	203	26	possibility	possibility	NOUN
ihlr-26084	203	27	of	of	ADP
ihlr-26084	203	28	competition.51	competition.51	NOUN
ihlr-26084	203	29	the	the	DET
ihlr-26084	203	30	supreme	supreme	PROPN
ihlr-26084	203	31	court	court	PROPN
ihlr-26084	203	32	followed	follow	VERB
ihlr-26084	203	33	a	a	DET
ihlr-26084	203	34	similar	similar	ADJ
ihlr-26084	203	35	line	line	NOUN
ihlr-26084	203	36	of	of	ADP
ihlr-26084	203	37	reasoning	reasoning	NOUN
ihlr-26084	203	38	in	in	ADP
ihlr-26084	203	39	ftc	ftc	PROPN
ihlr-26084	203	40	v.	v.	ADP
ihlr-26084	203	41	actavis	actavis	PROPN
ihlr-26084	203	42	,	,	PUNCT
ihlr-26084	203	43	inc.52	inc.52	NOUN
ihlr-26084	203	44	the	the	DET
ihlr-26084	203	45	brand	brand	PROPN
ihlr-26084	203	46	firm	firm	PROPN
ihlr-26084	203	47	solvay	solvay	PROPN
ihlr-26084	203	48	sued	sue	VERB
ihlr-26084	203	49	the	the	DET
ihlr-26084	203	50	generic	generic	ADJ
ihlr-26084	203	51	firm	firm	NOUN
ihlr-26084	203	52	actavis	actavis	NOUN
ihlr-26084	203	53	for	for	ADP
ihlr-26084	203	54	allegedly	allegedly	ADV
ihlr-26084	203	55	violating	violate	VERB
ihlr-26084	203	56	its	its	PRON
ihlr-26084	203	57	patents	patent	NOUN
ihlr-26084	203	58	in	in	ADP
ihlr-26084	203	59	creating	create	VERB
ihlr-26084	203	60	a	a	DET
ihlr-26084	203	61	generic	generic	ADJ
ihlr-26084	203	62	alternative	alternative	NOUN
ihlr-26084	203	63	of	of	ADP
ihlr-26084	203	64	the	the	DET
ihlr-26084	203	65	testosterone	testosterone	NOUN
ihlr-26084	203	66	drug	drug	NOUN
ihlr-26084	203	67	androgel.53	androgel.53	PROPN
ihlr-26084	203	68	solvay	solvay	PROPN
ihlr-26084	203	69	than	than	SCONJ
ihlr-26084	203	70	settled	settle	VERB
ihlr-26084	203	71	with	with	ADP
ihlr-26084	203	72	actavis	actavi	NOUN
ihlr-26084	203	73	,	,	PUNCT
ihlr-26084	203	74	agreeing	agree	VERB
ihlr-26084	203	75	to	to	PART
ihlr-26084	203	76	pay	pay	VERB
ihlr-26084	203	77	$	$	SYM
ihlr-26084	203	78	19	19	NUM
ihlr-26084	203	79	-	-	SYM
ihlr-26084	203	80	30	30	NUM
ihlr-26084	203	81	million	million	NUM
ihlr-26084	203	82	per	per	ADP
ihlr-26084	203	83	year	year	NOUN
ihlr-26084	203	84	to	to	PART
ihlr-26084	203	85	delay	delay	VERB
ihlr-26084	203	86	generic	generic	PROPN
ihlr-26084	203	87	entry.54	entry.54	PROPN
ihlr-26084	203	88	solvay	solvay	PROPN
ihlr-26084	203	89	sued	sue	VERB
ihlr-26084	203	90	and	and	CCONJ
ihlr-26084	203	91	settled	settle	VERB
ihlr-26084	203	92	with	with	ADP
ihlr-26084	203	93	other	other	ADJ
ihlr-26084	203	94	generic	generic	ADJ
ihlr-26084	203	95	companies	company	NOUN
ihlr-26084	203	96	as	as	ADP
ihlr-26084	203	97	well.55	well.55	NOUN
ihlr-26084	203	98	in	in	ADP
ihlr-26084	203	99	2009	2009	NUM
ihlr-26084	203	100	,	,	PUNCT
ihlr-26084	203	101	the	the	DET
ihlr-26084	203	102	ftc	ftc	PROPN
ihlr-26084	203	103	sued	sue	VERB
ihlr-26084	203	104	all	all	DET
ihlr-26084	203	105	parties	party	NOUN
ihlr-26084	203	106	,	,	PUNCT
ihlr-26084	203	107	alleging	allege	VERB
ihlr-26084	203	108	illegal	illegal	ADJ
ihlr-26084	203	109	monopoly	monopoly	NOUN
ihlr-26084	203	110	profit	profit	NOUN
ihlr-26084	203	111	sharing.56	sharing.56	NOUN
ihlr-26084	203	112	the	the	DET
ihlr-26084	203	113	appeals	appeal	NOUN
ihlr-26084	203	114	court	court	NOUN
ihlr-26084	203	115	ruled	rule	VERB
ihlr-26084	203	116	that	that	SCONJ
ihlr-26084	203	117	the	the	DET
ihlr-26084	203	118	settlement	settlement	NOUN
ihlr-26084	203	119	scheme	scheme	NOUN
ihlr-26084	203	120	could	could	AUX
ihlr-26084	203	121	not	not	PART
ihlr-26084	203	122	be	be	AUX
ihlr-26084	203	123	illegal	illegal	ADJ
ihlr-26084	203	124	because	because	SCONJ
ihlr-26084	203	125	solvay	solvay	NOUN
ihlr-26084	203	126	’s	’s	PART
ihlr-26084	203	127	agreements	agreement	NOUN
ihlr-26084	203	128	fell	fall	VERB
ihlr-26084	203	129	within	within	ADP
ihlr-26084	203	130	the	the	DET
ihlr-26084	203	131	scope	scope	NOUN
ihlr-26084	203	132	of	of	ADP
ihlr-26084	203	133	its	its	PRON
ihlr-26084	203	134	patent	patent	NOUN
ihlr-26084	203	135	rights.57	rights.57	NOUN
ihlr-26084	203	136	at	at	ADP
ihlr-26084	203	137	the	the	DET
ihlr-26084	203	138	ftc	ftc	PROPN
ihlr-26084	203	139	’s	’s	PART
ihlr-26084	203	140	request	request	NOUN
ihlr-26084	203	141	,	,	PUNCT
ihlr-26084	203	142	the	the	DET
ihlr-26084	203	143	court	court	NOUN
ihlr-26084	203	144	granted	grant	VERB
ihlr-26084	203	145	certiorari	certiorari	NOUN
ihlr-26084	203	146	.	.	PUNCT
ihlr-26084	204	1	to	to	PART
ihlr-26084	204	2	evaluate	evaluate	VERB
ihlr-26084	204	3	whether	whether	SCONJ
ihlr-26084	204	4	a	a	DET
ihlr-26084	204	5	reverse	reverse	ADJ
ihlr-26084	204	6	payment	payment	NOUN
ihlr-26084	204	7	scheme	scheme	NOUN
ihlr-26084	204	8	is	be	AUX
ihlr-26084	204	9	anticompetitive	anticompetitive	ADJ
ihlr-26084	204	10	,	,	PUNCT
ihlr-26084	204	11	the	the	DET
ihlr-26084	204	12	court	court	NOUN
ihlr-26084	204	13	adopted	adopt	VERB
ihlr-26084	204	14	an	an	DET
ihlr-26084	204	15	unjustified	unjustified	ADJ
ihlr-26084	204	16	payment	payment	NOUN
ihlr-26084	204	17	size	size	NOUN
ihlr-26084	204	18	test.58	test.58	NOUN
ihlr-26084	204	19	in	in	ADP
ihlr-26084	204	20	the	the	DET
ihlr-26084	204	21	court	court	NOUN
ihlr-26084	204	22	’s	’s	PART
ihlr-26084	204	23	reasoning	reasoning	NOUN
ihlr-26084	204	24	,	,	PUNCT
ihlr-26084	204	25	a	a	DET
ihlr-26084	204	26	larger	large	ADJ
ihlr-26084	204	27	payment	payment	NOUN
ihlr-26084	204	28	by	by	ADP
ihlr-26084	204	29	the	the	DET
ihlr-26084	204	30	plaintiff	plaintiff	NOUN
ihlr-26084	204	31	suggests	suggest	VERB
ihlr-26084	204	32	that	that	SCONJ
ihlr-26084	204	33	the	the	DET
ihlr-26084	204	34	plaintiff	plaintiff	NOUN
ihlr-26084	204	35	did	do	AUX
ihlr-26084	204	36	not	not	PART
ihlr-26084	204	37	expect	expect	VERB
ihlr-26084	204	38	to	to	PART
ihlr-26084	204	39	win	win	VERB
ihlr-26084	204	40	the	the	DET
ihlr-26084	204	41	infringement	infringement	NOUN
ihlr-26084	204	42	case	case	NOUN
ihlr-26084	204	43	.	.	PUNCT
ihlr-26084	205	1	payment	payment	NOUN
ihlr-26084	205	2	size	size	NOUN
ihlr-26084	205	3	could	could	AUX
ihlr-26084	205	4	serve	serve	VERB
ihlr-26084	205	5	as	as	ADP
ihlr-26084	205	6	a	a	DET
ihlr-26084	205	7	proxy	proxy	NOUN
ihlr-26084	205	8	for	for	ADP
ihlr-26084	205	9	patent	patent	NOUN
ihlr-26084	205	10	validity	validity	NOUN
ihlr-26084	205	11	.	.	PUNCT
ihlr-26084	206	1	the	the	DET
ihlr-26084	206	2	question	question	NOUN
ihlr-26084	206	3	that	that	SCONJ
ihlr-26084	206	4	courts	court	NOUN
ihlr-26084	206	5	must	must	AUX
ihlr-26084	206	6	then	then	ADV
ihlr-26084	206	7	resolve	resolve	VERB
ihlr-26084	206	8	is	be	AUX
ihlr-26084	206	9	whether	whether	SCONJ
ihlr-26084	206	10	the	the	DET
ihlr-26084	206	11	payment	payment	NOUN
ihlr-26084	206	12	size	size	NOUN
ihlr-26084	206	13	is	be	AUX
ihlr-26084	206	14	“	"	PUNCT
ihlr-26084	206	15	large	large	ADJ
ihlr-26084	206	16	and	and	CCONJ
ihlr-26084	206	17	47	47	NUM
ihlr-26084	206	18	.	.	PUNCT
ihlr-26084	207	1	ftc	ftc	PROPN
ihlr-26084	207	2	v.	v.	ADP
ihlr-26084	207	3	actavis	actavis	PROPN
ihlr-26084	207	4	,	,	PUNCT
ihlr-26084	207	5	inc	inc	PROPN
ihlr-26084	207	6	.	.	PROPN
ihlr-26084	207	7	,	,	PUNCT
ihlr-26084	207	8	133	133	NUM
ihlr-26084	207	9	s.	s.	PROPN
ihlr-26084	207	10	ct	ct	PROPN
ihlr-26084	207	11	.	.	PROPN
ihlr-26084	207	12	2223	2223	NUM
ihlr-26084	207	13	,	,	PUNCT
ihlr-26084	207	14	2230	2230	NUM
ihlr-26084	207	15	(	(	PUNCT
ihlr-26084	207	16	2013	2013	NUM
ihlr-26084	207	17	)	)	PUNCT
ihlr-26084	207	18	(	(	PUNCT
ihlr-26084	207	19	citing	cite	VERB
ihlr-26084	207	20	ftc	ftc	PROPN
ihlr-26084	207	21	v.	v.	PROPN
ihlr-26084	207	22	watson	watson	PROPN
ihlr-26084	207	23	,	,	PUNCT
ihlr-26084	207	24	677	677	NUM
ihlr-26084	207	25	f.3d	f.3d	NUM
ihlr-26084	207	26	1298	1298	NUM
ihlr-26084	207	27	,	,	PUNCT
ihlr-26084	207	28	1312	1312	NUM
ihlr-26084	207	29	(	(	PUNCT
ihlr-26084	207	30	11th	11th	ADJ
ihlr-26084	207	31	cir	cir	NOUN
ihlr-26084	207	32	.	.	PROPN
ihlr-26084	207	33	2012	2012	NUM
ihlr-26084	207	34	)	)	PUNCT
ihlr-26084	207	35	)	)	PUNCT
ihlr-26084	207	36	.	.	PUNCT
ihlr-26084	208	1	48	48	NUM
ihlr-26084	208	2	.	.	PUNCT
ihlr-26084	209	1	i	i	PRON
ihlr-26084	209	2	d.	d.	PROPN
ihlr-26084	209	3	49	49	NUM
ihlr-26084	209	4	.	.	PUNCT
ihlr-26084	210	1	in	in	ADP
ihlr-26084	210	2	re	re	NOUN
ihlr-26084	210	3	k	k	X
ihlr-26084	210	4	-	-	ADJ
ihlr-26084	210	5	dur	dur	ADJ
ihlr-26084	210	6	antitrust	antitrust	ADJ
ihlr-26084	210	7	litig	litig	NOUN
ihlr-26084	210	8	.	.	PUNCT
ihlr-26084	211	1	,	,	PUNCT
ihlr-26084	211	2	686	686	NUM
ihlr-26084	211	3	f.3d	f.3d	NUM
ihlr-26084	211	4	at	at	ADP
ihlr-26084	211	5	211	211	NUM
ihlr-26084	211	6	(	(	PUNCT
ihlr-26084	211	7	“	"	PUNCT
ihlr-26084	211	8	we	we	PRON
ihlr-26084	211	9	do	do	AUX
ihlr-26084	211	10	not	not	PART
ihlr-26084	211	11	find	find	VERB
ihlr-26084	211	12	the	the	DET
ihlr-26084	211	13	eleventh	eleventh	ADJ
ihlr-26084	211	14	circuit	circuit	NOUN
ihlr-26084	211	15	’s	’s	PART
ihlr-26084	211	16	decision	decision	NOUN
ihlr-26084	211	17	in	in	ADP
ihlr-26084	211	18	schering	schering	NOUN
ihlr-26084	211	19	-	-	PUNCT
ihlr-26084	211	20	plough	plough	NOUN
ihlr-26084	211	21	persuasive	persuasive	NOUN
ihlr-26084	211	22	,	,	PUNCT
ihlr-26084	211	23	and	and	CCONJ
ihlr-26084	211	24	thus	thus	ADV
ihlr-26084	211	25	decline	decline	VERB
ihlr-26084	211	26	to	to	PART
ihlr-26084	211	27	follow	follow	VERB
ihlr-26084	211	28	it	it	PRON
ihlr-26084	211	29	.	.	PUNCT
ihlr-26084	211	30	”	"	PUNCT
ihlr-26084	211	31	)	)	PUNCT
ihlr-26084	211	32	.	.	PUNCT
ihlr-26084	212	1	50	50	NUM
ihlr-26084	212	2	.	.	PUNCT
ihlr-26084	213	1	i	i	PRON
ihlr-26084	213	2	d.	d.	PROPN
ihlr-26084	213	3	51	51	NUM
ihlr-26084	213	4	.	.	PUNCT
ihlr-26084	214	1	i	i	PRON
ihlr-26084	214	2	d.	d.	PROPN
ihlr-26084	214	3	52	52	NUM
ihlr-26084	214	4	.	.	PUNCT
ihlr-26084	215	1	actavis	actavis	PROPN
ihlr-26084	215	2	,	,	PUNCT
ihlr-26084	215	3	inc	inc	PROPN
ihlr-26084	215	4	.	.	PROPN
ihlr-26084	215	5	,	,	PUNCT
ihlr-26084	215	6	570	570	NUM
ihlr-26084	215	7	u.s	u.s	PROPN
ihlr-26084	215	8	.	.	PROPN
ihlr-26084	215	9	at	at	ADP
ihlr-26084	215	10	136	136	NUM
ihlr-26084	215	11	.	.	PUNCT
ihlr-26084	216	1	53	53	NUM
ihlr-26084	216	2	.	.	PUNCT
ihlr-26084	217	1	i	i	PRON
ihlr-26084	217	2	d.	d.	PROPN
ihlr-26084	217	3	at	at	ADP
ihlr-26084	217	4	144	144	NUM
ihlr-26084	217	5	-	-	SYM
ihlr-26084	217	6	46	46	NUM
ihlr-26084	217	7	.	.	PUNCT
ihlr-26084	218	1	54	54	NUM
ihlr-26084	218	2	.	.	PUNCT
ihlr-26084	219	1	i	i	PRON
ihlr-26084	219	2	d.	d.	PROPN
ihlr-26084	219	3	55	55	NUM
ihlr-26084	219	4	.	.	PUNCT
ihlr-26084	220	1	i	i	PRON
ihlr-26084	220	2	d.	d.	PROPN
ihlr-26084	220	3	56	56	NUM
ihlr-26084	220	4	.	.	PUNCT
ihlr-26084	221	1	i	i	PRON
ihlr-26084	221	2	d.	d.	PROPN
ihlr-26084	221	3	57	57	NUM
ihlr-26084	221	4	.	.	PUNCT
ihlr-26084	222	1	i	i	PRON
ihlr-26084	222	2	d.	d.	PROPN
ihlr-26084	222	3	58	58	NUM
ihlr-26084	222	4	.	.	PUNCT
ihlr-26084	223	1	i	i	PRON
ihlr-26084	223	2	d.	d.	PROPN
ihlr-26084	223	3	at	at	ADP
ihlr-26084	223	4	159	159	NUM
ihlr-26084	223	5	(	(	PUNCT
ihlr-26084	223	6	“	"	PUNCT
ihlr-26084	223	7	the	the	DET
ihlr-26084	223	8	likelihood	likelihood	NOUN
ihlr-26084	223	9	of	of	ADP
ihlr-26084	223	10	a	a	DET
ihlr-26084	223	11	reverse	reverse	ADJ
ihlr-26084	223	12	payment	payment	NOUN
ihlr-26084	223	13	bringing	bring	VERB
ihlr-26084	223	14	about	about	ADP
ihlr-26084	223	15	anticompetitive	anticompetitive	ADJ
ihlr-26084	223	16	effects	effect	NOUN
ihlr-26084	223	17	depends	depend	VERB
ihlr-26084	223	18	upon	upon	SCONJ
ihlr-26084	223	19	its	its	PRON
ihlr-26084	223	20	size	size	NOUN
ihlr-26084	223	21	.	.	PUNCT
ihlr-26084	223	22	”	"	PUNCT
ihlr-26084	224	1	)	)	PUNCT
ihlr-26084	224	2	30	30	NUM
ihlr-26084	224	3	indiana	indiana	PROPN
ihlr-26084	224	4	health	health	PROPN
ihlr-26084	224	5	law	law	PROPN
ihlr-26084	224	6	review	review	NOUN
ihlr-26084	225	1	[	[	X
ihlr-26084	225	2	vol	vol	NOUN
ihlr-26084	225	3	.	.	PUNCT
ihlr-26084	225	4	19:21	19:21	NUM
ihlr-26084	225	5	unjustified	unjustified	ADJ
ihlr-26084	225	6	.	.	PUNCT
ihlr-26084	226	1	”59	”59	ADJ
ihlr-26084	226	2	to	to	PART
ihlr-26084	226	3	do	do	VERB
ihlr-26084	226	4	so	so	ADV
ihlr-26084	226	5	,	,	PUNCT
ihlr-26084	226	6	courts	court	NOUN
ihlr-26084	226	7	should	should	AUX
ihlr-26084	226	8	look	look	VERB
ihlr-26084	226	9	at	at	ADP
ihlr-26084	226	10	“	"	PUNCT
ihlr-26084	226	11	[	[	X
ihlr-26084	226	12	the	the	DET
ihlr-26084	226	13	payment	payment	NOUN
ihlr-26084	226	14	]	]	PUNCT
ihlr-26084	226	15	size	size	NOUN
ihlr-26084	226	16	,	,	PUNCT
ihlr-26084	226	17	its	its	PRON
ihlr-26084	226	18	scale	scale	NOUN
ihlr-26084	226	19	in	in	ADP
ihlr-26084	226	20	relation	relation	NOUN
ihlr-26084	226	21	to	to	ADP
ihlr-26084	226	22	the	the	DET
ihlr-26084	226	23	payor	payor	NOUN
ihlr-26084	226	24	’s	’s	PART
ihlr-26084	226	25	anticipated	anticipate	VERB
ihlr-26084	226	26	future	future	ADJ
ihlr-26084	226	27	litigation	litigation	NOUN
ihlr-26084	226	28	costs	cost	NOUN
ihlr-26084	226	29	,	,	PUNCT
ihlr-26084	226	30	its	its	PRON
ihlr-26084	226	31	independence	independence	NOUN
ihlr-26084	226	32	from	from	ADP
ihlr-26084	226	33	other	other	ADJ
ihlr-26084	226	34	services	service	NOUN
ihlr-26084	226	35	for	for	ADP
ihlr-26084	226	36	which	which	PRON
ihlr-26084	226	37	it	it	PRON
ihlr-26084	226	38	might	might	AUX
ihlr-26084	226	39	represent	represent	VERB
ihlr-26084	226	40	payment	payment	NOUN
ihlr-26084	226	41	,	,	PUNCT
ihlr-26084	226	42	and	and	CCONJ
ihlr-26084	226	43	the	the	DET
ihlr-26084	226	44	lack	lack	NOUN
ihlr-26084	226	45	of	of	ADP
ihlr-26084	226	46	any	any	DET
ihlr-26084	226	47	other	other	ADJ
ihlr-26084	226	48	convincing	convincing	ADJ
ihlr-26084	226	49	[	[	X
ihlr-26084	226	50	procompetitive	procompetitive	ADJ
ihlr-26084	226	51	]	]	PUNCT
ihlr-26084	226	52	justification	justification	NOUN
ihlr-26084	226	53	.	.	PUNCT
ihlr-26084	227	1	”60	”60	PROPN
ihlr-26084	227	2	actavis	actavis	PROPN
ihlr-26084	227	3	was	be	AUX
ihlr-26084	227	4	a	a	DET
ihlr-26084	227	5	victory	victory	NOUN
ihlr-26084	227	6	for	for	ADP
ihlr-26084	227	7	consumers	consumer	NOUN
ihlr-26084	227	8	.	.	PUNCT
ihlr-26084	228	1	it	it	PRON
ihlr-26084	228	2	established	establish	VERB
ihlr-26084	228	3	that	that	PRON
ihlr-26084	228	4	reverse	reverse	ADJ
ihlr-26084	228	5	payment	payment	NOUN
ihlr-26084	228	6	schemes	scheme	NOUN
ihlr-26084	228	7	can	can	AUX
ihlr-26084	228	8	be	be	AUX
ihlr-26084	228	9	subject	subject	ADJ
ihlr-26084	228	10	to	to	ADP
ihlr-26084	228	11	antitrust	antitrust	ADJ
ihlr-26084	228	12	scrutiny	scrutiny	NOUN
ihlr-26084	228	13	under	under	ADP
ihlr-26084	228	14	an	an	DET
ihlr-26084	228	15	unjustifiability	unjustifiability	NOUN
ihlr-26084	228	16	standard	standard	NOUN
ihlr-26084	228	17	.	.	PUNCT
ihlr-26084	229	1	since	since	SCONJ
ihlr-26084	229	2	then	then	ADV
ihlr-26084	229	3	,	,	PUNCT
ihlr-26084	229	4	the	the	DET
ihlr-26084	229	5	number	number	NOUN
ihlr-26084	229	6	of	of	ADP
ihlr-26084	229	7	illegal	illegal	ADJ
ihlr-26084	229	8	reverse	reverse	ADJ
ihlr-26084	229	9	payment	payment	NOUN
ihlr-26084	229	10	schemes	scheme	NOUN
ihlr-26084	229	11	in	in	ADP
ihlr-26084	229	12	the	the	DET
ihlr-26084	229	13	united	united	PROPN
ihlr-26084	229	14	states	states	PROPN
ihlr-26084	229	15	has	have	AUX
ihlr-26084	229	16	reduced	reduce	VERB
ihlr-26084	229	17	considerably	considerably	ADV
ihlr-26084	229	18	(	(	PUNCT
ihlr-26084	229	19	according	accord	VERB
ihlr-26084	229	20	to	to	ADP
ihlr-26084	229	21	the	the	DET
ihlr-26084	229	22	ftc).61	ftc).61	NOUN
ihlr-26084	229	23	but	but	CCONJ
ihlr-26084	229	24	this	this	PRON
ihlr-26084	229	25	does	do	AUX
ihlr-26084	229	26	not	not	PART
ihlr-26084	229	27	mean	mean	VERB
ihlr-26084	229	28	that	that	SCONJ
ihlr-26084	229	29	reverse	reverse	ADJ
ihlr-26084	229	30	payment	payment	NOUN
ihlr-26084	229	31	schemes	scheme	NOUN
ihlr-26084	229	32	have	have	AUX
ihlr-26084	229	33	disappeared	disappear	VERB
ihlr-26084	229	34	.	.	PUNCT
ihlr-26084	230	1	instead	instead	ADV
ihlr-26084	230	2	,	,	PUNCT
ihlr-26084	230	3	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	230	4	companies	company	NOUN
ihlr-26084	230	5	have	have	AUX
ihlr-26084	230	6	established	establish	VERB
ihlr-26084	230	7	many	many	ADJ
ihlr-26084	230	8	creative	creative	ADJ
ihlr-26084	230	9	arrangements	arrangement	NOUN
ihlr-26084	230	10	that	that	PRON
ihlr-26084	230	11	make	make	VERB
ihlr-26084	230	12	prosecution	prosecution	NOUN
ihlr-26084	230	13	harder.62	harder.62	NOUN
ihlr-26084	230	14	courts	court	NOUN
ihlr-26084	230	15	have	have	AUX
ihlr-26084	230	16	also	also	ADV
ihlr-26084	230	17	disarmed	disarm	VERB
ihlr-26084	230	18	some	some	DET
ihlr-26084	230	19	public	public	ADJ
ihlr-26084	230	20	and	and	CCONJ
ihlr-26084	230	21	private	private	ADJ
ihlr-26084	230	22	enforcers	enforcer	NOUN
ihlr-26084	230	23	from	from	ADP
ihlr-26084	230	24	disincentivizing	disincentivize	VERB
ihlr-26084	230	25	pay	pay	NOUN
ihlr-26084	230	26	-	-	PUNCT
ihlr-26084	230	27	for	for	ADP
ihlr-26084	230	28	-	-	PUNCT
ihlr-26084	230	29	delay	delay	NOUN
ihlr-26084	230	30	.	.	PUNCT
ihlr-26084	231	1	first	first	ADV
ihlr-26084	231	2	,	,	PUNCT
ihlr-26084	231	3	some	some	DET
ihlr-26084	231	4	courts	court	NOUN
ihlr-26084	231	5	have	have	AUX
ihlr-26084	231	6	constricted	constrict	VERB
ihlr-26084	231	7	the	the	DET
ihlr-26084	231	8	ability	ability	NOUN
ihlr-26084	231	9	of	of	ADP
ihlr-26084	231	10	private	private	ADJ
ihlr-26084	231	11	plaintiffs	plaintiff	NOUN
ihlr-26084	231	12	to	to	PART
ihlr-26084	231	13	claim	claim	VERB
ihlr-26084	231	14	antitrust	antitrust	ADJ
ihlr-26084	231	15	injury	injury	NOUN
ihlr-26084	231	16	.	.	PUNCT
ihlr-26084	232	1	in	in	ADP
ihlr-26084	232	2	wellbutrin,63	wellbutrin,63	ADJ
ihlr-26084	232	3	a	a	DET
ihlr-26084	232	4	pay	pay	VERB
ihlr-26084	232	5	-	-	PUNCT
ihlr-26084	232	6	for	for	ADP
ihlr-26084	232	7	-	-	PUNCT
ihlr-26084	232	8	delay	delay	NOUN
ihlr-26084	232	9	scheme	scheme	NOUN
ihlr-26084	232	10	settled	settle	VERB
ihlr-26084	232	11	several	several	ADJ
ihlr-26084	232	12	patent	patent	NOUN
ihlr-26084	232	13	disputes	dispute	NOUN
ihlr-26084	232	14	for	for	ADP
ihlr-26084	232	15	a	a	DET
ihlr-26084	232	16	brand	brand	NOUN
ihlr-26084	232	17	-	-	PUNCT
ihlr-26084	232	18	name	name	NOUN
ihlr-26084	232	19	drug	drug	NOUN
ihlr-26084	232	20	but	but	CCONJ
ihlr-26084	232	21	left	leave	VERB
ihlr-26084	232	22	one	one	NUM
ihlr-26084	232	23	dispute	dispute	NOUN
ihlr-26084	232	24	unresolved	unresolved	ADJ
ihlr-26084	232	25	because	because	SCONJ
ihlr-26084	232	26	the	the	DET
ihlr-26084	232	27	patent	patent	NOUN
ihlr-26084	232	28	belonged	belong	VERB
ihlr-26084	232	29	to	to	ADP
ihlr-26084	232	30	a	a	DET
ihlr-26084	232	31	third	third	ADJ
ihlr-26084	232	32	party.64	party.64	NOUN
ihlr-26084	232	33	the	the	DET
ihlr-26084	232	34	court	court	NOUN
ihlr-26084	232	35	ruled	rule	VERB
ihlr-26084	232	36	that	that	SCONJ
ihlr-26084	232	37	plaintiffs	plaintiff	NOUN
ihlr-26084	232	38	could	could	AUX
ihlr-26084	232	39	not	not	PART
ihlr-26084	232	40	claim	claim	VERB
ihlr-26084	232	41	injury	injury	NOUN
ihlr-26084	232	42	without	without	ADP
ihlr-26084	232	43	showing	show	VERB
ihlr-26084	232	44	that	that	SCONJ
ihlr-26084	232	45	the	the	DET
ihlr-26084	232	46	outstanding	outstanding	ADJ
ihlr-26084	232	47	patent	patent	NOUN
ihlr-26084	232	48	dispute	dispute	NOUN
ihlr-26084	232	49	was	be	AUX
ihlr-26084	232	50	likely	likely	ADJ
ihlr-26084	232	51	to	to	PART
ihlr-26084	232	52	be	be	AUX
ihlr-26084	232	53	resolved	resolve	VERB
ihlr-26084	232	54	in	in	ADP
ihlr-26084	232	55	favor	favor	NOUN
ihlr-26084	232	56	of	of	ADP
ihlr-26084	232	57	the	the	DET
ihlr-26084	232	58	generics.65	generics.65	NOUN
ihlr-26084	232	59	to	to	PART
ihlr-26084	232	60	make	make	VERB
ihlr-26084	232	61	this	this	DET
ihlr-26084	232	62	showing	showing	NOUN
ihlr-26084	232	63	,	,	PUNCT
ihlr-26084	232	64	the	the	DET
ihlr-26084	232	65	court	court	NOUN
ihlr-26084	232	66	expected	expect	VERB
ihlr-26084	232	67	plaintiffs	plaintiff	NOUN
ihlr-26084	232	68	to	to	PART
ihlr-26084	232	69	discuss	discuss	VERB
ihlr-26084	232	70	the	the	DET
ihlr-26084	232	71	underlying	underlie	VERB
ihlr-26084	232	72	patent	patent	NOUN
ihlr-26084	232	73	’s	’s	PART
ihlr-26084	232	74	validity	validity	NOUN
ihlr-26084	232	75	;	;	PUNCT
ihlr-26084	232	76	it	it	PRON
ihlr-26084	232	77	held	hold	VERB
ihlr-26084	232	78	that	that	SCONJ
ihlr-26084	232	79	the	the	DET
ihlr-26084	232	80	unjustified	unjustified	ADJ
ihlr-26084	232	81	payment	payment	NOUN
ihlr-26084	232	82	size	size	NOUN
ihlr-26084	232	83	alone	alone	ADV
ihlr-26084	232	84	was	be	AUX
ihlr-26084	232	85	insufficient	insufficient	ADJ
ihlr-26084	232	86	evidence.66	evidence.66	NOUN
ihlr-26084	232	87	in	in	ADP
ihlr-26084	232	88	nexium	nexium	NOUN
ihlr-26084	232	89	,	,	PUNCT
ihlr-26084	232	90	the	the	DET
ihlr-26084	232	91	first	first	ADJ
ihlr-26084	232	92	circuit	circuit	NOUN
ihlr-26084	232	93	similarly	similarly	ADV
ihlr-26084	232	94	ruled	rule	VERB
ihlr-26084	232	95	that	that	SCONJ
ihlr-26084	232	96	defendants	defendant	NOUN
ihlr-26084	232	97	did	do	AUX
ihlr-26084	232	98	not	not	PART
ihlr-26084	232	99	cause	cause	VERB
ihlr-26084	232	100	injury	injury	NOUN
ihlr-26084	232	101	even	even	ADV
ihlr-26084	232	102	though	though	SCONJ
ihlr-26084	232	103	they	they	PRON
ihlr-26084	232	104	were	be	AUX
ihlr-26084	232	105	liable.67	liable.67	ADJ
ihlr-26084	232	106	the	the	DET
ihlr-26084	232	107	companies	company	NOUN
ihlr-26084	232	108	astrazeneca	astrazeneca	PROPN
ihlr-26084	232	109	and	and	CCONJ
ihlr-26084	232	110	ranbaxy	ranbaxy	PROPN
ihlr-26084	232	111	formed	form	VERB
ihlr-26084	232	112	a	a	DET
ihlr-26084	232	113	billion	billion	NUM
ihlr-26084	232	114	-	-	PUNCT
ihlr-26084	232	115	dollar	dollar	NOUN
ihlr-26084	232	116	reverse	reverse	ADJ
ihlr-26084	232	117	payment	payment	NOUN
ihlr-26084	232	118	scheme	scheme	NOUN
ihlr-26084	232	119	.	.	PUNCT
ihlr-26084	233	1	ranbaxy	ranbaxy	PROPN
ihlr-26084	233	2	,	,	PUNCT
ihlr-26084	233	3	however	however	ADV
ihlr-26084	233	4	,	,	PUNCT
ihlr-26084	233	5	was	be	AUX
ihlr-26084	233	6	soon	soon	ADV
ihlr-26084	233	7	thereafter	thereafter	ADV
ihlr-26084	233	8	suspended	suspend	VERB
ihlr-26084	233	9	from	from	ADP
ihlr-26084	233	10	marketing	market	VERB
ihlr-26084	233	11	any	any	DET
ihlr-26084	233	12	drugs	drug	NOUN
ihlr-26084	233	13	by	by	ADP
ihlr-26084	233	14	the	the	DET
ihlr-26084	233	15	fda	fda	PROPN
ihlr-26084	233	16	after	after	SCONJ
ihlr-26084	233	17	a	a	DET
ihlr-26084	233	18	quality	quality	NOUN
ihlr-26084	233	19	control	control	NOUN
ihlr-26084	233	20	scandal.68	scandal.68	PROPN
ihlr-26084	233	21	so	so	ADV
ihlr-26084	233	22	,	,	PUNCT
ihlr-26084	233	23	the	the	DET
ihlr-26084	233	24	court	court	NOUN
ihlr-26084	233	25	reasoned	reason	VERB
ihlr-26084	233	26	that	that	SCONJ
ihlr-26084	233	27	generic	generic	ADJ
ihlr-26084	233	28	entry	entry	NOUN
ihlr-26084	233	29	by	by	ADP
ihlr-26084	233	30	ranbaxy	ranbaxy	PROPN
ihlr-26084	233	31	never	never	ADV
ihlr-26084	233	32	would	would	AUX
ihlr-26084	233	33	have	have	VERB
ihlr-26084	233	34	59	59	NUM
ihlr-26084	233	35	.	.	PUNCT
ihlr-26084	234	1	i	i	PRON
ihlr-26084	234	2	d.	d.	PROPN
ihlr-26084	234	3	60	60	NUM
ihlr-26084	234	4	.	.	PUNCT
ihlr-26084	235	1	i	i	PRON
ihlr-26084	235	2	d.	d.	PROPN
ihlr-26084	235	3	61	61	NUM
ihlr-26084	235	4	.	.	PUNCT
ihlr-26084	236	1	jamie	jamie	PROPN
ihlr-26084	236	2	towey	towey	PROPN
ihlr-26084	236	3	&	&	CCONJ
ihlr-26084	236	4	brad	brad	PROPN
ihlr-26084	236	5	albert	albert	PROPN
ihlr-26084	236	6	,	,	PUNCT
ihlr-26084	236	7	then	then	ADV
ihlr-26084	236	8	,	,	PUNCT
ihlr-26084	236	9	now	now	ADV
ihlr-26084	236	10	,	,	PUNCT
ihlr-26084	236	11	and	and	CCONJ
ihlr-26084	236	12	down	down	ADP
ihlr-26084	236	13	the	the	DET
ihlr-26084	236	14	road	road	NOUN
ihlr-26084	236	15	:	:	PUNCT
ihlr-26084	236	16	trends	trend	NOUN
ihlr-26084	236	17	in	in	ADP
ihlr-26084	236	18	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	236	19	patent	patent	NOUN
ihlr-26084	236	20	settlements	settlement	NOUN
ihlr-26084	236	21	after	after	ADP
ihlr-26084	236	22	ftc	ftc	PROPN
ihlr-26084	236	23	v.	v.	CCONJ
ihlr-26084	236	24	actavis	actavis	PROPN
ihlr-26084	236	25	,	,	PUNCT
ihlr-26084	236	26	fed	fed	PROPN
ihlr-26084	236	27	.	.	PUNCT
ihlr-26084	237	1	trade	trade	NOUN
ihlr-26084	237	2	comm’n	comm’n	NOUN
ihlr-26084	237	3	(	(	PUNCT
ihlr-26084	237	4	may	may	PROPN
ihlr-26084	237	5	28	28	NUM
ihlr-26084	237	6	,	,	PUNCT
ihlr-26084	237	7	2019	2019	NUM
ihlr-26084	237	8	,	,	PUNCT
ihlr-26084	237	9	12:23	12:23	NUM
ihlr-26084	237	10	pm	pm	NOUN
ihlr-26084	237	11	)	)	PUNCT
ihlr-26084	237	12	,	,	PUNCT
ihlr-26084	237	13	https://www.ftc.gov/news-events/blogs/competition-matters/2019/05/then-now-down-road-trendspharmaceutical-patent	https://www.ftc.gov/news-events/blogs/competition-matters/2019/05/then-now-down-road-trendspharmaceutical-patent	ADP
ihlr-26084	238	1	[	[	X
ihlr-26084	238	2	https://perma.cc/zq3x-6r7e	https://perma.cc/zq3x-6r7e	NOUN
ihlr-26084	238	3	]	]	PUNCT
ihlr-26084	238	4	.	.	PUNCT
ihlr-26084	239	1	62	62	NUM
ihlr-26084	239	2	.	.	PUNCT
ihlr-26084	240	1	see	see	VERB
ihlr-26084	240	2	garry	garry	PROPN
ihlr-26084	240	3	a.	a.	PROPN
ihlr-26084	240	4	gabison	gabison	PROPN
ihlr-26084	240	5	and	and	CCONJ
ihlr-26084	240	6	zaakir	zaakir	PROPN
ihlr-26084	240	7	tameez	tameez	VERB
ihlr-26084	240	8	,	,	PUNCT
ihlr-26084	240	9	multilateral	multilateral	ADJ
ihlr-26084	240	10	reverse	reverse	ADJ
ihlr-26084	240	11	payment	payment	NOUN
ihlr-26084	240	12	settlements	settlement	NOUN
ihlr-26084	240	13	,	,	PUNCT
ihlr-26084	240	14	16	16	NUM
ihlr-26084	240	15	rutgers	rutgers	PROPN
ihlr-26084	240	16	bus	bus	NOUN
ihlr-26084	240	17	.	.	PUNCT
ihlr-26084	241	1	l.	l.	PROPN
ihlr-26084	241	2	rev	rev	PROPN
ihlr-26084	241	3	.	.	PROPN
ihlr-26084	241	4	340	340	NUM
ihlr-26084	241	5	(	(	PUNCT
ihlr-26084	241	6	2021	2021	NUM
ihlr-26084	241	7	)	)	PUNCT
ihlr-26084	241	8	.	.	PUNCT
ihlr-26084	242	1	in	in	ADP
ihlr-26084	242	2	recent	recent	ADJ
ihlr-26084	242	3	years	year	NOUN
ihlr-26084	242	4	,	,	PUNCT
ihlr-26084	242	5	brand	brand	NOUN
ihlr-26084	242	6	and	and	CCONJ
ihlr-26084	242	7	generic	generic	ADJ
ihlr-26084	242	8	companies	company	NOUN
ihlr-26084	242	9	have	have	AUX
ihlr-26084	242	10	formed	form	VERB
ihlr-26084	242	11	complex	complex	ADJ
ihlr-26084	242	12	pay	pay	VERB
ihlr-26084	242	13	-	-	PUNCT
ihlr-26084	242	14	for	for	ADP
ihlr-26084	242	15	-	-	PUNCT
ihlr-26084	242	16	delay	delay	NOUN
ihlr-26084	242	17	schemes	scheme	NOUN
ihlr-26084	242	18	involving	involve	VERB
ihlr-26084	242	19	multiple	multiple	ADJ
ihlr-26084	242	20	parties	party	NOUN
ihlr-26084	242	21	,	,	PUNCT
ihlr-26084	242	22	drugs	drug	NOUN
ihlr-26084	242	23	,	,	PUNCT
ihlr-26084	242	24	or	or	CCONJ
ihlr-26084	242	25	jurisdictions	jurisdiction	NOUN
ihlr-26084	242	26	.	.	PUNCT
ihlr-26084	243	1	63	63	NUM
ihlr-26084	243	2	.	.	PUNCT
ihlr-26084	244	1	in	in	ADP
ihlr-26084	244	2	re	re	PROPN
ihlr-26084	244	3	wellbutrin	wellbutrin	PROPN
ihlr-26084	244	4	xl	xl	PROPN
ihlr-26084	244	5	antitrust	antitrust	ADJ
ihlr-26084	244	6	litigation	litigation	NOUN
ihlr-26084	244	7	,	,	PUNCT
ihlr-26084	244	8	868	868	NUM
ihlr-26084	244	9	f.3d	f.3d	NUM
ihlr-26084	244	10	132	132	NUM
ihlr-26084	244	11	,	,	PUNCT
ihlr-26084	244	12	141	141	NUM
ihlr-26084	244	13	(	(	PUNCT
ihlr-26084	244	14	3d	3d	NUM
ihlr-26084	244	15	cir	cir	NOUN
ihlr-26084	244	16	.	.	PROPN
ihlr-26084	244	17	2017	2017	NUM
ihlr-26084	244	18	)	)	PUNCT
ihlr-26084	244	19	.	.	PUNCT
ihlr-26084	245	1	64	64	NUM
ihlr-26084	245	2	.	.	PUNCT
ihlr-26084	246	1	i	i	PRON
ihlr-26084	246	2	d.	d.	PROPN
ihlr-26084	246	3	at	at	ADP
ihlr-26084	246	4	167	167	NUM
ihlr-26084	246	5	.	.	PUNCT
ihlr-26084	247	1	65	65	NUM
ihlr-26084	247	2	.	.	PUNCT
ihlr-26084	248	1	i	i	PRON
ihlr-26084	248	2	d.	d.	PROPN
ihlr-26084	248	3	66	66	NUM
ihlr-26084	248	4	.	.	PUNCT
ihlr-26084	249	1	i	i	PRON
ihlr-26084	249	2	d.	d.	PROPN
ihlr-26084	249	3	at	at	ADP
ihlr-26084	249	4	168	168	NUM
ihlr-26084	249	5	n.58	n.58	PROPN
ihlr-26084	249	6	(	(	PUNCT
ihlr-26084	249	7	“	"	PUNCT
ihlr-26084	249	8	we	we	PRON
ihlr-26084	249	9	can	can	AUX
ihlr-26084	249	10	not	not	PART
ihlr-26084	249	11	resolve	resolve	VERB
ihlr-26084	249	12	this	this	DET
ihlr-26084	249	13	aspect	aspect	NOUN
ihlr-26084	249	14	of	of	ADP
ihlr-26084	249	15	the	the	DET
ihlr-26084	249	16	case	case	NOUN
ihlr-26084	249	17	without	without	ADP
ihlr-26084	249	18	considering	consider	VERB
ihlr-26084	249	19	the	the	DET
ihlr-26084	249	20	merits	merit	NOUN
ihlr-26084	249	21	of	of	ADP
ihlr-26084	249	22	the	the	DET
ihlr-26084	249	23	underlying	underlie	VERB
ihlr-26084	249	24	patent	patent	NOUN
ihlr-26084	249	25	dispute	dispute	NOUN
ihlr-26084	249	26	.	.	PUNCT
ihlr-26084	249	27	”	"	PUNCT
ihlr-26084	249	28	)	)	PUNCT
ihlr-26084	249	29	.	.	PUNCT
ihlr-26084	250	1	67	67	NUM
ihlr-26084	250	2	.	.	PUNCT
ihlr-26084	251	1	see	see	VERB
ihlr-26084	251	2	am	be	AUX
ihlr-26084	251	3	.	.	PUNCT
ihlr-26084	252	1	sales	sales	PROPN
ihlr-26084	252	2	co.	co.	PROPN
ihlr-26084	252	3	,	,	PUNCT
ihlr-26084	252	4	llc	llc	PROPN
ihlr-26084	252	5	v.	v.	PROPN
ihlr-26084	252	6	astrazeneca	astrazeneca	PROPN
ihlr-26084	252	7	lp	lp	PROPN
ihlr-26084	252	8	(	(	PUNCT
ihlr-26084	252	9	in	in	ADP
ihlr-26084	252	10	re	re	PROPN
ihlr-26084	252	11	nexium	nexium	NOUN
ihlr-26084	252	12	(	(	PUNCT
ihlr-26084	252	13	esomeprazole	esomeprazole	PROPN
ihlr-26084	252	14	)	)	PUNCT
ihlr-26084	252	15	antitrust	antitrust	ADJ
ihlr-26084	252	16	litig	litig	NOUN
ihlr-26084	252	17	.	.	PUNCT
ihlr-26084	252	18	)	)	PUNCT
ihlr-26084	252	19	,	,	PUNCT
ihlr-26084	252	20	842	842	NUM
ihlr-26084	252	21	f.3d	f.3d	NUM
ihlr-26084	252	22	34	34	NUM
ihlr-26084	252	23	(	(	PUNCT
ihlr-26084	252	24	1st	1st	ADJ
ihlr-26084	252	25	cir	cir	NOUN
ihlr-26084	252	26	.	.	PROPN
ihlr-26084	252	27	2016	2016	NUM
ihlr-26084	252	28	)	)	PUNCT
ihlr-26084	252	29	.	.	PUNCT
ihlr-26084	253	1	68	68	NUM
ihlr-26084	253	2	.	.	PUNCT
ihlr-26084	254	1	i	i	PRON
ihlr-26084	254	2	d.	d.	PROPN
ihlr-26084	254	3	at	at	ADP
ihlr-26084	254	4	43	43	NUM
ihlr-26084	254	5	.	.	PUNCT
ihlr-26084	255	1	see	see	VERB
ihlr-26084	255	2	also	also	ADV
ihlr-26084	255	3	katherine	katherine	PROPN
ihlr-26084	255	4	eban	eban	PROPN
ihlr-26084	255	5	,	,	PUNCT
ihlr-26084	255	6	how	how	SCONJ
ihlr-26084	255	7	ranbaxy	ranbaxy	PROPN
ihlr-26084	255	8	hurtled	hurtle	VERB
ihlr-26084	255	9	towards	towards	ADP
ihlr-26084	255	10	a	a	DET
ihlr-26084	255	11	meltdown	meltdown	NOUN
ihlr-26084	255	12	,	,	PUNCT
ihlr-26084	255	13	mint	mint	NOUN
ihlr-26084	255	14	,	,	PUNCT
ihlr-26084	255	15	(	(	PUNCT
ihlr-26084	255	16	july	july	PROPN
ihlr-26084	255	17	11	11	NUM
ihlr-26084	255	18	,	,	PUNCT
ihlr-26084	255	19	2019	2019	NUM
ihlr-26084	255	20	,	,	PUNCT
ihlr-26084	255	21	10:13	10:13	NUM
ihlr-26084	255	22	pm	pm	NOUN
ihlr-26084	255	23	)	)	PUNCT
ihlr-26084	255	24	,	,	PUNCT
ihlr-26084	255	25	https://www.livemint.com/companies/news/how-ranbaxy-hurtledtowards-a-meltdown-1562861830620.html	https://www.livemint.com/companies/news/how-ranbaxy-hurtledtowards-a-meltdown-1562861830620.html	PUNCT
ihlr-26084	256	1	[	[	X
ihlr-26084	256	2	https://perma.cc/tt4e-ww37	https://perma.cc/tt4e-ww37	X
ihlr-26084	256	3	]	]	X
ihlr-26084	256	4	.	.	PUNCT
ihlr-26084	256	5	2022	2022	NUM
ihlr-26084	256	6	]	]	PUNCT
ihlr-26084	256	7	reverse	reverse	ADJ
ihlr-26084	256	8	payment	payment	NOUN
ihlr-26084	256	9	:	:	PUNCT
ihlr-26084	256	10	a	a	DET
ihlr-26084	256	11	comparative	comparative	ADJ
ihlr-26084	256	12	study	study	NOUN
ihlr-26084	256	13	31	31	NUM
ihlr-26084	256	14	happened	happen	VERB
ihlr-26084	256	15	regardless	regardless	ADV
ihlr-26084	256	16	of	of	ADP
ihlr-26084	256	17	the	the	DET
ihlr-26084	256	18	illegal	illegal	ADJ
ihlr-26084	256	19	pay	pay	NOUN
ihlr-26084	256	20	-	-	PUNCT
ihlr-26084	256	21	for	for	ADP
ihlr-26084	256	22	-	-	PUNCT
ihlr-26084	256	23	delay	delay	NOUN
ihlr-26084	256	24	scheme.69	scheme.69	NOUN
ihlr-26084	256	25	the	the	DET
ihlr-26084	256	26	court	court	NOUN
ihlr-26084	256	27	denied	deny	VERB
ihlr-26084	256	28	plaintiffs	plaintiff	NOUN
ihlr-26084	256	29	any	any	DET
ihlr-26084	256	30	relief	relief	NOUN
ihlr-26084	256	31	.	.	PUNCT
ihlr-26084	257	1	second	second	ADJ
ihlr-26084	257	2	,	,	PUNCT
ihlr-26084	257	3	other	other	ADJ
ihlr-26084	257	4	courts	court	NOUN
ihlr-26084	257	5	have	have	AUX
ihlr-26084	257	6	undermined	undermine	VERB
ihlr-26084	257	7	the	the	DET
ihlr-26084	257	8	ability	ability	NOUN
ihlr-26084	257	9	of	of	ADP
ihlr-26084	257	10	the	the	DET
ihlr-26084	257	11	government	government	NOUN
ihlr-26084	257	12	to	to	PART
ihlr-26084	257	13	disincentivize	disincentivize	VERB
ihlr-26084	257	14	pay	pay	VERB
ihlr-26084	257	15	-	-	PUNCT
ihlr-26084	257	16	for	for	ADP
ihlr-26084	257	17	-	-	PUNCT
ihlr-26084	257	18	delay	delay	NOUN
ihlr-26084	257	19	.	.	PUNCT
ihlr-26084	258	1	in	in	ADP
ihlr-26084	258	2	ftc	ftc	PROPN
ihlr-26084	258	3	v.	v.	ADP
ihlr-26084	258	4	abbvie	abbvie	PROPN
ihlr-26084	258	5	,	,	PUNCT
ihlr-26084	258	6	inc	inc	PROPN
ihlr-26084	258	7	.	.	PROPN
ihlr-26084	258	8	,70	,70	PUNCT
ihlr-26084	258	9	the	the	DET
ihlr-26084	258	10	third	third	ADJ
ihlr-26084	258	11	circuit	circuit	NOUN
ihlr-26084	258	12	held	hold	VERB
ihlr-26084	258	13	that	that	DET
ihlr-26084	258	14	section	section	NOUN
ihlr-26084	258	15	13	13	NUM
ihlr-26084	258	16	of	of	ADP
ihlr-26084	258	17	the	the	DET
ihlr-26084	258	18	federal	federal	PROPN
ihlr-26084	258	19	trade	trade	PROPN
ihlr-26084	258	20	commission	commission	PROPN
ihlr-26084	258	21	act	act	NOUN
ihlr-26084	258	22	does	do	AUX
ihlr-26084	258	23	not	not	PART
ihlr-26084	258	24	grant	grant	VERB
ihlr-26084	258	25	the	the	DET
ihlr-26084	258	26	agency	agency	NOUN
ihlr-26084	258	27	the	the	DET
ihlr-26084	258	28	authority	authority	NOUN
ihlr-26084	258	29	to	to	PART
ihlr-26084	258	30	order	order	VERB
ihlr-26084	258	31	disgorgement	disgorgement	NOUN
ihlr-26084	258	32	of	of	ADP
ihlr-26084	258	33	the	the	DET
ihlr-26084	258	34	profits	profit	NOUN
ihlr-26084	258	35	made	make	VERB
ihlr-26084	258	36	from	from	ADP
ihlr-26084	258	37	a	a	DET
ihlr-26084	258	38	reverse	reverse	ADJ
ihlr-26084	258	39	payment	payment	NOUN
ihlr-26084	258	40	scheme.71	scheme.71	NOUN
ihlr-26084	258	41	in	in	ADP
ihlr-26084	258	42	the	the	DET
ihlr-26084	258	43	court	court	NOUN
ihlr-26084	258	44	’s	’s	PART
ihlr-26084	258	45	view	view	NOUN
ihlr-26084	258	46	,	,	PUNCT
ihlr-26084	258	47	the	the	DET
ihlr-26084	258	48	ftc	ftc	PROPN
ihlr-26084	258	49	can	can	AUX
ihlr-26084	258	50	only	only	ADV
ihlr-26084	258	51	enjoin	enjoin	VERB
ihlr-26084	258	52	antitrust	antitrust	ADJ
ihlr-26084	258	53	defendants	defendant	NOUN
ihlr-26084	258	54	from	from	ADP
ihlr-26084	258	55	committing	commit	VERB
ihlr-26084	258	56	future	future	NOUN
ihlr-26084	258	57	harm.72	harm.72	ADP
ihlr-26084	258	58	this	this	DET
ihlr-26084	258	59	statutory	statutory	ADJ
ihlr-26084	258	60	interpretation	interpretation	NOUN
ihlr-26084	258	61	was	be	AUX
ihlr-26084	258	62	echoed	echo	VERB
ihlr-26084	258	63	by	by	ADP
ihlr-26084	258	64	a	a	DET
ihlr-26084	258	65	unanimous	unanimous	ADJ
ihlr-26084	258	66	supreme	supreme	PROPN
ihlr-26084	258	67	court	court	PROPN
ihlr-26084	258	68	in	in	ADP
ihlr-26084	258	69	a	a	DET
ihlr-26084	258	70	recent	recent	ADJ
ihlr-26084	258	71	ruling.73	ruling.73	NOUN
ihlr-26084	258	72	finally	finally	ADV
ihlr-26084	258	73	,	,	PUNCT
ihlr-26084	258	74	courts	court	NOUN
ihlr-26084	258	75	have	have	AUX
ihlr-26084	258	76	only	only	ADV
ihlr-26084	258	77	accepted	accept	VERB
ihlr-26084	258	78	federal	federal	ADJ
ihlr-26084	258	79	antitrust	antitrust	ADJ
ihlr-26084	258	80	damage	damage	NOUN
ihlr-26084	258	81	claims	claim	NOUN
ihlr-26084	258	82	from	from	ADP
ihlr-26084	258	83	direct	direct	ADJ
ihlr-26084	258	84	purchasers	purchaser	NOUN
ihlr-26084	258	85	of	of	ADP
ihlr-26084	258	86	brand	brand	NOUN
ihlr-26084	258	87	-	-	PUNCT
ihlr-26084	258	88	name	name	NOUN
ihlr-26084	258	89	drugs.74	drugs.74	ADJ
ihlr-26084	258	90	while	while	SCONJ
ihlr-26084	258	91	this	this	DET
ihlr-26084	258	92	approach	approach	NOUN
ihlr-26084	258	93	is	be	AUX
ihlr-26084	258	94	consistent	consistent	ADJ
ihlr-26084	258	95	with	with	ADP
ihlr-26084	258	96	wellestablished	wellestablished	ADJ
ihlr-26084	258	97	supreme	supreme	PROPN
ihlr-26084	258	98	court	court	PROPN
ihlr-26084	258	99	doctrine,75	doctrine,75	NOUN
ihlr-26084	258	100	it	it	PRON
ihlr-26084	258	101	is	be	AUX
ihlr-26084	258	102	poorly	poorly	ADV
ihlr-26084	258	103	suited	suit	VERB
ihlr-26084	258	104	for	for	ADP
ihlr-26084	258	105	a	a	DET
ihlr-26084	258	106	market	market	NOUN
ihlr-26084	258	107	where	where	SCONJ
ihlr-26084	258	108	direct	direct	ADJ
ihlr-26084	258	109	purchasers	purchaser	NOUN
ihlr-26084	258	110	have	have	VERB
ihlr-26084	258	111	mixed	mix	VERB
ihlr-26084	258	112	incentives	incentive	NOUN
ihlr-26084	258	113	on	on	ADP
ihlr-26084	258	114	reducing	reduce	VERB
ihlr-26084	258	115	prices	price	NOUN
ihlr-26084	258	116	.	.	PUNCT
ihlr-26084	259	1	direct	direct	ADJ
ihlr-26084	259	2	purchasers	purchaser	NOUN
ihlr-26084	259	3	are	be	AUX
ihlr-26084	259	4	typically	typically	ADV
ihlr-26084	259	5	wholesalers	wholesaler	NOUN
ihlr-26084	259	6	but	but	CCONJ
ihlr-26084	259	7	can	can	AUX
ihlr-26084	259	8	also	also	ADV
ihlr-26084	259	9	be	be	AUX
ihlr-26084	259	10	pbms	pbm	NOUN
ihlr-26084	259	11	,	,	PUNCT
ihlr-26084	259	12	pharmacies	pharmacy	NOUN
ihlr-26084	259	13	,	,	PUNCT
ihlr-26084	259	14	or	or	CCONJ
ihlr-26084	259	15	insurers.76	insurers.76	PROPN
ihlr-26084	259	16	wholesalers	wholesaler	NOUN
ihlr-26084	259	17	purchase	purchase	VERB
ihlr-26084	259	18	drugs	drug	NOUN
ihlr-26084	259	19	from	from	ADP
ihlr-26084	259	20	manufacturers	manufacturer	NOUN
ihlr-26084	259	21	and	and	CCONJ
ihlr-26084	259	22	re	re	NOUN
ihlr-26084	259	23	-	-	VERB
ihlr-26084	259	24	sell	sell	VERB
ihlr-26084	259	25	them	they	PRON
ihlr-26084	259	26	to	to	ADP
ihlr-26084	259	27	pharmacies	pharmacy	NOUN
ihlr-26084	259	28	to	to	PART
ihlr-26084	259	29	make	make	VERB
ihlr-26084	259	30	profit	profit	NOUN
ihlr-26084	259	31	on	on	ADP
ihlr-26084	259	32	the	the	DET
ihlr-26084	259	33	margins.77	margins.77	ADJ
ihlr-26084	259	34	pharmacies	pharmacy	NOUN
ihlr-26084	259	35	pass	pass	VERB
ihlr-26084	259	36	on	on	ADP
ihlr-26084	259	37	most	most	ADJ
ihlr-26084	259	38	costs	cost	NOUN
ihlr-26084	259	39	to	to	ADP
ihlr-26084	259	40	consumers	consumer	NOUN
ihlr-26084	259	41	and	and	CCONJ
ihlr-26084	259	42	make	make	VERB
ihlr-26084	259	43	profit	profit	NOUN
ihlr-26084	259	44	on	on	ADP
ihlr-26084	259	45	privately	privately	ADV
ihlr-26084	259	46	negotiated	negotiate	VERB
ihlr-26084	259	47	reimbursements	reimbursement	NOUN
ihlr-26084	259	48	from	from	ADP
ihlr-26084	259	49	pbms	pbms	PROPN
ihlr-26084	259	50	.	.	PUNCT
ihlr-26084	260	1	pbms	pbms	PROPN
ihlr-26084	260	2	pass	pass	VERB
ihlr-26084	260	3	on	on	ADP
ihlr-26084	260	4	most	most	ADJ
ihlr-26084	260	5	costs	cost	NOUN
ihlr-26084	260	6	to	to	ADP
ihlr-26084	260	7	insurers	insurer	NOUN
ihlr-26084	260	8	and	and	CCONJ
ihlr-26084	260	9	make	make	VERB
ihlr-26084	260	10	profit	profit	NOUN
ihlr-26084	260	11	on	on	ADP
ihlr-26084	260	12	privately	privately	ADV
ihlr-26084	260	13	negotiated	negotiate	VERB
ihlr-26084	260	14	rebates	rebate	NOUN
ihlr-26084	260	15	with	with	ADP
ihlr-26084	260	16	manufacturers	manufacturer	NOUN
ihlr-26084	260	17	.	.	PUNCT
ihlr-26084	261	1	and	and	CCONJ
ihlr-26084	261	2	insurers	insurer	NOUN
ihlr-26084	261	3	pass	pass	VERB
ihlr-26084	261	4	on	on	ADP
ihlr-26084	261	5	most	most	ADJ
ihlr-26084	261	6	costs	cost	NOUN
ihlr-26084	261	7	to	to	ADP
ihlr-26084	261	8	consumers	consumer	NOUN
ihlr-26084	261	9	indirectly	indirectly	ADV
ihlr-26084	261	10	through	through	ADP
ihlr-26084	261	11	insurance	insurance	NOUN
ihlr-26084	261	12	premiums.78	premiums.78	NOUN
ihlr-26084	261	13	each	each	PRON
ihlr-26084	261	14	of	of	ADP
ihlr-26084	261	15	these	these	DET
ihlr-26084	261	16	participants	participant	NOUN
ihlr-26084	261	17	in	in	ADP
ihlr-26084	261	18	the	the	DET
ihlr-26084	261	19	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	261	20	supply	supply	NOUN
ihlr-26084	261	21	chain	chain	NOUN
ihlr-26084	261	22	makes	make	VERB
ihlr-26084	261	23	profit	profit	NOUN
ihlr-26084	261	24	from	from	ADP
ihlr-26084	261	25	private	private	ADJ
ihlr-26084	261	26	or	or	CCONJ
ihlr-26084	261	27	nontransparent	nontransparent	ADJ
ihlr-26084	261	28	margins	margin	NOUN
ihlr-26084	261	29	that	that	PRON
ihlr-26084	261	30	are	be	AUX
ihlr-26084	261	31	benchmarked	benchmarke	VERB
ihlr-26084	261	32	to	to	ADP
ihlr-26084	261	33	the	the	DET
ihlr-26084	261	34	public	public	ADJ
ihlr-26084	261	35	list	list	NOUN
ihlr-26084	261	36	prices	price	NOUN
ihlr-26084	261	37	set	set	VERB
ihlr-26084	261	38	by	by	ADP
ihlr-26084	261	39	manufacturers.79	manufacturers.79	VERB
ihlr-26084	261	40	these	these	DET
ihlr-26084	261	41	public	public	ADJ
ihlr-26084	261	42	list	list	NOUN
ihlr-26084	261	43	prices	price	NOUN
ihlr-26084	261	44	,	,	PUNCT
ihlr-26084	261	45	therefore	therefore	ADV
ihlr-26084	261	46	,	,	PUNCT
ihlr-26084	261	47	are	be	AUX
ihlr-26084	261	48	subject	subject	ADJ
ihlr-26084	261	49	to	to	ADP
ihlr-26084	261	50	distorted	distorted	ADJ
ihlr-26084	261	51	incentives	incentive	NOUN
ihlr-26084	261	52	.	.	PUNCT
ihlr-26084	262	1	but	but	CCONJ
ihlr-26084	262	2	the	the	DET
ihlr-26084	262	3	downstream	downstream	ADJ
ihlr-26084	262	4	implications	implication	NOUN
ihlr-26084	262	5	are	be	AUX
ihlr-26084	262	6	serious	serious	ADJ
ihlr-26084	262	7	for	for	ADP
ihlr-26084	262	8	consumers	consumer	NOUN
ihlr-26084	262	9	,	,	PUNCT
ihlr-26084	262	10	who	who	PRON
ihlr-26084	262	11	suffer	suffer	VERB
ihlr-26084	262	12	the	the	DET
ihlr-26084	262	13	brunt	brunt	NOUN
ihlr-26084	262	14	of	of	ADP
ihlr-26084	262	15	brand	brand	NOUN
ihlr-26084	262	16	-	-	PUNCT
ihlr-26084	262	17	name	name	NOUN
ihlr-26084	262	18	drug	drug	NOUN
ihlr-26084	262	19	overcharges	overcharge	NOUN
ihlr-26084	262	20	but	but	CCONJ
ihlr-26084	262	21	lack	lack	VERB
ihlr-26084	262	22	federal	federal	ADJ
ihlr-26084	262	23	standing	stand	VERB
ihlr-26084	262	24	in	in	ADP
ihlr-26084	262	25	antitrust	antitrust	ADJ
ihlr-26084	262	26	claims	claim	NOUN
ihlr-26084	262	27	as	as	ADP
ihlr-26084	262	28	indirect	indirect	ADJ
ihlr-26084	262	29	purchasers	purchaser	NOUN
ihlr-26084	262	30	.	.	PUNCT
ihlr-26084	263	1	while	while	SCONJ
ihlr-26084	263	2	this	this	DET
ihlr-26084	263	3	issue	issue	NOUN
ihlr-26084	263	4	does	do	AUX
ihlr-26084	263	5	not	not	PART
ihlr-26084	263	6	have	have	VERB
ihlr-26084	263	7	a	a	DET
ihlr-26084	263	8	clear	clear	ADJ
ihlr-26084	263	9	resolution	resolution	NOUN
ihlr-26084	263	10	under	under	ADP
ihlr-26084	263	11	standard	standard	ADJ
ihlr-26084	263	12	antitrust	antitrust	ADJ
ihlr-26084	263	13	doctrine	doctrine	NOUN
ihlr-26084	263	14	,	,	PUNCT
ihlr-26084	263	15	it	it	PRON
ihlr-26084	263	16	highlights	highlight	VERB
ihlr-26084	263	17	an	an	DET
ihlr-26084	263	18	additional	additional	ADJ
ihlr-26084	263	19	challenge	challenge	NOUN
ihlr-26084	263	20	that	that	PRON
ihlr-26084	263	21	plaintiffs	plaintiff	NOUN
ihlr-26084	263	22	face	face	VERB
ihlr-26084	263	23	to	to	PART
ihlr-26084	263	24	disincentivize	disincentivize	VERB
ihlr-26084	263	25	pay	pay	VERB
ihlr-26084	263	26	-	-	PUNCT
ihlr-26084	263	27	for	for	ADP
ihlr-26084	263	28	-	-	PUNCT
ihlr-26084	263	29	delay	delay	NOUN
ihlr-26084	263	30	in	in	ADP
ihlr-26084	263	31	the	the	DET
ihlr-26084	263	32	united	united	PROPN
ihlr-26084	263	33	states	states	PROPN
ihlr-26084	263	34	.	.	PUNCT
ihlr-26084	264	1	69	69	NUM
ihlr-26084	264	2	.	.	PUNCT
ihlr-26084	265	1	i	i	PRON
ihlr-26084	265	2	d.	d.	PROPN
ihlr-26084	265	3	70	70	NUM
ihlr-26084	265	4	.	.	PUNCT
ihlr-26084	266	1	see	see	VERB
ihlr-26084	266	2	ftc	ftc	PROPN
ihlr-26084	266	3	v.	v.	PROPN
ihlr-26084	266	4	abbvie	abbvie	PROPN
ihlr-26084	266	5	inc	inc	PROPN
ihlr-26084	266	6	.	.	PROPN
ihlr-26084	266	7	,	,	PUNCT
ihlr-26084	266	8	976	976	NUM
ihlr-26084	266	9	f.3d	f.3d	NUM
ihlr-26084	266	10	327	327	NUM
ihlr-26084	266	11	(	(	PUNCT
ihlr-26084	266	12	3d	3d	PROPN
ihlr-26084	266	13	cir	cir	NOUN
ihlr-26084	266	14	.	.	PUNCT
ihlr-26084	266	15	2020	2020	NUM
ihlr-26084	266	16	)	)	PUNCT
ihlr-26084	266	17	.	.	PUNCT
ihlr-26084	267	1	71	71	NUM
ihlr-26084	267	2	.	.	PUNCT
ihlr-26084	268	1	i	i	PRON
ihlr-26084	268	2	d.	d.	PROPN
ihlr-26084	268	3	at	at	ADP
ihlr-26084	268	4	374	374	NUM
ihlr-26084	268	5	-	-	SYM
ihlr-26084	268	6	81	81	NUM
ihlr-26084	268	7	.	.	PUNCT
ihlr-26084	269	1	72	72	NUM
ihlr-26084	269	2	.	.	PUNCT
ihlr-26084	270	1	i	i	PRON
ihlr-26084	270	2	d.	d.	PROPN
ihlr-26084	270	3	73	73	NUM
ihlr-26084	270	4	.	.	PUNCT
ihlr-26084	271	1	see	see	VERB
ihlr-26084	271	2	amg	amg	PROPN
ihlr-26084	271	3	cap	cap	PROPN
ihlr-26084	271	4	.	.	PUNCT
ihlr-26084	272	1	mgmt	mgmt	PROPN
ihlr-26084	272	2	.	.	PROPN
ihlr-26084	272	3	,	,	PUNCT
ihlr-26084	272	4	llc	llc	PROPN
ihlr-26084	272	5	v.	v.	PROPN
ihlr-26084	272	6	ftc	ftc	PROPN
ihlr-26084	272	7	,	,	PUNCT
ihlr-26084	272	8	141	141	NUM
ihlr-26084	272	9	s.ct	s.ct	NOUN
ihlr-26084	272	10	.	.	NOUN
ihlr-26084	272	11	1341	1341	NUM
ihlr-26084	272	12	(	(	PUNCT
ihlr-26084	272	13	2021	2021	NUM
ihlr-26084	272	14	)	)	PUNCT
ihlr-26084	272	15	.	.	PUNCT
ihlr-26084	273	1	74	74	NUM
ihlr-26084	273	2	.	.	PUNCT
ihlr-26084	274	1	see	see	VERB
ihlr-26084	274	2	,	,	PUNCT
ihlr-26084	274	3	e.g.	e.g.	ADV
ihlr-26084	274	4	,	,	PUNCT
ihlr-26084	274	5	in	in	ADP
ihlr-26084	274	6	re	re	VERB
ihlr-26084	274	7	niaspan	niaspan	VERB
ihlr-26084	274	8	antitrust	antitrust	ADJ
ihlr-26084	274	9	litigation	litigation	NOUN
ihlr-26084	274	10	,	,	PUNCT
ihlr-26084	274	11	42	42	NUM
ihlr-26084	274	12	f.	f.	PROPN
ihlr-26084	274	13	supp	supp	PROPN
ihlr-26084	274	14	.	.	PUNCT
ihlr-26084	275	1	3d	3d	NUM
ihlr-26084	275	2	735	735	NUM
ihlr-26084	275	3	(	(	PUNCT
ihlr-26084	275	4	2014	2014	NUM
ihlr-26084	275	5	)	)	PUNCT
ihlr-26084	275	6	;	;	PUNCT
ihlr-26084	275	7	in	in	ADP
ihlr-26084	275	8	re	re	NOUN
ihlr-26084	275	9	nexium	nexium	PROPN
ihlr-26084	275	10	antitrust	antitrust	ADJ
ihlr-26084	275	11	litigation	litigation	NOUN
ihlr-26084	275	12	,	,	PUNCT
ihlr-26084	275	13	777	777	NUM
ihlr-26084	275	14	f.3d	f.3d	NUM
ihlr-26084	275	15	9	9	NUM
ihlr-26084	275	16	(	(	PUNCT
ihlr-26084	275	17	1st	1st	ADJ
ihlr-26084	275	18	cir	cir	NOUN
ihlr-26084	275	19	.	.	PROPN
ihlr-26084	275	20	2015	2015	NUM
ihlr-26084	275	21	)	)	PUNCT
ihlr-26084	275	22	;	;	PUNCT
ihlr-26084	275	23	in	in	ADP
ihlr-26084	275	24	re	re	PROPN
ihlr-26084	275	25	aggrenox	aggrenox	PROPN
ihlr-26084	275	26	antitrust	antitrust	ADJ
ihlr-26084	275	27	litigation	litigation	NOUN
ihlr-26084	275	28	,	,	PUNCT
ihlr-26084	275	29	94	94	NUM
ihlr-26084	275	30	f.	f.	PROPN
ihlr-26084	275	31	supp	supp	PROPN
ihlr-26084	275	32	.	.	PUNCT
ihlr-26084	276	1	3d	3d	NOUN
ihlr-26084	276	2	224	224	NUM
ihlr-26084	276	3	(	(	PUNCT
ihlr-26084	276	4	2015	2015	NUM
ihlr-26084	276	5	)	)	PUNCT
ihlr-26084	276	6	;	;	PUNCT
ihlr-26084	276	7	in	in	ADP
ihlr-26084	276	8	re	re	PROPN
ihlr-26084	276	9	humira	humira	PROPN
ihlr-26084	276	10	(	(	PUNCT
ihlr-26084	276	11	adalimumab	adalimumab	NOUN
ihlr-26084	276	12	)	)	PUNCT
ihlr-26084	276	13	antitrust	antitrust	ADJ
ihlr-26084	276	14	litigation	litigation	NOUN
ihlr-26084	276	15	,	,	PUNCT
ihlr-26084	276	16	465	465	NUM
ihlr-26084	276	17	f.	f.	NOUN
ihlr-26084	276	18	supp	supp	PROPN
ihlr-26084	276	19	.	.	PUNCT
ihlr-26084	277	1	3d	3d	NUM
ihlr-26084	277	2	811	811	NUM
ihlr-26084	277	3	(	(	PUNCT
ihlr-26084	277	4	n.d	n.d	PROPN
ihlr-26084	277	5	.	.	PROPN
ihlr-26084	277	6	ill	ill	PROPN
ihlr-26084	277	7	.	.	PUNCT
ihlr-26084	277	8	2020	2020	NUM
ihlr-26084	277	9	)	)	PUNCT
ihlr-26084	277	10	.	.	PUNCT
ihlr-26084	278	1	75	75	NUM
ihlr-26084	278	2	.	.	PUNCT
ihlr-26084	279	1	see	see	VERB
ihlr-26084	279	2	illinois	illinois	PROPN
ihlr-26084	279	3	brick	brick	PROPN
ihlr-26084	279	4	v.	v.	ADP
ihlr-26084	279	5	state	state	NOUN
ihlr-26084	279	6	of	of	ADP
ihlr-26084	279	7	illinois	illinois	PROPN
ihlr-26084	279	8	,	,	PUNCT
ihlr-26084	279	9	431	431	NUM
ihlr-26084	279	10	u.s	u.s	PROPN
ihlr-26084	279	11	.	.	PROPN
ihlr-26084	279	12	720	720	NUM
ihlr-26084	279	13	(	(	PUNCT
ihlr-26084	279	14	1977	1977	NUM
ihlr-26084	279	15	)	)	PUNCT
ihlr-26084	279	16	.	.	PUNCT
ihlr-26084	280	1	76	76	NUM
ihlr-26084	280	2	.	.	PUNCT
ihlr-26084	281	1	for	for	ADP
ihlr-26084	281	2	example	example	NOUN
ihlr-26084	281	3	,	,	PUNCT
ihlr-26084	281	4	all	all	PRON
ihlr-26084	281	5	of	of	ADP
ihlr-26084	281	6	these	these	DET
ihlr-26084	281	7	classes	class	NOUN
ihlr-26084	281	8	were	be	AUX
ihlr-26084	281	9	litigants	litigant	NOUN
ihlr-26084	281	10	in	in	ADP
ihlr-26084	281	11	in	in	ADP
ihlr-26084	281	12	re	re	NOUN
ihlr-26084	281	13	lipitor	lipitor	NOUN
ihlr-26084	281	14	antitrust	antitrust	ADJ
ihlr-26084	281	15	litigation	litigation	NOUN
ihlr-26084	281	16	,	,	PUNCT
ihlr-26084	281	17	868	868	NUM
ihlr-26084	281	18	f.3d	f.3d	NUM
ihlr-26084	281	19	231	231	NUM
ihlr-26084	281	20	(	(	PUNCT
ihlr-26084	281	21	3d	3d	PROPN
ihlr-26084	281	22	cir	cir	NOUN
ihlr-26084	281	23	.	.	PROPN
ihlr-26084	281	24	2017	2017	NUM
ihlr-26084	281	25	)	)	PUNCT
ihlr-26084	281	26	.	.	PUNCT
ihlr-26084	282	1	77	77	NUM
ihlr-26084	282	2	.	.	PUNCT
ihlr-26084	283	1	national	national	ADJ
ihlr-26084	283	2	academies	academy	NOUN
ihlr-26084	283	3	,	,	PUNCT
ihlr-26084	283	4	supra	supra	PROPN
ihlr-26084	283	5	note	note	PROPN
ihlr-26084	283	6	14	14	NUM
ihlr-26084	283	7	,	,	PUNCT
ihlr-26084	283	8	at	at	ADP
ihlr-26084	283	9	41	41	NUM
ihlr-26084	283	10	-	-	SYM
ihlr-26084	283	11	47	47	NUM
ihlr-26084	283	12	.	.	PUNCT
ihlr-26084	284	1	78	78	NUM
ihlr-26084	284	2	.	.	PUNCT
ihlr-26084	285	1	i	i	PRON
ihlr-26084	285	2	d.	d.	PROPN
ihlr-26084	285	3	79	79	NUM
ihlr-26084	285	4	.	.	PUNCT
ihlr-26084	286	1	neeraj	neeraj	PROPN
ihlr-26084	286	2	sood	sood	PROPN
ihlr-26084	286	3	et	et	PROPN
ihlr-26084	286	4	al	al	PROPN
ihlr-26084	286	5	.	.	PROPN
ihlr-26084	286	6	,	,	PUNCT
ihlr-26084	286	7	follow	follow	VERB
ihlr-26084	286	8	the	the	DET
ihlr-26084	286	9	money	money	NOUN
ihlr-26084	286	10	:	:	PUNCT
ihlr-26084	286	11	the	the	DET
ihlr-26084	286	12	flow	flow	NOUN
ihlr-26084	286	13	of	of	ADP
ihlr-26084	286	14	funds	fund	NOUN
ihlr-26084	286	15	in	in	ADP
ihlr-26084	286	16	the	the	DET
ihlr-26084	286	17	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	286	18	distribution	distribution	NOUN
ihlr-26084	286	19	system	system	NOUN
ihlr-26084	286	20	,	,	PUNCT
ihlr-26084	286	21	usc	usc	PROPN
ihlr-26084	286	22	schaeffer	schaeffer	PROPN
ihlr-26084	286	23	ctr	ctr	PROPN
ihlr-26084	286	24	.	.	PUNCT
ihlr-26084	287	1	for	for	ADP
ihlr-26084	287	2	health	health	NOUN
ihlr-26084	287	3	pol’y	pol’y	NOUN
ihlr-26084	287	4	&	&	CCONJ
ihlr-26084	287	5	econ	econ	PROPN
ihlr-26084	287	6	.	.	PUNCT
ihlr-26084	287	7	,	,	PUNCT
ihlr-26084	287	8	figure	figure	VERB
ihlr-26084	287	9	2	2	NUM
ihlr-26084	287	10	(	(	PUNCT
ihlr-26084	287	11	2017	2017	NUM
ihlr-26084	287	12	)	)	PUNCT
ihlr-26084	287	13	.	.	PUNCT
ihlr-26084	288	1	32	32	NUM
ihlr-26084	288	2	indiana	indiana	PROPN
ihlr-26084	288	3	health	health	PROPN
ihlr-26084	288	4	law	law	PROPN
ihlr-26084	288	5	review	review	NOUN
ihlr-26084	288	6	[	[	X
ihlr-26084	288	7	vol	vol	NOUN
ihlr-26084	288	8	.	.	PUNCT
ihlr-26084	289	1	19:21	19:21	NUM
ihlr-26084	289	2	iii	iii	NOUN
ihlr-26084	289	3	.	.	PUNCT
ihlr-26084	289	4	reverse	reverse	ADJ
ihlr-26084	289	5	payments	payment	NOUN
ihlr-26084	289	6	in	in	ADP
ihlr-26084	289	7	the	the	DET
ihlr-26084	289	8	eu	eu	PROPN
ihlr-26084	289	9	this	this	DET
ihlr-26084	289	10	section	section	NOUN
ihlr-26084	289	11	investigates	investigate	VERB
ihlr-26084	289	12	the	the	DET
ihlr-26084	289	13	importance	importance	NOUN
ihlr-26084	289	14	of	of	ADP
ihlr-26084	289	15	generics	generic	NOUN
ihlr-26084	289	16	in	in	ADP
ihlr-26084	289	17	europe	europe	PROPN
ihlr-26084	289	18	and	and	CCONJ
ihlr-26084	289	19	the	the	DET
ihlr-26084	289	20	need	need	NOUN
ihlr-26084	289	21	to	to	PART
ihlr-26084	289	22	decrease	decrease	VERB
ihlr-26084	289	23	reverse	reverse	VERB
ihlr-26084	289	24	payment	payment	NOUN
ihlr-26084	289	25	settlement	settlement	NOUN
ihlr-26084	289	26	in	in	ADP
ihlr-26084	289	27	europe	europe	PROPN
ihlr-26084	289	28	–	–	PUNCT
ihlr-26084	289	29	even	even	ADV
ihlr-26084	289	30	though	though	SCONJ
ihlr-26084	289	31	prices	price	NOUN
ihlr-26084	289	32	are	be	AUX
ihlr-26084	289	33	controlled	control	VERB
ihlr-26084	289	34	through	through	ADP
ihlr-26084	289	35	a	a	DET
ihlr-26084	289	36	centralized	centralized	ADJ
ihlr-26084	289	37	health	health	NOUN
ihlr-26084	289	38	care	care	NOUN
ihlr-26084	289	39	system	system	NOUN
ihlr-26084	289	40	.	.	PUNCT
ihlr-26084	290	1	a.	a.	NOUN
ihlr-26084	290	2	monopsony	monopsony	PROPN
ihlr-26084	290	3	decreases	decrease	VERB
ihlr-26084	290	4	the	the	DET
ihlr-26084	290	5	incentive	incentive	NOUN
ihlr-26084	290	6	but	but	CCONJ
ihlr-26084	290	7	does	do	AUX
ihlr-26084	290	8	not	not	PART
ihlr-26084	290	9	eliminate	eliminate	VERB
ihlr-26084	290	10	pay	pay	NOUN
ihlr-26084	290	11	-	-	PUNCT
ihlr-26084	290	12	for	for	ADP
ihlr-26084	290	13	-	-	PUNCT
ihlr-26084	290	14	delay	delay	NOUN
ihlr-26084	290	15	all	all	DET
ihlr-26084	290	16	european	european	ADJ
ihlr-26084	290	17	countries	country	NOUN
ihlr-26084	290	18	have	have	AUX
ihlr-26084	290	19	socialized	socialize	VERB
ihlr-26084	290	20	health	health	NOUN
ihlr-26084	290	21	care	care	NOUN
ihlr-26084	290	22	.	.	PUNCT
ihlr-26084	291	1	the	the	DET
ihlr-26084	291	2	entities	entity	NOUN
ihlr-26084	291	3	in	in	ADP
ihlr-26084	291	4	charge	charge	NOUN
ihlr-26084	291	5	of	of	ADP
ihlr-26084	291	6	health	health	PROPN
ihlr-26084	291	7	care	care	PROPN
ihlr-26084	291	8	act	act	NOUN
ihlr-26084	291	9	as	as	ADP
ihlr-26084	291	10	monopsonists	monopsonist	NOUN
ihlr-26084	291	11	.	.	PUNCT
ihlr-26084	292	1	these	these	DET
ihlr-26084	292	2	monopsonists	monopsonist	NOUN
ihlr-26084	292	3	control	control	VERB
ihlr-26084	292	4	prices	price	NOUN
ihlr-26084	292	5	and	and	CCONJ
ihlr-26084	292	6	hence	hence	ADV
ihlr-26084	292	7	may	may	AUX
ihlr-26084	292	8	decrease	decrease	VERB
ihlr-26084	292	9	the	the	DET
ihlr-26084	292	10	incentive	incentive	NOUN
ihlr-26084	292	11	of	of	ADP
ihlr-26084	292	12	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	292	13	companies	company	NOUN
ihlr-26084	292	14	to	to	PART
ihlr-26084	292	15	attempt	attempt	VERB
ihlr-26084	292	16	pay	pay	NOUN
ihlr-26084	292	17	-	-	PUNCT
ihlr-26084	292	18	fordelay	fordelay	NOUN
ihlr-26084	292	19	.	.	PUNCT
ihlr-26084	293	1	the	the	DET
ihlr-26084	293	2	first	first	ADJ
ihlr-26084	293	3	subsection	subsection	NOUN
ihlr-26084	293	4	below	below	ADV
ihlr-26084	293	5	discusses	discuss	VERB
ihlr-26084	293	6	the	the	DET
ihlr-26084	293	7	healthcare	healthcare	NOUN
ihlr-26084	293	8	system	system	NOUN
ihlr-26084	293	9	in	in	ADP
ihlr-26084	293	10	the	the	DET
ihlr-26084	293	11	uk	uk	PROPN
ihlr-26084	293	12	and	and	CCONJ
ihlr-26084	293	13	france	france	PROPN
ihlr-26084	293	14	.	.	PUNCT
ihlr-26084	294	1	the	the	DET
ihlr-26084	294	2	second	second	ADJ
ihlr-26084	294	3	subsection	subsection	NOUN
ihlr-26084	294	4	discusses	discuss	VERB
ihlr-26084	294	5	the	the	DET
ihlr-26084	294	6	need	need	NOUN
ihlr-26084	294	7	to	to	PART
ihlr-26084	294	8	enable	enable	VERB
ihlr-26084	294	9	generic	generic	ADJ
ihlr-26084	294	10	competition	competition	NOUN
ihlr-26084	294	11	.	.	PUNCT
ihlr-26084	295	1	1	1	X
ihlr-26084	295	2	.	.	X
ihlr-26084	295	3	the	the	DET
ihlr-26084	295	4	health	health	NOUN
ihlr-26084	295	5	care	care	NOUN
ihlr-26084	295	6	system	system	NOUN
ihlr-26084	295	7	in	in	ADP
ihlr-26084	295	8	the	the	DET
ihlr-26084	295	9	uk	uk	PROPN
ihlr-26084	295	10	and	and	CCONJ
ihlr-26084	295	11	france	france	PROPN
ihlr-26084	295	12	in	in	ADP
ihlr-26084	295	13	both	both	CCONJ
ihlr-26084	295	14	the	the	DET
ihlr-26084	295	15	uk	uk	PROPN
ihlr-26084	295	16	and	and	CCONJ
ihlr-26084	295	17	france	france	PROPN
ihlr-26084	295	18	,	,	PUNCT
ihlr-26084	295	19	the	the	DET
ihlr-26084	295	20	regulated	regulated	ADJ
ihlr-26084	295	21	prices	price	NOUN
ihlr-26084	295	22	of	of	ADP
ihlr-26084	295	23	medication	medication	NOUN
ihlr-26084	295	24	used	use	VERB
ihlr-26084	295	25	to	to	PART
ihlr-26084	295	26	be	be	AUX
ihlr-26084	295	27	derived	derive	VERB
ihlr-26084	295	28	through	through	ADP
ihlr-26084	295	29	a	a	DET
ihlr-26084	295	30	cost	cost	NOUN
ihlr-26084	295	31	-	-	PUNCT
ihlr-26084	295	32	plus	plus	CCONJ
ihlr-26084	295	33	-	-	PUNCT
ihlr-26084	295	34	profit	profit	NOUN
ihlr-26084	295	35	margin	margin	NOUN
ihlr-26084	295	36	model	model	NOUN
ihlr-26084	295	37	.	.	PUNCT
ihlr-26084	296	1	both	both	DET
ihlr-26084	296	2	countries	country	NOUN
ihlr-26084	296	3	deviated	deviate	VERB
ihlr-26084	296	4	from	from	ADP
ihlr-26084	296	5	this	this	DET
ihlr-26084	296	6	model	model	NOUN
ihlr-26084	296	7	because	because	SCONJ
ihlr-26084	296	8	of	of	ADP
ihlr-26084	296	9	the	the	DET
ihlr-26084	296	10	difficulties	difficulty	NOUN
ihlr-26084	296	11	in	in	ADP
ihlr-26084	296	12	proving	prove	VERB
ihlr-26084	296	13	costs.80	costs.80	NOUN
ihlr-26084	296	14	in	in	ADP
ihlr-26084	296	15	the	the	DET
ihlr-26084	296	16	uk	uk	PROPN
ihlr-26084	296	17	,	,	PUNCT
ihlr-26084	296	18	the	the	DET
ihlr-26084	296	19	national	national	PROPN
ihlr-26084	296	20	health	health	PROPN
ihlr-26084	296	21	service	service	NOUN
ihlr-26084	296	22	(	(	PUNCT
ihlr-26084	296	23	“	"	PUNCT
ihlr-26084	296	24	nhs	nhs	NOUN
ihlr-26084	296	25	”	"	PUNCT
ihlr-26084	296	26	)	)	PUNCT
ihlr-26084	296	27	is	be	AUX
ihlr-26084	296	28	the	the	DET
ihlr-26084	296	29	main	main	ADJ
ihlr-26084	296	30	purchaser	purchaser	NOUN
ihlr-26084	296	31	of	of	ADP
ihlr-26084	296	32	medications	medication	NOUN
ihlr-26084	296	33	.	.	PUNCT
ihlr-26084	297	1	the	the	DET
ihlr-26084	297	2	national	national	PROPN
ihlr-26084	297	3	institute	institute	PROPN
ihlr-26084	297	4	for	for	ADP
ihlr-26084	297	5	health	health	NOUN
ihlr-26084	297	6	and	and	CCONJ
ihlr-26084	297	7	care	care	PROPN
ihlr-26084	297	8	excellence	excellence	PROPN
ihlr-26084	297	9	(	(	PUNCT
ihlr-26084	297	10	“	"	PUNCT
ihlr-26084	297	11	nice	nice	ADJ
ihlr-26084	297	12	”	"	PUNCT
ihlr-26084	297	13	)	)	PUNCT
ihlr-26084	297	14	measures	measure	VERB
ihlr-26084	297	15	the	the	DET
ihlr-26084	297	16	cost	cost	NOUN
ihlr-26084	297	17	efficiency	efficiency	NOUN
ihlr-26084	297	18	of	of	ADP
ihlr-26084	297	19	a	a	DET
ihlr-26084	297	20	medication	medication	NOUN
ihlr-26084	297	21	based	base	VERB
ihlr-26084	297	22	on	on	ADP
ihlr-26084	297	23	the	the	DET
ihlr-26084	297	24	offer	offer	NOUN
ihlr-26084	297	25	made	make	VERB
ihlr-26084	297	26	by	by	ADP
ihlr-26084	297	27	the	the	DET
ihlr-26084	297	28	manufacturer.81	manufacturer.81	PROPN
ihlr-26084	297	29	new	new	ADJ
ihlr-26084	297	30	drug	drug	NOUN
ihlr-26084	297	31	manufacturers	manufacturer	NOUN
ihlr-26084	297	32	must	must	AUX
ihlr-26084	297	33	show	show	VERB
ihlr-26084	297	34	that	that	SCONJ
ihlr-26084	297	35	the	the	DET
ihlr-26084	297	36	new	new	ADJ
ihlr-26084	297	37	drug	drug	NOUN
ihlr-26084	297	38	“	"	PUNCT
ihlr-26084	297	39	provides	provide	VERB
ihlr-26084	297	40	an	an	DET
ihlr-26084	297	41	economic	economic	ADJ
ihlr-26084	297	42	advantage	advantage	NOUN
ihlr-26084	297	43	over	over	ADP
ihlr-26084	297	44	the	the	DET
ihlr-26084	297	45	currently	currently	ADV
ihlr-26084	297	46	used	use	VERB
ihlr-26084	297	47	next	next	ADJ
ihlr-26084	297	48	best	good	ADJ
ihlr-26084	297	49	treatment	treatment	NOUN
ihlr-26084	297	50	for	for	ADP
ihlr-26084	297	51	the	the	DET
ihlr-26084	297	52	same	same	ADJ
ihlr-26084	297	53	condition	condition	NOUN
ihlr-26084	297	54	.	.	PUNCT
ihlr-26084	298	1	”82	”82	ADV
ihlr-26084	298	2	if	if	SCONJ
ihlr-26084	298	3	the	the	DET
ihlr-26084	298	4	treatment	treatment	NOUN
ihlr-26084	298	5	passes	pass	VERB
ihlr-26084	298	6	a	a	DET
ihlr-26084	298	7	certain	certain	ADJ
ihlr-26084	298	8	cost	cost	NOUN
ihlr-26084	298	9	-	-	PUNCT
ihlr-26084	298	10	effectiveness	effectiveness	NOUN
ihlr-26084	298	11	threshold	threshold	NOUN
ihlr-26084	298	12	,	,	PUNCT
ihlr-26084	298	13	nice	nice	ADJ
ihlr-26084	298	14	recommends	recommend	VERB
ihlr-26084	298	15	it	it	PRON
ihlr-26084	298	16	for	for	ADP
ihlr-26084	298	17	adoption.83	adoption.83	PROPN
ihlr-26084	298	18	if	if	SCONJ
ihlr-26084	298	19	the	the	DET
ihlr-26084	298	20	threshold	threshold	NOUN
ihlr-26084	298	21	is	be	AUX
ihlr-26084	298	22	not	not	PART
ihlr-26084	298	23	passed	pass	VERB
ihlr-26084	298	24	,	,	PUNCT
ihlr-26084	298	25	the	the	DET
ihlr-26084	298	26	manufacturer	manufacturer	NOUN
ihlr-26084	298	27	may	may	AUX
ihlr-26084	298	28	negotiate	negotiate	VERB
ihlr-26084	298	29	with	with	ADP
ihlr-26084	298	30	the	the	DET
ihlr-26084	298	31	nhs.84	nhs.84	ADV
ihlr-26084	298	32	generic	generic	ADJ
ihlr-26084	298	33	entry	entry	NOUN
ihlr-26084	298	34	undercuts	undercut	VERB
ihlr-26084	298	35	brand	brand	NOUN
ihlr-26084	298	36	-	-	PUNCT
ihlr-26084	298	37	name	name	NOUN
ihlr-26084	298	38	drug	drug	NOUN
ihlr-26084	298	39	profits	profit	NOUN
ihlr-26084	298	40	in	in	ADP
ihlr-26084	298	41	two	two	NUM
ihlr-26084	298	42	ways	way	NOUN
ihlr-26084	298	43	.	.	PUNCT
ihlr-26084	299	1	first	first	ADV
ihlr-26084	299	2	,	,	PUNCT
ihlr-26084	299	3	uk	uk	PROPN
ihlr-26084	299	4	pharmacists	pharmacist	NOUN
ihlr-26084	299	5	can	can	AUX
ihlr-26084	299	6	substitute	substitute	VERB
ihlr-26084	299	7	a	a	DET
ihlr-26084	299	8	brand	brand	NOUN
ihlr-26084	299	9	drug	drug	NOUN
ihlr-26084	299	10	with	with	ADP
ihlr-26084	299	11	a	a	DET
ihlr-26084	299	12	generic	generic	ADJ
ihlr-26084	299	13	and	and	CCONJ
ihlr-26084	299	14	pocket	pocket	VERB
ihlr-26084	299	15	the	the	DET
ihlr-26084	299	16	difference.85	difference.85	PROPN
ihlr-26084	299	17	thus	thus	ADV
ihlr-26084	299	18	,	,	PUNCT
ihlr-26084	299	19	they	they	PRON
ihlr-26084	299	20	are	be	AUX
ihlr-26084	299	21	incentivized	incentivize	VERB
ihlr-26084	299	22	to	to	PART
ihlr-26084	299	23	look	look	VERB
ihlr-26084	299	24	for	for	ADP
ihlr-26084	299	25	the	the	DET
ihlr-26084	299	26	cheapest	cheap	ADJ
ihlr-26084	299	27	generic86	generic86	NOUN
ihlr-26084	299	28	and	and	CCONJ
ihlr-26084	299	29	often	often	ADV
ihlr-26084	299	30	benefit	benefit	VERB
ihlr-26084	299	31	from	from	ADP
ihlr-26084	299	32	the	the	DET
ihlr-26084	299	33	cheaper	cheap	ADJ
ihlr-26084	299	34	products.87	products.87	NOUN
ihlr-26084	299	35	second	second	ADV
ihlr-26084	299	36	,	,	PUNCT
ihlr-26084	299	37	after	after	ADP
ihlr-26084	299	38	generic	generic	ADJ
ihlr-26084	299	39	entry	entry	NOUN
ihlr-26084	299	40	,	,	PUNCT
ihlr-26084	299	41	nice	nice	ADJ
ihlr-26084	299	42	80	80	NUM
ihlr-26084	299	43	.	.	PUNCT
ihlr-26084	300	1	see	see	VERB
ihlr-26084	300	2	vivek	vivek	PROPN
ihlr-26084	300	3	kotecha	kotecha	PROPN
ihlr-26084	300	4	&	&	CCONJ
ihlr-26084	300	5	karl	karl	PROPN
ihlr-26084	300	6	claxton	claxton	PROPN
ihlr-26084	300	7	,	,	PUNCT
ihlr-26084	300	8	who	who	PRON
ihlr-26084	300	9	decides	decide	VERB
ihlr-26084	300	10	the	the	DET
ihlr-26084	300	11	price	price	NOUN
ihlr-26084	300	12	and	and	CCONJ
ihlr-26084	300	13	availability	availability	NOUN
ihlr-26084	300	14	of	of	ADP
ihlr-26084	300	15	nhs	nhs	PROPN
ihlr-26084	300	16	medicines	medicine	NOUN
ihlr-26084	300	17	?	?	PUNCT
ihlr-26084	300	18	,	,	PUNCT
ihlr-26084	300	19	ctr	ctr	PROPN
ihlr-26084	300	20	.	.	PROPN
ihlr-26084	301	1	for	for	ADP
ihlr-26084	301	2	health	health	PROPN
ihlr-26084	301	3	&	&	CCONJ
ihlr-26084	301	4	pub	pub	NOUN
ihlr-26084	301	5	.	.	PUNCT
ihlr-26084	302	1	int	int	NOUN
ihlr-26084	302	2	.	.	PUNCT
ihlr-26084	303	1	1	1	NUM
ihlr-26084	303	2	(	(	PUNCT
ihlr-26084	303	3	2019	2019	NUM
ihlr-26084	303	4	)	)	PUNCT
ihlr-26084	303	5	.	.	PUNCT
ihlr-26084	304	1	81	81	NUM
ihlr-26084	304	2	.	.	PUNCT
ihlr-26084	305	1	see	see	VERB
ihlr-26084	305	2	the	the	DET
ihlr-26084	305	3	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	305	4	price	price	NOUN
ihlr-26084	305	5	regulation	regulation	NOUN
ihlr-26084	305	6	scheme	scheme	NOUN
ihlr-26084	305	7	2014	2014	NUM
ihlr-26084	305	8	,	,	PUNCT
ihlr-26084	305	9	u.k	u.k	PROPN
ihlr-26084	305	10	.	.	PROPN
ihlr-26084	305	11	dep’t	dep’t	PROPN
ihlr-26084	305	12	health	health	NOUN
ihlr-26084	305	13	1	1	NUM
ihlr-26084	305	14	(	(	PUNCT
ihlr-26084	305	15	2013	2013	NUM
ihlr-26084	305	16	)	)	PUNCT
ihlr-26084	305	17	.	.	PUNCT
ihlr-26084	306	1	82	82	NUM
ihlr-26084	306	2	.	.	PUNCT
ihlr-26084	307	1	i	i	PRON
ihlr-26084	307	2	d.	d.	PROPN
ihlr-26084	307	3	at	at	ADP
ihlr-26084	307	4	¶	¶	PROPN
ihlr-26084	307	5	13	13	NUM
ihlr-26084	307	6	.	.	PUNCT
ihlr-26084	307	7	83	83	NUM
ihlr-26084	307	8	.	.	PUNCT
ihlr-26084	308	1	changes	change	NOUN
ihlr-26084	308	2	to	to	ADP
ihlr-26084	308	3	nice	nice	ADJ
ihlr-26084	308	4	drug	drug	NOUN
ihlr-26084	308	5	aappraisals	aappraisal	NOUN
ihlr-26084	308	6	:	:	PUNCT
ihlr-26084	308	7	what	what	PRON
ihlr-26084	308	8	you	you	PRON
ihlr-26084	308	9	need	need	VERB
ihlr-26084	308	10	to	to	PART
ihlr-26084	308	11	know	know	VERB
ihlr-26084	308	12	,	,	PUNCT
ihlr-26084	308	13	nat’l	nat’l	NOUN
ihlr-26084	308	14	inst	inst	NOUN
ihlr-26084	308	15	.	.	PUNCT
ihlr-26084	309	1	for	for	ADP
ihlr-26084	309	2	health	health	PROPN
ihlr-26084	309	3	&	&	CCONJ
ihlr-26084	309	4	care	care	PROPN
ihlr-26084	309	5	excellence	excellence	PROPN
ihlr-26084	309	6	(	(	PUNCT
ihlr-26084	309	7	apr	apr	PROPN
ihlr-26084	309	8	.	.	PROPN
ihlr-26084	309	9	4	4	NUM
ihlr-26084	309	10	,	,	PUNCT
ihlr-26084	309	11	2017	2017	NUM
ihlr-26084	309	12	)	)	PUNCT
ihlr-26084	309	13	https://www.nice.org.uk/news/feature/changes-to-nice-drugappraisals-what-you-need-to-know	https://www.nice.org.uk/news/feature/changes-to-nice-drugappraisals-what-you-need-to-know	PROPN
ihlr-26084	310	1	[	[	X
ihlr-26084	310	2	https://perma.cc/j5vg-udse	https://perma.cc/j5vg-udse	NOUN
ihlr-26084	310	3	]	]	X
ihlr-26084	310	4	.	.	PUNCT
ihlr-26084	311	1	84	84	NUM
ihlr-26084	311	2	.	.	PUNCT
ihlr-26084	312	1	see	see	VERB
ihlr-26084	312	2	leo	leo	PROPN
ihlr-26084	312	3	ewbank	ewbank	PROPN
ihlr-26084	312	4	et	et	PROPN
ihlr-26084	312	5	al	al	PROPN
ihlr-26084	312	6	.	.	PROPN
ihlr-26084	312	7	,	,	PUNCT
ihlr-26084	312	8	the	the	DET
ihlr-26084	312	9	rising	rise	VERB
ihlr-26084	312	10	cost	cost	NOUN
ihlr-26084	312	11	of	of	ADP
ihlr-26084	312	12	medicines	medicine	NOUN
ihlr-26084	312	13	to	to	ADP
ihlr-26084	312	14	the	the	DET
ihlr-26084	312	15	nhs	nhs	NOUN
ihlr-26084	312	16	:	:	PUNCT
ihlr-26084	312	17	what	what	PRON
ihlr-26084	312	18	’s	’	VERB
ihlr-26084	312	19	the	the	DET
ihlr-26084	312	20	story	story	NOUN
ihlr-26084	312	21	?	?	PUNCT
ihlr-26084	312	22	,	,	PUNCT
ihlr-26084	312	23	king	king	PROPN
ihlr-26084	312	24	’s	’s	PART
ihlr-26084	312	25	fund	fund	NOUN
ihlr-26084	312	26	1	1	NUM
ihlr-26084	312	27	(	(	PUNCT
ihlr-26084	312	28	2018	2018	NUM
ihlr-26084	312	29	)	)	PUNCT
ihlr-26084	312	30	.	.	PUNCT
ihlr-26084	313	1	85	85	NUM
ihlr-26084	313	2	.	.	PUNCT
ihlr-26084	314	1	see	see	VERB
ihlr-26084	314	2	the	the	DET
ihlr-26084	314	3	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	314	4	price	price	NOUN
ihlr-26084	314	5	regulation	regulation	NOUN
ihlr-26084	314	6	scheme	scheme	NOUN
ihlr-26084	314	7	2009	2009	NUM
ihlr-26084	314	8	,	,	PUNCT
ihlr-26084	314	9	ass’n	ass’n	NOUN
ihlr-26084	314	10	brit	brit	NOUN
ihlr-26084	314	11	.	.	PUNCT
ihlr-26084	315	1	pharm	pharm	PROPN
ihlr-26084	315	2	.	.	PUNCT
ihlr-26084	316	1	indus	indus	PROPN
ihlr-26084	316	2	.	.	PUNCT
ihlr-26084	317	1	1	1	NUM
ihlr-26084	317	2	(	(	PUNCT
ihlr-26084	317	3	2008	2008	NUM
ihlr-26084	317	4	)	)	PUNCT
ihlr-26084	317	5	.	.	PUNCT
ihlr-26084	318	1	86	86	NUM
ihlr-26084	318	2	.	.	PUNCT
ihlr-26084	319	1	i	i	PRON
ihlr-26084	319	2	d.	d.	PROPN
ihlr-26084	319	3	at	at	ADP
ihlr-26084	319	4	23	23	NUM
ihlr-26084	319	5	.	.	PUNCT
ihlr-26084	320	1	87	87	NUM
ihlr-26084	320	2	.	.	PUNCT
ihlr-26084	321	1	panos	panos	PROPN
ihlr-26084	321	2	kanavos	kanavos	NOUN
ihlr-26084	321	3	et	et	PROPN
ihlr-26084	321	4	al	al	PROPN
ihlr-26084	321	5	.	.	PROPN
ihlr-26084	321	6	,	,	PUNCT
ihlr-26084	321	7	the	the	DET
ihlr-26084	321	8	economic	economic	ADJ
ihlr-26084	321	9	impact	impact	NOUN
ihlr-26084	321	10	of	of	ADP
ihlr-26084	321	11	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	321	12	parallel	parallel	ADJ
ihlr-26084	321	13	trade	trade	NOUN
ihlr-26084	321	14	in	in	ADP
ihlr-26084	321	15	european	european	PROPN
ihlr-26084	321	16	union	union	PROPN
ihlr-26084	321	17	member	member	NOUN
ihlr-26084	321	18	states	state	NOUN
ihlr-26084	321	19	:	:	PUNCT
ihlr-26084	321	20	a	a	DET
ihlr-26084	321	21	stakeholder	stakeholder	NOUN
ihlr-26084	321	22	analysis	analysis	NOUN
ihlr-26084	321	23	,	,	PUNCT
ihlr-26084	321	24	london	london	PROPN
ihlr-26084	321	25	sch	sch	PROPN
ihlr-26084	321	26	.	.	PROPN
ihlr-26084	321	27	econ	econ	PROPN
ihlr-26084	321	28	.	.	PROPN
ihlr-26084	321	29	&	&	CCONJ
ihlr-26084	321	30	pol	pol	PROPN
ihlr-26084	321	31	.	.	PUNCT
ihlr-26084	322	1	sci	sci	PROPN
ihlr-26084	322	2	.	.	PROPN
ihlr-26084	323	1	1	1	NUM
ihlr-26084	323	2	,	,	PUNCT
ihlr-26084	323	3	123	123	NUM
ihlr-26084	323	4	(	(	PUNCT
ihlr-26084	323	5	2004	2004	NUM
ihlr-26084	323	6	)	)	PUNCT
ihlr-26084	323	7	.	.	PUNCT
ihlr-26084	324	1	2022	2022	NUM
ihlr-26084	324	2	]	]	PUNCT
ihlr-26084	324	3	reverse	reverse	ADJ
ihlr-26084	324	4	payment	payment	NOUN
ihlr-26084	324	5	:	:	PUNCT
ihlr-26084	324	6	a	a	DET
ihlr-26084	324	7	comparative	comparative	ADJ
ihlr-26084	324	8	study	study	NOUN
ihlr-26084	324	9	33	33	NUM
ihlr-26084	324	10	measures	measure	NOUN
ihlr-26084	324	11	the	the	DET
ihlr-26084	324	12	cost	cost	NOUN
ihlr-26084	324	13	-	-	PUNCT
ihlr-26084	324	14	effectiveness	effectiveness	NOUN
ihlr-26084	324	15	of	of	ADP
ihlr-26084	324	16	the	the	DET
ihlr-26084	324	17	generic	generic	ADJ
ihlr-26084	324	18	alternative	alternative	NOUN
ihlr-26084	324	19	rather	rather	ADV
ihlr-26084	324	20	than	than	ADP
ihlr-26084	324	21	the	the	DET
ihlr-26084	324	22	original	original	ADJ
ihlr-26084	324	23	brand	brand	NOUN
ihlr-26084	324	24	-	-	PUNCT
ihlr-26084	324	25	name	name	NOUN
ihlr-26084	324	26	drug	drug	NOUN
ihlr-26084	324	27	.	.	PUNCT
ihlr-26084	325	1	in	in	ADP
ihlr-26084	325	2	france	france	PROPN
ihlr-26084	325	3	,	,	PUNCT
ihlr-26084	325	4	the	the	DET
ihlr-26084	325	5	social	social	ADJ
ihlr-26084	325	6	security	security	NOUN
ihlr-26084	325	7	(	(	PUNCT
ihlr-26084	325	8	securité	securité	NOUN
ihlr-26084	325	9	sociale	sociale	PROPN
ihlr-26084	325	10	)	)	PUNCT
ihlr-26084	325	11	reimburses	reimburse	VERB
ihlr-26084	325	12	the	the	DET
ihlr-26084	325	13	cost	cost	NOUN
ihlr-26084	325	14	of	of	ADP
ihlr-26084	325	15	medication	medication	NOUN
ihlr-26084	325	16	.	.	PUNCT
ihlr-26084	326	1	the	the	DET
ihlr-26084	326	2	system	system	NOUN
ihlr-26084	326	3	is	be	AUX
ihlr-26084	326	4	financed	finance	VERB
ihlr-26084	326	5	through	through	ADP
ihlr-26084	326	6	taxes	taxis	NOUN
ihlr-26084	326	7	on	on	ADP
ihlr-26084	326	8	income	income	NOUN
ihlr-26084	326	9	and	and	CCONJ
ihlr-26084	326	10	on	on	ADP
ihlr-26084	326	11	alcohol	alcohol	NOUN
ihlr-26084	326	12	and	and	CCONJ
ihlr-26084	326	13	tobacco	tobacco	NOUN
ihlr-26084	326	14	.	.	PUNCT
ihlr-26084	327	1	according	accord	VERB
ihlr-26084	327	2	to	to	ADP
ihlr-26084	327	3	the	the	DET
ihlr-26084	327	4	french	french	ADJ
ihlr-26084	327	5	pharmaceutical	pharmaceutical	PROPN
ihlr-26084	327	6	association	association	PROPN
ihlr-26084	327	7	,	,	PUNCT
ihlr-26084	327	8	french	french	ADJ
ihlr-26084	327	9	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	327	10	manufacturers	manufacturer	NOUN
ihlr-26084	327	11	earn	earn	VERB
ihlr-26084	327	12	over	over	ADP
ihlr-26084	327	13	80	80	NUM
ihlr-26084	327	14	%	%	NOUN
ihlr-26084	327	15	of	of	ADP
ihlr-26084	327	16	their	their	PRON
ihlr-26084	327	17	income	income	NOUN
ihlr-26084	327	18	through	through	ADP
ihlr-26084	327	19	sales	sale	NOUN
ihlr-26084	327	20	to	to	ADP
ihlr-26084	327	21	the	the	DET
ihlr-26084	327	22	social	social	ADJ
ihlr-26084	327	23	security	security	NOUN
ihlr-26084	327	24	system.88	system.88	NOUN
ihlr-26084	327	25	the	the	DET
ihlr-26084	327	26	price	price	NOUN
ihlr-26084	327	27	of	of	ADP
ihlr-26084	327	28	a	a	DET
ihlr-26084	327	29	medication	medication	NOUN
ihlr-26084	327	30	depends	depend	VERB
ihlr-26084	327	31	on	on	ADP
ihlr-26084	327	32	several	several	ADJ
ihlr-26084	327	33	factors.89	factors.89	NOUN
ihlr-26084	327	34	first	first	ADV
ihlr-26084	327	35	,	,	PUNCT
ihlr-26084	327	36	the	the	DET
ihlr-26084	327	37	manufacturer	manufacturer	NOUN
ihlr-26084	327	38	must	must	AUX
ihlr-26084	327	39	decide	decide	VERB
ihlr-26084	327	40	whether	whether	SCONJ
ihlr-26084	327	41	it	it	PRON
ihlr-26084	327	42	wants	want	VERB
ihlr-26084	327	43	the	the	DET
ihlr-26084	327	44	product	product	NOUN
ihlr-26084	327	45	reimbursed	reimburse	VERB
ihlr-26084	327	46	.	.	PUNCT
ihlr-26084	328	1	if	if	SCONJ
ihlr-26084	328	2	the	the	DET
ihlr-26084	328	3	medication	medication	NOUN
ihlr-26084	328	4	is	be	AUX
ihlr-26084	328	5	not	not	PART
ihlr-26084	328	6	reimbursed	reimburse	VERB
ihlr-26084	328	7	,	,	PUNCT
ihlr-26084	328	8	the	the	DET
ihlr-26084	328	9	manufacturer	manufacturer	NOUN
ihlr-26084	328	10	can	can	AUX
ihlr-26084	328	11	set	set	VERB
ihlr-26084	328	12	its	its	PRON
ihlr-26084	328	13	wholesale	wholesale	ADJ
ihlr-26084	328	14	price	price	NOUN
ihlr-26084	328	15	based	base	VERB
ihlr-26084	328	16	on	on	ADP
ihlr-26084	328	17	economic	economic	ADJ
ihlr-26084	328	18	forces	force	NOUN
ihlr-26084	328	19	(	(	PUNCT
ihlr-26084	328	20	i.e.	i.e.	X
ihlr-26084	328	21	,	,	PUNCT
ihlr-26084	328	22	competition	competition	NOUN
ihlr-26084	328	23	,	,	PUNCT
ihlr-26084	328	24	demand	demand	NOUN
ihlr-26084	328	25	,	,	PUNCT
ihlr-26084	328	26	etc	etc	X
ihlr-26084	328	27	.	.	X
ihlr-26084	328	28	)	)	PUNCT
ihlr-26084	328	29	.	.	PUNCT
ihlr-26084	329	1	pharmacists	pharmacist	NOUN
ihlr-26084	329	2	can	can	AUX
ihlr-26084	329	3	also	also	ADV
ihlr-26084	329	4	set	set	VERB
ihlr-26084	329	5	their	their	PRON
ihlr-26084	329	6	margin	margin	NOUN
ihlr-26084	329	7	freely	freely	ADV
ihlr-26084	329	8	.	.	PUNCT
ihlr-26084	330	1	this	this	PRON
ihlr-26084	330	2	may	may	AUX
ihlr-26084	330	3	lead	lead	VERB
ihlr-26084	330	4	to	to	ADP
ihlr-26084	330	5	double	double	ADJ
ihlr-26084	330	6	marginalization	marginalization	NOUN
ihlr-26084	330	7	,	,	PUNCT
ihlr-26084	330	8	which	which	PRON
ihlr-26084	330	9	means	mean	VERB
ihlr-26084	330	10	higher	high	ADJ
ihlr-26084	330	11	prices	price	NOUN
ihlr-26084	330	12	but	but	CCONJ
ihlr-26084	330	13	lower	low	ADJ
ihlr-26084	330	14	demand	demand	NOUN
ihlr-26084	330	15	.	.	PUNCT
ihlr-26084	331	1	if	if	SCONJ
ihlr-26084	331	2	a	a	DET
ihlr-26084	331	3	manufacturer	manufacturer	NOUN
ihlr-26084	331	4	decides	decide	VERB
ihlr-26084	331	5	to	to	PART
ihlr-26084	331	6	have	have	VERB
ihlr-26084	331	7	its	its	PRON
ihlr-26084	331	8	medication	medication	NOUN
ihlr-26084	331	9	reimbursed	reimburse	VERB
ihlr-26084	331	10	,	,	PUNCT
ihlr-26084	331	11	then	then	ADV
ihlr-26084	331	12	the	the	DET
ihlr-26084	331	13	social	social	ADJ
ihlr-26084	331	14	security	security	NOUN
ihlr-26084	331	15	determines	determine	VERB
ihlr-26084	331	16	how	how	SCONJ
ihlr-26084	331	17	the	the	DET
ihlr-26084	331	18	prices	price	NOUN
ihlr-26084	331	19	are	be	AUX
ihlr-26084	331	20	fixed	fix	VERB
ihlr-26084	331	21	in	in	ADP
ihlr-26084	331	22	accordance	accordance	NOUN
ihlr-26084	331	23	with	with	ADP
ihlr-26084	331	24	the	the	DET
ihlr-26084	331	25	law.90	law.90	NOUN
ihlr-26084	331	26	reimbursement	reimbursement	NOUN
ihlr-26084	331	27	will	will	AUX
ihlr-26084	331	28	mean	mean	VERB
ihlr-26084	331	29	wider	wide	ADJ
ihlr-26084	331	30	access	access	NOUN
ihlr-26084	331	31	and	and	CCONJ
ihlr-26084	331	32	demand	demand	NOUN
ihlr-26084	331	33	,	,	PUNCT
ihlr-26084	331	34	but	but	CCONJ
ihlr-26084	331	35	lower	low	ADJ
ihlr-26084	331	36	prices	price	NOUN
ihlr-26084	331	37	.	.	PUNCT
ihlr-26084	332	1	the	the	DET
ihlr-26084	332	2	comité	comité	PROPN
ihlr-26084	332	3	économique	économique	PROPN
ihlr-26084	332	4	des	des	PROPN
ihlr-26084	332	5	produits	produits	X
ihlr-26084	332	6	de	de	X
ihlr-26084	332	7	santé	santé	X
ihlr-26084	332	8	(	(	PUNCT
ihlr-26084	332	9	“	"	PUNCT
ihlr-26084	332	10	ceps	cep	NOUN
ihlr-26084	332	11	”	"	PUNCT
ihlr-26084	332	12	)	)	PUNCT
ihlr-26084	332	13	negotiates	negotiate	VERB
ihlr-26084	332	14	the	the	DET
ihlr-26084	332	15	price	price	NOUN
ihlr-26084	332	16	with	with	ADP
ihlr-26084	332	17	the	the	DET
ihlr-26084	332	18	manufacturer	manufacturer	NOUN
ihlr-26084	332	19	.	.	PUNCT
ihlr-26084	333	1	the	the	DET
ihlr-26084	333	2	price	price	NOUN
ihlr-26084	333	3	will	will	AUX
ihlr-26084	333	4	depend	depend	VERB
ihlr-26084	333	5	on	on	ADP
ihlr-26084	333	6	four	four	NUM
ihlr-26084	333	7	factors	factor	NOUN
ihlr-26084	333	8	:	:	PUNCT
ihlr-26084	333	9	(	(	PUNCT
ihlr-26084	333	10	1	1	X
ihlr-26084	333	11	)	)	PUNCT
ihlr-26084	333	12	improvement	improvement	NOUN
ihlr-26084	333	13	on	on	ADP
ihlr-26084	333	14	existing	exist	VERB
ihlr-26084	333	15	medication(s	medication(s	NOUN
ihlr-26084	333	16	)	)	PUNCT
ihlr-26084	333	17	;	;	PUNCT
ihlr-26084	333	18	(	(	PUNCT
ihlr-26084	333	19	2	2	X
ihlr-26084	333	20	)	)	PUNCT
ihlr-26084	333	21	price	price	NOUN
ihlr-26084	333	22	of	of	ADP
ihlr-26084	333	23	existing	exist	VERB
ihlr-26084	333	24	therapeutic	therapeutic	ADJ
ihlr-26084	333	25	treatment(s	treatment(s	PROPN
ihlr-26084	333	26	)	)	PUNCT
ihlr-26084	333	27	;	;	PUNCT
ihlr-26084	333	28	(	(	PUNCT
ihlr-26084	333	29	3	3	X
ihlr-26084	333	30	)	)	PUNCT
ihlr-26084	333	31	expected	expect	VERB
ihlr-26084	333	32	demand	demand	NOUN
ihlr-26084	333	33	of	of	ADP
ihlr-26084	333	34	the	the	DET
ihlr-26084	333	35	medication	medication	NOUN
ihlr-26084	333	36	;	;	PUNCT
ihlr-26084	333	37	and	and	CCONJ
ihlr-26084	333	38	(	(	PUNCT
ihlr-26084	333	39	4	4	X
ihlr-26084	333	40	)	)	PUNCT
ihlr-26084	333	41	actual	actual	ADJ
ihlr-26084	333	42	use	use	NOUN
ihlr-26084	333	43	of	of	ADP
ihlr-26084	333	44	the	the	DET
ihlr-26084	333	45	medication.91	medication.91	NOUN
ihlr-26084	333	46	depending	depend	VERB
ihlr-26084	333	47	on	on	ADP
ihlr-26084	333	48	its	its	PRON
ihlr-26084	333	49	therapeutic	therapeutic	ADJ
ihlr-26084	333	50	offering	offering	NOUN
ihlr-26084	333	51	,	,	PUNCT
ihlr-26084	333	52	the	the	DET
ihlr-26084	333	53	medication	medication	NOUN
ihlr-26084	333	54	will	will	AUX
ihlr-26084	333	55	be	be	AUX
ihlr-26084	333	56	reimbursed	reimburse	VERB
ihlr-26084	333	57	at	at	ADP
ihlr-26084	333	58	0	0	NUM
ihlr-26084	333	59	%	%	NOUN
ihlr-26084	333	60	,	,	PUNCT
ihlr-26084	333	61	35	35	NUM
ihlr-26084	333	62	%	%	NOUN
ihlr-26084	333	63	,	,	PUNCT
ihlr-26084	333	64	65	65	NUM
ihlr-26084	333	65	%	%	NOUN
ihlr-26084	333	66	,	,	PUNCT
ihlr-26084	333	67	or	or	CCONJ
ihlr-26084	333	68	100	100	NUM
ihlr-26084	333	69	%	%	NOUN
ihlr-26084	333	70	of	of	ADP
ihlr-26084	333	71	the	the	DET
ihlr-26084	333	72	medication	medication	NOUN
ihlr-26084	333	73	price	price	NOUN
ihlr-26084	333	74	while	while	SCONJ
ihlr-26084	333	75	the	the	DET
ihlr-26084	333	76	rest	rest	NOUN
ihlr-26084	333	77	is	be	AUX
ihlr-26084	333	78	paid	pay	VERB
ihlr-26084	333	79	by	by	ADP
ihlr-26084	333	80	the	the	DET
ihlr-26084	333	81	consumer	consumer	NOUN
ihlr-26084	333	82	(	(	PUNCT
ihlr-26084	333	83	or	or	CCONJ
ihlr-26084	333	84	their	their	PRON
ihlr-26084	333	85	complementary	complementary	ADJ
ihlr-26084	333	86	insurance).92	insurance).92	PROPN
ihlr-26084	333	87	the	the	DET
ihlr-26084	333	88	ceps	cep	NOUN
ihlr-26084	333	89	will	will	AUX
ihlr-26084	333	90	negotiate	negotiate	VERB
ihlr-26084	333	91	the	the	DET
ihlr-26084	333	92	price	price	NOUN
ihlr-26084	333	93	up	up	ADV
ihlr-26084	333	94	or	or	CCONJ
ihlr-26084	333	95	down	down	ADV
ihlr-26084	333	96	from	from	ADP
ihlr-26084	333	97	the	the	DET
ihlr-26084	333	98	price	price	NOUN
ihlr-26084	333	99	of	of	ADP
ihlr-26084	333	100	existing	exist	VERB
ihlr-26084	333	101	treatment	treatment	NOUN
ihlr-26084	333	102	based	base	VERB
ihlr-26084	333	103	on	on	ADP
ihlr-26084	333	104	the	the	DET
ihlr-26084	333	105	improvement	improvement	NOUN
ihlr-26084	333	106	offered	offer	VERB
ihlr-26084	333	107	.	.	PUNCT
ihlr-26084	334	1	once	once	ADV
ihlr-26084	334	2	a	a	DET
ihlr-26084	334	3	generic	generic	ADJ
ihlr-26084	334	4	enters	enter	NOUN
ihlr-26084	334	5	,	,	PUNCT
ihlr-26084	334	6	the	the	DET
ihlr-26084	334	7	price	price	NOUN
ihlr-26084	334	8	of	of	ADP
ihlr-26084	334	9	the	the	DET
ihlr-26084	334	10	generic	generic	ADJ
ihlr-26084	334	11	is	be	AUX
ihlr-26084	334	12	fixed	fix	VERB
ihlr-26084	334	13	at	at	ADP
ihlr-26084	334	14	60	60	NUM
ihlr-26084	334	15	%	%	NOUN
ihlr-26084	334	16	of	of	ADP
ihlr-26084	334	17	the	the	DET
ihlr-26084	334	18	original	original	ADJ
ihlr-26084	334	19	negotiated	negotiate	VERB
ihlr-26084	334	20	price	price	NOUN
ihlr-26084	334	21	and	and	CCONJ
ihlr-26084	334	22	the	the	DET
ihlr-26084	334	23	price	price	NOUN
ihlr-26084	334	24	of	of	ADP
ihlr-26084	334	25	the	the	DET
ihlr-26084	334	26	brand	brand	NOUN
ihlr-26084	334	27	is	be	AUX
ihlr-26084	334	28	decreased	decrease	VERB
ihlr-26084	334	29	by	by	ADP
ihlr-26084	334	30	20%.93	20%.93	NUM
ihlr-26084	334	31	after	after	ADP
ihlr-26084	334	32	18	18	NUM
ihlr-26084	334	33	months	month	NOUN
ihlr-26084	334	34	,	,	PUNCT
ihlr-26084	334	35	the	the	DET
ihlr-26084	334	36	branded	brand	VERB
ihlr-26084	334	37	medication	medication	NOUN
ihlr-26084	334	38	is	be	AUX
ihlr-26084	334	39	reimbursed	reimburse	VERB
ihlr-26084	334	40	based	base	VERB
ihlr-26084	334	41	on	on	ADP
ihlr-26084	334	42	the	the	DET
ihlr-26084	334	43	generic	generic	ADJ
ihlr-26084	334	44	price	price	NOUN
ihlr-26084	334	45	or	or	CCONJ
ihlr-26084	334	46	both	both	DET
ihlr-26084	334	47	88	88	NUM
ihlr-26084	334	48	.	.	PUNCT
ihlr-26084	335	1	bilan	bilan	PROPN
ihlr-26084	335	2	économique	économique	PROPN
ihlr-26084	335	3	,	,	PUNCT
ihlr-26084	335	4	les	les	PROPN
ihlr-26084	335	5	enterprises	enterprise	NOUN
ihlr-26084	335	6	du	du	X
ihlr-26084	335	7	medicament	medicament	NOUN
ihlr-26084	335	8	1	1	NUM
ihlr-26084	335	9	,	,	PUNCT
ihlr-26084	335	10	6	6	NUM
ihlr-26084	335	11	(	(	PUNCT
ihlr-26084	335	12	2020	2020	NUM
ihlr-26084	335	13	)	)	PUNCT
ihlr-26084	335	14	.	.	PUNCT
ihlr-26084	336	1	the	the	DET
ihlr-26084	336	2	industry	industry	NOUN
ihlr-26084	336	3	makes	make	VERB
ihlr-26084	336	4	€	€	SYM
ihlr-26084	336	5	60bn	60bn	NOUN
ihlr-26084	336	6	in	in	ADP
ihlr-26084	336	7	france	france	PROPN
ihlr-26084	336	8	.	.	PUNCT
ihlr-26084	337	1	50	50	NUM
ihlr-26084	337	2	%	%	NOUN
ihlr-26084	337	3	of	of	ADP
ihlr-26084	337	4	this	this	DET
ihlr-26084	337	5	revenue	revenue	NOUN
ihlr-26084	337	6	is	be	AUX
ihlr-26084	337	7	from	from	ADP
ihlr-26084	337	8	exports	export	NOUN
ihlr-26084	337	9	.	.	PUNCT
ihlr-26084	338	1	€	€	SYM
ihlr-26084	338	2	25.5bn	25.5bn	NOUN
ihlr-26084	338	3	come	come	VERB
ihlr-26084	338	4	reimbursement	reimbursement	NOUN
ihlr-26084	338	5	from	from	ADP
ihlr-26084	338	6	insurances	insurance	NOUN
ihlr-26084	338	7	,	,	PUNCT
ihlr-26084	338	8	which	which	PRON
ihlr-26084	338	9	include	include	VERB
ihlr-26084	338	10	both	both	CCONJ
ihlr-26084	338	11	the	the	DET
ihlr-26084	338	12	social	social	ADJ
ihlr-26084	338	13	security	security	NOUN
ihlr-26084	338	14	system	system	NOUN
ihlr-26084	338	15	and	and	CCONJ
ihlr-26084	338	16	private	private	ADJ
ihlr-26084	338	17	top	top	ADJ
ihlr-26084	338	18	-	-	PUNCT
ihlr-26084	338	19	up	up	ADP
ihlr-26084	338	20	insurances	insurance	NOUN
ihlr-26084	338	21	,	,	PUNCT
ihlr-26084	338	22	who	who	PRON
ihlr-26084	338	23	complement	complement	VERB
ihlr-26084	338	24	the	the	DET
ihlr-26084	338	25	social	social	ADJ
ihlr-26084	338	26	security	security	NOUN
ihlr-26084	338	27	for	for	ADP
ihlr-26084	338	28	deductibles	deductible	NOUN
ihlr-26084	338	29	.	.	PUNCT
ihlr-26084	339	1	89	89	NUM
ihlr-26084	339	2	.	.	PUNCT
ihlr-26084	340	1	sophie	sophie	PROPN
ihlr-26084	340	2	rémond	rémond	PROPN
ihlr-26084	340	3	,	,	PUNCT
ihlr-26084	340	4	the	the	DET
ihlr-26084	340	5	price	price	NOUN
ihlr-26084	340	6	of	of	ADP
ihlr-26084	340	7	drugs	drug	NOUN
ihlr-26084	340	8	,	,	PUNCT
ihlr-26084	340	9	institut	institut	PROPN
ihlr-26084	340	10	national	national	PROPN
ihlr-26084	340	11	de	de	PROPN
ihlr-26084	340	12	la	la	PROPN
ihlr-26084	340	13	consommation	consommation	PROPN
ihlr-26084	340	14	(	(	PUNCT
ihlr-26084	340	15	sept	sept	PROPN
ihlr-26084	340	16	.	.	PROPN
ihlr-26084	340	17	12	12	NUM
ihlr-26084	340	18	,	,	PUNCT
ihlr-26084	340	19	2020	2020	NUM
ihlr-26084	340	20	)	)	PUNCT
ihlr-26084	340	21	https://www.inc-conso.fr/content/le-prix-des-medicaments	https://www.inc-conso.fr/content/le-prix-des-medicament	NOUN
ihlr-26084	341	1	[	[	X
ihlr-26084	341	2	https://perma.cc/m854yv9l	https://perma.cc/m854yv9l	X
ihlr-26084	341	3	]	]	X
ihlr-26084	341	4	.	.	PUNCT
ihlr-26084	342	1	90	90	NUM
ihlr-26084	342	2	.	.	PUNCT
ihlr-26084	342	3	l’article	l’article	PROPN
ihlr-26084	342	4	l.	l.	PROPN
ihlr-26084	342	5	162	162	NUM
ihlr-26084	342	6	-	-	SYM
ihlr-26084	342	7	16	16	NUM
ihlr-26084	342	8	-	-	SYM
ihlr-26084	342	9	4	4	NUM
ihlr-26084	342	10	du	du	NOUN
ihlr-26084	342	11	code	code	PROPN
ihlr-26084	342	12	de	de	X
ihlr-26084	342	13	la	la	PROPN
ihlr-26084	342	14	sécurité	sécurité	PROPN
ihlr-26084	342	15	sociale	sociale	PROPN
ihlr-26084	342	16	.	.	PROPN
ihlr-26084	342	17	91	91	NUM
ihlr-26084	342	18	.	.	PUNCT
ihlr-26084	343	1	i	i	PRON
ihlr-26084	343	2	d.	d.	PROPN
ihlr-26084	343	3	(	(	PUNCT
ihlr-26084	343	4	“	"	PUNCT
ihlr-26084	343	5	la	la	X
ihlr-26084	343	6	fixation	fixation	NOUN
ihlr-26084	343	7	de	de	PROPN
ihlr-26084	343	8	ce	ce	PROPN
ihlr-26084	343	9	prix	prix	PROPN
ihlr-26084	343	10	tient	tient	PROPN
ihlr-26084	343	11	compte	compte	PROPN
ihlr-26084	343	12	principalement	principalement	PROPN
ihlr-26084	343	13	de	de	X
ihlr-26084	343	14	l'amélioration	l'amélioration	PROPN
ihlr-26084	343	15	du	du	PROPN
ihlr-26084	343	16	service	service	PROPN
ihlr-26084	343	17	médical	médical	PROPN
ihlr-26084	343	18	rendu	rendu	NOUN
ihlr-26084	343	19	par	par	PROPN
ihlr-26084	343	20	le	le	X
ihlr-26084	343	21	médicament	médicament	PROPN
ihlr-26084	343	22	,	,	PUNCT
ihlr-26084	343	23	le	le	X
ihlr-26084	343	24	cas	cas	PROPN
ihlr-26084	343	25	échéant	échéant	PROPN
ihlr-26084	343	26	des	des	PROPN
ihlr-26084	343	27	résultats	résultats	X
ihlr-26084	343	28	de	de	X
ihlr-26084	343	29	l'évaluation	l'évaluation	PROPN
ihlr-26084	343	30	médico	médico	PROPN
ihlr-26084	343	31	-	-	PUNCT
ihlr-26084	343	32	économique	économique	NOUN
ihlr-26084	343	33	,	,	PUNCT
ihlr-26084	343	34	des	des	PROPN
ihlr-26084	343	35	prix	prix	X
ihlr-26084	343	36	des	des	X
ihlr-26084	343	37	médicaments	médicaments	X
ihlr-26084	343	38	à	à	X
ihlr-26084	343	39	même	même	PROPN
ihlr-26084	343	40	visée	visée	PROPN
ihlr-26084	343	41	thérapeutique	thérapeutique	PROPN
ihlr-26084	343	42	,	,	PUNCT
ihlr-26084	343	43	des	des	X
ihlr-26084	343	44	volumes	volumes	PROPN
ihlr-26084	343	45	de	de	X
ihlr-26084	343	46	vente	vente	PROPN
ihlr-26084	343	47	prévus	prévus	PROPN
ihlr-26084	343	48	ou	ou	PROPN
ihlr-26084	343	49	constatés	constatés	PROPN
ihlr-26084	343	50	ainsi	ainsi	PROPN
ihlr-26084	343	51	que	que	PROPN
ihlr-26084	343	52	des	des	PROPN
ihlr-26084	343	53	conditions	conditions	PROPN
ihlr-26084	343	54	prévisibles	prévisible	NOUN
ihlr-26084	343	55	et	et	NOUN
ihlr-26084	343	56	réelles	réelle	NOUN
ihlr-26084	343	57	d'utilisation	d'utilisation	PROPN
ihlr-26084	343	58	du	du	X
ihlr-26084	343	59	médicament	médicament	PROPN
ihlr-26084	343	60	.	.	PUNCT
ihlr-26084	343	61	”	"	PUNCT
ihlr-26084	343	62	)	)	PUNCT
ihlr-26084	344	1	92	92	NUM
ihlr-26084	344	2	.	.	PUNCT
ihlr-26084	345	1	rémond	rémond	ADJ
ihlr-26084	345	2	,	,	PUNCT
ihlr-26084	345	3	supra	supra	PROPN
ihlr-26084	345	4	note	note	NOUN
ihlr-26084	345	5	89	89	NUM
ihlr-26084	345	6	.	.	PUNCT
ihlr-26084	346	1	the	the	DET
ihlr-26084	346	2	price	price	NOUN
ihlr-26084	346	3	will	will	AUX
ihlr-26084	346	4	also	also	ADV
ihlr-26084	346	5	depend	depend	VERB
ihlr-26084	346	6	on	on	ADP
ihlr-26084	346	7	comparable	comparable	ADJ
ihlr-26084	346	8	european	european	ADJ
ihlr-26084	346	9	country	country	NOUN
ihlr-26084	346	10	.	.	PUNCT
ihlr-26084	347	1	the	the	DET
ihlr-26084	347	2	reimbursement	reimbursement	NOUN
ihlr-26084	347	3	system	system	NOUN
ihlr-26084	347	4	was	be	AUX
ihlr-26084	347	5	introduced	introduce	VERB
ihlr-26084	347	6	because	because	SCONJ
ihlr-26084	347	7	france	france	PROPN
ihlr-26084	347	8	was	be	AUX
ihlr-26084	347	9	the	the	DET
ihlr-26084	347	10	highest	high	ADJ
ihlr-26084	347	11	consuming	consume	VERB
ihlr-26084	347	12	country	country	NOUN
ihlr-26084	347	13	in	in	ADP
ihlr-26084	347	14	the	the	DET
ihlr-26084	347	15	world	world	NOUN
ihlr-26084	347	16	.	.	PUNCT
ihlr-26084	348	1	see	see	AUX
ihlr-26084	348	2	also	also	ADV
ihlr-26084	348	3	sylvain	sylvain	VERB
ihlr-26084	348	4	duffaud	duffaud	PROPN
ihlr-26084	348	5	&	&	CCONJ
ihlr-26084	348	6	sandra	sandra	PROPN
ihlr-26084	348	7	liébart	liébart	PROPN
ihlr-26084	348	8	,	,	PUNCT
ihlr-26084	348	9	how	how	SCONJ
ihlr-26084	348	10	do	do	AUX
ihlr-26084	348	11	general	general	ADJ
ihlr-26084	348	12	practitioners	practitioner	NOUN
ihlr-26084	348	13	limit	limit	VERB
ihlr-26084	348	14	their	their	PRON
ihlr-26084	348	15	prescriptions	prescription	NOUN
ihlr-26084	348	16	?	?	PUNCT
ihlr-26084	349	1	qualitative	qualitative	ADJ
ihlr-26084	349	2	study	study	NOUN
ihlr-26084	349	3	by	by	ADP
ihlr-26084	349	4	collective	collective	ADJ
ihlr-26084	349	5	interviews	interview	NOUN
ihlr-26084	349	6	,	,	PUNCT
ihlr-26084	349	7	26	26	NUM
ihlr-26084	349	8	santé	santé	X
ihlr-26084	349	9	publique	publique	X
ihlr-26084	349	10	323	323	NUM
ihlr-26084	349	11	(	(	PUNCT
ihlr-26084	349	12	2014	2014	NUM
ihlr-26084	349	13	)	)	PUNCT
ihlr-26084	349	14	.	.	PUNCT
ihlr-26084	350	1	93	93	NUM
ihlr-26084	350	2	.	.	PUNCT
ihlr-26084	351	1	rémond	rémond	ADJ
ihlr-26084	351	2	,	,	PUNCT
ihlr-26084	351	3	supra	supra	PROPN
ihlr-26084	351	4	note	note	NOUN
ihlr-26084	351	5	89	89	NUM
ihlr-26084	351	6	.	.	PUNCT
ihlr-26084	352	1	34	34	NUM
ihlr-26084	352	2	indiana	indiana	PROPN
ihlr-26084	352	3	health	health	PROPN
ihlr-26084	352	4	law	law	PROPN
ihlr-26084	352	5	review	review	NOUN
ihlr-26084	352	6	[	[	X
ihlr-26084	352	7	vol	vol	NOUN
ihlr-26084	352	8	.	.	PUNCT
ihlr-26084	353	1	19:21	19:21	NUM
ihlr-26084	353	2	prices	price	NOUN
ihlr-26084	353	3	are	be	AUX
ihlr-26084	353	4	further	further	ADJ
ihlr-26084	353	5	dropped.94	dropped.94	NOUN
ihlr-26084	353	6	for	for	ADP
ihlr-26084	353	7	reimbursed	reimbursed	ADJ
ihlr-26084	353	8	medication	medication	NOUN
ihlr-26084	353	9	,	,	PUNCT
ihlr-26084	353	10	the	the	DET
ihlr-26084	353	11	margins	margin	NOUN
ihlr-26084	353	12	of	of	ADP
ihlr-26084	353	13	pharmacists	pharmacist	NOUN
ihlr-26084	353	14	are	be	AUX
ihlr-26084	353	15	also	also	ADV
ihlr-26084	353	16	regulated	regulate	VERB
ihlr-26084	353	17	:	:	PUNCT
ihlr-26084	353	18	on	on	ADP
ihlr-26084	353	19	average	average	ADJ
ihlr-26084	353	20	,	,	PUNCT
ihlr-26084	353	21	76	76	NUM
ihlr-26084	353	22	%	%	NOUN
ihlr-26084	353	23	of	of	ADP
ihlr-26084	353	24	the	the	DET
ihlr-26084	353	25	medication	medication	NOUN
ihlr-26084	353	26	price	price	NOUN
ihlr-26084	353	27	is	be	AUX
ihlr-26084	353	28	pocketed	pocket	VERB
ihlr-26084	353	29	by	by	ADP
ihlr-26084	353	30	the	the	DET
ihlr-26084	353	31	manufacturer	manufacturer	NOUN
ihlr-26084	353	32	,	,	PUNCT
ihlr-26084	353	33	while	while	SCONJ
ihlr-26084	353	34	the	the	DET
ihlr-26084	353	35	pharmacists	pharmacist	NOUN
ihlr-26084	353	36	and	and	CCONJ
ihlr-26084	353	37	wholesalers	wholesaler	NOUN
ihlr-26084	353	38	make	make	VERB
ihlr-26084	353	39	22	22	NUM
ihlr-26084	353	40	%	%	NOUN
ihlr-26084	353	41	combined	combine	VERB
ihlr-26084	353	42	and	and	CCONJ
ihlr-26084	353	43	the	the	DET
ihlr-26084	353	44	remaining	remain	VERB
ihlr-26084	353	45	2	2	NUM
ihlr-26084	353	46	%	%	NOUN
ihlr-26084	353	47	is	be	AUX
ihlr-26084	353	48	the	the	DET
ihlr-26084	353	49	tax.95	tax.95	NOUN
ihlr-26084	353	50	the	the	DET
ihlr-26084	353	51	monopsony	monopsony	ADJ
ihlr-26084	353	52	power	power	NOUN
ihlr-26084	353	53	of	of	ADP
ihlr-26084	353	54	the	the	DET
ihlr-26084	353	55	uk	uk	PROPN
ihlr-26084	353	56	and	and	CCONJ
ihlr-26084	353	57	french	french	ADJ
ihlr-26084	353	58	governments	government	NOUN
ihlr-26084	353	59	allows	allow	VERB
ihlr-26084	353	60	them	they	PRON
ihlr-26084	353	61	to	to	PART
ihlr-26084	353	62	negotiate	negotiate	VERB
ihlr-26084	353	63	prices	price	NOUN
ihlr-26084	353	64	lower	low	ADJ
ihlr-26084	353	65	than	than	ADP
ihlr-26084	353	66	us	we	PRON
ihlr-26084	353	67	insurers.96	insurers.96	PROPN
ihlr-26084	353	68	however	however	ADV
ihlr-26084	353	69	,	,	PUNCT
ihlr-26084	353	70	monopsony	monopsony	ADJ
ihlr-26084	353	71	power	power	NOUN
ihlr-26084	353	72	does	do	AUX
ihlr-26084	353	73	not	not	PART
ihlr-26084	353	74	eliminate	eliminate	VERB
ihlr-26084	353	75	the	the	DET
ihlr-26084	353	76	need	need	NOUN
ihlr-26084	353	77	for	for	ADP
ihlr-26084	353	78	generics	generic	NOUN
ihlr-26084	353	79	.	.	PUNCT
ihlr-26084	354	1	the	the	DET
ihlr-26084	354	2	next	next	ADJ
ihlr-26084	354	3	section	section	NOUN
ihlr-26084	354	4	investigates	investigate	VERB
ihlr-26084	354	5	drug	drug	NOUN
ihlr-26084	354	6	competition	competition	NOUN
ihlr-26084	354	7	in	in	ADP
ihlr-26084	354	8	countries	country	NOUN
ihlr-26084	354	9	with	with	ADP
ihlr-26084	354	10	drug	drug	NOUN
ihlr-26084	354	11	price	price	NOUN
ihlr-26084	354	12	regulations	regulation	NOUN
ihlr-26084	354	13	.	.	PUNCT
ihlr-26084	355	1	2	2	X
ihlr-26084	355	2	.	.	X
ihlr-26084	355	3	intra	intra	ADJ
ihlr-26084	355	4	-	-	ADJ
ihlr-26084	355	5	brand	brand	ADJ
ihlr-26084	355	6	vs.	vs.	ADP
ihlr-26084	355	7	inter	inter	ADJ
ihlr-26084	355	8	-	-	ADJ
ihlr-26084	355	9	brand	brand	ADJ
ihlr-26084	355	10	competition	competition	NOUN
ihlr-26084	355	11	:	:	PUNCT
ihlr-26084	355	12	the	the	DET
ihlr-26084	355	13	eu	eu	PROPN
ihlr-26084	355	14	functioning	function	VERB
ihlr-26084	355	15	and	and	CCONJ
ihlr-26084	355	16	drug	drug	NOUN
ihlr-26084	355	17	circulation	circulation	NOUN
ihlr-26084	355	18	in	in	ADP
ihlr-26084	355	19	the	the	DET
ihlr-26084	355	20	eu	eu	PROPN
ihlr-26084	355	21	competition	competition	NOUN
ihlr-26084	355	22	plays	play	VERB
ihlr-26084	355	23	an	an	DET
ihlr-26084	355	24	important	important	ADJ
ihlr-26084	355	25	role	role	NOUN
ihlr-26084	355	26	in	in	ADP
ihlr-26084	355	27	decreasing	decrease	VERB
ihlr-26084	355	28	prices	price	NOUN
ihlr-26084	355	29	.	.	PUNCT
ihlr-26084	356	1	in	in	ADP
ihlr-26084	356	2	any	any	DET
ihlr-26084	356	3	country	country	NOUN
ihlr-26084	356	4	,	,	PUNCT
ihlr-26084	356	5	competition	competition	NOUN
ihlr-26084	356	6	comes	come	VERB
ihlr-26084	356	7	from	from	ADP
ihlr-26084	356	8	:	:	PUNCT
ihlr-26084	356	9	(	(	PUNCT
ihlr-26084	356	10	1	1	X
ihlr-26084	356	11	)	)	PUNCT
ihlr-26084	356	12	the	the	DET
ihlr-26084	356	13	same	same	ADJ
ihlr-26084	356	14	drug	drug	NOUN
ihlr-26084	356	15	coming	come	VERB
ihlr-26084	356	16	from	from	ADP
ihlr-26084	356	17	abroad	abroad	ADV
ihlr-26084	356	18	through	through	ADP
ihlr-26084	356	19	parallel	parallel	ADJ
ihlr-26084	356	20	imports	import	NOUN
ihlr-26084	356	21	(	(	PUNCT
ihlr-26084	356	22	intra	intra	ADJ
ihlr-26084	356	23	-	-	ADJ
ihlr-26084	356	24	brand	brand	ADJ
ihlr-26084	356	25	competition	competition	NOUN
ihlr-26084	356	26	)	)	PUNCT
ihlr-26084	356	27	;	;	PUNCT
ihlr-26084	356	28	(	(	PUNCT
ihlr-26084	356	29	2	2	X
ihlr-26084	356	30	)	)	PUNCT
ihlr-26084	356	31	different	different	ADJ
ihlr-26084	356	32	drugs	drug	NOUN
ihlr-26084	356	33	with	with	ADP
ihlr-26084	356	34	similar	similar	ADJ
ihlr-26084	356	35	therapeutical	therapeutical	ADJ
ihlr-26084	356	36	treatment	treatment	NOUN
ihlr-26084	356	37	(	(	PUNCT
ihlr-26084	356	38	“	"	PUNCT
ihlr-26084	356	39	me	i	PRON
ihlr-26084	356	40	-	-	PUNCT
ihlr-26084	356	41	too	too	ADV
ihlr-26084	356	42	”	"	PUNCT
ihlr-26084	356	43	drugs	drug	NOUN
ihlr-26084	356	44	)	)	PUNCT
ihlr-26084	356	45	;	;	PUNCT
ihlr-26084	356	46	and	and	CCONJ
ihlr-26084	356	47	(	(	PUNCT
ihlr-26084	356	48	3	3	X
ihlr-26084	356	49	)	)	PUNCT
ihlr-26084	356	50	generics	generic	NOUN
ihlr-26084	356	51	competition	competition	NOUN
ihlr-26084	356	52	(	(	PUNCT
ihlr-26084	356	53	inter	inter	ADJ
ihlr-26084	356	54	-	-	ADJ
ihlr-26084	356	55	brand	brand	ADJ
ihlr-26084	356	56	competition	competition	NOUN
ihlr-26084	356	57	)	)	PUNCT
ihlr-26084	356	58	.	.	PUNCT
ihlr-26084	357	1	of	of	ADP
ihlr-26084	357	2	these	these	DET
ihlr-26084	357	3	three	three	NUM
ihlr-26084	357	4	,	,	PUNCT
ihlr-26084	357	5	only	only	ADV
ihlr-26084	357	6	generic	generic	ADJ
ihlr-26084	357	7	competition	competition	NOUN
ihlr-26084	357	8	exerts	exert	VERB
ihlr-26084	357	9	significant	significant	ADJ
ihlr-26084	357	10	downward	downward	ADJ
ihlr-26084	357	11	pressure	pressure	NOUN
ihlr-26084	357	12	on	on	ADP
ihlr-26084	357	13	drug	drug	NOUN
ihlr-26084	357	14	prices	price	NOUN
ihlr-26084	357	15	.	.	PUNCT
ihlr-26084	358	1	first	first	ADV
ihlr-26084	358	2	,	,	PUNCT
ihlr-26084	358	3	intra	intra	ADJ
ihlr-26084	358	4	-	-	ADJ
ihlr-26084	358	5	brand	brand	ADJ
ihlr-26084	358	6	competition	competition	NOUN
ihlr-26084	358	7	occurs	occur	VERB
ihlr-26084	358	8	when	when	SCONJ
ihlr-26084	358	9	a	a	DET
ihlr-26084	358	10	branded	brand	VERB
ihlr-26084	358	11	drug	drug	NOUN
ihlr-26084	358	12	competes	compete	VERB
ihlr-26084	358	13	with	with	ADP
ihlr-26084	358	14	itself	itself	PRON
ihlr-26084	358	15	.	.	PUNCT
ihlr-26084	359	1	in	in	ADP
ihlr-26084	359	2	europe	europe	PROPN
ihlr-26084	359	3	,	,	PUNCT
ihlr-26084	359	4	a	a	DET
ihlr-26084	359	5	branded	brand	VERB
ihlr-26084	359	6	drug	drug	NOUN
ihlr-26084	359	7	may	may	AUX
ihlr-26084	359	8	compete	compete	VERB
ihlr-26084	359	9	with	with	ADP
ihlr-26084	359	10	itself	itself	PRON
ihlr-26084	359	11	through	through	ADP
ihlr-26084	359	12	parallel	parallel	ADJ
ihlr-26084	359	13	imports	import	NOUN
ihlr-26084	359	14	.	.	PUNCT
ihlr-26084	360	1	parallel	parallel	ADJ
ihlr-26084	360	2	imports	import	NOUN
ihlr-26084	360	3	occur	occur	VERB
ihlr-26084	360	4	when	when	SCONJ
ihlr-26084	360	5	a	a	DET
ihlr-26084	360	6	branded	brand	VERB
ihlr-26084	360	7	drug	drug	NOUN
ihlr-26084	360	8	marketed	market	VERB
ihlr-26084	360	9	for	for	ADP
ihlr-26084	360	10	one	one	NUM
ihlr-26084	360	11	country	country	NOUN
ihlr-26084	360	12	is	be	AUX
ihlr-26084	360	13	sold	sell	VERB
ihlr-26084	360	14	in	in	ADP
ihlr-26084	360	15	another	another	DET
ihlr-26084	360	16	country	country	NOUN
ihlr-26084	360	17	.	.	PUNCT
ihlr-26084	361	1	aside	aside	ADV
ihlr-26084	361	2	from	from	ADP
ihlr-26084	361	3	the	the	DET
ihlr-26084	361	4	coronavirus	coronavirus	NOUN
ihlr-26084	361	5	pandemic	pandemic	NOUN
ihlr-26084	361	6	(	(	PUNCT
ihlr-26084	361	7	when	when	SCONJ
ihlr-26084	361	8	the	the	DET
ihlr-26084	361	9	european	european	PROPN
ihlr-26084	361	10	commission	commission	PROPN
ihlr-26084	361	11	intervened),97	intervened),97	VERB
ihlr-26084	361	12	each	each	DET
ihlr-26084	361	13	member	member	NOUN
ihlr-26084	361	14	state	state	NOUN
ihlr-26084	361	15	individually	individually	ADV
ihlr-26084	361	16	negotiates	negotiate	VERB
ihlr-26084	361	17	with	with	ADP
ihlr-26084	361	18	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	361	19	companies.98	companies.98	NOUN
ihlr-26084	361	20	these	these	DET
ihlr-26084	361	21	individual	individual	ADJ
ihlr-26084	361	22	negotiations	negotiation	NOUN
ihlr-26084	361	23	lead	lead	VERB
ihlr-26084	361	24	to	to	ADP
ihlr-26084	361	25	different	different	ADJ
ihlr-26084	361	26	prices	price	NOUN
ihlr-26084	361	27	in	in	ADP
ihlr-26084	361	28	different	different	ADJ
ihlr-26084	361	29	jurisdictions	jurisdiction	NOUN
ihlr-26084	361	30	.	.	PUNCT
ihlr-26084	362	1	parallel	parallel	ADJ
ihlr-26084	362	2	importers	importer	NOUN
ihlr-26084	362	3	can	can	AUX
ihlr-26084	362	4	take	take	VERB
ihlr-26084	362	5	advantage	advantage	NOUN
ihlr-26084	362	6	of	of	ADP
ihlr-26084	362	7	those	those	DET
ihlr-26084	362	8	different	different	ADJ
ihlr-26084	362	9	prices	price	NOUN
ihlr-26084	362	10	to	to	PART
ihlr-26084	362	11	profit.99	profit.99	NOUN
ihlr-26084	362	12	parallel	parallel	ADJ
ihlr-26084	362	13	imports	import	NOUN
ihlr-26084	362	14	rely	rely	VERB
ihlr-26084	362	15	on	on	ADP
ihlr-26084	362	16	the	the	DET
ihlr-26084	362	17	patent	patent	NOUN
ihlr-26084	362	18	exhaustion	exhaustion	NOUN
ihlr-26084	362	19	doctrine	doctrine	NOUN
ihlr-26084	362	20	:	:	PUNCT
ihlr-26084	362	21	once	once	SCONJ
ihlr-26084	362	22	a	a	DET
ihlr-26084	362	23	patent	patent	NOUN
ihlr-26084	362	24	holder	holder	NOUN
ihlr-26084	362	25	sells	sell	VERB
ihlr-26084	362	26	a	a	DET
ihlr-26084	362	27	patented	patented	ADJ
ihlr-26084	362	28	product	product	NOUN
ihlr-26084	362	29	,	,	PUNCT
ihlr-26084	362	30	the	the	DET
ihlr-26084	362	31	product	product	NOUN
ihlr-26084	362	32	can	can	AUX
ihlr-26084	362	33	circulate	circulate	VERB
ihlr-26084	362	34	freely	freely	ADV
ihlr-26084	362	35	inside	inside	ADP
ihlr-26084	362	36	the	the	DET
ihlr-26084	362	37	stream	stream	NOUN
ihlr-26084	362	38	of	of	ADP
ihlr-26084	362	39	commerce	commerce	NOUN
ihlr-26084	362	40	.	.	PUNCT
ihlr-26084	363	1	in	in	ADP
ihlr-26084	363	2	the	the	DET
ihlr-26084	363	3	european	european	ADJ
ihlr-26084	363	4	economic	economic	ADJ
ihlr-26084	363	5	area	area	NOUN
ihlr-26084	363	6	(	(	PUNCT
ihlr-26084	363	7	“	"	PUNCT
ihlr-26084	363	8	eea	eea	PROPN
ihlr-26084	363	9	”	"	PUNCT
ihlr-26084	363	10	)	)	PUNCT
ihlr-26084	363	11	,	,	PUNCT
ihlr-26084	363	12	the	the	DET
ihlr-26084	363	13	patent	patent	NOUN
ihlr-26084	363	14	exhaustion	exhaustion	NOUN
ihlr-26084	363	15	doctrine	doctrine	NOUN
ihlr-26084	363	16	applies	apply	VERB
ihlr-26084	363	17	to	to	ADP
ihlr-26084	363	18	all	all	DET
ihlr-26084	363	19	patented	patented	ADJ
ihlr-26084	363	20	products	product	NOUN
ihlr-26084	363	21	within	within	ADP
ihlr-26084	363	22	the	the	DET
ihlr-26084	363	23	stream	stream	NOUN
ihlr-26084	363	24	of	of	ADP
ihlr-26084	363	25	commerce	commerce	NOUN
ihlr-26084	363	26	–	–	PUNCT
ihlr-26084	363	27	even	even	ADV
ihlr-26084	363	28	though	though	SCONJ
ihlr-26084	363	29	patent	patent	NOUN
ihlr-26084	363	30	protection	protection	NOUN
ihlr-26084	363	31	remains	remain	VERB
ihlr-26084	363	32	member	member	NOUN
ihlr-26084	363	33	state	state	NOUN
ihlr-26084	363	34	-	-	PUNCT
ihlr-26084	363	35	specific.100	specific.100	NOUN
ihlr-26084	363	36	in	in	ADP
ihlr-26084	363	37	the	the	DET
ihlr-26084	363	38	post	post	ADJ
ihlr-26084	363	39	-	-	ADJ
ihlr-26084	363	40	brexit	brexit	ADJ
ihlr-26084	363	41	united	united	ADJ
ihlr-26084	363	42	kingdom	kingdom	PROPN
ihlr-26084	363	43	,	,	PUNCT
ihlr-26084	363	44	parallel	parallel	ADJ
ihlr-26084	363	45	imports	import	NOUN
ihlr-26084	363	46	are	be	AUX
ihlr-26084	363	47	accepted	accept	VERB
ihlr-26084	363	48	from	from	ADP
ihlr-26084	363	49	the	the	DET
ihlr-26084	363	50	eea	eea	PROPN
ihlr-26084	363	51	,	,	PUNCT
ihlr-26084	363	52	but	but	CCONJ
ihlr-26084	363	53	not	not	PART
ihlr-26084	363	54	vice94	vice94	ADV
ihlr-26084	363	55	.	.	PUNCT
ihlr-26084	364	1	i	i	PRON
ihlr-26084	364	2	d.	d.	PROPN
ihlr-26084	364	3	95	95	NUM
ihlr-26084	364	4	.	.	PUNCT
ihlr-26084	365	1	i	i	PRON
ihlr-26084	365	2	d.	d.	PROPN
ihlr-26084	365	3	96	96	NUM
ihlr-26084	365	4	.	.	PUNCT
ihlr-26084	366	1	prescription	prescription	NOUN
ihlr-26084	366	2	drugs	drug	NOUN
ihlr-26084	366	3	,	,	PUNCT
ihlr-26084	366	4	supra	supra	PROPN
ihlr-26084	366	5	note	note	NOUN
ihlr-26084	366	6	32	32	NUM
ihlr-26084	366	7	.	.	PUNCT
ihlr-26084	367	1	97	97	NUM
ihlr-26084	367	2	.	.	PUNCT
ihlr-26084	368	1	see	see	VERB
ihlr-26084	368	2	commission	commission	NOUN
ihlr-26084	368	3	decision	decision	NOUN
ihlr-26084	368	4	of	of	ADP
ihlr-26084	368	5	june	june	PROPN
ihlr-26084	368	6	18	18	NUM
ihlr-26084	368	7	,	,	PUNCT
ihlr-26084	368	8	2020	2020	NUM
ihlr-26084	368	9	,	,	PUNCT
ihlr-26084	368	10	eur	eur	PROPN
ihlr-26084	368	11	.	.	PUNCT
ihlr-26084	368	12	comm’n	comm’n	NOUN
ihlr-26084	369	1	1	1	NUM
ihlr-26084	369	2	(	(	PUNCT
ihlr-26084	369	3	2020	2020	NUM
ihlr-26084	369	4	)	)	PUNCT
ihlr-26084	369	5	(	(	PUNCT
ihlr-26084	369	6	approving	approve	VERB
ihlr-26084	369	7	the	the	DET
ihlr-26084	369	8	agreement	agreement	NOUN
ihlr-26084	369	9	with	with	ADP
ihlr-26084	369	10	member	member	NOUN
ihlr-26084	369	11	states	state	NOUN
ihlr-26084	369	12	on	on	ADP
ihlr-26084	369	13	procuring	procure	VERB
ihlr-26084	369	14	covid-19	covid-19	PROPN
ihlr-26084	369	15	vaccines	vaccine	NOUN
ihlr-26084	369	16	on	on	ADP
ihlr-26084	369	17	behalf	behalf	NOUN
ihlr-26084	369	18	of	of	ADP
ihlr-26084	369	19	the	the	DET
ihlr-26084	369	20	member	member	NOUN
ihlr-26084	369	21	states	state	NOUN
ihlr-26084	369	22	and	and	CCONJ
ihlr-26084	369	23	related	related	ADJ
ihlr-26084	369	24	procedures	procedure	NOUN
ihlr-26084	369	25	)	)	PUNCT
ihlr-26084	369	26	;	;	PUNCT
ihlr-26084	369	27	annex	annex	VERB
ihlr-26084	369	28	to	to	ADP
ihlr-26084	369	29	the	the	DET
ihlr-26084	369	30	commission	commission	NOUN
ihlr-26084	369	31	decision	decision	NOUN
ihlr-26084	369	32	,	,	PUNCT
ihlr-26084	369	33	eur	eur	PROPN
ihlr-26084	369	34	.	.	PUNCT
ihlr-26084	369	35	comm’n	comm’n	NOUN
ihlr-26084	370	1	1	1	NUM
ihlr-26084	370	2	(	(	PUNCT
ihlr-26084	370	3	2020	2020	NUM
ihlr-26084	370	4	)	)	PUNCT
ihlr-26084	370	5	.	.	PUNCT
ihlr-26084	371	1	98	98	NUM
ihlr-26084	371	2	.	.	PUNCT
ihlr-26084	371	3	nicole	nicole	PROPN
ihlr-26084	371	4	scholz	scholz	PROPN
ihlr-26084	371	5	,	,	PUNCT
ihlr-26084	371	6	medicinal	medicinal	ADJ
ihlr-26084	371	7	products	product	NOUN
ihlr-26084	371	8	in	in	ADP
ihlr-26084	371	9	the	the	DET
ihlr-26084	371	10	european	european	PROPN
ihlr-26084	371	11	union	union	PROPN
ihlr-26084	371	12	,	,	PUNCT
ihlr-26084	371	13	eur	eur	PROPN
ihlr-26084	371	14	.	.	PUNCT
ihlr-26084	372	1	parliamentary	parliamentary	ADJ
ihlr-26084	372	2	rsch	rsch	NOUN
ihlr-26084	372	3	.	.	PUNCT
ihlr-26084	373	1	serv	serv	X
ihlr-26084	373	2	.	.	PROPN
ihlr-26084	373	3	9	9	NUM
ihlr-26084	373	4	(	(	PUNCT
ihlr-26084	373	5	2015	2015	NUM
ihlr-26084	373	6	)	)	PUNCT
ihlr-26084	373	7	.	.	PUNCT
ihlr-26084	374	1	99	99	NUM
ihlr-26084	374	2	.	.	PUNCT
ihlr-26084	375	1	kanavos	kanavos	PROPN
ihlr-26084	375	2	et	et	PROPN
ihlr-26084	375	3	al	al	PROPN
ihlr-26084	375	4	.	.	PROPN
ihlr-26084	375	5	,	,	PUNCT
ihlr-26084	375	6	supra	supra	PROPN
ihlr-26084	375	7	note	note	VERB
ihlr-26084	375	8	87	87	NUM
ihlr-26084	375	9	,	,	PUNCT
ihlr-26084	375	10	table	table	NOUN
ihlr-26084	375	11	6.20	6.20	NUM
ihlr-26084	375	12	(	(	PUNCT
ihlr-26084	375	13	showing	show	VERB
ihlr-26084	375	14	parallel	parallel	ADJ
ihlr-26084	375	15	importers	importer	NOUN
ihlr-26084	375	16	are	be	AUX
ihlr-26084	375	17	the	the	DET
ihlr-26084	375	18	main	main	ADJ
ihlr-26084	375	19	beneficiary	beneficiary	NOUN
ihlr-26084	375	20	of	of	ADP
ihlr-26084	375	21	this	this	DET
ihlr-26084	375	22	practice	practice	NOUN
ihlr-26084	375	23	)	)	PUNCT
ihlr-26084	375	24	.	.	PUNCT
ihlr-26084	376	1	100	100	NUM
ihlr-26084	376	2	.	.	PUNCT
ihlr-26084	377	1	garry	garry	PROPN
ihlr-26084	377	2	a.	a.	PROPN
ihlr-26084	377	3	gabison	gabison	PROPN
ihlr-26084	377	4	,	,	PUNCT
ihlr-26084	377	5	worldwide	worldwide	ADJ
ihlr-26084	377	6	frand	frand	NOUN
ihlr-26084	377	7	licensing	licensing	NOUN
ihlr-26084	377	8	standard	standard	NOUN
ihlr-26084	377	9	,	,	PUNCT
ihlr-26084	377	10	8	8	NUM
ihlr-26084	377	11	am	am	NOUN
ihlr-26084	377	12	.	.	PUNCT
ihlr-26084	378	1	u.	u.	PROPN
ihlr-26084	378	2	bus	bus	PROPN
ihlr-26084	378	3	.	.	PUNCT
ihlr-26084	379	1	l.	l.	PROPN
ihlr-26084	379	2	rev	rev	PROPN
ihlr-26084	379	3	.	.	PROPN
ihlr-26084	379	4	139	139	NUM
ihlr-26084	379	5	,	,	PUNCT
ihlr-26084	379	6	154	154	NUM
ihlr-26084	379	7	-	-	SYM
ihlr-26084	379	8	62	62	NUM
ihlr-26084	379	9	(	(	PUNCT
ihlr-26084	379	10	2019	2019	NUM
ihlr-26084	379	11	)	)	PUNCT
ihlr-26084	379	12	.	.	PUNCT
ihlr-26084	380	1	2022	2022	NUM
ihlr-26084	380	2	]	]	PUNCT
ihlr-26084	380	3	reverse	reverse	ADJ
ihlr-26084	380	4	payment	payment	NOUN
ihlr-26084	380	5	:	:	PUNCT
ihlr-26084	380	6	a	a	DET
ihlr-26084	380	7	comparative	comparative	ADJ
ihlr-26084	380	8	study	study	NOUN
ihlr-26084	380	9	35	35	NUM
ihlr-26084	380	10	versa.101	versa.101	ADJ
ihlr-26084	380	11	in	in	ADP
ihlr-26084	380	12	centrafarm	centrafarm	NOUN
ihlr-26084	380	13	bv	bv	PROPN
ihlr-26084	380	14	et	et	PROPN
ihlr-26084	380	15	adriaan	adriaan	PROPN
ihlr-26084	380	16	de	de	PROPN
ihlr-26084	380	17	peijper	peijper	PROPN
ihlr-26084	380	18	v.	v.	ADP
ihlr-26084	380	19	sterling	sterling	PROPN
ihlr-26084	380	20	drug	drug	PROPN
ihlr-26084	380	21	inc	inc	PROPN
ihlr-26084	380	22	.	.	PROPN
ihlr-26084	380	23	,102	,102	PUNCT
ihlr-26084	380	24	sterling	sterling	PROPN
ihlr-26084	380	25	drug	drug	PROPN
ihlr-26084	380	26	inc	inc	PROPN
ihlr-26084	380	27	.	.	PROPN
ihlr-26084	380	28	sought	seek	VERB
ihlr-26084	380	29	an	an	DET
ihlr-26084	380	30	injunction	injunction	NOUN
ihlr-26084	380	31	to	to	PART
ihlr-26084	380	32	stop	stop	VERB
ihlr-26084	380	33	the	the	DET
ihlr-26084	380	34	dutch	dutch	ADJ
ihlr-26084	380	35	drug	drug	NOUN
ihlr-26084	380	36	seller	seller	NOUN
ihlr-26084	380	37	centrafarm	centrafarm	NOUN
ihlr-26084	380	38	from	from	ADP
ihlr-26084	380	39	importing	import	VERB
ihlr-26084	380	40	sterling	sterling	NOUN
ihlr-26084	380	41	-	-	PUNCT
ihlr-26084	380	42	patented	patent	VERB
ihlr-26084	380	43	drugs	drug	NOUN
ihlr-26084	380	44	from	from	ADP
ihlr-26084	380	45	germany	germany	PROPN
ihlr-26084	380	46	and	and	CCONJ
ihlr-26084	380	47	england	england	PROPN
ihlr-26084	380	48	to	to	PART
ihlr-26084	380	49	sell	sell	VERB
ihlr-26084	380	50	in	in	ADP
ihlr-26084	380	51	the	the	DET
ihlr-26084	380	52	netherlands.103	netherlands.103	NOUN
ihlr-26084	380	53	the	the	DET
ihlr-26084	380	54	dutch	dutch	ADJ
ihlr-26084	380	55	court	court	NOUN
ihlr-26084	380	56	referred	refer	VERB
ihlr-26084	380	57	the	the	DET
ihlr-26084	380	58	case	case	NOUN
ihlr-26084	380	59	to	to	ADP
ihlr-26084	380	60	the	the	DET
ihlr-26084	380	61	european	european	PROPN
ihlr-26084	380	62	court	court	PROPN
ihlr-26084	380	63	of	of	ADP
ihlr-26084	380	64	justice	justice	PROPN
ihlr-26084	380	65	.	.	PUNCT
ihlr-26084	381	1	the	the	DET
ihlr-26084	381	2	court	court	NOUN
ihlr-26084	381	3	concluded	conclude	VERB
ihlr-26084	381	4	that	that	SCONJ
ihlr-26084	381	5	the	the	DET
ihlr-26084	381	6	right	right	NOUN
ihlr-26084	381	7	of	of	ADP
ihlr-26084	381	8	a	a	DET
ihlr-26084	381	9	patentee	patentee	NOUN
ihlr-26084	381	10	“	"	PUNCT
ihlr-26084	381	11	to	to	PART
ihlr-26084	381	12	prohibit	prohibit	VERB
ihlr-26084	381	13	the	the	DET
ihlr-26084	381	14	sale	sale	NOUN
ihlr-26084	381	15	.	.	PUNCT
ihlr-26084	381	16	.	.	PUNCT
ihlr-26084	382	1	.	.	PUNCT
ihlr-26084	383	1	is	be	AUX
ihlr-26084	383	2	incompatible	incompatible	ADJ
ihlr-26084	383	3	with	with	ADP
ihlr-26084	383	4	the	the	DET
ihlr-26084	383	5	rules	rule	NOUN
ihlr-26084	383	6	of	of	ADP
ihlr-26084	383	7	the	the	DET
ihlr-26084	383	8	eec	eec	PROPN
ihlr-26084	383	9	treaty	treaty	NOUN
ihlr-26084	383	10	concerning	concern	VERB
ihlr-26084	383	11	the	the	DET
ihlr-26084	383	12	free	free	ADJ
ihlr-26084	383	13	movement	movement	NOUN
ihlr-26084	383	14	of	of	ADP
ihlr-26084	383	15	goods	good	NOUN
ihlr-26084	383	16	within	within	ADP
ihlr-26084	383	17	the	the	DET
ihlr-26084	383	18	common	common	ADJ
ihlr-26084	383	19	market	market	NOUN
ihlr-26084	383	20	.	.	PUNCT
ihlr-26084	383	21	”104	”104	PUNCT
ihlr-26084	384	1	the	the	DET
ihlr-26084	384	2	court	court	NOUN
ihlr-26084	384	3	also	also	ADV
ihlr-26084	384	4	allowed	allow	VERB
ihlr-26084	384	5	parallel	parallel	ADJ
ihlr-26084	384	6	imports	import	NOUN
ihlr-26084	384	7	from	from	ADP
ihlr-26084	384	8	a	a	DET
ihlr-26084	384	9	member	member	NOUN
ihlr-26084	384	10	state	state	NOUN
ihlr-26084	384	11	where	where	SCONJ
ihlr-26084	384	12	the	the	DET
ihlr-26084	384	13	patent	patent	NOUN
ihlr-26084	384	14	holder	holder	NOUN
ihlr-26084	384	15	freely	freely	ADV
ihlr-26084	384	16	marketed	market	VERB
ihlr-26084	384	17	the	the	DET
ihlr-26084	384	18	drug	drug	NOUN
ihlr-26084	384	19	but	but	CCONJ
ihlr-26084	384	20	did	do	AUX
ihlr-26084	384	21	not	not	PART
ihlr-26084	384	22	hold	hold	VERB
ihlr-26084	384	23	a	a	DET
ihlr-26084	384	24	patent105	patent105	PROPN
ihlr-26084	384	25	into	into	ADP
ihlr-26084	384	26	a	a	DET
ihlr-26084	384	27	member	member	NOUN
ihlr-26084	384	28	state	state	NOUN
ihlr-26084	384	29	where	where	SCONJ
ihlr-26084	384	30	it	it	PRON
ihlr-26084	384	31	did	do	VERB
ihlr-26084	384	32	.	.	PUNCT
ihlr-26084	385	1	more	more	ADV
ihlr-26084	385	2	importantly	importantly	ADV
ihlr-26084	385	3	,	,	PUNCT
ihlr-26084	385	4	the	the	DET
ihlr-26084	385	5	court	court	NOUN
ihlr-26084	385	6	also	also	ADV
ihlr-26084	385	7	barred	bar	VERB
ihlr-26084	385	8	laws	law	NOUN
ihlr-26084	385	9	that	that	PRON
ihlr-26084	385	10	impede	impede	VERB
ihlr-26084	385	11	the	the	DET
ihlr-26084	385	12	movement	movement	NOUN
ihlr-26084	385	13	of	of	ADP
ihlr-26084	385	14	generics	generic	NOUN
ihlr-26084	385	15	between	between	ADP
ihlr-26084	385	16	european	european	PROPN
ihlr-26084	385	17	countries.106	countries.106	PROPN
ihlr-26084	385	18	however	however	ADV
ihlr-26084	385	19	,	,	PUNCT
ihlr-26084	385	20	the	the	DET
ihlr-26084	385	21	court	court	NOUN
ihlr-26084	385	22	held	hold	VERB
ihlr-26084	385	23	that	that	SCONJ
ihlr-26084	385	24	if	if	SCONJ
ihlr-26084	385	25	the	the	DET
ihlr-26084	385	26	drug	drug	NOUN
ihlr-26084	385	27	was	be	AUX
ihlr-26084	385	28	manufactured	manufacture	VERB
ihlr-26084	385	29	in	in	ADP
ihlr-26084	385	30	one	one	NUM
ihlr-26084	385	31	country	country	NOUN
ihlr-26084	385	32	under	under	ADP
ihlr-26084	385	33	a	a	DET
ihlr-26084	385	34	compulsory	compulsory	ADJ
ihlr-26084	385	35	license	license	NOUN
ihlr-26084	385	36	,	,	PUNCT
ihlr-26084	385	37	the	the	DET
ihlr-26084	385	38	patent	patent	NOUN
ihlr-26084	385	39	holder	holder	NOUN
ihlr-26084	385	40	may	may	AUX
ihlr-26084	385	41	prevent	prevent	VERB
ihlr-26084	385	42	import	import	NOUN
ihlr-26084	385	43	to	to	ADP
ihlr-26084	385	44	another	another	DET
ihlr-26084	385	45	european	european	ADJ
ihlr-26084	385	46	country	country	NOUN
ihlr-26084	385	47	where	where	SCONJ
ihlr-26084	385	48	it	it	PRON
ihlr-26084	385	49	holds	hold	VERB
ihlr-26084	385	50	another	another	DET
ihlr-26084	385	51	patent.107	patent.107	ADJ
ihlr-26084	385	52	parallel	parallel	ADJ
ihlr-26084	385	53	imports	import	NOUN
ihlr-26084	385	54	enabled	enable	VERB
ihlr-26084	385	55	some	some	DET
ihlr-26084	385	56	arbitrage	arbitrage	NOUN
ihlr-26084	385	57	.	.	PUNCT
ihlr-26084	386	1	prices	price	NOUN
ihlr-26084	386	2	decrease	decrease	VERB
ihlr-26084	386	3	in	in	ADP
ihlr-26084	386	4	countries	country	NOUN
ihlr-26084	386	5	where	where	SCONJ
ihlr-26084	386	6	drugs	drug	NOUN
ihlr-26084	386	7	are	be	AUX
ihlr-26084	386	8	more	more	ADV
ihlr-26084	386	9	expensive108	expensive108	PROPN
ihlr-26084	386	10	and	and	CCONJ
ihlr-26084	386	11	the	the	DET
ihlr-26084	386	12	national	national	ADJ
ihlr-26084	386	13	insurance	insurance	NOUN
ihlr-26084	386	14	system	system	NOUN
ihlr-26084	386	15	garner	garner	VERB
ihlr-26084	386	16	some	some	DET
ihlr-26084	386	17	benefits.109	benefits.109	VERB
ihlr-26084	386	18	however	however	ADV
ihlr-26084	386	19	,	,	PUNCT
ihlr-26084	386	20	these	these	DET
ihlr-26084	386	21	benefits	benefit	NOUN
ihlr-26084	386	22	are	be	AUX
ihlr-26084	386	23	limited	limited	ADJ
ihlr-26084	386	24	.	.	PUNCT
ihlr-26084	387	1	regulated	regulate	VERB
ihlr-26084	387	2	prices	price	NOUN
ihlr-26084	387	3	deter	deter	VERB
ihlr-26084	387	4	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	387	5	manufacturers	manufacturer	NOUN
ihlr-26084	387	6	from	from	ADP
ihlr-26084	387	7	introducing	introduce	VERB
ihlr-26084	387	8	their	their	PRON
ihlr-26084	387	9	own	own	ADJ
ihlr-26084	387	10	generics	generic	NOUN
ihlr-26084	387	11	,	,	PUNCT
ihlr-26084	387	12	which	which	PRON
ihlr-26084	387	13	would	would	AUX
ihlr-26084	387	14	create	create	VERB
ihlr-26084	387	15	undesired	undesired	ADJ
ihlr-26084	387	16	intra	intra	ADJ
ihlr-26084	387	17	-	-	ADJ
ihlr-26084	387	18	brand	brand	ADJ
ihlr-26084	387	19	competition	competition	NOUN
ihlr-26084	387	20	.	.	PUNCT
ihlr-26084	388	1	parallel	parallel	ADJ
ihlr-26084	388	2	imports	import	NOUN
ihlr-26084	388	3	increase	increase	VERB
ihlr-26084	388	4	this	this	DET
ihlr-26084	388	5	101	101	NUM
ihlr-26084	388	6	.	.	PUNCT
ihlr-26084	389	1	exhaustion	exhaustion	NOUN
ihlr-26084	389	2	of	of	ADP
ihlr-26084	389	3	ip	ip	PRON
ihlr-26084	389	4	rights	right	NOUN
ihlr-26084	389	5	and	and	CCONJ
ihlr-26084	389	6	parallel	parallel	ADJ
ihlr-26084	389	7	trade	trade	NOUN
ihlr-26084	389	8	,	,	PUNCT
ihlr-26084	389	9	uk	uk	PROPN
ihlr-26084	389	10	i.p	i.p	PROPN
ihlr-26084	389	11	.	.	PROPN
ihlr-26084	389	12	off	off	ADP
ihlr-26084	389	13	.	.	PUNCT
ihlr-26084	390	1	,	,	PUNCT
ihlr-26084	390	2	https://www.gov.uk/	https://www.gov.uk/	PRON
ihlr-26084	390	3	guidance	guidance	NOUN
ihlr-26084	390	4	/	/	SYM
ihlr-26084	390	5	exhaustion	exhaustion	NOUN
ihlr-26084	390	6	-	-	PUNCT
ihlr-26084	390	7	of	of	ADP
ihlr-26084	390	8	-	-	PUNCT
ihlr-26084	390	9	ip	ip	NOUN
ihlr-26084	390	10	-	-	PUNCT
ihlr-26084	390	11	rights	right	NOUN
ihlr-26084	390	12	-	-	PUNCT
ihlr-26084	390	13	and	and	CCONJ
ihlr-26084	390	14	-	-	PUNCT
ihlr-26084	390	15	parallel	parallel	NOUN
ihlr-26084	390	16	-	-	PUNCT
ihlr-26084	390	17	trade	trade	NOUN
ihlr-26084	390	18	(	(	PUNCT
ihlr-26084	390	19	last	last	ADJ
ihlr-26084	390	20	updated	update	VERB
ihlr-26084	390	21	june	june	PROPN
ihlr-26084	390	22	21	21	NUM
ihlr-26084	390	23	,	,	PUNCT
ihlr-26084	390	24	2021	2021	NUM
ihlr-26084	390	25	)	)	PUNCT
ihlr-26084	390	26	.	.	PUNCT
ihlr-26084	391	1	102	102	NUM
ihlr-26084	391	2	.	.	PUNCT
ihlr-26084	392	1	centrafarm	centrafarm	PROPN
ihlr-26084	392	2	bv	bv	PROPN
ihlr-26084	392	3	and	and	CCONJ
ihlr-26084	392	4	adriaan	adriaan	PROPN
ihlr-26084	392	5	de	de	PROPN
ihlr-26084	392	6	peijper	peijper	PROPN
ihlr-26084	392	7	v.	v.	ADP
ihlr-26084	392	8	sterling	sterling	PROPN
ihlr-26084	392	9	drug	drug	PROPN
ihlr-26084	392	10	inc	inc	PROPN
ihlr-26084	392	11	,	,	PUNCT
ihlr-26084	392	12	case	case	NOUN
ihlr-26084	392	13	15	15	NUM
ihlr-26084	392	14	-	-	SYM
ihlr-26084	392	15	74	74	NUM
ihlr-26084	392	16	(	(	PUNCT
ihlr-26084	392	17	1974	1974	NUM
ihlr-26084	392	18	)	)	PUNCT
ihlr-26084	392	19	.	.	PUNCT
ihlr-26084	393	1	103	103	NUM
ihlr-26084	393	2	.	.	PUNCT
ihlr-26084	394	1	centrafarm	centrafarm	PROPN
ihlr-26084	394	2	b.v	b.v	PROPN
ihlr-26084	394	3	.	.	PROPN
ihlr-26084	394	4	and	and	CCONJ
ihlr-26084	394	5	adriaan	adriaan	PROPN
ihlr-26084	394	6	de	de	PROPN
ihlr-26084	394	7	peijper	peijper	PROPN
ihlr-26084	394	8	v	v	ADP
ihlr-26084	394	9	sterling	sterling	PROPN
ihlr-26084	394	10	drug	drug	PROPN
ihlr-26084	394	11	inc	inc	PROPN
ihlr-26084	394	12	.	.	PROPN
ihlr-26084	394	13	,	,	PUNCT
ihlr-26084	395	1	[	[	X
ihlr-26084	395	2	1974	1974	NUM
ihlr-26084	395	3	]	]	SYM
ihlr-26084	395	4	2	2	NUM
ihlr-26084	395	5	c.m.l.r	c.m.l.r	PROPN
ihlr-26084	395	6	.	.	PROPN
ihlr-26084	395	7	1	1	NUM
ihlr-26084	395	8	.	.	X
ihlr-26084	395	9	104	104	NUM
ihlr-26084	395	10	.	.	PUNCT
ihlr-26084	395	11	case	case	NOUN
ihlr-26084	395	12	15	15	NUM
ihlr-26084	395	13	-	-	SYM
ihlr-26084	395	14	74	74	NUM
ihlr-26084	395	15	at	at	ADP
ihlr-26084	395	16	¶	¶	PROPN
ihlr-26084	395	17	15	15	NUM
ihlr-26084	395	18	.	.	PUNCT
ihlr-26084	395	19	105	105	NUM
ihlr-26084	395	20	.	.	PUNCT
ihlr-26084	396	1	see	see	VERB
ihlr-26084	396	2	e.g.	e.g.	ADV
ihlr-26084	396	3	,	,	PUNCT
ihlr-26084	396	4	merck	merck	PROPN
ihlr-26084	396	5	&	&	CCONJ
ihlr-26084	396	6	co.	co.	PROPN
ihlr-26084	396	7	inc	inc	PROPN
ihlr-26084	396	8	.	.	PROPN
ihlr-26084	397	1	v.	v.	ADP
ihlr-26084	397	2	stephar	stephar	PROPN
ihlr-26084	397	3	bv	bv	PROPN
ihlr-26084	397	4	,	,	PUNCT
ihlr-26084	397	5	case	case	NOUN
ihlr-26084	397	6	187/80	187/80	NUM
ihlr-26084	397	7	(	(	PUNCT
ihlr-26084	397	8	1980	1980	NUM
ihlr-26084	397	9	)	)	PUNCT
ihlr-26084	397	10	(	(	PUNCT
ihlr-26084	397	11	allowing	allow	VERB
ihlr-26084	397	12	the	the	DET
ihlr-26084	397	13	free	free	ADJ
ihlr-26084	397	14	movement	movement	NOUN
ihlr-26084	397	15	of	of	ADP
ihlr-26084	397	16	a	a	DET
ihlr-26084	397	17	drug	drug	NOUN
ihlr-26084	397	18	from	from	ADP
ihlr-26084	397	19	a	a	DET
ihlr-26084	397	20	country	country	NOUN
ihlr-26084	397	21	where	where	SCONJ
ihlr-26084	397	22	the	the	DET
ihlr-26084	397	23	patent	patent	NOUN
ihlr-26084	397	24	holder	holder	NOUN
ihlr-26084	397	25	marketed	market	VERB
ihlr-26084	397	26	the	the	DET
ihlr-26084	397	27	drug	drug	NOUN
ihlr-26084	397	28	but	but	CCONJ
ihlr-26084	397	29	did	do	AUX
ihlr-26084	397	30	not	not	PART
ihlr-26084	397	31	have	have	VERB
ihlr-26084	397	32	a	a	DET
ihlr-26084	397	33	patent	patent	NOUN
ihlr-26084	397	34	to	to	ADP
ihlr-26084	397	35	a	a	DET
ihlr-26084	397	36	county	county	NOUN
ihlr-26084	397	37	where	where	SCONJ
ihlr-26084	397	38	it	it	PRON
ihlr-26084	397	39	holds	hold	VERB
ihlr-26084	397	40	a	a	DET
ihlr-26084	397	41	patent	patent	NOUN
ihlr-26084	397	42	)	)	PUNCT
ihlr-26084	397	43	;	;	PUNCT
ihlr-26084	397	44	merck	merck	PROPN
ihlr-26084	397	45	&	&	CCONJ
ihlr-26084	397	46	co.	co.	PROPN
ihlr-26084	397	47	inc	inc	PROPN
ihlr-26084	397	48	.	.	PROPN
ihlr-26084	397	49	v	v	PROPN
ihlr-26084	397	50	primecrown	primecrown	PROPN
ihlr-26084	397	51	ltd	ltd	PROPN
ihlr-26084	397	52	.	.	PROPN
ihlr-26084	397	53	,	,	PUNCT
ihlr-26084	397	54	case	case	NOUN
ihlr-26084	397	55	267/95	267/95	NUM
ihlr-26084	397	56	(	(	PUNCT
ihlr-26084	397	57	1997	1997	NUM
ihlr-26084	397	58	)	)	PUNCT
ihlr-26084	397	59	(	(	PUNCT
ihlr-26084	397	60	allowing	allow	VERB
ihlr-26084	397	61	the	the	DET
ihlr-26084	397	62	free	free	ADJ
ihlr-26084	397	63	movement	movement	NOUN
ihlr-26084	397	64	of	of	ADP
ihlr-26084	397	65	a	a	DET
ihlr-26084	397	66	drug	drug	NOUN
ihlr-26084	397	67	from	from	ADP
ihlr-26084	397	68	a	a	DET
ihlr-26084	397	69	country	country	NOUN
ihlr-26084	397	70	where	where	SCONJ
ihlr-26084	397	71	the	the	DET
ihlr-26084	397	72	patent	patent	NOUN
ihlr-26084	397	73	holder	holder	NOUN
ihlr-26084	397	74	marketed	market	VERB
ihlr-26084	397	75	the	the	DET
ihlr-26084	397	76	drug	drug	NOUN
ihlr-26084	397	77	but	but	CCONJ
ihlr-26084	397	78	did	do	AUX
ihlr-26084	397	79	not	not	PART
ihlr-26084	397	80	have	have	VERB
ihlr-26084	397	81	a	a	DET
ihlr-26084	397	82	patent	patent	NOUN
ihlr-26084	397	83	because	because	SCONJ
ihlr-26084	397	84	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	397	85	were	be	AUX
ihlr-26084	397	86	not	not	PART
ihlr-26084	397	87	patentable	patentable	ADJ
ihlr-26084	397	88	to	to	ADP
ihlr-26084	397	89	a	a	DET
ihlr-26084	397	90	county	county	NOUN
ihlr-26084	397	91	where	where	SCONJ
ihlr-26084	397	92	it	it	PRON
ihlr-26084	397	93	holds	hold	VERB
ihlr-26084	397	94	a	a	DET
ihlr-26084	397	95	patent	patent	NOUN
ihlr-26084	397	96	)	)	PUNCT
ihlr-26084	397	97	.	.	PUNCT
ihlr-26084	398	1	106	106	NUM
ihlr-26084	398	2	.	.	PUNCT
ihlr-26084	399	1	kohlpharma	kohlpharma	PROPN
ihlr-26084	399	2	gmbh	gmbh	PROPN
ihlr-26084	399	3	v.	v.	ADP
ihlr-26084	399	4	bundesrepublik	bundesrepublik	ADJ
ihlr-26084	399	5	deutschland	deutschland	NOUN
ihlr-26084	399	6	,	,	PUNCT
ihlr-26084	399	7	case	case	NOUN
ihlr-26084	399	8	c-112/02	c-112/02	NOUN
ihlr-26084	399	9	(	(	PUNCT
ihlr-26084	399	10	2004	2004	NUM
ihlr-26084	399	11	)	)	PUNCT
ihlr-26084	399	12	(	(	PUNCT
ihlr-26084	399	13	barring	bar	VERB
ihlr-26084	399	14	laws	law	NOUN
ihlr-26084	399	15	that	that	PRON
ihlr-26084	399	16	affect	affect	VERB
ihlr-26084	399	17	the	the	DET
ihlr-26084	399	18	free	free	ADJ
ihlr-26084	399	19	movement	movement	NOUN
ihlr-26084	399	20	of	of	ADP
ihlr-26084	399	21	a	a	DET
ihlr-26084	399	22	drugs	drug	NOUN
ihlr-26084	399	23	even	even	ADV
ihlr-26084	399	24	when	when	SCONJ
ihlr-26084	399	25	the	the	DET
ihlr-26084	399	26	parallel	parallel	ADJ
ihlr-26084	399	27	importer	importer	NOUN
ihlr-26084	399	28	did	do	AUX
ihlr-26084	399	29	not	not	PART
ihlr-26084	399	30	obtain	obtain	VERB
ihlr-26084	399	31	marketing	marketing	NOUN
ihlr-26084	399	32	authorization	authorization	NOUN
ihlr-26084	399	33	when	when	SCONJ
ihlr-26084	399	34	it	it	PRON
ihlr-26084	399	35	has	have	VERB
ihlr-26084	399	36	the	the	DET
ihlr-26084	399	37	same	same	ADJ
ihlr-26084	399	38	active	active	ADJ
ihlr-26084	399	39	ingredients	ingredient	NOUN
ihlr-26084	399	40	as	as	ADP
ihlr-26084	399	41	another	another	DET
ihlr-26084	399	42	authorized	authorize	VERB
ihlr-26084	399	43	drug	drug	NOUN
ihlr-26084	399	44	–	–	PUNCT
ihlr-26084	399	45	even	even	ADV
ihlr-26084	399	46	if	if	SCONJ
ihlr-26084	399	47	the	the	DET
ihlr-26084	399	48	drug	drug	NOUN
ihlr-26084	399	49	does	do	AUX
ihlr-26084	399	50	not	not	PART
ihlr-26084	399	51	originate	originate	VERB
ihlr-26084	399	52	from	from	ADP
ihlr-26084	399	53	the	the	DET
ihlr-26084	399	54	same	same	ADJ
ihlr-26084	399	55	entity	entity	NOUN
ihlr-26084	399	56	)	)	PUNCT
ihlr-26084	399	57	;	;	PUNCT
ihlr-26084	399	58	delfarma	delfarma	NOUN
ihlr-26084	399	59	sp	sp	NOUN
ihlr-26084	399	60	.	.	PROPN
ihlr-26084	399	61	z	z	PROPN
ihlr-26084	399	62	o.o	o.o	PROPN
ihlr-26084	399	63	.	.	PROPN
ihlr-26084	400	1	v.	v.	PROPN
ihlr-26084	400	2	prezes	preze	VERB
ihlr-26084	400	3	urzêdu	urzêdu	PROPN
ihlr-26084	400	4	rejestracji	rejestracji	PROPN
ihlr-26084	400	5	produktów	produktów	PROPN
ihlr-26084	400	6	leczniczych	leczniczych	PROPN
ihlr-26084	400	7	,	,	PUNCT
ihlr-26084	400	8	wyrobów	wyrobów	NOUN
ihlr-26084	400	9	medycznych	medycznych	PROPN
ihlr-26084	400	10	i	i	PRON
ihlr-26084	400	11	produktów	produktów	PROPN
ihlr-26084	400	12	biobójczych	biobójczych	NOUN
ihlr-26084	400	13	,	,	PUNCT
ihlr-26084	400	14	case	case	NOUN
ihlr-26084	400	15	c-387/18	c-387/18	X
ihlr-26084	400	16	(	(	PUNCT
ihlr-26084	400	17	2019	2019	NUM
ihlr-26084	400	18	)	)	PUNCT
ihlr-26084	400	19	(	(	PUNCT
ihlr-26084	400	20	barring	bar	VERB
ihlr-26084	400	21	laws	law	NOUN
ihlr-26084	400	22	that	that	PRON
ihlr-26084	400	23	affect	affect	VERB
ihlr-26084	400	24	the	the	DET
ihlr-26084	400	25	free	free	ADJ
ihlr-26084	400	26	movement	movement	NOUN
ihlr-26084	400	27	of	of	ADP
ihlr-26084	400	28	a	a	DET
ihlr-26084	400	29	generics	generic	NOUN
ihlr-26084	400	30	even	even	ADV
ihlr-26084	400	31	if	if	SCONJ
ihlr-26084	400	32	the	the	DET
ihlr-26084	400	33	parallel	parallel	ADJ
ihlr-26084	400	34	importer	importer	NOUN
ihlr-26084	400	35	did	do	AUX
ihlr-26084	400	36	not	not	PART
ihlr-26084	400	37	obtain	obtain	VERB
ihlr-26084	400	38	a	a	DET
ihlr-26084	400	39	marketing	marketing	NOUN
ihlr-26084	400	40	authorization	authorization	NOUN
ihlr-26084	400	41	when	when	SCONJ
ihlr-26084	400	42	it	it	PRON
ihlr-26084	400	43	has	have	VERB
ihlr-26084	400	44	the	the	DET
ihlr-26084	400	45	same	same	ADJ
ihlr-26084	400	46	active	active	ADJ
ihlr-26084	400	47	ingredients	ingredient	NOUN
ihlr-26084	400	48	as	as	ADP
ihlr-26084	400	49	an	an	DET
ihlr-26084	400	50	authorized	authorized	ADJ
ihlr-26084	400	51	patented	patented	ADJ
ihlr-26084	400	52	drug	drug	NOUN
ihlr-26084	400	53	)	)	PUNCT
ihlr-26084	400	54	.	.	PUNCT
ihlr-26084	401	1	107	107	NUM
ihlr-26084	401	2	.	.	PUNCT
ihlr-26084	402	1	pharmon	pharmon	PROPN
ihlr-26084	402	2	bv	bv	PROPN
ihlr-26084	402	3	v.	v.	PROPN
ihlr-26084	402	4	hoechst	hoechst	PROPN
ihlr-26084	402	5	ag	ag	PROPN
ihlr-26084	402	6	,	,	PUNCT
ihlr-26084	402	7	case	case	NOUN
ihlr-26084	402	8	19/84	19/84	NUM
ihlr-26084	402	9	(	(	PUNCT
ihlr-26084	402	10	1984	1984	NUM
ihlr-26084	402	11	)	)	PUNCT
ihlr-26084	402	12	(	(	PUNCT
ihlr-26084	402	13	allowing	allow	VERB
ihlr-26084	402	14	the	the	DET
ihlr-26084	402	15	patent	patent	NOUN
ihlr-26084	402	16	holder	holder	NOUN
ihlr-26084	402	17	to	to	PART
ihlr-26084	402	18	block	block	VERB
ihlr-26084	402	19	the	the	DET
ihlr-26084	402	20	importation	importation	NOUN
ihlr-26084	402	21	of	of	ADP
ihlr-26084	402	22	patented	patented	ADJ
ihlr-26084	402	23	drugs	drug	NOUN
ihlr-26084	402	24	that	that	PRON
ihlr-26084	402	25	were	be	AUX
ihlr-26084	402	26	produced	produce	VERB
ihlr-26084	402	27	under	under	ADP
ihlr-26084	402	28	a	a	DET
ihlr-26084	402	29	compulsory	compulsory	NOUN
ihlr-26084	402	30	because	because	SCONJ
ihlr-26084	402	31	he	he	PRON
ihlr-26084	402	32	did	do	AUX
ihlr-26084	402	33	not	not	PART
ihlr-26084	402	34	freely	freely	ADV
ihlr-26084	402	35	choose	choose	VERB
ihlr-26084	402	36	to	to	PART
ihlr-26084	402	37	market	market	VERB
ihlr-26084	402	38	the	the	DET
ihlr-26084	402	39	drug	drug	NOUN
ihlr-26084	402	40	)	)	PUNCT
ihlr-26084	402	41	.	.	PUNCT
ihlr-26084	403	1	108	108	NUM
ihlr-26084	403	2	.	.	PUNCT
ihlr-26084	404	1	see	see	VERB
ihlr-26084	404	2	e.g.	e.g.	ADV
ihlr-26084	404	3	,	,	PUNCT
ihlr-26084	404	4	mattias	mattias	PROPN
ihlr-26084	404	5	ganslandt	ganslandt	PROPN
ihlr-26084	404	6	&	&	CCONJ
ihlr-26084	404	7	keith	keith	PROPN
ihlr-26084	404	8	e.	e.	PROPN
ihlr-26084	404	9	maskus	maskus	PROPN
ihlr-26084	404	10	,	,	PUNCT
ihlr-26084	404	11	parallel	parallel	ADJ
ihlr-26084	404	12	imports	import	NOUN
ihlr-26084	404	13	and	and	CCONJ
ihlr-26084	404	14	the	the	DET
ihlr-26084	404	15	pricing	pricing	NOUN
ihlr-26084	404	16	of	of	ADP
ihlr-26084	404	17	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	404	18	products	product	NOUN
ihlr-26084	404	19	:	:	PUNCT
ihlr-26084	404	20	evidence	evidence	NOUN
ihlr-26084	404	21	from	from	ADP
ihlr-26084	404	22	the	the	DET
ihlr-26084	404	23	european	european	PROPN
ihlr-26084	404	24	union	union	PROPN
ihlr-26084	404	25	,	,	PUNCT
ihlr-26084	404	26	23	23	NUM
ihlr-26084	404	27	j.	j.	PROPN
ihlr-26084	404	28	health	health	PROPN
ihlr-26084	404	29	econ	econ	PROPN
ihlr-26084	404	30	.	.	PUNCT
ihlr-26084	405	1	1035	1035	NUM
ihlr-26084	405	2	(	(	PUNCT
ihlr-26084	405	3	2004	2004	NUM
ihlr-26084	405	4	)	)	PUNCT
ihlr-26084	406	1	(	(	PUNCT
ihlr-26084	406	2	finding	find	VERB
ihlr-26084	406	3	parallel	parallel	ADJ
ihlr-26084	406	4	imports	import	NOUN
ihlr-26084	406	5	lead	lead	VERB
ihlr-26084	406	6	to	to	ADP
ihlr-26084	406	7	a	a	DET
ihlr-26084	406	8	price	price	NOUN
ihlr-26084	406	9	decrease	decrease	NOUN
ihlr-26084	406	10	in	in	ADP
ihlr-26084	406	11	sweden	sweden	PROPN
ihlr-26084	406	12	)	)	PUNCT
ihlr-26084	406	13	.	.	PUNCT
ihlr-26084	407	1	109	109	NUM
ihlr-26084	407	2	.	.	PUNCT
ihlr-26084	408	1	kanavos	kanavos	PROPN
ihlr-26084	408	2	et	et	PROPN
ihlr-26084	408	3	al	al	PROPN
ihlr-26084	408	4	.	.	PROPN
ihlr-26084	408	5	,	,	PUNCT
ihlr-26084	408	6	supra	supra	PROPN
ihlr-26084	408	7	note	note	VERB
ihlr-26084	408	8	87	87	NUM
ihlr-26084	408	9	,	,	PUNCT
ihlr-26084	408	10	table	table	NOUN
ihlr-26084	408	11	6.16	6.16	NUM
ihlr-26084	408	12	.	.	PUNCT
ihlr-26084	409	1	36	36	NUM
ihlr-26084	409	2	indiana	indiana	PROPN
ihlr-26084	409	3	health	health	PROPN
ihlr-26084	409	4	law	law	PROPN
ihlr-26084	409	5	review	review	NOUN
ihlr-26084	409	6	[	[	X
ihlr-26084	409	7	vol	vol	NOUN
ihlr-26084	409	8	.	.	PUNCT
ihlr-26084	410	1	19:21	19:21	NUM
ihlr-26084	410	2	deterrence	deterrence	NOUN
ihlr-26084	410	3	because	because	SCONJ
ihlr-26084	410	4	introducing	introduce	VERB
ihlr-26084	410	5	a	a	DET
ihlr-26084	410	6	generic	generic	NOUN
ihlr-26084	410	7	could	could	AUX
ihlr-26084	410	8	affect	affect	VERB
ihlr-26084	410	9	all	all	DET
ihlr-26084	410	10	other	other	ADJ
ihlr-26084	410	11	countries	country	NOUN
ihlr-26084	410	12	in	in	ADP
ihlr-26084	410	13	the	the	DET
ihlr-26084	410	14	european	european	ADJ
ihlr-26084	410	15	common	common	ADJ
ihlr-26084	410	16	market	market	NOUN
ihlr-26084	410	17	.	.	PUNCT
ihlr-26084	411	1	parallel	parallel	ADJ
ihlr-26084	411	2	imports	import	NOUN
ihlr-26084	411	3	have	have	AUX
ihlr-26084	411	4	also	also	ADV
ihlr-26084	411	5	incentivized	incentivize	VERB
ihlr-26084	411	6	drugs	drug	NOUN
ihlr-26084	411	7	companies	company	NOUN
ihlr-26084	411	8	to	to	PART
ihlr-26084	411	9	negotiate	negotiate	VERB
ihlr-26084	411	10	higher	high	ADJ
ihlr-26084	411	11	prices	price	NOUN
ihlr-26084	411	12	in	in	ADP
ihlr-26084	411	13	countries	country	NOUN
ihlr-26084	411	14	where	where	SCONJ
ihlr-26084	411	15	prices	price	NOUN
ihlr-26084	411	16	were	be	AUX
ihlr-26084	411	17	previously	previously	ADV
ihlr-26084	411	18	lower	low	ADJ
ihlr-26084	411	19	.	.	PUNCT
ihlr-26084	412	1	these	these	DET
ihlr-26084	412	2	low	low	ADJ
ihlr-26084	412	3	-	-	PUNCT
ihlr-26084	412	4	price	price	NOUN
ihlr-26084	412	5	countries	country	NOUN
ihlr-26084	412	6	have	have	AUX
ihlr-26084	412	7	had	have	VERB
ihlr-26084	412	8	to	to	PART
ihlr-26084	412	9	react	react	VERB
ihlr-26084	412	10	and	and	CCONJ
ihlr-26084	412	11	change	change	VERB
ihlr-26084	412	12	their	their	PRON
ihlr-26084	412	13	laws	law	NOUN
ihlr-26084	412	14	to	to	PART
ihlr-26084	412	15	account	account	VERB
ihlr-26084	412	16	for	for	ADP
ihlr-26084	412	17	parallel	parallel	ADJ
ihlr-26084	412	18	exports.110	exports.110	NOUN
ihlr-26084	412	19	this	this	DET
ihlr-26084	412	20	reaction	reaction	NOUN
ihlr-26084	412	21	explains	explain	VERB
ihlr-26084	412	22	why	why	SCONJ
ihlr-26084	412	23	the	the	DET
ihlr-26084	412	24	french	french	ADJ
ihlr-26084	412	25	ceps	cep	NOUN
ihlr-26084	412	26	looks	look	VERB
ihlr-26084	412	27	at	at	ADP
ihlr-26084	412	28	the	the	DET
ihlr-26084	412	29	prices	price	NOUN
ihlr-26084	412	30	set	set	VERB
ihlr-26084	412	31	in	in	ADP
ihlr-26084	412	32	the	the	DET
ihlr-26084	412	33	uk	uk	PROPN
ihlr-26084	412	34	,	,	PUNCT
ihlr-26084	412	35	germany	germany	PROPN
ihlr-26084	412	36	,	,	PUNCT
ihlr-26084	412	37	italy	italy	PROPN
ihlr-26084	412	38	,	,	PUNCT
ihlr-26084	412	39	and	and	CCONJ
ihlr-26084	412	40	spain	spain	PROPN
ihlr-26084	412	41	when	when	SCONJ
ihlr-26084	412	42	negotiating	negotiate	VERB
ihlr-26084	412	43	its	its	PRON
ihlr-26084	412	44	prices	price	NOUN
ihlr-26084	412	45	with	with	ADP
ihlr-26084	412	46	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	412	47	companies.111	companies.111	PROPN
ihlr-26084	412	48	the	the	DET
ihlr-26084	412	49	limited	limited	ADJ
ihlr-26084	412	50	success	success	NOUN
ihlr-26084	412	51	of	of	ADP
ihlr-26084	412	52	parallel	parallel	ADJ
ihlr-26084	412	53	import	import	NOUN
ihlr-26084	412	54	at	at	ADP
ihlr-26084	412	55	creating	create	VERB
ihlr-26084	412	56	competition	competition	NOUN
ihlr-26084	412	57	means	mean	VERB
ihlr-26084	412	58	that	that	SCONJ
ihlr-26084	412	59	competition	competition	NOUN
ihlr-26084	412	60	must	must	AUX
ihlr-26084	412	61	either	either	CCONJ
ihlr-26084	412	62	come	come	VERB
ihlr-26084	412	63	from	from	ADP
ihlr-26084	412	64	a	a	DET
ihlr-26084	412	65	drug	drug	NOUN
ihlr-26084	412	66	with	with	ADP
ihlr-26084	412	67	a	a	DET
ihlr-26084	412	68	similar	similar	ADJ
ihlr-26084	412	69	therapeutic	therapeutic	ADJ
ihlr-26084	412	70	treatment	treatment	NOUN
ihlr-26084	412	71	or	or	CCONJ
ihlr-26084	412	72	from	from	ADP
ihlr-26084	412	73	a	a	DET
ihlr-26084	412	74	generic	generic	ADJ
ihlr-26084	412	75	.	.	PUNCT
ihlr-26084	413	1	drugs	drug	NOUN
ihlr-26084	413	2	with	with	ADP
ihlr-26084	413	3	similar	similar	ADJ
ihlr-26084	413	4	therapeutic	therapeutic	ADJ
ihlr-26084	413	5	treatment	treatment	NOUN
ihlr-26084	413	6	are	be	AUX
ihlr-26084	413	7	known	know	VERB
ihlr-26084	413	8	as	as	ADP
ihlr-26084	413	9	“	"	PUNCT
ihlr-26084	413	10	me	i	PRON
ihlr-26084	413	11	-	-	PUNCT
ihlr-26084	413	12	too	too	ADV
ihlr-26084	413	13	”	"	PUNCT
ihlr-26084	413	14	drugs	drug	NOUN
ihlr-26084	413	15	.	.	PUNCT
ihlr-26084	414	1	these	these	DET
ihlr-26084	414	2	me	i	PRON
ihlr-26084	414	3	-	-	PUNCT
ihlr-26084	414	4	too	too	ADV
ihlr-26084	414	5	drugs	drug	NOUN
ihlr-26084	414	6	have	have	AUX
ihlr-26084	414	7	not	not	PART
ihlr-26084	414	8	created	create	VERB
ihlr-26084	414	9	the	the	DET
ihlr-26084	414	10	desired	desire	VERB
ihlr-26084	414	11	competition.112	competition.112	PROPN
ihlr-26084	414	12	this	this	DET
ihlr-26084	414	13	limited	limited	ADJ
ihlr-26084	414	14	competition	competition	NOUN
ihlr-26084	414	15	has	have	AUX
ihlr-26084	414	16	been	be	AUX
ihlr-26084	414	17	linked	link	VERB
ihlr-26084	414	18	to	to	ADP
ihlr-26084	414	19	the	the	DET
ihlr-26084	414	20	pricing	pricing	NOUN
ihlr-26084	414	21	mechanisms	mechanism	NOUN
ihlr-26084	414	22	in	in	ADP
ihlr-26084	414	23	countries	country	NOUN
ihlr-26084	414	24	with	with	ADP
ihlr-26084	414	25	large	large	ADJ
ihlr-26084	414	26	monopsonist	monopsonist	ADJ
ihlr-26084	414	27	health	health	NOUN
ihlr-26084	414	28	insurance.113	insurance.113	PROPN
ihlr-26084	414	29	for	for	ADP
ihlr-26084	414	30	example	example	NOUN
ihlr-26084	414	31	,	,	PUNCT
ihlr-26084	414	32	the	the	DET
ihlr-26084	414	33	french	french	ADJ
ihlr-26084	414	34	system	system	NOUN
ihlr-26084	414	35	creates	create	VERB
ihlr-26084	414	36	no	no	DET
ihlr-26084	414	37	incentive	incentive	NOUN
ihlr-26084	414	38	for	for	ADP
ihlr-26084	414	39	me	i	PRON
ihlr-26084	414	40	-	-	PUNCT
ihlr-26084	414	41	too	too	ADV
ihlr-26084	414	42	drugs	drug	NOUN
ihlr-26084	414	43	to	to	PART
ihlr-26084	414	44	compete	compete	VERB
ihlr-26084	414	45	on	on	ADP
ihlr-26084	414	46	price	price	NOUN
ihlr-26084	414	47	:	:	PUNCT
ihlr-26084	414	48	doctors	doctor	NOUN
ihlr-26084	414	49	prescribe	prescribe	VERB
ihlr-26084	414	50	the	the	DET
ihlr-26084	414	51	drug	drug	NOUN
ihlr-26084	414	52	based	base	VERB
ihlr-26084	414	53	on	on	ADP
ihlr-26084	414	54	treatment	treatment	NOUN
ihlr-26084	414	55	,	,	PUNCT
ihlr-26084	414	56	not	not	PART
ihlr-26084	414	57	on	on	ADP
ihlr-26084	414	58	cost	cost	NOUN
ihlr-26084	414	59	.	.	PUNCT
ihlr-26084	415	1	the	the	DET
ihlr-26084	415	2	doctor	doctor	NOUN
ihlr-26084	415	3	has	have	VERB
ihlr-26084	415	4	no	no	DET
ihlr-26084	415	5	incentive	incentive	NOUN
ihlr-26084	415	6	to	to	PART
ihlr-26084	415	7	look	look	VERB
ihlr-26084	415	8	at	at	ADP
ihlr-26084	415	9	treatment	treatment	NOUN
ihlr-26084	415	10	cost	cost	NOUN
ihlr-26084	415	11	when	when	SCONJ
ihlr-26084	415	12	prescribing	prescribing	NOUN
ihlr-26084	415	13	drugs.114	drugs.114	NOUN
ihlr-26084	415	14	the	the	DET
ihlr-26084	415	15	decisionmaker	decisionmaker	NOUN
ihlr-26084	415	16	in	in	ADP
ihlr-26084	415	17	the	the	DET
ihlr-26084	415	18	market	market	NOUN
ihlr-26084	415	19	for	for	ADP
ihlr-26084	415	20	drug	drug	NOUN
ihlr-26084	415	21	consumption	consumption	NOUN
ihlr-26084	415	22	is	be	AUX
ihlr-26084	415	23	the	the	DET
ihlr-26084	415	24	doctor	doctor	NOUN
ihlr-26084	415	25	,	,	PUNCT
ihlr-26084	415	26	whereas	whereas	SCONJ
ihlr-26084	415	27	the	the	DET
ihlr-26084	415	28	payors	payor	NOUN
ihlr-26084	415	29	are	be	AUX
ihlr-26084	415	30	the	the	DET
ihlr-26084	415	31	health	health	NOUN
ihlr-26084	415	32	agency	agency	NOUN
ihlr-26084	415	33	and	and	CCONJ
ihlr-26084	415	34	consumers	consumer	NOUN
ihlr-26084	415	35	(	(	PUNCT
ihlr-26084	415	36	through	through	ADP
ihlr-26084	415	37	deductibles	deductible	NOUN
ihlr-26084	415	38	)	)	PUNCT
ihlr-26084	415	39	.	.	PUNCT
ihlr-26084	416	1	this	this	DET
ihlr-26084	416	2	relationship	relationship	NOUN
ihlr-26084	416	3	raises	raise	VERB
ihlr-26084	416	4	a	a	DET
ihlr-26084	416	5	principal	principal	ADJ
ihlr-26084	416	6	-	-	PUNCT
ihlr-26084	416	7	agent	agent	NOUN
ihlr-26084	416	8	problem	problem	NOUN
ihlr-26084	416	9	because	because	SCONJ
ihlr-26084	416	10	the	the	DET
ihlr-26084	416	11	decisionmaker	decisionmaker	NOUN
ihlr-26084	416	12	differs	differ	VERB
ihlr-26084	416	13	from	from	ADP
ihlr-26084	416	14	the	the	DET
ihlr-26084	416	15	cost	cost	NOUN
ihlr-26084	416	16	bearer.115	bearer.115	PROPN
ihlr-26084	416	17	thus	thus	ADV
ihlr-26084	416	18	,	,	PUNCT
ihlr-26084	416	19	generics	generic	NOUN
ihlr-26084	416	20	remain	remain	VERB
ihlr-26084	416	21	the	the	DET
ihlr-26084	416	22	only	only	ADJ
ihlr-26084	416	23	mechanism	mechanism	NOUN
ihlr-26084	416	24	for	for	ADP
ihlr-26084	416	25	competition	competition	NOUN
ihlr-26084	416	26	in	in	ADP
ihlr-26084	416	27	the	the	DET
ihlr-26084	416	28	110	110	NUM
ihlr-26084	416	29	.	.	PUNCT
ihlr-26084	417	1	i	i	PRON
ihlr-26084	417	2	d.	d.	PROPN
ihlr-26084	417	3	at	at	ADP
ihlr-26084	417	4	table	table	NOUN
ihlr-26084	417	5	4.3	4.3	NUM
ihlr-26084	417	6	.	.	NOUN
ihlr-26084	417	7	111	111	NUM
ihlr-26084	417	8	.	.	PUNCT
ihlr-26084	417	9	see	see	VERB
ihlr-26084	417	10	rémond	rémond	ADJ
ihlr-26084	417	11	,	,	PUNCT
ihlr-26084	417	12	supra	supra	ADJ
ihlr-26084	417	13	note	note	NOUN
ihlr-26084	417	14	89	89	NUM
ihlr-26084	417	15	(	(	PUNCT
ihlr-26084	417	16	«	«	PUNCT
ihlr-26084	417	17	ce	ce	PROPN
ihlr-26084	417	18	prix	prix	PROPN
ihlr-26084	417	19	dépend	dépend	PROPN
ihlr-26084	417	20	:	:	PUNCT
ihlr-26084	417	21	.	.	PUNCT
ihlr-26084	417	22	.	.	PUNCT
ihlr-26084	417	23	.	.	PUNCT
ihlr-26084	418	1	des	des	PROPN
ihlr-26084	418	2	prix	prix	PROPN
ihlr-26084	418	3	pratiqués	pratiqués	NOUN
ihlr-26084	418	4	à	à	X
ihlr-26084	418	5	l’étranger	l’étranger	NOUN
ihlr-26084	418	6	:	:	PUNCT
ihlr-26084	418	7	le	le	X
ihlr-26084	418	8	ceps	ceps	PROPN
ihlr-26084	418	9	est	est	PROPN
ihlr-26084	418	10	soumis	soumis	PROPN
ihlr-26084	418	11	au	au	VERB
ihlr-26084	418	12	"	"	PUNCT
ihlr-26084	418	13	comparateur	comparateur	PROPN
ihlr-26084	418	14	de	de	X
ihlr-26084	418	15	prix	prix	X
ihlr-26084	418	16	européen	européen	X
ihlr-26084	418	17	"	"	PUNCT
ihlr-26084	418	18	qui	qui	X
ihlr-26084	418	19	est	est	X
ihlr-26084	418	20	une	une	PROPN
ihlr-26084	418	21	disposition	disposition	NOUN
ihlr-26084	418	22	par	par	PROPN
ihlr-26084	418	23	laquelle	laquelle	PROPN
ihlr-26084	418	24	il	il	PROPN
ihlr-26084	418	25	s’oblige	s’oblige	PROPN
ihlr-26084	418	26	à	à	X
ihlr-26084	418	27	fixer	fixer	PROPN
ihlr-26084	418	28	un	un	PROPN
ihlr-26084	418	29	prix	prix	PROPN
ihlr-26084	418	30	similaire	similaire	PROPN
ihlr-26084	418	31	à	à	X
ihlr-26084	418	32	ceux	ceux	X
ihlr-26084	418	33	pratiquées	pratiquées	PROPN
ihlr-26084	418	34	au	au	X
ihlr-26084	418	35	royaume	royaume	PROPN
ihlr-26084	418	36	-	-	ADJ
ihlr-26084	418	37	uni	uni	ADJ
ihlr-26084	418	38	,	,	PUNCT
ihlr-26084	418	39	en	en	PROPN
ihlr-26084	418	40	allemagne	allemagne	PROPN
ihlr-26084	418	41	,	,	PUNCT
ihlr-26084	418	42	en	en	X
ihlr-26084	418	43	italie	italie	PROPN
ihlr-26084	418	44	et	et	PROPN
ihlr-26084	418	45	en	en	X
ihlr-26084	418	46	espagne	espagne	PROPN
ihlr-26084	418	47	.	.	PUNCT
ihlr-26084	419	1	le	le	PROPN
ihlr-26084	419	2	prix	prix	PROPN
ihlr-26084	419	3	du	du	PROPN
ihlr-26084	419	4	médicament	médicament	PROPN
ihlr-26084	419	5	ne	ne	PROPN
ihlr-26084	419	6	peut	peut	PROPN
ihlr-26084	419	7	être	être	PROPN
ihlr-26084	419	8	inférieur	inférieur	PROPN
ihlr-26084	419	9	aux	aux	PROPN
ihlr-26084	419	10	prix	prix	PROPN
ihlr-26084	419	11	pratiqués	pratiqués	X
ihlr-26084	419	12	dans	dans	X
ihlr-26084	419	13	ces	ces	PROPN
ihlr-26084	419	14	quatre	quatre	PROPN
ihlr-26084	419	15	pays	pay	VERB
ihlr-26084	419	16	.	.	PUNCT
ihlr-26084	420	1	»	»	PUNCT
ihlr-26084	420	2	which	which	PRON
ihlr-26084	420	3	translates	translate	VERB
ihlr-26084	420	4	to	to	ADP
ihlr-26084	420	5	“	"	PUNCT
ihlr-26084	420	6	the	the	DET
ihlr-26084	420	7	price	price	NOUN
ihlr-26084	420	8	depends	depend	VERB
ihlr-26084	420	9	on	on	ADP
ihlr-26084	420	10	the	the	DET
ihlr-26084	420	11	prices	price	NOUN
ihlr-26084	420	12	practiced	practice	VERB
ihlr-26084	420	13	abroad	abroad	ADV
ihlr-26084	420	14	:	:	PUNCT
ihlr-26084	420	15	the	the	DET
ihlr-26084	420	16	ceps	cep	NOUN
ihlr-26084	420	17	must	must	AUX
ihlr-26084	420	18	“	"	PUNCT
ihlr-26084	420	19	compares	compare	VERB
ihlr-26084	420	20	with	with	ADP
ihlr-26084	420	21	other	other	ADJ
ihlr-26084	420	22	european	european	ADJ
ihlr-26084	420	23	prices	price	NOUN
ihlr-26084	420	24	”	"	PUNCT
ihlr-26084	420	25	which	which	PRON
ihlr-26084	420	26	obliges	oblige	VERB
ihlr-26084	420	27	the	the	DET
ihlr-26084	420	28	ceps	cep	NOUN
ihlr-26084	420	29	to	to	PART
ihlr-26084	420	30	fix	fix	VERB
ihlr-26084	420	31	a	a	DET
ihlr-26084	420	32	similar	similar	ADJ
ihlr-26084	420	33	price	price	NOUN
ihlr-26084	420	34	to	to	ADP
ihlr-26084	420	35	those	those	DET
ihlr-26084	420	36	practices	practice	NOUN
ihlr-26084	420	37	in	in	ADP
ihlr-26084	420	38	the	the	DET
ihlr-26084	420	39	uk	uk	PROPN
ihlr-26084	420	40	,	,	PUNCT
ihlr-26084	420	41	germany	germany	PROPN
ihlr-26084	420	42	,	,	PUNCT
ihlr-26084	420	43	italy	italy	PROPN
ihlr-26084	420	44	,	,	PUNCT
ihlr-26084	420	45	and	and	CCONJ
ihlr-26084	420	46	spain	spain	PROPN
ihlr-26084	420	47	.	.	PUNCT
ihlr-26084	421	1	the	the	DET
ihlr-26084	421	2	price	price	NOUN
ihlr-26084	421	3	of	of	ADP
ihlr-26084	421	4	medication	medication	NOUN
ihlr-26084	421	5	can	can	AUX
ihlr-26084	421	6	not	not	PART
ihlr-26084	421	7	be	be	AUX
ihlr-26084	421	8	inferior	inferior	ADJ
ihlr-26084	421	9	to	to	ADP
ihlr-26084	421	10	the	the	DET
ihlr-26084	421	11	price	price	NOUN
ihlr-26084	421	12	practices	practice	NOUN
ihlr-26084	421	13	in	in	ADP
ihlr-26084	421	14	those	those	DET
ihlr-26084	421	15	four	four	NUM
ihlr-26084	421	16	countries	country	NOUN
ihlr-26084	421	17	.	.	PUNCT
ihlr-26084	421	18	”	"	PUNCT
ihlr-26084	421	19	)	)	PUNCT
ihlr-26084	421	20	.	.	PUNCT
ihlr-26084	422	1	112	112	NUM
ihlr-26084	422	2	.	.	PUNCT
ihlr-26084	422	3	see	see	VERB
ihlr-26084	422	4	e.g.	e.g.	ADV
ihlr-26084	422	5	,	,	PUNCT
ihlr-26084	422	6	gisela	gisela	PROPN
ihlr-26084	422	7	hostenkamp	hostenkamp	PROPN
ihlr-26084	422	8	,	,	PUNCT
ihlr-26084	422	9	do	do	AUX
ihlr-26084	422	10	follow	follow	VERB
ihlr-26084	422	11	-	-	PUNCT
ihlr-26084	422	12	on	on	ADP
ihlr-26084	422	13	therapeutic	therapeutic	ADJ
ihlr-26084	422	14	substitutes	substitute	NOUN
ihlr-26084	422	15	induce	induce	VERB
ihlr-26084	422	16	price	price	NOUN
ihlr-26084	422	17	competition	competition	NOUN
ihlr-26084	422	18	between	between	ADP
ihlr-26084	422	19	hospital	hospital	NOUN
ihlr-26084	422	20	medicines	medicine	NOUN
ihlr-26084	422	21	?	?	PUNCT
ihlr-26084	423	1	evidence	evidence	NOUN
ihlr-26084	423	2	from	from	ADP
ihlr-26084	423	3	the	the	DET
ihlr-26084	423	4	danish	danish	ADJ
ihlr-26084	423	5	hospital	hospital	NOUN
ihlr-26084	423	6	sector	sector	NOUN
ihlr-26084	423	7	,	,	PUNCT
ihlr-26084	423	8	111	111	NUM
ihlr-26084	423	9	health	health	NOUN
ihlr-26084	423	10	pol’y	pol’y	NOUN
ihlr-26084	423	11	68	68	NUM
ihlr-26084	423	12	(	(	PUNCT
ihlr-26084	423	13	2013	2013	NUM
ihlr-26084	423	14	)	)	PUNCT
ihlr-26084	423	15	(	(	PUNCT
ihlr-26084	423	16	finding	find	VERB
ihlr-26084	423	17	limited	limited	ADJ
ihlr-26084	423	18	evidence	evidence	NOUN
ihlr-26084	423	19	of	of	ADP
ihlr-26084	423	20	price	price	NOUN
ihlr-26084	423	21	decreased	decreased	AUX
ihlr-26084	423	22	linked	link	VERB
ihlr-26084	423	23	to	to	ADP
ihlr-26084	423	24	the	the	DET
ihlr-26084	423	25	introduction	introduction	NOUN
ihlr-26084	423	26	of	of	ADP
ihlr-26084	423	27	competing	compete	VERB
ihlr-26084	423	28	therapeutic	therapeutic	ADJ
ihlr-26084	423	29	treatment	treatment	NOUN
ihlr-26084	423	30	)	)	PUNCT
ihlr-26084	423	31	.	.	PUNCT
ihlr-26084	424	1	113	113	NUM
ihlr-26084	424	2	.	.	PUNCT
ihlr-26084	425	1	see	see	VERB
ihlr-26084	425	2	mats	mat	NOUN
ihlr-26084	425	3	ekelund	ekelund	ADV
ihlr-26084	425	4	&	&	CCONJ
ihlr-26084	425	5	björn	björn	PROPN
ihlr-26084	425	6	persson	persson	PROPN
ihlr-26084	425	7	,	,	PUNCT
ihlr-26084	425	8	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	425	9	pricing	pricing	NOUN
ihlr-26084	425	10	in	in	ADP
ihlr-26084	425	11	a	a	DET
ihlr-26084	425	12	regulated	regulated	ADJ
ihlr-26084	425	13	market	market	NOUN
ihlr-26084	425	14	,	,	PUNCT
ihlr-26084	425	15	85	85	NUM
ihlr-26084	425	16	rev	rev	X
ihlr-26084	425	17	.	.	PROPN
ihlr-26084	425	18	econ	econ	PROPN
ihlr-26084	425	19	.	.	PUNCT
ihlr-26084	425	20	&	&	CCONJ
ihlr-26084	425	21	stat	stat	PROPN
ihlr-26084	425	22	.	.	PUNCT
ihlr-26084	426	1	298	298	NUM
ihlr-26084	426	2	(	(	PUNCT
ihlr-26084	426	3	2003	2003	NUM
ihlr-26084	426	4	)	)	PUNCT
ihlr-26084	426	5	(	(	PUNCT
ihlr-26084	426	6	comparing	compare	VERB
ihlr-26084	426	7	the	the	DET
ihlr-26084	426	8	us	us	PROPN
ihlr-26084	426	9	to	to	PART
ihlr-26084	426	10	sweden	sweden	VERB
ihlr-26084	426	11	in	in	ADP
ihlr-26084	426	12	their	their	PRON
ihlr-26084	426	13	pricing	pricing	NOUN
ihlr-26084	426	14	,	,	PUNCT
ihlr-26084	426	15	finding	find	VERB
ihlr-26084	426	16	that	that	SCONJ
ihlr-26084	426	17	,	,	PUNCT
ihlr-26084	426	18	in	in	ADP
ihlr-26084	426	19	sweden	sweden	PROPN
ihlr-26084	426	20	,	,	PUNCT
ihlr-26084	426	21	price	price	NOUN
ihlr-26084	426	22	less	less	ADJ
ihlr-26084	426	23	competition	competition	NOUN
ihlr-26084	426	24	occurs	occur	VERB
ihlr-26084	426	25	when	when	SCONJ
ihlr-26084	426	26	new	new	ADJ
ihlr-26084	426	27	therapeutic	therapeutic	ADJ
ihlr-26084	426	28	drugs	drug	NOUN
ihlr-26084	426	29	were	be	AUX
ihlr-26084	426	30	introduced	introduce	VERB
ihlr-26084	426	31	when	when	SCONJ
ihlr-26084	426	32	controlling	control	VERB
ihlr-26084	426	33	to	to	ADP
ihlr-26084	426	34	therapeutic	therapeutic	ADJ
ihlr-26084	426	35	improvements	improvement	NOUN
ihlr-26084	426	36	,	,	PUNCT
ihlr-26084	426	37	and	and	CCONJ
ihlr-26084	426	38	concluding	conclude	VERB
ihlr-26084	426	39	that	that	SCONJ
ihlr-26084	426	40	the	the	DET
ihlr-26084	426	41	price	price	NOUN
ihlr-26084	426	42	-	-	PUNCT
ihlr-26084	426	43	cap	cap	NOUN
ihlr-26084	426	44	system	system	NOUN
ihlr-26084	426	45	has	have	AUX
ihlr-26084	426	46	led	lead	VERB
ihlr-26084	426	47	to	to	ADP
ihlr-26084	426	48	less	less	ADJ
ihlr-26084	426	49	declining	decline	VERB
ihlr-26084	426	50	prices	price	NOUN
ihlr-26084	426	51	over	over	ADP
ihlr-26084	426	52	time	time	NOUN
ihlr-26084	426	53	)	)	PUNCT
ihlr-26084	426	54	.	.	PUNCT
ihlr-26084	427	1	114	114	NUM
ihlr-26084	427	2	.	.	PUNCT
ihlr-26084	427	3	duffaud	duffaud	PROPN
ihlr-26084	427	4	&	&	CCONJ
ihlr-26084	427	5	liébart	liébart	PROPN
ihlr-26084	427	6	,	,	PUNCT
ihlr-26084	427	7	supra	supra	PROPN
ihlr-26084	427	8	note	note	NOUN
ihlr-26084	427	9	92	92	NUM
ihlr-26084	427	10	,	,	PUNCT
ihlr-26084	427	11	at	at	ADP
ihlr-26084	427	12	¶	¶	PROPN
ihlr-26084	427	13	41	41	NUM
ihlr-26084	427	14	&	&	CCONJ
ihlr-26084	427	15	¶	¶	PROPN
ihlr-26084	427	16	47	47	NUM
ihlr-26084	427	17	(	(	PUNCT
ihlr-26084	427	18	surveying	survey	VERB
ihlr-26084	427	19	french	french	ADJ
ihlr-26084	427	20	doctors	doctor	NOUN
ihlr-26084	427	21	and	and	CCONJ
ihlr-26084	427	22	they	they	PRON
ihlr-26084	427	23	observed	observe	VERB
ihlr-26084	427	24	that	that	SCONJ
ihlr-26084	427	25	doctors	doctor	NOUN
ihlr-26084	427	26	did	do	AUX
ihlr-26084	427	27	not	not	PART
ihlr-26084	427	28	consider	consider	VERB
ihlr-26084	427	29	the	the	DET
ihlr-26084	427	30	price	price	NOUN
ihlr-26084	427	31	or	or	CCONJ
ihlr-26084	427	32	the	the	DET
ihlr-26084	427	33	reimbursement	reimbursement	NOUN
ihlr-26084	427	34	rate	rate	NOUN
ihlr-26084	427	35	when	when	SCONJ
ihlr-26084	427	36	making	make	VERB
ihlr-26084	427	37	prescriptions	prescription	NOUN
ihlr-26084	427	38	)	)	PUNCT
ihlr-26084	427	39	.	.	PUNCT
ihlr-26084	428	1	115	115	NUM
ihlr-26084	428	2	.	.	PUNCT
ihlr-26084	429	1	see	see	VERB
ihlr-26084	429	2	e.g.	e.g.	ADV
ihlr-26084	429	3	,	,	PUNCT
ihlr-26084	429	4	oliver	oliver	PROPN
ihlr-26084	429	5	d.	d.	PROPN
ihlr-26084	429	6	hart	hart	PROPN
ihlr-26084	429	7	&	&	CCONJ
ihlr-26084	429	8	bengt	bengt	PROPN
ihlr-26084	429	9	hölmstrom	hölmstrom	PROPN
ihlr-26084	429	10	,	,	PUNCT
ihlr-26084	429	11	the	the	DET
ihlr-26084	429	12	theory	theory	NOUN
ihlr-26084	429	13	of	of	ADP
ihlr-26084	429	14	contracts	contract	NOUN
ihlr-26084	429	15	,	,	PUNCT
ihlr-26084	429	16	advances	advance	NOUN
ihlr-26084	429	17	econ	econ	PROPN
ihlr-26084	429	18	.	.	PUNCT
ihlr-26084	430	1	theory	theory	NOUN
ihlr-26084	430	2	:	:	PUNCT
ihlr-26084	430	3	fifth	fifth	ADJ
ihlr-26084	430	4	world	world	NOUN
ihlr-26084	430	5	cong	cong	NOUN
ihlr-26084	430	6	.	.	PUNCT
ihlr-26084	431	1	75	75	NUM
ihlr-26084	431	2	-	-	SYM
ihlr-26084	431	3	106	106	NUM
ihlr-26084	431	4	(	(	PUNCT
ihlr-26084	431	5	t.	t.	PROPN
ihlr-26084	431	6	bewley	bewley	PROPN
ihlr-26084	431	7	ed	ed	PROPN
ihlr-26084	431	8	.	.	PROPN
ihlr-26084	431	9	1987	1987	NUM
ihlr-26084	431	10	)	)	PUNCT
ihlr-26084	431	11	.	.	PUNCT
ihlr-26084	432	1	2022	2022	NUM
ihlr-26084	432	2	]	]	PUNCT
ihlr-26084	432	3	reverse	reverse	ADJ
ihlr-26084	432	4	payment	payment	NOUN
ihlr-26084	432	5	:	:	PUNCT
ihlr-26084	432	6	a	a	DET
ihlr-26084	432	7	comparative	comparative	ADJ
ihlr-26084	432	8	study	study	NOUN
ihlr-26084	432	9	37	37	NUM
ihlr-26084	432	10	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	432	11	industry	industry	NOUN
ihlr-26084	432	12	when	when	SCONJ
ihlr-26084	432	13	health	health	NOUN
ihlr-26084	432	14	systems	system	NOUN
ihlr-26084	432	15	implement	implement	VERB
ihlr-26084	432	16	a	a	DET
ihlr-26084	432	17	regulated	regulated	ADJ
ihlr-26084	432	18	pricing	pricing	NOUN
ihlr-26084	432	19	mechanism	mechanism	NOUN
ihlr-26084	432	20	.	.	PUNCT
ihlr-26084	433	1	therefore	therefore	ADV
ihlr-26084	433	2	,	,	PUNCT
ihlr-26084	433	3	health	health	NOUN
ihlr-26084	433	4	agencies	agency	NOUN
ihlr-26084	433	5	in	in	ADP
ihlr-26084	433	6	those	those	DET
ihlr-26084	433	7	countries	country	NOUN
ihlr-26084	433	8	should	should	AUX
ihlr-26084	433	9	pay	pay	VERB
ihlr-26084	433	10	more	more	ADJ
ihlr-26084	433	11	attention	attention	NOUN
ihlr-26084	433	12	to	to	ADP
ihlr-26084	433	13	any	any	DET
ihlr-26084	433	14	barriers	barrier	NOUN
ihlr-26084	433	15	to	to	ADP
ihlr-26084	433	16	generic	generic	ADJ
ihlr-26084	433	17	entry	entry	NOUN
ihlr-26084	433	18	because	because	SCONJ
ihlr-26084	433	19	these	these	DET
ihlr-26084	433	20	barriers	barrier	NOUN
ihlr-26084	433	21	can	can	AUX
ihlr-26084	433	22	cost	cost	VERB
ihlr-26084	433	23	taxpayers	taxpayer	NOUN
ihlr-26084	433	24	billions	billion	NOUN
ihlr-26084	433	25	of	of	ADP
ihlr-26084	433	26	pounds	pound	NOUN
ihlr-26084	433	27	or	or	CCONJ
ihlr-26084	433	28	euros	euro	NOUN
ihlr-26084	433	29	.	.	PUNCT
ihlr-26084	434	1	brand	brand	NOUN
ihlr-26084	434	2	-	-	PUNCT
ihlr-26084	434	3	name	name	NOUN
ihlr-26084	434	4	drug	drug	NOUN
ihlr-26084	434	5	manufacturers	manufacturer	NOUN
ihlr-26084	434	6	in	in	ADP
ihlr-26084	434	7	the	the	DET
ihlr-26084	434	8	uk	uk	PROPN
ihlr-26084	434	9	and	and	CCONJ
ihlr-26084	434	10	france	france	PROPN
ihlr-26084	434	11	have	have	VERB
ihlr-26084	434	12	a	a	DET
ihlr-26084	434	13	strong	strong	ADJ
ihlr-26084	434	14	incentive	incentive	NOUN
ihlr-26084	434	15	to	to	PART
ihlr-26084	434	16	cartelize	cartelize	VERB
ihlr-26084	434	17	with	with	ADP
ihlr-26084	434	18	generic	generic	ADJ
ihlr-26084	434	19	entrants	entrant	NOUN
ihlr-26084	434	20	because	because	SCONJ
ihlr-26084	434	21	of	of	ADP
ihlr-26084	434	22	the	the	DET
ihlr-26084	434	23	pricing	pricing	NOUN
ihlr-26084	434	24	mechanism	mechanism	NOUN
ihlr-26084	434	25	.	.	PUNCT
ihlr-26084	435	1	as	as	SCONJ
ihlr-26084	435	2	discussed	discuss	VERB
ihlr-26084	435	3	,	,	PUNCT
ihlr-26084	435	4	uk	uk	PROPN
ihlr-26084	435	5	generic	generic	ADJ
ihlr-26084	435	6	manufacturers	manufacturer	NOUN
ihlr-26084	435	7	set	set	VERB
ihlr-26084	435	8	their	their	PRON
ihlr-26084	435	9	own	own	ADJ
ihlr-26084	435	10	prices	price	NOUN
ihlr-26084	435	11	,	,	PUNCT
ihlr-26084	435	12	compete	compete	VERB
ihlr-26084	435	13	directly	directly	ADV
ihlr-26084	435	14	with	with	ADP
ihlr-26084	435	15	brand	brand	NOUN
ihlr-26084	435	16	-	-	PUNCT
ihlr-26084	435	17	name	name	NOUN
ihlr-26084	435	18	drugs	drug	NOUN
ihlr-26084	435	19	,	,	PUNCT
ihlr-26084	435	20	and	and	CCONJ
ihlr-26084	435	21	lower	lower	VERB
ihlr-26084	435	22	the	the	DET
ihlr-26084	435	23	cost	cost	NOUN
ihlr-26084	435	24	-	-	PUNCT
ihlr-26084	435	25	effectiveness	effectiveness	NOUN
ihlr-26084	435	26	benchmark	benchmark	NOUN
ihlr-26084	435	27	for	for	ADP
ihlr-26084	435	28	alternative	alternative	ADJ
ihlr-26084	435	29	branded	brand	VERB
ihlr-26084	435	30	drugs	drug	NOUN
ihlr-26084	435	31	.	.	PUNCT
ihlr-26084	436	1	this	this	DET
ihlr-26084	436	2	combination	combination	NOUN
ihlr-26084	436	3	has	have	VERB
ihlr-26084	436	4	the	the	DET
ihlr-26084	436	5	potential	potential	NOUN
ihlr-26084	436	6	to	to	PART
ihlr-26084	436	7	destroy	destroy	VERB
ihlr-26084	436	8	the	the	DET
ihlr-26084	436	9	monopoly	monopoly	NOUN
ihlr-26084	436	10	profits	profit	NOUN
ihlr-26084	436	11	of	of	ADP
ihlr-26084	436	12	a	a	DET
ihlr-26084	436	13	brand	brand	NOUN
ihlr-26084	436	14	-	-	PUNCT
ihlr-26084	436	15	name	name	NOUN
ihlr-26084	436	16	drug	drug	NOUN
ihlr-26084	436	17	.	.	PUNCT
ihlr-26084	437	1	and	and	CCONJ
ihlr-26084	437	2	in	in	ADP
ihlr-26084	437	3	france	france	PROPN
ihlr-26084	437	4	,	,	PUNCT
ihlr-26084	437	5	branded	brand	VERB
ihlr-26084	437	6	drugs	drug	NOUN
ihlr-26084	437	7	lose	lose	VERB
ihlr-26084	437	8	20	20	NUM
ihlr-26084	437	9	%	%	NOUN
ihlr-26084	437	10	of	of	ADP
ihlr-26084	437	11	the	the	DET
ihlr-26084	437	12	price	price	NOUN
ihlr-26084	437	13	of	of	ADP
ihlr-26084	437	14	the	the	DET
ihlr-26084	437	15	medication	medication	NOUN
ihlr-26084	437	16	immediately	immediately	ADV
ihlr-26084	437	17	upon	upon	SCONJ
ihlr-26084	437	18	generic	generic	ADJ
ihlr-26084	437	19	entry	entry	NOUN
ihlr-26084	437	20	and	and	CCONJ
ihlr-26084	437	21	60	60	NUM
ihlr-26084	437	22	%	%	NOUN
ihlr-26084	437	23	of	of	ADP
ihlr-26084	437	24	the	the	DET
ihlr-26084	437	25	price	price	NOUN
ihlr-26084	437	26	after	after	SCONJ
ihlr-26084	437	27	eighteen	eighteen	NUM
ihlr-26084	437	28	months.116	months.116	PRON
ihlr-26084	437	29	this	this	DET
ihlr-26084	437	30	price	price	NOUN
ihlr-26084	437	31	decrease	decrease	NOUN
ihlr-26084	437	32	does	do	AUX
ihlr-26084	437	33	not	not	PART
ihlr-26084	437	34	even	even	ADV
ihlr-26084	437	35	account	account	VERB
ihlr-26084	437	36	for	for	ADP
ihlr-26084	437	37	the	the	DET
ihlr-26084	437	38	substitution	substitution	NOUN
ihlr-26084	437	39	effect	effect	NOUN
ihlr-26084	437	40	linked	link	VERB
ihlr-26084	437	41	to	to	ADP
ihlr-26084	437	42	consumers	consumer	NOUN
ihlr-26084	437	43	buying	buy	VERB
ihlr-26084	437	44	from	from	ADP
ihlr-26084	437	45	the	the	DET
ihlr-26084	437	46	generic	generic	ADJ
ihlr-26084	437	47	company	company	NOUN
ihlr-26084	437	48	instead	instead	ADV
ihlr-26084	437	49	of	of	ADP
ihlr-26084	437	50	the	the	DET
ihlr-26084	437	51	branded	brand	VERB
ihlr-26084	437	52	manufacturer	manufacturer	NOUN
ihlr-26084	437	53	.	.	PUNCT
ihlr-26084	438	1	the	the	DET
ihlr-26084	438	2	margins	margin	NOUN
ihlr-26084	438	3	in	in	ADP
ihlr-26084	438	4	the	the	DET
ihlr-26084	438	5	uk	uk	PROPN
ihlr-26084	438	6	and	and	CCONJ
ihlr-26084	438	7	france	france	PROPN
ihlr-26084	438	8	are	be	AUX
ihlr-26084	438	9	still	still	ADV
ihlr-26084	438	10	smaller	small	ADJ
ihlr-26084	438	11	than	than	ADP
ihlr-26084	438	12	in	in	ADP
ihlr-26084	438	13	the	the	DET
ihlr-26084	438	14	us	us	PROPN
ihlr-26084	438	15	,	,	PUNCT
ihlr-26084	438	16	where	where	SCONJ
ihlr-26084	438	17	pay	pay	NOUN
ihlr-26084	438	18	-	-	PUNCT
ihlr-26084	438	19	fordelay	fordelay	NOUN
ihlr-26084	438	20	is	be	AUX
ihlr-26084	438	21	more	more	ADV
ihlr-26084	438	22	common.117	common.117	ADV
ihlr-26084	438	23	but	but	CCONJ
ihlr-26084	438	24	this	this	PRON
ihlr-26084	438	25	does	do	AUX
ihlr-26084	438	26	not	not	PART
ihlr-26084	438	27	negate	negate	VERB
ihlr-26084	438	28	the	the	DET
ihlr-26084	438	29	incentive	incentive	NOUN
ihlr-26084	438	30	for	for	SCONJ
ihlr-26084	438	31	european	european	ADJ
ihlr-26084	438	32	drug	drug	NOUN
ihlr-26084	438	33	manufacturers	manufacturer	NOUN
ihlr-26084	438	34	to	to	PART
ihlr-26084	438	35	introduce	introduce	VERB
ihlr-26084	438	36	barriers	barrier	NOUN
ihlr-26084	438	37	to	to	ADP
ihlr-26084	438	38	entry	entry	NOUN
ihlr-26084	438	39	.	.	PUNCT
ihlr-26084	439	1	the	the	DET
ihlr-26084	439	2	next	next	ADJ
ihlr-26084	439	3	section	section	NOUN
ihlr-26084	439	4	discusses	discuss	VERB
ihlr-26084	439	5	european	european	ADJ
ihlr-26084	439	6	cases	case	NOUN
ihlr-26084	439	7	of	of	ADP
ihlr-26084	439	8	pay	pay	NOUN
ihlr-26084	439	9	-	-	PUNCT
ihlr-26084	439	10	for	for	ADP
ihlr-26084	439	11	-	-	PUNCT
ihlr-26084	439	12	delay	delay	NOUN
ihlr-26084	439	13	.	.	PUNCT
ihlr-26084	440	1	b.	b.	PROPN
ihlr-26084	440	2	the	the	DET
ihlr-26084	440	3	“	"	PUNCT
ihlr-26084	440	4	no	no	DET
ihlr-26084	440	5	-	-	PUNCT
ihlr-26084	440	6	alternative	alternative	ADJ
ihlr-26084	440	7	-	-	PUNCT
ihlr-26084	440	8	explanation	explanation	NOUN
ihlr-26084	440	9	”	"	PUNCT
ihlr-26084	440	10	test	test	NOUN
ihlr-26084	440	11	the	the	DET
ihlr-26084	440	12	european	european	PROPN
ihlr-26084	440	13	commission	commission	PROPN
ihlr-26084	440	14	(	(	PUNCT
ihlr-26084	440	15	“	"	PUNCT
ihlr-26084	440	16	commission	commission	NOUN
ihlr-26084	440	17	”	"	PUNCT
ihlr-26084	440	18	)	)	PUNCT
ihlr-26084	440	19	has	have	AUX
ihlr-26084	440	20	fined	fine	VERB
ihlr-26084	440	21	a	a	DET
ihlr-26084	440	22	few	few	ADJ
ihlr-26084	440	23	companies	company	NOUN
ihlr-26084	440	24	over	over	ADP
ihlr-26084	440	25	the	the	DET
ihlr-26084	440	26	years	year	NOUN
ihlr-26084	440	27	for	for	ADP
ihlr-26084	440	28	“	"	PUNCT
ihlr-26084	440	29	pay	pay	VERB
ihlr-26084	440	30	-	-	PUNCT
ihlr-26084	440	31	for	for	ADP
ihlr-26084	440	32	-	-	PUNCT
ihlr-26084	440	33	delay	delay	NOUN
ihlr-26084	440	34	”	"	PUNCT
ihlr-26084	440	35	agreements	agreement	NOUN
ihlr-26084	440	36	.	.	PUNCT
ihlr-26084	441	1	however	however	ADV
ihlr-26084	441	2	,	,	PUNCT
ihlr-26084	441	3	cases	case	NOUN
ihlr-26084	441	4	are	be	AUX
ihlr-26084	441	5	far	far	ADV
ihlr-26084	441	6	and	and	CCONJ
ihlr-26084	441	7	few	few	ADJ
ihlr-26084	441	8	by	by	ADP
ihlr-26084	441	9	comparison	comparison	NOUN
ihlr-26084	441	10	with	with	ADP
ihlr-26084	441	11	the	the	DET
ihlr-26084	441	12	number	number	NOUN
ihlr-26084	441	13	of	of	ADP
ihlr-26084	441	14	cases	case	NOUN
ihlr-26084	441	15	in	in	ADP
ihlr-26084	441	16	the	the	DET
ihlr-26084	441	17	us	us	PROPN
ihlr-26084	441	18	.	.	PUNCT
ihlr-26084	442	1	on	on	ADP
ihlr-26084	442	2	june	june	PROPN
ihlr-26084	442	3	19	19	NUM
ihlr-26084	442	4	,	,	PUNCT
ihlr-26084	442	5	2013	2013	NUM
ihlr-26084	442	6	,	,	PUNCT
ihlr-26084	442	7	the	the	DET
ihlr-26084	442	8	commission	commission	NOUN
ihlr-26084	442	9	fined	fine	VERB
ihlr-26084	442	10	a	a	DET
ihlr-26084	442	11	brand	brand	NOUN
ihlr-26084	442	12	manufacturer	manufacturer	NOUN
ihlr-26084	442	13	,	,	PUNCT
ihlr-26084	442	14	lundbeck	lundbeck	NOUN
ihlr-26084	442	15	,	,	PUNCT
ihlr-26084	442	16	and	and	CCONJ
ihlr-26084	442	17	four	four	NUM
ihlr-26084	442	18	generic	generic	ADJ
ihlr-26084	442	19	manufacturers	manufacturer	NOUN
ihlr-26084	442	20	—	—	PUNCT
ihlr-26084	442	21	generics	generics	PROPN
ihlr-26084	442	22	(	(	PUNCT
ihlr-26084	442	23	uk	uk	PROPN
ihlr-26084	442	24	)	)	PUNCT
ihlr-26084	442	25	(	(	PUNCT
ihlr-26084	442	26	a	a	DET
ihlr-26084	442	27	merck	merck	PROPN
ihlr-26084	442	28	subsidiary	subsidiary	NOUN
ihlr-26084	442	29	)	)	PUNCT
ihlr-26084	442	30	,	,	PUNCT
ihlr-26084	442	31	arrow	arrow	NOUN
ihlr-26084	442	32	,	,	PUNCT
ihlr-26084	442	33	alpharma	alpharma	NOUN
ihlr-26084	442	34	,	,	PUNCT
ihlr-26084	442	35	and	and	CCONJ
ihlr-26084	442	36	ranbaxy	ranbaxy	PROPN
ihlr-26084	442	37	—	—	PUNCT
ihlr-26084	442	38	for	for	ADP
ihlr-26084	442	39	six	six	NUM
ihlr-26084	442	40	agreements	agreement	NOUN
ihlr-26084	442	41	spanning	span	VERB
ihlr-26084	442	42	across	across	ADP
ihlr-26084	442	43	different	different	ADJ
ihlr-26084	442	44	countries	country	NOUN
ihlr-26084	442	45	within	within	ADP
ihlr-26084	442	46	the	the	DET
ihlr-26084	442	47	european	european	ADJ
ihlr-26084	442	48	economic	economic	PROPN
ihlr-26084	442	49	area.118	area.118	VERB
ihlr-26084	442	50	the	the	DET
ihlr-26084	442	51	commission	commission	NOUN
ihlr-26084	442	52	found	find	VERB
ihlr-26084	442	53	that	that	SCONJ
ihlr-26084	442	54	the	the	DET
ihlr-26084	442	55	agreements	agreement	NOUN
ihlr-26084	442	56	did	do	AUX
ihlr-26084	442	57	not	not	PART
ihlr-26084	442	58	resolve	resolve	VERB
ihlr-26084	442	59	any	any	DET
ihlr-26084	442	60	patent	patent	NOUN
ihlr-26084	442	61	disputes	dispute	NOUN
ihlr-26084	442	62	and	and	CCONJ
ihlr-26084	442	63	delayed	delay	VERB
ihlr-26084	442	64	generic	generic	ADJ
ihlr-26084	442	65	market	market	NOUN
ihlr-26084	442	66	entry	entry	NOUN
ihlr-26084	442	67	beyond	beyond	ADP
ihlr-26084	442	68	what	what	PRON
ihlr-26084	442	69	the	the	DET
ihlr-26084	442	70	patent	patent	NOUN
ihlr-26084	442	71	protection	protection	NOUN
ihlr-26084	442	72	would	would	AUX
ihlr-26084	442	73	have	have	AUX
ihlr-26084	442	74	allowed	allow	VERB
ihlr-26084	442	75	:	:	PUNCT
ihlr-26084	442	76	the	the	DET
ihlr-26084	442	77	brand	brand	NOUN
ihlr-26084	442	78	manufacturer	manufacturer	NOUN
ihlr-26084	442	79	paid	pay	VERB
ihlr-26084	442	80	the	the	DET
ihlr-26084	442	81	generic	generic	ADJ
ihlr-26084	442	82	companies	company	NOUN
ihlr-26084	442	83	lump	lump	VERB
ihlr-26084	442	84	sums	sum	NOUN
ihlr-26084	442	85	and	and	CCONJ
ihlr-26084	442	86	bought	buy	VERB
ihlr-26084	442	87	their	their	PRON
ihlr-26084	442	88	drug	drug	NOUN
ihlr-26084	442	89	stocks	stock	NOUN
ihlr-26084	442	90	to	to	PART
ihlr-26084	442	91	destroy	destroy	VERB
ihlr-26084	442	92	them.119	them.119	PROPN
ihlr-26084	442	93	the	the	DET
ihlr-26084	442	94	participants	participant	NOUN
ihlr-26084	442	95	appealed	appeal	VERB
ihlr-26084	442	96	the	the	DET
ihlr-26084	442	97	commission	commission	NOUN
ihlr-26084	442	98	’s	’s	PART
ihlr-26084	442	99	decisions.120	decisions.120	ADV
ihlr-26084	442	100	in	in	ADP
ihlr-26084	442	101	2016	2016	NUM
ihlr-26084	442	102	,	,	PUNCT
ihlr-26084	442	103	a	a	DET
ihlr-26084	442	104	general	general	ADJ
ihlr-26084	442	105	court	court	NOUN
ihlr-26084	442	106	of	of	ADP
ihlr-26084	442	107	the	the	DET
ihlr-26084	442	108	european	european	PROPN
ihlr-26084	442	109	union	union	PROPN
ihlr-26084	442	110	found	find	VERB
ihlr-26084	442	111	that	that	SCONJ
ihlr-26084	442	112	the	the	DET
ihlr-26084	442	113	agreements	agreement	NOUN
ihlr-26084	442	114	had	have	VERB
ihlr-26084	442	115	for	for	ADP
ihlr-26084	442	116	object	object	NOUN
ihlr-26084	442	117	a	a	DET
ihlr-26084	442	118	restriction	restriction	NOUN
ihlr-26084	442	119	of	of	ADP
ihlr-26084	442	120	competition	competition	NOUN
ihlr-26084	442	121	and	and	CCONJ
ihlr-26084	442	122	that	that	SCONJ
ihlr-26084	442	123	the	the	DET
ihlr-26084	442	124	brand	brand	NOUN
ihlr-26084	442	125	manufacturer	manufacturer	NOUN
ihlr-26084	442	126	failed	fail	VERB
ihlr-26084	442	127	to	to	PART
ihlr-26084	442	128	demonstrate	demonstrate	VERB
ihlr-26084	442	129	116	116	NUM
ihlr-26084	442	130	.	.	PUNCT
ihlr-26084	443	1	rémond	rémond	ADJ
ihlr-26084	443	2	,	,	PUNCT
ihlr-26084	443	3	supra	supra	PROPN
ihlr-26084	443	4	note	note	NOUN
ihlr-26084	443	5	89	89	NUM
ihlr-26084	443	6	.	.	PUNCT
ihlr-26084	443	7	117	117	NUM
ihlr-26084	443	8	.	.	PUNCT
ihlr-26084	444	1	comparaison	comparaison	PROPN
ihlr-26084	444	2	internationale	internationale	PROPN
ihlr-26084	444	3	des	des	PROPN
ihlr-26084	444	4	prix	prix	PROPN
ihlr-26084	444	5	des	des	X
ihlr-26084	444	6	medicaments	medicament	NOUN
ihlr-26084	444	7	,	,	PUNCT
ihlr-26084	444	8	ministère	ministère	PROPN
ihlr-26084	444	9	des	des	X
ihlr-26084	444	10	solidarités	solidarités	PROPN
ihlr-26084	444	11	et	et	PROPN
ihlr-26084	444	12	de	de	X
ihlr-26084	444	13	la	la	X
ihlr-26084	444	14	santé	santé	X
ihlr-26084	444	15	1	1	NUM
ihlr-26084	444	16	(	(	PUNCT
ihlr-26084	444	17	2015	2015	NUM
ihlr-26084	444	18	)	)	PUNCT
ihlr-26084	444	19	.	.	PUNCT
ihlr-26084	445	1	118	118	NUM
ihlr-26084	445	2	.	.	PUNCT
ihlr-26084	445	3	case	case	NOUN
ihlr-26084	445	4	at.39226	at.39226	PROPN
ihlr-26084	445	5	–	–	PUNCT
ihlr-26084	445	6	lundbeck	lundbeck	NOUN
ihlr-26084	445	7	(	(	PUNCT
ihlr-26084	445	8	2013	2013	NUM
ihlr-26084	445	9	)	)	PUNCT
ihlr-26084	445	10	.	.	PUNCT
ihlr-26084	446	1	119	119	NUM
ihlr-26084	446	2	.	.	PUNCT
ihlr-26084	447	1	i	i	PRON
ihlr-26084	447	2	d.	d.	PROPN
ihlr-26084	447	3	120	120	NUM
ihlr-26084	447	4	.	.	PUNCT
ihlr-26084	448	1	see	see	VERB
ihlr-26084	448	2	case	case	NOUN
ihlr-26084	448	3	t-460/13	t-460/13	PROPN
ihlr-26084	448	4	sun	sun	PROPN
ihlr-26084	448	5	pharmaceutical	pharmaceutical	PROPN
ihlr-26084	448	6	indus	indus	PROPN
ihlr-26084	448	7	.	.	PUNCT
ihlr-26084	449	1	&	&	CCONJ
ihlr-26084	449	2	ranbaxy	ranbaxy	PROPN
ihlr-26084	449	3	v.	v.	ADP
ihlr-26084	449	4	comm’n	comm’n	NOUN
ihlr-26084	449	5	;	;	PUNCT
ihlr-26084	449	6	t467/13	t467/13	PROPN
ihlr-26084	449	7	arrow	arrow	NOUN
ihlr-26084	449	8	grp	grp	PROPN
ihlr-26084	449	9	.	.	PROPN
ihlr-26084	449	10	&	&	CCONJ
ihlr-26084	449	11	arrow	arrow	NOUN
ihlr-26084	449	12	generics	generic	NOUN
ihlr-26084	449	13	v.	v.	ADP
ihlr-26084	449	14	comm’n	comm’n	NOUN
ihlr-26084	449	15	;	;	PUNCT
ihlr-26084	450	1	t-469/13	t-469/13	PROPN
ihlr-26084	450	2	generics	generics	PROPN
ihlr-26084	450	3	(	(	PUNCT
ihlr-26084	450	4	uk	uk	PROPN
ihlr-26084	450	5	)	)	PUNCT
ihlr-26084	450	6	v	v	ADP
ihlr-26084	450	7	comm’n	comm’n	NOUN
ihlr-26084	450	8	;	;	PUNCT
ihlr-26084	450	9	t-470/13	t-470/13	NOUN
ihlr-26084	450	10	merck	merck	NOUN
ihlr-26084	450	11	v.	v.	ADP
ihlr-26084	450	12	comm’n	comm’n	NOUN
ihlr-26084	450	13	;	;	PUNCT
ihlr-26084	450	14	t-471/13	t-471/13	PROPN
ihlr-26084	450	15	xellia	xellia	PROPN
ihlr-26084	450	16	pharmaceuticals	pharmaceuticals	PROPN
ihlr-26084	450	17	&	&	CCONJ
ihlr-26084	450	18	alpharma	alpharma	PROPN
ihlr-26084	450	19	v.	v.	CCONJ
ihlr-26084	450	20	comm’n	comm’n	NOUN
ihlr-26084	450	21	;	;	PUNCT
ihlr-26084	450	22	t-472/13	t-472/13	ADJ
ihlr-26084	450	23	lundbeck	lundbeck	NOUN
ihlr-26084	450	24	v.	v.	CCONJ
ihlr-26084	450	25	comm’n	comm’n	NOUN
ihlr-26084	450	26	.	.	PUNCT
ihlr-26084	451	1	38	38	NUM
ihlr-26084	451	2	indiana	indiana	PROPN
ihlr-26084	451	3	health	health	PROPN
ihlr-26084	451	4	law	law	NOUN
ihlr-26084	451	5	review	review	NOUN
ihlr-26084	451	6	[	[	X
ihlr-26084	451	7	vol	vol	NOUN
ihlr-26084	451	8	.	.	PUNCT
ihlr-26084	452	1	19:21	19:21	NUM
ihlr-26084	452	2	that	that	PRON
ihlr-26084	452	3	the	the	DET
ihlr-26084	452	4	agreements	agreement	NOUN
ihlr-26084	452	5	were	be	AUX
ihlr-26084	452	6	necessary	necessary	ADJ
ihlr-26084	452	7	to	to	PART
ihlr-26084	452	8	protect	protect	VERB
ihlr-26084	452	9	its	its	PRON
ihlr-26084	452	10	intellectual	intellectual	ADJ
ihlr-26084	452	11	property	property	NOUN
ihlr-26084	452	12	rights.121	rights.121	NOUN
ihlr-26084	452	13	because	because	SCONJ
ihlr-26084	452	14	of	of	ADP
ihlr-26084	452	15	the	the	DET
ihlr-26084	452	16	anticompetitive	anticompetitive	ADJ
ihlr-26084	452	17	object	object	NOUN
ihlr-26084	452	18	of	of	ADP
ihlr-26084	452	19	the	the	DET
ihlr-26084	452	20	agreement	agreement	NOUN
ihlr-26084	452	21	,	,	PUNCT
ihlr-26084	452	22	the	the	DET
ihlr-26084	452	23	commission	commission	NOUN
ihlr-26084	452	24	did	do	AUX
ihlr-26084	452	25	not	not	PART
ihlr-26084	452	26	have	have	VERB
ihlr-26084	452	27	to	to	PART
ihlr-26084	452	28	investigate	investigate	VERB
ihlr-26084	452	29	the	the	DET
ihlr-26084	452	30	effect	effect	NOUN
ihlr-26084	452	31	of	of	ADP
ihlr-26084	452	32	the	the	DET
ihlr-26084	452	33	agreement.122	agreement.122	NOUN
ihlr-26084	452	34	the	the	DET
ihlr-26084	452	35	general	general	ADJ
ihlr-26084	452	36	court	court	NOUN
ihlr-26084	452	37	affirmed	affirm	VERB
ihlr-26084	452	38	the	the	DET
ihlr-26084	452	39	€	€	SYM
ihlr-26084	452	40	150	150	NUM
ihlr-26084	452	41	million	million	NUM
ihlr-26084	452	42	fines	fine	NOUN
ihlr-26084	452	43	.	.	PUNCT
ihlr-26084	453	1	the	the	DET
ihlr-26084	453	2	general	general	ADJ
ihlr-26084	453	3	court	court	NOUN
ihlr-26084	453	4	spent	spend	VERB
ihlr-26084	453	5	a	a	DET
ihlr-26084	453	6	large	large	ADJ
ihlr-26084	453	7	part	part	NOUN
ihlr-26084	453	8	of	of	ADP
ihlr-26084	453	9	the	the	DET
ihlr-26084	453	10	decision	decision	NOUN
ihlr-26084	453	11	assessing	assess	VERB
ihlr-26084	453	12	whether	whether	SCONJ
ihlr-26084	453	13	generic	generic	ADJ
ihlr-26084	453	14	manufacturers	manufacturer	NOUN
ihlr-26084	453	15	were	be	AUX
ihlr-26084	453	16	competitors.123	competitors.123	NOUN
ihlr-26084	453	17	it	it	PRON
ihlr-26084	453	18	looked	look	VERB
ihlr-26084	453	19	at	at	ADP
ihlr-26084	453	20	whether	whether	SCONJ
ihlr-26084	453	21	the	the	DET
ihlr-26084	453	22	companies	company	NOUN
ihlr-26084	453	23	believed	believe	VERB
ihlr-26084	453	24	that	that	SCONJ
ihlr-26084	453	25	the	the	DET
ihlr-26084	453	26	generic	generic	PROPN
ihlr-26084	453	27	had	have	VERB
ihlr-26084	453	28	the	the	DET
ihlr-26084	453	29	ability	ability	NOUN
ihlr-26084	453	30	to	to	PART
ihlr-26084	453	31	enter	enter	VERB
ihlr-26084	453	32	the	the	DET
ihlr-26084	453	33	market.124	market.124	NOUN
ihlr-26084	453	34	the	the	DET
ihlr-26084	453	35	court	court	NOUN
ihlr-26084	453	36	reasoned	reason	VERB
ihlr-26084	453	37	that	that	SCONJ
ihlr-26084	453	38	the	the	DET
ihlr-26084	453	39	fact	fact	NOUN
ihlr-26084	453	40	that	that	SCONJ
ihlr-26084	453	41	brand	brand	NOUN
ihlr-26084	453	42	manufacturer	manufacturer	NOUN
ihlr-26084	453	43	concluded	conclude	VERB
ihlr-26084	453	44	these	these	DET
ihlr-26084	453	45	“	"	PUNCT
ihlr-26084	453	46	agreements	agreement	NOUN
ihlr-26084	453	47	with	with	ADP
ihlr-26084	453	48	the	the	DET
ihlr-26084	453	49	generic	generic	ADJ
ihlr-26084	453	50	undertakings	undertaking	NOUN
ihlr-26084	453	51	is	be	AUX
ihlr-26084	453	52	a	a	DET
ihlr-26084	453	53	strong	strong	ADJ
ihlr-26084	453	54	indication	indication	NOUN
ihlr-26084	453	55	that	that	SCONJ
ihlr-26084	453	56	it	it	PRON
ihlr-26084	453	57	perceived	perceive	VERB
ihlr-26084	453	58	those	those	DET
ihlr-26084	453	59	undertakings	undertaking	NOUN
ihlr-26084	453	60	as	as	ADP
ihlr-26084	453	61	a	a	DET
ihlr-26084	453	62	potential	potential	ADJ
ihlr-26084	453	63	threat	threat	NOUN
ihlr-26084	453	64	.	.	PUNCT
ihlr-26084	453	65	”125	”125	PROPN
ihlr-26084	454	1	the	the	DET
ihlr-26084	454	2	general	general	ADJ
ihlr-26084	454	3	court	court	NOUN
ihlr-26084	454	4	also	also	ADV
ihlr-26084	454	5	rejected	reject	VERB
ihlr-26084	454	6	the	the	DET
ihlr-26084	454	7	scope	scope	NOUN
ihlr-26084	454	8	-	-	PUNCT
ihlr-26084	454	9	of	of	ADP
ihlr-26084	454	10	-	-	PUNCT
ihlr-26084	454	11	the	the	DET
ihlr-26084	454	12	-	-	PUNCT
ihlr-26084	454	13	patent	patent	NOUN
ihlr-26084	454	14	test	test	NOUN
ihlr-26084	454	15	,	,	PUNCT
ihlr-26084	454	16	citing	cite	VERB
ihlr-26084	454	17	actavis.126	actavis.126	NOUN
ihlr-26084	454	18	in	in	ADP
ihlr-26084	454	19	2013	2013	NUM
ihlr-26084	454	20	,	,	PUNCT
ihlr-26084	454	21	the	the	DET
ihlr-26084	454	22	commission	commission	NOUN
ihlr-26084	454	23	fined	fine	VERB
ihlr-26084	454	24	the	the	DET
ihlr-26084	454	25	brand	brand	NOUN
ihlr-26084	454	26	manufacturer	manufacturer	NOUN
ihlr-26084	454	27	,	,	PUNCT
ihlr-26084	454	28	janssen	janssen	NOUN
ihlr-26084	454	29	-	-	PUNCT
ihlr-26084	454	30	cilag	cilag	PROPN
ihlr-26084	454	31	(	(	PUNCT
ihlr-26084	454	32	a	a	DET
ihlr-26084	454	33	johnson	johnson	PROPN
ihlr-26084	454	34	&	&	CCONJ
ihlr-26084	454	35	johnson	johnson	PROPN
ihlr-26084	454	36	subsidiary	subsidiary	PROPN
ihlr-26084	454	37	)	)	PUNCT
ihlr-26084	454	38	,	,	PUNCT
ihlr-26084	454	39	and	and	CCONJ
ihlr-26084	454	40	the	the	DET
ihlr-26084	454	41	generic	generic	ADJ
ihlr-26084	454	42	manufacturer	manufacturer	NOUN
ihlr-26084	454	43	,	,	PUNCT
ihlr-26084	454	44	sandoz	sandoz	PROPN
ihlr-26084	454	45	(	(	PUNCT
ihlr-26084	454	46	a	a	DET
ihlr-26084	454	47	novartis	novartis	NOUN
ihlr-26084	454	48	subsidiary	subsidiary	NOUN
ihlr-26084	454	49	)	)	PUNCT
ihlr-26084	454	50	,	,	PUNCT
ihlr-26084	454	51	for	for	ADP
ihlr-26084	454	52	pay	pay	NOUN
ihlr-26084	454	53	-	-	PUNCT
ihlr-26084	454	54	for	for	ADP
ihlr-26084	454	55	-	-	PUNCT
ihlr-26084	454	56	delay	delay	NOUN
ihlr-26084	454	57	in	in	ADP
ihlr-26084	454	58	the	the	DET
ihlr-26084	454	59	netherlands.127	netherlands.127	NOUN
ihlr-26084	454	60	the	the	DET
ihlr-26084	454	61	“	"	PUNCT
ihlr-26084	454	62	co	co	NOUN
ihlr-26084	454	63	-	-	NOUN
ihlr-26084	454	64	promotion	promotion	NOUN
ihlr-26084	454	65	”	"	PUNCT
ihlr-26084	454	66	agreement	agreement	NOUN
ihlr-26084	454	67	set	set	VERB
ihlr-26084	454	68	out	out	ADP
ihlr-26084	454	69	profit	profit	NOUN
ihlr-26084	454	70	transfer	transfer	NOUN
ihlr-26084	454	71	to	to	ADP
ihlr-26084	454	72	sandoz	sandoz	PROPN
ihlr-26084	454	73	in	in	ADP
ihlr-26084	454	74	exchange	exchange	NOUN
ihlr-26084	454	75	for	for	ADP
ihlr-26084	454	76	promoting	promote	VERB
ihlr-26084	454	77	the	the	DET
ihlr-26084	454	78	branded	brand	VERB
ihlr-26084	454	79	product	product	NOUN
ihlr-26084	454	80	and	and	CCONJ
ihlr-26084	454	81	refraining	refrain	VERB
ihlr-26084	454	82	from	from	ADP
ihlr-26084	454	83	introducing	introduce	VERB
ihlr-26084	454	84	its	its	PRON
ihlr-26084	454	85	own	own	ADJ
ihlr-26084	454	86	generic	generic	NOUN
ihlr-26084	454	87	.	.	PUNCT
ihlr-26084	455	1	this	this	DET
ihlr-26084	455	2	agreement	agreement	NOUN
ihlr-26084	455	3	delayed	delay	VERB
ihlr-26084	455	4	entry	entry	NOUN
ihlr-26084	455	5	from	from	ADP
ihlr-26084	455	6	july	july	PROPN
ihlr-26084	455	7	2005	2005	NUM
ihlr-26084	455	8	to	to	ADP
ihlr-26084	455	9	december	december	PROPN
ihlr-26084	455	10	2006	2006	NUM
ihlr-26084	455	11	.	.	PUNCT
ihlr-26084	456	1	the	the	DET
ihlr-26084	456	2	parties	party	NOUN
ihlr-26084	456	3	did	do	AUX
ihlr-26084	456	4	not	not	PART
ihlr-26084	456	5	appeal	appeal	VERB
ihlr-26084	456	6	the	the	DET
ihlr-26084	456	7	€	€	SYM
ihlr-26084	456	8	16	16	NUM
ihlr-26084	456	9	million	million	NUM
ihlr-26084	456	10	fines	fine	NOUN
ihlr-26084	456	11	.	.	PUNCT
ihlr-26084	457	1	in	in	ADP
ihlr-26084	457	2	2014	2014	NUM
ihlr-26084	457	3	,	,	PUNCT
ihlr-26084	457	4	the	the	DET
ihlr-26084	457	5	commission	commission	NOUN
ihlr-26084	457	6	fined	fine	VERB
ihlr-26084	457	7	a	a	DET
ihlr-26084	457	8	brand	brand	NOUN
ihlr-26084	457	9	manufacturer	manufacturer	NOUN
ihlr-26084	457	10	,	,	PUNCT
ihlr-26084	457	11	servier	servier	NOUN
ihlr-26084	457	12	,	,	PUNCT
ihlr-26084	457	13	and	and	CCONJ
ihlr-26084	457	14	five	five	NUM
ihlr-26084	457	15	generic	generic	ADJ
ihlr-26084	457	16	manufacturers	manufacturer	NOUN
ihlr-26084	457	17	(	(	PUNCT
ihlr-26084	457	18	niche	niche	NOUN
ihlr-26084	457	19	/	/	SYM
ihlr-26084	457	20	unichem	unichem	SYM
ihlr-26084	457	21	,	,	PUNCT
ihlr-26084	457	22	matrix	matrix	NOUN
ihlr-26084	457	23	(	(	PUNCT
ihlr-26084	457	24	a	a	DET
ihlr-26084	457	25	mylan	mylan	PROPN
ihlr-26084	457	26	subsidiary	subsidiary	NOUN
ihlr-26084	457	27	)	)	PUNCT
ihlr-26084	457	28	,	,	PUNCT
ihlr-26084	457	29	teva	teva	PROPN
ihlr-26084	457	30	,	,	PUNCT
ihlr-26084	457	31	krka	krka	NOUN
ihlr-26084	457	32	and	and	CCONJ
ihlr-26084	457	33	lupin	lupin	NOUN
ihlr-26084	457	34	)	)	PUNCT
ihlr-26084	457	35	€	€	SYM
ihlr-26084	457	36	427.7	427.7	NUM
ihlr-26084	457	37	million	million	NUM
ihlr-26084	457	38	for	for	ADP
ihlr-26084	457	39	multiple	multiple	ADJ
ihlr-26084	457	40	deals	deal	NOUN
ihlr-26084	457	41	delaying	delay	VERB
ihlr-26084	457	42	the	the	DET
ihlr-26084	457	43	entry	entry	NOUN
ihlr-26084	457	44	of	of	ADP
ihlr-26084	457	45	generics.128	generics.128	NOUN
ihlr-26084	457	46	servier	servier	NOUN
ihlr-26084	457	47	deployed	deploy	VERB
ihlr-26084	457	48	different	different	ADJ
ihlr-26084	457	49	strategies	strategy	NOUN
ihlr-26084	457	50	(	(	PUNCT
ihlr-26084	457	51	including	include	VERB
ihlr-26084	457	52	catch	catch	NOUN
ihlr-26084	457	53	-	-	PUNCT
ihlr-26084	457	54	and	and	CCONJ
ihlr-26084	457	55	-	-	PUNCT
ihlr-26084	457	56	kill129	kill129	PROPN
ihlr-26084	457	57	of	of	ADP
ihlr-26084	457	58	compound	compound	NOUN
ihlr-26084	457	59	manufacturers	manufacturer	NOUN
ihlr-26084	457	60	)	)	PUNCT
ihlr-26084	457	61	to	to	PART
ihlr-26084	457	62	maintain	maintain	VERB
ihlr-26084	457	63	its	its	PRON
ihlr-26084	457	64	monopoly	monopoly	NOUN
ihlr-26084	457	65	.	.	PUNCT
ihlr-26084	458	1	on	on	ADP
ihlr-26084	458	2	appeal	appeal	NOUN
ihlr-26084	458	3	,	,	PUNCT
ihlr-26084	458	4	the	the	DET
ihlr-26084	458	5	general	general	ADJ
ihlr-26084	458	6	court	court	NOUN
ihlr-26084	458	7	affirmed	affirm	VERB
ihlr-26084	458	8	the	the	DET
ihlr-26084	458	9	commission	commission	NOUN
ihlr-26084	458	10	’s	’s	PART
ihlr-26084	458	11	decision	decision	NOUN
ihlr-26084	458	12	with	with	ADP
ihlr-26084	458	13	respect	respect	NOUN
ihlr-26084	458	14	to	to	ADP
ihlr-26084	458	15	four	four	NUM
ihlr-26084	458	16	of	of	ADP
ihlr-26084	458	17	the	the	DET
ihlr-26084	458	18	five	five	NUM
ihlr-26084	458	19	generics	generic	NOUN
ihlr-26084	458	20	based	base	VERB
ihlr-26084	458	21	on	on	ADP
ihlr-26084	458	22	the	the	DET
ihlr-26084	458	23	object	object	NOUN
ihlr-26084	458	24	of	of	ADP
ihlr-26084	458	25	the	the	DET
ihlr-26084	458	26	agreements.130	agreements.130	NOUN
ihlr-26084	458	27	it	it	PRON
ihlr-26084	458	28	confirmed	confirm	VERB
ihlr-26084	458	29	the	the	DET
ihlr-26084	458	30	amount	amount	NOUN
ihlr-26084	458	31	of	of	ADP
ihlr-26084	458	32	servier	servier	NOUN
ihlr-26084	458	33	’s	’s	PART
ihlr-26084	458	34	fine	fine	ADJ
ihlr-26084	458	35	with	with	ADP
ihlr-26084	458	36	respect	respect	NOUN
ihlr-26084	458	37	to	to	ADP
ihlr-26084	458	38	three	three	NUM
ihlr-26084	458	39	agreements	agreement	NOUN
ihlr-26084	458	40	and	and	CCONJ
ihlr-26084	458	41	reduced	reduce	VERB
ihlr-26084	458	42	it	it	PRON
ihlr-26084	458	43	with	with	ADP
ihlr-26084	458	44	respect	respect	NOUN
ihlr-26084	458	45	to	to	ADP
ihlr-26084	458	46	the	the	DET
ihlr-26084	458	47	fourth	fourth	ADJ
ihlr-26084	458	48	agreement	agreement	NOUN
ihlr-26084	458	49	(	(	PUNCT
ihlr-26084	458	50	with	with	ADP
ihlr-26084	458	51	matrix	matrix	NOUN
ihlr-26084	458	52	)	)	PUNCT
ihlr-26084	458	53	.	.	PUNCT
ihlr-26084	459	1	the	the	DET
ihlr-26084	459	2	general	general	ADJ
ihlr-26084	459	3	court	court	NOUN
ihlr-26084	459	4	focused	focus	VERB
ihlr-26084	459	5	on	on	ADP
ihlr-26084	459	6	the	the	DET
ihlr-26084	459	7	commission	commission	NOUN
ihlr-26084	459	8	’s	’s	PART
ihlr-26084	459	9	findings	finding	NOUN
ihlr-26084	459	10	to	to	PART
ihlr-26084	459	11	conclude	conclude	VERB
ihlr-26084	459	12	that	that	SCONJ
ihlr-26084	459	13	the	the	DET
ihlr-26084	459	14	agreement	agreement	NOUN
ihlr-26084	459	15	had	have	VERB
ihlr-26084	459	16	an	an	DET
ihlr-26084	459	17	anticompetitive	anticompetitive	ADJ
ihlr-26084	459	18	object	object	NOUN
ihlr-26084	459	19	.	.	PUNCT
ihlr-26084	460	1	the	the	DET
ihlr-26084	460	2	court	court	NOUN
ihlr-26084	460	3	stated	state	VERB
ihlr-26084	460	4	that	that	SCONJ
ihlr-26084	460	5	the	the	DET
ihlr-26084	460	6	commission	commission	NOUN
ihlr-26084	460	7	121	121	NUM
ihlr-26084	460	8	.	.	PUNCT
ihlr-26084	461	1	case	case	NOUN
ihlr-26084	461	2	t-472/13	t-472/13	NOUN
ihlr-26084	461	3	at	at	ADP
ihlr-26084	461	4	¶¶	¶¶	PROPN
ihlr-26084	461	5	478	478	NUM
ihlr-26084	461	6	-	-	SYM
ihlr-26084	461	7	501	501	NUM
ihlr-26084	461	8	(	(	PUNCT
ihlr-26084	461	9	“	"	PUNCT
ihlr-26084	461	10	in	in	ADP
ihlr-26084	461	11	that	that	DET
ihlr-26084	461	12	respect	respect	NOUN
ihlr-26084	461	13	,	,	PUNCT
ihlr-26084	461	14	even	even	ADV
ihlr-26084	461	15	if	if	SCONJ
ihlr-26084	461	16	the	the	DET
ihlr-26084	461	17	agreements	agreement	NOUN
ihlr-26084	461	18	at	at	ADP
ihlr-26084	461	19	issue	issue	NOUN
ihlr-26084	461	20	also	also	ADV
ihlr-26084	461	21	contained	contain	VERB
ihlr-26084	461	22	restrictions	restriction	NOUN
ihlr-26084	461	23	potentially	potentially	ADV
ihlr-26084	461	24	falling	fall	VERB
ihlr-26084	461	25	within	within	ADP
ihlr-26084	461	26	the	the	DET
ihlr-26084	461	27	scope	scope	NOUN
ihlr-26084	461	28	of	of	ADP
ihlr-26084	461	29	the	the	DET
ihlr-26084	461	30	applicants	applicant	NOUN
ihlr-26084	461	31	’	'	PUNCT
ihlr-26084	461	32	patents	patent	NOUN
ihlr-26084	461	33	,	,	PUNCT
ihlr-26084	461	34	those	those	DET
ihlr-26084	461	35	agreements	agreement	NOUN
ihlr-26084	461	36	went	go	VERB
ihlr-26084	461	37	beyond	beyond	ADP
ihlr-26084	461	38	the	the	DET
ihlr-26084	461	39	specific	specific	ADJ
ihlr-26084	461	40	subject	subject	NOUN
ihlr-26084	461	41	matter	matter	NOUN
ihlr-26084	461	42	of	of	ADP
ihlr-26084	461	43	their	their	PRON
ihlr-26084	461	44	intellectual	intellectual	ADJ
ihlr-26084	461	45	property	property	NOUN
ihlr-26084	461	46	rights	right	NOUN
ihlr-26084	461	47	,	,	PUNCT
ihlr-26084	461	48	which	which	PRON
ihlr-26084	461	49	indeed	indeed	ADV
ihlr-26084	461	50	included	include	VERB
ihlr-26084	461	51	the	the	DET
ihlr-26084	461	52	right	right	NOUN
ihlr-26084	461	53	to	to	PART
ihlr-26084	461	54	oppose	oppose	VERB
ihlr-26084	461	55	infringements	infringement	NOUN
ihlr-26084	461	56	,	,	PUNCT
ihlr-26084	461	57	but	but	CCONJ
ihlr-26084	461	58	not	not	PART
ihlr-26084	461	59	the	the	DET
ihlr-26084	461	60	right	right	NOUN
ihlr-26084	461	61	to	to	PART
ihlr-26084	461	62	conclude	conclude	VERB
ihlr-26084	461	63	agreements	agreement	NOUN
ihlr-26084	461	64	by	by	ADP
ihlr-26084	461	65	which	which	PRON
ihlr-26084	461	66	actual	actual	ADJ
ihlr-26084	461	67	or	or	CCONJ
ihlr-26084	461	68	potential	potential	ADJ
ihlr-26084	461	69	competitors	competitor	NOUN
ihlr-26084	461	70	were	be	AUX
ihlr-26084	461	71	paid	pay	VERB
ihlr-26084	461	72	not	not	PART
ihlr-26084	461	73	to	to	PART
ihlr-26084	461	74	enter	enter	VERB
ihlr-26084	461	75	the	the	DET
ihlr-26084	461	76	market	market	NOUN
ihlr-26084	461	77	.	.	PUNCT
ihlr-26084	461	78	”	"	PUNCT
ihlr-26084	461	79	)	)	PUNCT
ihlr-26084	461	80	.	.	PUNCT
ihlr-26084	462	1	122	122	NUM
ihlr-26084	462	2	.	.	PUNCT
ihlr-26084	463	1	i	i	PRON
ihlr-26084	463	2	d.	d.	PROPN
ihlr-26084	463	3	at	at	ADP
ihlr-26084	463	4	¶¶	¶¶	PROPN
ihlr-26084	463	5	418	418	NUM
ihlr-26084	463	6	-	-	SYM
ihlr-26084	463	7	40	40	NUM
ihlr-26084	463	8	.	.	PUNCT
ihlr-26084	464	1	123	123	NUM
ihlr-26084	464	2	.	.	PUNCT
ihlr-26084	465	1	i	i	PRON
ihlr-26084	465	2	d.	d.	PROPN
ihlr-26084	465	3	at	at	ADP
ihlr-26084	465	4	¶¶	¶¶	PROPN
ihlr-26084	465	5	88	88	NUM
ihlr-26084	465	6	-	-	SYM
ihlr-26084	465	7	330	330	NUM
ihlr-26084	465	8	.	.	PUNCT
ihlr-26084	465	9	124	124	NUM
ihlr-26084	465	10	.	.	PUNCT
ihlr-26084	466	1	i	i	PRON
ihlr-26084	466	2	d.	d.	PROPN
ihlr-26084	466	3	at	at	ADP
ihlr-26084	466	4	¶	¶	PROPN
ihlr-26084	466	5	131	131	NUM
ihlr-26084	466	6	.	.	PUNCT
ihlr-26084	467	1	125	125	NUM
ihlr-26084	467	2	.	.	PUNCT
ihlr-26084	468	1	i	i	PRON
ihlr-26084	468	2	d.	d.	PROPN
ihlr-26084	468	3	at	at	ADP
ihlr-26084	468	4	¶	¶	PROPN
ihlr-26084	468	5	181	181	NUM
ihlr-26084	468	6	.	.	PUNCT
ihlr-26084	469	1	126	126	NUM
ihlr-26084	469	2	.	.	PUNCT
ihlr-26084	470	1	i	i	PRON
ihlr-26084	470	2	d.	d.	PROPN
ihlr-26084	470	3	at	at	ADP
ihlr-26084	470	4	¶¶	¶¶	PROPN
ihlr-26084	470	5	353	353	NUM
ihlr-26084	470	6	,	,	PUNCT
ihlr-26084	470	7	492	492	NUM
ihlr-26084	470	8	-	-	SYM
ihlr-26084	470	9	93	93	NUM
ihlr-26084	470	10	(	(	PUNCT
ihlr-26084	470	11	citing	cite	VERB
ihlr-26084	470	12	actavis	actavis	NOUN
ihlr-26084	470	13	to	to	PART
ihlr-26084	470	14	support	support	VERB
ihlr-26084	470	15	its	its	PRON
ihlr-26084	470	16	rejection	rejection	NOUN
ihlr-26084	470	17	of	of	ADP
ihlr-26084	470	18	the	the	DET
ihlr-26084	470	19	patent	patent	NOUN
ihlr-26084	470	20	scope	scope	NOUN
ihlr-26084	470	21	test	test	NOUN
ihlr-26084	470	22	)	)	PUNCT
ihlr-26084	470	23	.	.	PUNCT
ihlr-26084	471	1	127	127	NUM
ihlr-26084	471	2	.	.	PUNCT
ihlr-26084	471	3	case	case	NOUN
ihlr-26084	471	4	at.39685	at.39685	PROPN
ihlr-26084	471	5	–	–	PUNCT
ihlr-26084	471	6	fentanyl	fentanyl	NOUN
ihlr-26084	471	7	.	.	PUNCT
ihlr-26084	472	1	128	128	NUM
ihlr-26084	472	2	.	.	PUNCT
ihlr-26084	472	3	case	case	NOUN
ihlr-26084	472	4	at.39612	at.39612	PROPN
ihlr-26084	472	5	–	–	PUNCT
ihlr-26084	472	6	perindopril	perindopril	ADJ
ihlr-26084	472	7	(	(	PUNCT
ihlr-26084	472	8	servier	servier	NOUN
ihlr-26084	472	9	)	)	PUNCT
ihlr-26084	472	10	129	129	NUM
ihlr-26084	472	11	.	.	PUNCT
ihlr-26084	473	1	catch	catch	VERB
ihlr-26084	473	2	-	-	PUNCT
ihlr-26084	473	3	and	and	CCONJ
ihlr-26084	473	4	-	-	PUNCT
ihlr-26084	473	5	kill	kill	VERB
ihlr-26084	473	6	or	or	CCONJ
ihlr-26084	473	7	“	"	PUNCT
ihlr-26084	473	8	killer	killer	NOUN
ihlr-26084	473	9	acquisitions	acquisition	NOUN
ihlr-26084	473	10	”	"	PUNCT
ihlr-26084	473	11	refers	refer	VERB
ihlr-26084	473	12	to	to	ADP
ihlr-26084	473	13	purchasing	purchase	VERB
ihlr-26084	473	14	and	and	CCONJ
ihlr-26084	473	15	shutting	shut	VERB
ihlr-26084	473	16	down	down	ADP
ihlr-26084	473	17	a	a	DET
ihlr-26084	473	18	competitor	competitor	NOUN
ihlr-26084	473	19	before	before	SCONJ
ihlr-26084	473	20	they	they	PRON
ihlr-26084	473	21	can	can	AUX
ihlr-26084	473	22	start	start	VERB
ihlr-26084	473	23	marketing	market	VERB
ihlr-26084	473	24	the	the	DET
ihlr-26084	473	25	product	product	NOUN
ihlr-26084	473	26	.	.	PUNCT
ihlr-26084	474	1	see	see	VERB
ihlr-26084	474	2	e.g.	e.g.	ADV
ihlr-26084	474	3	,	,	PUNCT
ihlr-26084	474	4	colleen	colleen	PROPN
ihlr-26084	474	5	cunningham	cunningham	PROPN
ihlr-26084	474	6	et	et	PROPN
ihlr-26084	474	7	al	al	PROPN
ihlr-26084	474	8	.	.	PROPN
ihlr-26084	474	9	,	,	PUNCT
ihlr-26084	474	10	killer	killer	NOUN
ihlr-26084	474	11	acquisitions	acquisition	NOUN
ihlr-26084	474	12	,	,	PUNCT
ihlr-26084	474	13	3	3	NUM
ihlr-26084	474	14	j.	j.	PROPN
ihlr-26084	474	15	pol	pol	PROPN
ihlr-26084	474	16	.	.	PUNCT
ihlr-26084	474	17	econ	econ	PROPN
ihlr-26084	474	18	.	.	PUNCT
ihlr-26084	475	1	129	129	NUM
ihlr-26084	475	2	,	,	PUNCT
ihlr-26084	475	3	649	649	NUM
ihlr-26084	475	4	-	-	SYM
ihlr-26084	475	5	702	702	NUM
ihlr-26084	475	6	(	(	PUNCT
ihlr-26084	475	7	2021	2021	NUM
ihlr-26084	475	8	)	)	PUNCT
ihlr-26084	475	9	.	.	PUNCT
ihlr-26084	476	1	130	130	NUM
ihlr-26084	476	2	.	.	PUNCT
ihlr-26084	476	3	case	case	NOUN
ihlr-26084	476	4	t-691/14	t-691/14	NOUN
ihlr-26084	476	5	.	.	PUNCT
ihlr-26084	477	1	2022	2022	NUM
ihlr-26084	477	2	]	]	PUNCT
ihlr-26084	477	3	reverse	reverse	ADJ
ihlr-26084	477	4	payment	payment	NOUN
ihlr-26084	477	5	:	:	PUNCT
ihlr-26084	477	6	a	a	DET
ihlr-26084	477	7	comparative	comparative	ADJ
ihlr-26084	477	8	study	study	NOUN
ihlr-26084	477	9	39	39	NUM
ihlr-26084	477	10	rightly	rightly	ADV
ihlr-26084	477	11	considered	consider	VERB
ihlr-26084	477	12	(	(	PUNCT
ihlr-26084	477	13	1	1	NUM
ihlr-26084	477	14	)	)	PUNCT
ihlr-26084	477	15	“	"	PUNCT
ihlr-26084	477	16	transfer	transfer	NOUN
ihlr-26084	477	17	of	of	ADP
ihlr-26084	477	18	value	value	NOUN
ihlr-26084	477	19	from	from	ADP
ihlr-26084	477	20	the	the	DET
ihlr-26084	477	21	originator	originator	NOUN
ihlr-26084	477	22	company	company	NOUN
ihlr-26084	477	23	to	to	ADP
ihlr-26084	477	24	the	the	DET
ihlr-26084	477	25	generic	generic	ADJ
ihlr-26084	477	26	company	company	NOUN
ihlr-26084	477	27	”	"	PUNCT
ihlr-26084	477	28	;	;	PUNCT
ihlr-26084	477	29	(	(	PUNCT
ihlr-26084	477	30	2	2	X
ihlr-26084	477	31	)	)	PUNCT
ihlr-26084	477	32	whether	whether	SCONJ
ihlr-26084	477	33	the	the	DET
ihlr-26084	477	34	parties	party	NOUN
ihlr-26084	477	35	were	be	AUX
ihlr-26084	477	36	“	"	PUNCT
ihlr-26084	477	37	potential	potential	ADJ
ihlr-26084	477	38	competitors	competitor	NOUN
ihlr-26084	477	39	”	"	PUNCT
ihlr-26084	477	40	;	;	PUNCT
ihlr-26084	477	41	(	(	PUNCT
ihlr-26084	477	42	3	3	X
ihlr-26084	477	43	)	)	PUNCT
ihlr-26084	477	44	“	"	PUNCT
ihlr-26084	477	45	whether	whether	SCONJ
ihlr-26084	477	46	those	those	DET
ihlr-26084	477	47	settlements	settlement	NOUN
ihlr-26084	477	48	included	include	VERB
ihlr-26084	477	49	non	non	ADJ
ihlr-26084	477	50	-	-	ADJ
ihlr-26084	477	51	challenge	challenge	ADJ
ihlr-26084	477	52	and	and	CCONJ
ihlr-26084	477	53	non	non	ADJ
ihlr-26084	477	54	-	-	ADJ
ihlr-26084	477	55	marketing	marketing	ADJ
ihlr-26084	477	56	clauses	clause	NOUN
ihlr-26084	477	57	”	"	PUNCT
ihlr-26084	477	58	;	;	PUNCT
ihlr-26084	477	59	and	and	CCONJ
ihlr-26084	477	60	(	(	PUNCT
ihlr-26084	477	61	4	4	X
ihlr-26084	477	62	)	)	PUNCT
ihlr-26084	477	63	whether	whether	SCONJ
ihlr-26084	477	64	the	the	DET
ihlr-26084	477	65	parties	party	NOUN
ihlr-26084	477	66	signed	sign	VERB
ihlr-26084	477	67	to	to	ADP
ihlr-26084	477	68	these	these	DET
ihlr-26084	477	69	non	non	ADJ
ihlr-26084	477	70	-	-	ADJ
ihlr-26084	477	71	marketing	marketing	ADJ
ihlr-26084	477	72	and	and	CCONJ
ihlr-26084	477	73	non	non	ADJ
ihlr-26084	477	74	-	-	ADJ
ihlr-26084	477	75	challenge	challenge	ADJ
ihlr-26084	477	76	clauses	clause	NOUN
ihlr-26084	477	77	“	"	PUNCT
ihlr-26084	477	78	in	in	ADP
ihlr-26084	477	79	return	return	NOUN
ihlr-26084	477	80	for	for	ADP
ihlr-26084	477	81	a	a	DET
ihlr-26084	477	82	transfer	transfer	NOUN
ihlr-26084	477	83	of	of	ADP
ihlr-26084	477	84	value	value	NOUN
ihlr-26084	477	85	.	.	PUNCT
ihlr-26084	477	86	”131	”131	PUNCT
ihlr-26084	478	1	the	the	DET
ihlr-26084	478	2	general	general	ADJ
ihlr-26084	478	3	court	court	NOUN
ihlr-26084	478	4	also	also	ADV
ihlr-26084	478	5	focused	focus	VERB
ihlr-26084	478	6	on	on	ADP
ihlr-26084	478	7	the	the	DET
ihlr-26084	478	8	existence	existence	NOUN
ihlr-26084	478	9	of	of	ADP
ihlr-26084	478	10	“	"	PUNCT
ihlr-26084	478	11	side	side	ADJ
ihlr-26084	478	12	deals	deal	NOUN
ihlr-26084	478	13	”	"	PUNCT
ihlr-26084	478	14	that	that	PRON
ihlr-26084	478	15	can	can	AUX
ihlr-26084	478	16	be	be	AUX
ihlr-26084	478	17	used	use	VERB
ihlr-26084	478	18	to	to	PART
ihlr-26084	478	19	induce	induce	VERB
ihlr-26084	478	20	the	the	DET
ihlr-26084	478	21	parties	party	NOUN
ihlr-26084	478	22	to	to	PART
ihlr-26084	478	23	sign	sign	VERB
ihlr-26084	478	24	onto	onto	ADP
ihlr-26084	478	25	those	those	PRON
ihlr-26084	478	26	agreements.132	agreements.132	NUM
ihlr-26084	478	27	the	the	DET
ihlr-26084	478	28	court	court	NOUN
ihlr-26084	478	29	acknowledged	acknowledge	VERB
ihlr-26084	478	30	that	that	SCONJ
ihlr-26084	478	31	the	the	DET
ihlr-26084	478	32	commission	commission	NOUN
ihlr-26084	478	33	would	would	AUX
ihlr-26084	478	34	struggle	struggle	VERB
ihlr-26084	478	35	making	making	NOUN
ihlr-26084	478	36	connections	connection	NOUN
ihlr-26084	478	37	between	between	ADP
ihlr-26084	478	38	side	side	NOUN
ihlr-26084	478	39	deals	deal	NOUN
ihlr-26084	478	40	unless	unless	SCONJ
ihlr-26084	478	41	they	they	PRON
ihlr-26084	478	42	are	be	AUX
ihlr-26084	478	43	“	"	PUNCT
ihlr-26084	478	44	concluded	conclude	VERB
ihlr-26084	478	45	on	on	ADP
ihlr-26084	478	46	the	the	DET
ihlr-26084	478	47	same	same	ADJ
ihlr-26084	478	48	day	day	NOUN
ihlr-26084	478	49	,	,	PUNCT
ihlr-26084	478	50	where	where	SCONJ
ihlr-26084	478	51	they	they	PRON
ihlr-26084	478	52	are	be	AUX
ihlr-26084	478	53	legally	legally	ADV
ihlr-26084	478	54	linked	link	VERB
ihlr-26084	478	55	,	,	PUNCT
ihlr-26084	478	56	the	the	DET
ihlr-26084	478	57	binding	bind	VERB
ihlr-26084	478	58	nature	nature	NOUN
ihlr-26084	478	59	of	of	ADP
ihlr-26084	478	60	one	one	NUM
ihlr-26084	478	61	of	of	ADP
ihlr-26084	478	62	the	the	DET
ihlr-26084	478	63	agreements	agreement	NOUN
ihlr-26084	478	64	being	be	AUX
ihlr-26084	478	65	conditional	conditional	ADJ
ihlr-26084	478	66	upon	upon	SCONJ
ihlr-26084	478	67	the	the	DET
ihlr-26084	478	68	conclusion	conclusion	NOUN
ihlr-26084	478	69	of	of	ADP
ihlr-26084	478	70	the	the	DET
ihlr-26084	478	71	other	other	ADJ
ihlr-26084	478	72	agreement	agreement	NOUN
ihlr-26084	478	73	,	,	PUNCT
ihlr-26084	478	74	or	or	CCONJ
ihlr-26084	478	75	.	.	PUNCT
ihlr-26084	478	76	.	.	PUNCT
ihlr-26084	478	77	.	.	PUNCT
ihlr-26084	479	1	they	they	PRON
ihlr-26084	479	2	are	be	AUX
ihlr-26084	479	3	indissociable	indissociable	ADJ
ihlr-26084	479	4	.	.	PUNCT
ihlr-26084	480	1	”133	”133	VERB
ihlr-26084	480	2	the	the	DET
ihlr-26084	480	3	general	general	ADJ
ihlr-26084	480	4	court	court	NOUN
ihlr-26084	480	5	spent	spend	VERB
ihlr-26084	480	6	a	a	DET
ihlr-26084	480	7	lot	lot	NOUN
ihlr-26084	480	8	of	of	ADP
ihlr-26084	480	9	time	time	NOUN
ihlr-26084	480	10	on	on	ADP
ihlr-26084	480	11	appeal	appeal	NOUN
ihlr-26084	480	12	establishing	establish	VERB
ihlr-26084	480	13	the	the	DET
ihlr-26084	480	14	market	market	NOUN
ihlr-26084	480	15	definition	definition	NOUN
ihlr-26084	480	16	and	and	CCONJ
ihlr-26084	480	17	discussing	discuss	VERB
ihlr-26084	480	18	whether	whether	SCONJ
ihlr-26084	480	19	the	the	DET
ihlr-26084	480	20	non	non	ADJ
ihlr-26084	480	21	-	-	ADJ
ihlr-26084	480	22	identical	identical	ADJ
ihlr-26084	480	23	generics	generic	NOUN
ihlr-26084	480	24	compete	compete	VERB
ihlr-26084	480	25	with	with	ADP
ihlr-26084	480	26	the	the	DET
ihlr-26084	480	27	branded	brand	VERB
ihlr-26084	480	28	products	product	NOUN
ihlr-26084	480	29	.	.	PUNCT
ihlr-26084	481	1	the	the	DET
ihlr-26084	481	2	former	former	ADJ
ihlr-26084	481	3	question	question	NOUN
ihlr-26084	481	4	focused	focus	VERB
ihlr-26084	481	5	on	on	ADP
ihlr-26084	481	6	treatment;134	treatment;134	PROPN
ihlr-26084	481	7	but	but	CCONJ
ihlr-26084	481	8	the	the	DET
ihlr-26084	481	9	court	court	NOUN
ihlr-26084	481	10	found	find	VERB
ihlr-26084	481	11	that	that	SCONJ
ihlr-26084	481	12	me	i	PRON
ihlr-26084	481	13	-	-	PUNCT
ihlr-26084	481	14	too	too	ADV
ihlr-26084	481	15	drugs	drug	NOUN
ihlr-26084	481	16	“	"	PUNCT
ihlr-26084	481	17	exercised	exercise	VERB
ihlr-26084	481	18	little	little	ADJ
ihlr-26084	481	19	pressure	pressure	NOUN
ihlr-26084	481	20	on	on	ADP
ihlr-26084	481	21	the	the	DET
ihlr-26084	481	22	prices	price	NOUN
ihlr-26084	481	23	of	of	ADP
ihlr-26084	481	24	”	"	PUNCT
ihlr-26084	481	25	the	the	DET
ihlr-26084	481	26	patented	patent	VERB
ihlr-26084	481	27	drug.135	drug.135	NOUN
ihlr-26084	481	28	in	in	ADP
ihlr-26084	481	29	the	the	DET
ihlr-26084	481	30	latter	latter	ADJ
ihlr-26084	481	31	inquiry	inquiry	NOUN
ihlr-26084	481	32	,	,	PUNCT
ihlr-26084	481	33	the	the	DET
ihlr-26084	481	34	court	court	NOUN
ihlr-26084	481	35	found	find	VERB
ihlr-26084	481	36	medications	medication	NOUN
ihlr-26084	481	37	–	–	PUNCT
ihlr-26084	481	38	generics	generic	NOUN
ihlr-26084	481	39	included	include	VERB
ihlr-26084	481	40	–	–	PUNCT
ihlr-26084	481	41	with	with	SCONJ
ihlr-26084	481	42	the	the	DET
ihlr-26084	481	43	same	same	ADJ
ihlr-26084	481	44	active	active	ADJ
ihlr-26084	481	45	ingredients	ingredient	NOUN
ihlr-26084	481	46	may	may	AUX
ihlr-26084	481	47	be	be	AUX
ihlr-26084	481	48	considered	consider	VERB
ihlr-26084	481	49	competitors.136	competitors.136	NOUN
ihlr-26084	481	50	these	these	DET
ihlr-26084	481	51	cases	case	NOUN
ihlr-26084	481	52	show	show	VERB
ihlr-26084	481	53	that	that	SCONJ
ihlr-26084	481	54	the	the	DET
ihlr-26084	481	55	commission	commission	NOUN
ihlr-26084	481	56	has	have	AUX
ihlr-26084	481	57	taken	take	VERB
ihlr-26084	481	58	an	an	DET
ihlr-26084	481	59	active	active	ADJ
ihlr-26084	481	60	role	role	NOUN
ihlr-26084	481	61	in	in	ADP
ihlr-26084	481	62	enforcing	enforce	VERB
ihlr-26084	481	63	pay	pay	NOUN
ihlr-26084	481	64	-	-	PUNCT
ihlr-26084	481	65	for	for	ADP
ihlr-26084	481	66	-	-	PUNCT
ihlr-26084	481	67	delay	delay	NOUN
ihlr-26084	481	68	.	.	PUNCT
ihlr-26084	482	1	despite	despite	SCONJ
ihlr-26084	482	2	these	these	DET
ihlr-26084	482	3	cases	case	NOUN
ihlr-26084	482	4	,	,	PUNCT
ihlr-26084	482	5	in	in	ADP
ihlr-26084	482	6	many	many	ADJ
ihlr-26084	482	7	situations	situation	NOUN
ihlr-26084	482	8	,	,	PUNCT
ihlr-26084	482	9	pay	pay	NOUN
ihlr-26084	482	10	-	-	PUNCT
ihlr-26084	482	11	for	for	ADP
ihlr-26084	482	12	-	-	PUNCT
ihlr-26084	482	13	delays	delay	NOUN
ihlr-26084	482	14	do	do	AUX
ihlr-26084	482	15	not	not	PART
ihlr-26084	482	16	have	have	VERB
ihlr-26084	482	17	a	a	DET
ihlr-26084	482	18	european	european	ADJ
ihlr-26084	482	19	dimension	dimension	NOUN
ihlr-26084	482	20	that	that	PRON
ihlr-26084	482	21	would	would	AUX
ihlr-26084	482	22	require	require	VERB
ihlr-26084	482	23	the	the	DET
ihlr-26084	482	24	commission	commission	NOUN
ihlr-26084	482	25	’s	’s	PART
ihlr-26084	482	26	involvement	involvement	NOUN
ihlr-26084	482	27	.	.	PUNCT
ihlr-26084	483	1	for	for	ADP
ihlr-26084	483	2	example	example	NOUN
ihlr-26084	483	3	,	,	PUNCT
ihlr-26084	483	4	in	in	ADP
ihlr-26084	483	5	the	the	DET
ihlr-26084	483	6	generics	generic	NOUN
ihlr-26084	483	7	(	(	PUNCT
ihlr-26084	483	8	uk	uk	PROPN
ihlr-26084	483	9	)	)	PUNCT
ihlr-26084	483	10	ltd	ltd	PROPN
ihlr-26084	483	11	et	et	PROPN
ihlr-26084	483	12	al	al	PROPN
ihlr-26084	483	13	.	.	PUNCT
ihlr-26084	484	1	v.	v.	CCONJ
ihlr-26084	484	2	competition	competition	NOUN
ihlr-26084	484	3	and	and	CCONJ
ihlr-26084	484	4	markets	market	VERB
ihlr-26084	484	5	authority137	authority137	PROPN
ihlr-26084	484	6	case	case	NOUN
ihlr-26084	484	7	,	,	PUNCT
ihlr-26084	484	8	the	the	DET
ihlr-26084	484	9	uk	uk	PROPN
ihlr-26084	484	10	competition	competition	NOUN
ihlr-26084	484	11	authority	authority	NOUN
ihlr-26084	484	12	intervened	intervene	VERB
ihlr-26084	484	13	in	in	ADP
ihlr-26084	484	14	a	a	DET
ihlr-26084	484	15	case	case	NOUN
ihlr-26084	484	16	involving	involve	VERB
ihlr-26084	484	17	uk	uk	PROPN
ihlr-26084	484	18	sales.138	sales.138	PROPN
ihlr-26084	484	19	in	in	ADP
ihlr-26084	484	20	this	this	DET
ihlr-26084	484	21	case	case	NOUN
ihlr-26084	484	22	,	,	PUNCT
ihlr-26084	484	23	the	the	DET
ihlr-26084	484	24	patent	patent	NOUN
ihlr-26084	484	25	holder	holder	NOUN
ihlr-26084	484	26	,	,	PUNCT
ihlr-26084	484	27	glaxosmithkline	glaxosmithkline	PROPN
ihlr-26084	484	28	plc	plc	PROPN
ihlr-26084	484	29	(	(	PUNCT
ihlr-26084	484	30	gsk	gsk	PROPN
ihlr-26084	484	31	)	)	PUNCT
ihlr-26084	484	32	,	,	PUNCT
ihlr-26084	484	33	concluded	conclude	VERB
ihlr-26084	484	34	multiple	multiple	ADJ
ihlr-26084	484	35	agreements	agreement	NOUN
ihlr-26084	484	36	with	with	ADP
ihlr-26084	484	37	generic	generic	ADJ
ihlr-26084	484	38	manufacturers	manufacturer	NOUN
ihlr-26084	484	39	who	who	PRON
ihlr-26084	484	40	had	have	AUX
ihlr-26084	484	41	submitted	submit	VERB
ihlr-26084	484	42	or	or	CCONJ
ihlr-26084	484	43	obtained	obtain	VERB
ihlr-26084	484	44	market	market	NOUN
ihlr-26084	484	45	authorization139	authorization139	PROPN
ihlr-26084	484	46	applications	application	NOUN
ihlr-26084	484	47	in	in	ADP
ihlr-26084	484	48	different	different	ADJ
ihlr-26084	484	49	european	european	ADJ
ihlr-26084	484	50	countries	country	NOUN
ihlr-26084	484	51	:	:	PUNCT
ihlr-26084	484	52	ivax	ivax	PROPN
ihlr-26084	484	53	in	in	ADP
ihlr-26084	484	54	ireland	ireland	PROPN
ihlr-26084	484	55	;	;	PUNCT
ihlr-26084	484	56	guk	guk	PROPN
ihlr-26084	484	57	in	in	ADP
ihlr-26084	484	58	denmark	denmark	NOUN
ihlr-26084	484	59	;	;	PUNCT
ihlr-26084	484	60	and	and	CCONJ
ihlr-26084	484	61	alpharma	alpharma	NOUN
ihlr-26084	484	62	in	in	ADP
ihlr-26084	484	63	the	the	DET
ihlr-26084	484	64	uk	uk	PROPN
ihlr-26084	484	65	.	.	PUNCT
ihlr-26084	485	1	the	the	DET
ihlr-26084	485	2	generic	generic	ADJ
ihlr-26084	485	3	manufacturers	manufacturer	NOUN
ihlr-26084	485	4	agreed	agree	VERB
ihlr-26084	485	5	to	to	PART
ihlr-26084	485	6	stop	stop	VERB
ihlr-26084	485	7	ongoing	ongoing	ADJ
ihlr-26084	485	8	challenges	challenge	NOUN
ihlr-26084	485	9	to	to	ADP
ihlr-26084	485	10	gsk	gsk	NOUN
ihlr-26084	485	11	’s	’s	PART
ihlr-26084	485	12	patent	patent	NOUN
ihlr-26084	485	13	in	in	ADP
ihlr-26084	485	14	exchange	exchange	NOUN
ihlr-26084	485	15	for	for	ADP
ihlr-26084	485	16	exclusive	exclusive	ADJ
ihlr-26084	485	17	dealing	dealing	NOUN
ihlr-26084	485	18	agreements	agreement	NOUN
ihlr-26084	485	19	.	.	PUNCT
ihlr-26084	486	1	the	the	DET
ihlr-26084	486	2	uk	uk	PROPN
ihlr-26084	486	3	competition	competition	NOUN
ihlr-26084	486	4	and	and	CCONJ
ihlr-26084	486	5	markets	market	NOUN
ihlr-26084	486	6	authority	authority	NOUN
ihlr-26084	486	7	fined	fine	VERB
ihlr-26084	486	8	these	these	DET
ihlr-26084	486	9	companies	company	NOUN
ihlr-26084	486	10	for	for	ADP
ihlr-26084	486	11	131	131	NUM
ihlr-26084	486	12	.	.	PUNCT
ihlr-26084	487	1	i	i	PRON
ihlr-26084	487	2	d.	d.	PROPN
ihlr-26084	487	3	at	at	ADP
ihlr-26084	487	4	¶	¶	PROPN
ihlr-26084	487	5	406	406	NUM
ihlr-26084	487	6	and	and	CCONJ
ihlr-26084	487	7	affirmed	affirm	VERB
ihlr-26084	487	8	by	by	ADP
ihlr-26084	487	9	the	the	DET
ihlr-26084	487	10	general	general	ADJ
ihlr-26084	487	11	court	court	NOUN
ihlr-26084	487	12	in	in	ADP
ihlr-26084	487	13	¶	¶	PROPN
ihlr-26084	487	14	418	418	NUM
ihlr-26084	487	15	.	.	PUNCT
ihlr-26084	488	1	132	132	NUM
ihlr-26084	488	2	.	.	PUNCT
ihlr-26084	489	1	i	i	PRON
ihlr-26084	489	2	d.	d.	PROPN
ihlr-26084	489	3	at	at	ADP
ihlr-26084	489	4	¶	¶	PROPN
ihlr-26084	489	5	797	797	NUM
ihlr-26084	489	6	.	.	PUNCT
ihlr-26084	490	1	133	133	NUM
ihlr-26084	490	2	.	.	PUNCT
ihlr-26084	491	1	i	i	PRON
ihlr-26084	491	2	d.	d.	PROPN
ihlr-26084	491	3	at	at	ADP
ihlr-26084	491	4	¶	¶	PROPN
ihlr-26084	491	5	798	798	NUM
ihlr-26084	491	6	.	.	PUNCT
ihlr-26084	492	1	134	134	NUM
ihlr-26084	492	2	.	.	PUNCT
ihlr-26084	493	1	i	i	PRON
ihlr-26084	493	2	d.	d.	PROPN
ihlr-26084	493	3	at	at	ADP
ihlr-26084	493	4	¶¶	¶¶	PROPN
ihlr-26084	493	5	123	123	NUM
ihlr-26084	493	6	-	-	SYM
ihlr-26084	493	7	40	40	NUM
ihlr-26084	493	8	.	.	PUNCT
ihlr-26084	493	9	135	135	NUM
ihlr-26084	493	10	.	.	PUNCT
ihlr-26084	494	1	i	i	PRON
ihlr-26084	494	2	d.	d.	PROPN
ihlr-26084	494	3	at	at	ADP
ihlr-26084	494	4	¶	¶	PROPN
ihlr-26084	494	5	125	125	NUM
ihlr-26084	494	6	.	.	PUNCT
ihlr-26084	495	1	136	136	NUM
ihlr-26084	495	2	.	.	PUNCT
ihlr-26084	496	1	i	i	PRON
ihlr-26084	496	2	d.	d.	PROPN
ihlr-26084	496	3	at	at	ADP
ihlr-26084	496	4	¶	¶	PROPN
ihlr-26084	496	5	131	131	NUM
ihlr-26084	496	6	.	.	PUNCT
ihlr-26084	497	1	137	137	NUM
ihlr-26084	497	2	.	.	PUNCT
ihlr-26084	498	1	generics	generic	NOUN
ihlr-26084	498	2	(	(	PUNCT
ihlr-26084	498	3	uk	uk	PROPN
ihlr-26084	498	4	)	)	PUNCT
ihlr-26084	498	5	ltd	ltd	PROPN
ihlr-26084	498	6	.	.	PROPN
ihlr-26084	498	7	,	,	PUNCT
ihlr-26084	498	8	glaxosmithkline	glaxosmithkline	PROPN
ihlr-26084	498	9	plc	plc	PROPN
ihlr-26084	498	10	,	,	PUNCT
ihlr-26084	498	11	xellia	xellia	PROPN
ihlr-26084	498	12	pharmaceuticals	pharmaceuticals	PROPN
ihlr-26084	498	13	aps	ap	NOUN
ihlr-26084	498	14	,	,	PUNCT
ihlr-26084	498	15	alpharma	alpharma	PROPN
ihlr-26084	498	16	llc	llc	PROPN
ihlr-26084	498	17	,	,	PUNCT
ihlr-26084	498	18	formerly	formerly	ADV
ihlr-26084	498	19	zoetis	zoetis	PROPN
ihlr-26084	498	20	products	product	NOUN
ihlr-26084	498	21	llc	llc	PROPN
ihlr-26084	498	22	,	,	PUNCT
ihlr-26084	498	23	actavis	actavis	PROPN
ihlr-26084	498	24	uk	uk	PROPN
ihlr-26084	498	25	ltd	ltd	PROPN
ihlr-26084	498	26	.	.	PROPN
ihlr-26084	498	27	,	,	PUNCT
ihlr-26084	498	28	merck	merck	PROPN
ihlr-26084	498	29	kgaa	kgaa	PROPN
ihlr-26084	498	30	v.	v.	CCONJ
ihlr-26084	498	31	competition	competition	PROPN
ihlr-26084	498	32	&	&	CCONJ
ihlr-26084	498	33	markets	market	NOUN
ihlr-26084	498	34	authority	authority	NOUN
ihlr-26084	498	35	,	,	PUNCT
ihlr-26084	498	36	case	case	NOUN
ihlr-26084	498	37	c-307/18	c-307/18	X
ihlr-26084	498	38	(	(	PUNCT
ihlr-26084	498	39	2020	2020	NUM
ihlr-26084	498	40	)	)	PUNCT
ihlr-26084	498	41	.	.	PUNCT
ihlr-26084	499	1	138	138	NUM
ihlr-26084	499	2	.	.	PUNCT
ihlr-26084	499	3	note	note	VERB
ihlr-26084	499	4	that	that	SCONJ
ihlr-26084	499	5	this	this	DET
ihlr-26084	499	6	case	case	NOUN
ihlr-26084	499	7	was	be	AUX
ihlr-26084	499	8	expedited	expedite	VERB
ihlr-26084	499	9	because	because	SCONJ
ihlr-26084	499	10	of	of	ADP
ihlr-26084	499	11	the	the	DET
ihlr-26084	499	12	uk	uk	PROPN
ihlr-26084	499	13	’s	’s	PART
ihlr-26084	499	14	exit	exit	NOUN
ihlr-26084	499	15	from	from	ADP
ihlr-26084	499	16	the	the	DET
ihlr-26084	499	17	eu	eu	PROPN
ihlr-26084	499	18	.	.	PROPN
ihlr-26084	499	19	139	139	NUM
ihlr-26084	499	20	.	.	PUNCT
ihlr-26084	500	1	drug	drug	NOUN
ihlr-26084	500	2	manufacturers	manufacturer	NOUN
ihlr-26084	500	3	must	must	AUX
ihlr-26084	500	4	seek	seek	VERB
ihlr-26084	500	5	a	a	DET
ihlr-26084	500	6	market	market	NOUN
ihlr-26084	500	7	authorization	authorization	NOUN
ihlr-26084	500	8	from	from	ADP
ihlr-26084	500	9	“	"	PUNCT
ihlr-26084	500	10	the	the	DET
ihlr-26084	500	11	competent	competent	ADJ
ihlr-26084	500	12	authorities	authority	NOUN
ihlr-26084	500	13	of	of	ADP
ihlr-26084	500	14	that	that	DET
ihlr-26084	500	15	member	member	NOUN
ihlr-26084	500	16	state	state	NOUN
ihlr-26084	500	17	.	.	PUNCT
ihlr-26084	500	18	.	.	PUNCT
ihlr-26084	501	1	.	.	PUNCT
ihlr-26084	502	1	in	in	ADP
ihlr-26084	502	2	accordance	accordance	NOUN
ihlr-26084	502	3	with	with	ADP
ihlr-26084	502	4	regulation	regulation	NOUN
ihlr-26084	502	5	”	"	PUNCT
ihlr-26084	502	6	to	to	PART
ihlr-26084	502	7	commercialize	commercialize	VERB
ihlr-26084	502	8	a	a	DET
ihlr-26084	502	9	drug	drug	NOUN
ihlr-26084	502	10	in	in	ADP
ihlr-26084	502	11	the	the	DET
ihlr-26084	502	12	eu	eu	PROPN
ihlr-26084	502	13	.	.	PUNCT
ihlr-26084	503	1	i	i	PRON
ihlr-26084	503	2	d.	d.	PROPN
ihlr-26084	503	3	¶	¶	PROPN
ihlr-26084	503	4	40	40	NUM
ihlr-26084	503	5	.	.	PUNCT
ihlr-26084	504	1	mas	mas	PROPN
ihlr-26084	504	2	ensure	ensure	VERB
ihlr-26084	504	3	the	the	DET
ihlr-26084	504	4	protection	protection	NOUN
ihlr-26084	504	5	of	of	ADP
ihlr-26084	504	6	patients	patient	NOUN
ihlr-26084	504	7	and	and	CCONJ
ihlr-26084	504	8	public	public	ADJ
ihlr-26084	504	9	health	health	NOUN
ihlr-26084	504	10	.	.	PUNCT
ihlr-26084	505	1	i	i	PRON
ihlr-26084	505	2	d.	d.	PROPN
ihlr-26084	505	3	¶	¶	PROPN
ihlr-26084	505	4	139	139	NUM
ihlr-26084	505	5	.	.	PUNCT
ihlr-26084	506	1	patents	patent	NOUN
ihlr-26084	506	2	are	be	AUX
ihlr-26084	506	3	jurisdictional	jurisdictional	ADJ
ihlr-26084	506	4	in	in	ADP
ihlr-26084	506	5	the	the	DET
ihlr-26084	506	6	eu	eu	PROPN
ihlr-26084	506	7	:	:	PUNCT
ihlr-26084	506	8	with	with	ADP
ihlr-26084	506	9	such	such	ADJ
ihlr-26084	506	10	authorization	authorization	NOUN
ihlr-26084	506	11	,	,	PUNCT
ihlr-26084	506	12	the	the	DET
ihlr-26084	506	13	manufacturer	manufacturer	NOUN
ihlr-26084	506	14	can	can	AUX
ihlr-26084	506	15	sell	sell	VERB
ihlr-26084	506	16	across	across	ADP
ihlr-26084	506	17	eu	eu	PROPN
ihlr-26084	506	18	borders	border	NOUN
ihlr-26084	506	19	as	as	ADV
ihlr-26084	506	20	long	long	ADV
ihlr-26084	506	21	as	as	SCONJ
ihlr-26084	506	22	the	the	DET
ihlr-26084	506	23	drug	drug	NOUN
ihlr-26084	506	24	does	do	AUX
ihlr-26084	506	25	not	not	PART
ihlr-26084	506	26	infringe	infringe	VERB
ihlr-26084	506	27	any	any	DET
ihlr-26084	506	28	patents	patent	NOUN
ihlr-26084	506	29	.	.	PUNCT
ihlr-26084	507	1	40	40	NUM
ihlr-26084	507	2	indiana	indiana	PROPN
ihlr-26084	507	3	health	health	PROPN
ihlr-26084	507	4	law	law	PROPN
ihlr-26084	507	5	review	review	NOUN
ihlr-26084	507	6	[	[	X
ihlr-26084	507	7	vol	vol	NOUN
ihlr-26084	507	8	.	.	PUNCT
ihlr-26084	508	1	19:21	19:21	NUM
ihlr-26084	508	2	forming	form	VERB
ihlr-26084	508	3	a	a	DET
ihlr-26084	508	4	cartel	cartel	NOUN
ihlr-26084	508	5	(	(	PUNCT
ihlr-26084	508	6	unlawful	unlawful	ADJ
ihlr-26084	508	7	agreements	agreement	NOUN
ihlr-26084	508	8	and	and	CCONJ
ihlr-26084	508	9	concerted	concerted	ADJ
ihlr-26084	508	10	practices	practice	NOUN
ihlr-26084	508	11	)	)	PUNCT
ihlr-26084	508	12	and	and	CCONJ
ihlr-26084	508	13	gsk	gsk	NOUN
ihlr-26084	508	14	for	for	ADP
ihlr-26084	508	15	abusing	abuse	VERB
ihlr-26084	508	16	its	its	PRON
ihlr-26084	508	17	dominant	dominant	ADJ
ihlr-26084	508	18	position	position	NOUN
ihlr-26084	508	19	.	.	PUNCT
ihlr-26084	509	1	the	the	DET
ihlr-26084	509	2	parties	party	NOUN
ihlr-26084	509	3	appealed	appeal	VERB
ihlr-26084	509	4	the	the	DET
ihlr-26084	509	5	decision	decision	NOUN
ihlr-26084	509	6	to	to	ADP
ihlr-26084	509	7	the	the	DET
ihlr-26084	509	8	competition	competition	NOUN
ihlr-26084	509	9	appeal	appeal	NOUN
ihlr-26084	509	10	tribunal	tribunal	NOUN
ihlr-26084	509	11	who	who	PRON
ihlr-26084	509	12	referred	refer	VERB
ihlr-26084	509	13	some	some	DET
ihlr-26084	509	14	questions	question	NOUN
ihlr-26084	509	15	to	to	ADP
ihlr-26084	509	16	the	the	DET
ihlr-26084	509	17	general	general	ADJ
ihlr-26084	509	18	court	court	NOUN
ihlr-26084	509	19	of	of	ADP
ihlr-26084	509	20	the	the	DET
ihlr-26084	509	21	european	european	PROPN
ihlr-26084	509	22	union	union	PROPN
ihlr-26084	509	23	.	.	PUNCT
ihlr-26084	510	1	first	first	ADV
ihlr-26084	510	2	,	,	PUNCT
ihlr-26084	510	3	the	the	DET
ihlr-26084	510	4	appeal	appeal	NOUN
ihlr-26084	510	5	tribunal	tribunal	NOUN
ihlr-26084	510	6	asked	ask	VERB
ihlr-26084	510	7	:	:	PUNCT
ihlr-26084	510	8	“	"	PUNCT
ihlr-26084	510	9	for	for	ADP
ihlr-26084	510	10	the	the	DET
ihlr-26084	510	11	purpose	purpose	NOUN
ihlr-26084	510	12	of	of	ADP
ihlr-26084	510	13	article	article	NOUN
ihlr-26084	510	14	101(1	101(1	NUM
ihlr-26084	510	15	)	)	PUNCT
ihlr-26084	511	1	[	[	X
ihlr-26084	511	2	tfeu	tfeu	VERB
ihlr-26084	511	3	]	]	PUNCT
ihlr-26084	511	4	,	,	PUNCT
ihlr-26084	511	5	are	be	AUX
ihlr-26084	511	6	the	the	DET
ihlr-26084	511	7	holder	holder	NOUN
ihlr-26084	511	8	of	of	ADP
ihlr-26084	511	9	a	a	DET
ihlr-26084	511	10	patent	patent	NOUN
ihlr-26084	511	11	for	for	ADP
ihlr-26084	511	12	a	a	DET
ihlr-26084	511	13	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	511	14	drug	drug	NOUN
ihlr-26084	511	15	and	and	CCONJ
ihlr-26084	511	16	a	a	DET
ihlr-26084	511	17	generic	generic	ADJ
ihlr-26084	511	18	company	company	NOUN
ihlr-26084	511	19	seeking	seek	VERB
ihlr-26084	511	20	to	to	PART
ihlr-26084	511	21	enter	enter	VERB
ihlr-26084	511	22	the	the	DET
ihlr-26084	511	23	market	market	NOUN
ihlr-26084	511	24	with	with	ADP
ihlr-26084	511	25	a	a	DET
ihlr-26084	511	26	generic	generic	ADJ
ihlr-26084	511	27	version	version	NOUN
ihlr-26084	511	28	of	of	ADP
ihlr-26084	511	29	the	the	DET
ihlr-26084	511	30	drug	drug	NOUN
ihlr-26084	511	31	to	to	PART
ihlr-26084	511	32	be	be	AUX
ihlr-26084	511	33	regarded	regard	VERB
ihlr-26084	511	34	as	as	ADP
ihlr-26084	511	35	potential	potential	ADJ
ihlr-26084	511	36	competitors	competitor	NOUN
ihlr-26084	511	37	when	when	SCONJ
ihlr-26084	511	38	the	the	DET
ihlr-26084	511	39	parties	party	NOUN
ihlr-26084	511	40	are	be	AUX
ihlr-26084	511	41	in	in	ADP
ihlr-26084	511	42	bona	bona	ADJ
ihlr-26084	511	43	fide	fide	ADJ
ihlr-26084	511	44	dispute	dispute	NOUN
ihlr-26084	511	45	as	as	ADP
ihlr-26084	511	46	to	to	ADP
ihlr-26084	511	47	whether	whether	SCONJ
ihlr-26084	511	48	the	the	DET
ihlr-26084	511	49	patent	patent	NOUN
ihlr-26084	511	50	is	be	AUX
ihlr-26084	511	51	valid	valid	ADJ
ihlr-26084	511	52	and/or	and/or	CCONJ
ihlr-26084	511	53	the	the	DET
ihlr-26084	511	54	generic	generic	ADJ
ihlr-26084	511	55	product	product	NOUN
ihlr-26084	511	56	infringes	infringe	VERB
ihlr-26084	511	57	the	the	DET
ihlr-26084	511	58	patent?”140	patent?”140	PROPN
ihlr-26084	511	59	the	the	DET
ihlr-26084	511	60	uk	uk	PROPN
ihlr-26084	511	61	appeal	appeal	NOUN
ihlr-26084	511	62	tribunal	tribunal	NOUN
ihlr-26084	511	63	added	add	VERB
ihlr-26084	511	64	further	further	ADJ
ihlr-26084	511	65	sub	sub	NOUN
ihlr-26084	511	66	-	-	NOUN
ihlr-26084	511	67	questions	question	NOUN
ihlr-26084	511	68	to	to	ADP
ihlr-26084	511	69	the	the	DET
ihlr-26084	511	70	general	general	ADJ
ihlr-26084	511	71	court	court	NOUN
ihlr-26084	511	72	of	of	ADP
ihlr-26084	511	73	the	the	DET
ihlr-26084	511	74	european	european	PROPN
ihlr-26084	511	75	union	union	PROPN
ihlr-26084	511	76	.	.	PUNCT
ihlr-26084	512	1	first	first	ADV
ihlr-26084	512	2	,	,	PUNCT
ihlr-26084	512	3	it	it	PRON
ihlr-26084	512	4	asked	ask	VERB
ihlr-26084	512	5	whether	whether	SCONJ
ihlr-26084	512	6	ongoing	ongoing	ADJ
ihlr-26084	512	7	litigations	litigation	NOUN
ihlr-26084	512	8	would	would	AUX
ihlr-26084	512	9	impact	impact	VERB
ihlr-26084	512	10	the	the	DET
ihlr-26084	512	11	anticompetitive	anticompetitive	ADJ
ihlr-26084	512	12	ruling	ruling	NOUN
ihlr-26084	512	13	.	.	PUNCT
ihlr-26084	513	1	if	if	SCONJ
ihlr-26084	513	2	it	it	PRON
ihlr-26084	513	3	did	do	VERB
ihlr-26084	513	4	,	,	PUNCT
ihlr-26084	513	5	the	the	DET
ihlr-26084	513	6	tribunal	tribunal	NOUN
ihlr-26084	513	7	asked	ask	VERB
ihlr-26084	513	8	whether	whether	SCONJ
ihlr-26084	513	9	the	the	DET
ihlr-26084	513	10	probability	probability	NOUN
ihlr-26084	513	11	of	of	ADP
ihlr-26084	513	12	invalidation	invalidation	NOUN
ihlr-26084	513	13	/	/	SYM
ihlr-26084	513	14	success	success	NOUN
ihlr-26084	513	15	,	,	PUNCT
ihlr-26084	513	16	or	or	CCONJ
ihlr-26084	513	17	the	the	DET
ihlr-26084	513	18	duration	duration	NOUN
ihlr-26084	513	19	of	of	ADP
ihlr-26084	513	20	delay	delay	NOUN
ihlr-26084	513	21	versus	versus	ADP
ihlr-26084	513	22	the	the	DET
ihlr-26084	513	23	duration	duration	NOUN
ihlr-26084	513	24	of	of	ADP
ihlr-26084	513	25	patent	patent	NOUN
ihlr-26084	513	26	validity	validity	NOUN
ihlr-26084	513	27	,	,	PUNCT
ihlr-26084	513	28	would	would	AUX
ihlr-26084	513	29	affect	affect	VERB
ihlr-26084	513	30	the	the	DET
ihlr-26084	513	31	anticompetitive	anticompetitive	ADJ
ihlr-26084	513	32	finding	finding	NOUN
ihlr-26084	513	33	.	.	PUNCT
ihlr-26084	514	1	the	the	DET
ihlr-26084	514	2	european	european	PROPN
ihlr-26084	514	3	court	court	PROPN
ihlr-26084	514	4	of	of	ADP
ihlr-26084	514	5	justice	justice	PROPN
ihlr-26084	514	6	refers	refer	VERB
ihlr-26084	514	7	to	to	ADP
ihlr-26084	514	8	this	this	PRON
ihlr-26084	514	9	as	as	ADP
ihlr-26084	514	10	the	the	DET
ihlr-26084	514	11	“	"	PUNCT
ihlr-26084	514	12	effect	effect	NOUN
ihlr-26084	514	13	”	"	PUNCT
ihlr-26084	514	14	of	of	ADP
ihlr-26084	514	15	the	the	DET
ihlr-26084	514	16	agreement.141	agreement.141	NOUN
ihlr-26084	514	17	second	second	NOUN
ihlr-26084	514	18	,	,	PUNCT
ihlr-26084	514	19	it	it	PRON
ihlr-26084	514	20	asked	ask	VERB
ihlr-26084	514	21	whether	whether	SCONJ
ihlr-26084	514	22	the	the	DET
ihlr-26084	514	23	benefit	benefit	NOUN
ihlr-26084	514	24	or	or	CCONJ
ihlr-26084	514	25	payment	payment	NOUN
ihlr-26084	514	26	size	size	NOUN
ihlr-26084	514	27	would	would	AUX
ihlr-26084	514	28	affect	affect	VERB
ihlr-26084	514	29	this	this	DET
ihlr-26084	514	30	finding	finding	NOUN
ihlr-26084	514	31	as	as	SCONJ
ihlr-26084	514	32	compared	compare	VERB
ihlr-26084	514	33	to	to	ADP
ihlr-26084	514	34	:	:	PUNCT
ihlr-26084	514	35	(	(	PUNCT
ihlr-26084	514	36	1	1	X
ihlr-26084	514	37	)	)	PUNCT
ihlr-26084	514	38	the	the	DET
ihlr-26084	514	39	litigation	litigation	NOUN
ihlr-26084	514	40	costs	cost	NOUN
ihlr-26084	514	41	;	;	PUNCT
ihlr-26084	514	42	and	and	CCONJ
ihlr-26084	514	43	(	(	PUNCT
ihlr-26084	514	44	2	2	X
ihlr-26084	514	45	)	)	PUNCT
ihlr-26084	514	46	the	the	DET
ihlr-26084	514	47	potential	potential	ADJ
ihlr-26084	514	48	market	market	NOUN
ihlr-26084	514	49	earnings	earning	NOUN
ihlr-26084	514	50	if	if	SCONJ
ihlr-26084	514	51	the	the	DET
ihlr-26084	514	52	patent	patent	NOUN
ihlr-26084	514	53	is	be	AUX
ihlr-26084	514	54	invalidated	invalidated	ADJ
ihlr-26084	514	55	.	.	PUNCT
ihlr-26084	515	1	the	the	DET
ihlr-26084	515	2	european	european	PROPN
ihlr-26084	515	3	court	court	PROPN
ihlr-26084	515	4	of	of	ADP
ihlr-26084	515	5	justice	justice	PROPN
ihlr-26084	515	6	refers	refer	VERB
ihlr-26084	515	7	to	to	ADP
ihlr-26084	515	8	this	this	PRON
ihlr-26084	515	9	as	as	SCONJ
ihlr-26084	515	10	the	the	DET
ihlr-26084	515	11	“	"	PUNCT
ihlr-26084	515	12	object	object	NOUN
ihlr-26084	515	13	”	"	PUNCT
ihlr-26084	515	14	of	of	ADP
ihlr-26084	515	15	the	the	DET
ihlr-26084	515	16	agreement.142	agreement.142	PROPN
ihlr-26084	515	17	these	these	DET
ihlr-26084	515	18	questions	question	NOUN
ihlr-26084	515	19	mirror	mirror	VERB
ihlr-26084	515	20	the	the	DET
ihlr-26084	515	21	inquiry	inquiry	NOUN
ihlr-26084	515	22	that	that	PRON
ihlr-26084	515	23	took	take	VERB
ihlr-26084	515	24	place	place	NOUN
ihlr-26084	515	25	in	in	ADP
ihlr-26084	515	26	us	us	PROPN
ihlr-26084	515	27	courts	court	NOUN
ihlr-26084	515	28	.	.	PUNCT
ihlr-26084	516	1	the	the	DET
ihlr-26084	516	2	general	general	ADJ
ihlr-26084	516	3	court	court	NOUN
ihlr-26084	516	4	found	find	VERB
ihlr-26084	516	5	that	that	SCONJ
ihlr-26084	516	6	reverse	reverse	ADJ
ihlr-26084	516	7	payment	payment	NOUN
ihlr-26084	516	8	can	can	AUX
ihlr-26084	516	9	amount	amount	VERB
ihlr-26084	516	10	to	to	ADP
ihlr-26084	516	11	a	a	DET
ihlr-26084	516	12	violation	violation	NOUN
ihlr-26084	516	13	of	of	ADP
ihlr-26084	516	14	the	the	DET
ihlr-26084	516	15	competition	competition	NOUN
ihlr-26084	516	16	laws	law	NOUN
ihlr-26084	516	17	.	.	PUNCT
ihlr-26084	517	1	however	however	ADV
ihlr-26084	517	2	,	,	PUNCT
ihlr-26084	517	3	the	the	DET
ihlr-26084	517	4	general	general	ADJ
ihlr-26084	517	5	court	court	NOUN
ihlr-26084	517	6	went	go	VERB
ihlr-26084	517	7	further	far	ADV
ihlr-26084	517	8	.	.	PUNCT
ihlr-26084	518	1	first	first	ADV
ihlr-26084	518	2	,	,	PUNCT
ihlr-26084	518	3	the	the	DET
ihlr-26084	518	4	general	general	ADJ
ihlr-26084	518	5	court	court	NOUN
ihlr-26084	518	6	stated	state	VERB
ihlr-26084	518	7	that	that	SCONJ
ihlr-26084	518	8	courts	court	NOUN
ihlr-26084	518	9	must	must	AUX
ihlr-26084	518	10	still	still	ADV
ihlr-26084	518	11	assess	assess	VERB
ihlr-26084	518	12	barriers	barrier	NOUN
ihlr-26084	518	13	to	to	ADP
ihlr-26084	518	14	entry	entry	NOUN
ihlr-26084	518	15	;	;	PUNCT
ihlr-26084	518	16	but	but	CCONJ
ihlr-26084	518	17	the	the	DET
ihlr-26084	518	18	lawsuits	lawsuit	NOUN
ihlr-26084	518	19	against	against	ADP
ihlr-26084	518	20	the	the	DET
ihlr-26084	518	21	generic	generic	ADJ
ihlr-26084	518	22	manufacturers	manufacturer	NOUN
ihlr-26084	518	23	can	can	AUX
ihlr-26084	518	24	be	be	AUX
ihlr-26084	518	25	used	use	VERB
ihlr-26084	518	26	as	as	ADP
ihlr-26084	518	27	evidence	evidence	NOUN
ihlr-26084	518	28	that	that	SCONJ
ihlr-26084	518	29	the	the	DET
ihlr-26084	518	30	brand	brand	NOUN
ihlr-26084	518	31	manufacturer	manufacturer	NOUN
ihlr-26084	518	32	sees	see	VERB
ihlr-26084	518	33	the	the	DET
ihlr-26084	518	34	generic	generic	ADJ
ihlr-26084	518	35	manufacturers	manufacturer	NOUN
ihlr-26084	518	36	as	as	ADP
ihlr-26084	518	37	possible	possible	ADJ
ihlr-26084	518	38	entrants.143	entrants.143	PROPN
ihlr-26084	518	39	second	second	NOUN
ihlr-26084	518	40	,	,	PUNCT
ihlr-26084	518	41	the	the	DET
ihlr-26084	518	42	general	general	ADJ
ihlr-26084	518	43	court	court	NOUN
ihlr-26084	518	44	stated	state	VERB
ihlr-26084	518	45	that	that	SCONJ
ihlr-26084	518	46	courts	court	NOUN
ihlr-26084	518	47	do	do	AUX
ihlr-26084	518	48	not	not	PART
ihlr-26084	518	49	have	have	VERB
ihlr-26084	518	50	to	to	PART
ihlr-26084	518	51	investigate	investigate	VERB
ihlr-26084	518	52	the	the	DET
ihlr-26084	518	53	validity	validity	NOUN
ihlr-26084	518	54	of	of	ADP
ihlr-26084	518	55	the	the	DET
ihlr-26084	518	56	underlying	underlie	VERB
ihlr-26084	518	57	patent.144	patent.144	PRON
ihlr-26084	518	58	the	the	DET
ihlr-26084	518	59	agreement	agreement	NOUN
ihlr-26084	518	60	to	to	PART
ihlr-26084	518	61	limit	limit	VERB
ihlr-26084	518	62	trade	trade	NOUN
ihlr-26084	518	63	was	be	AUX
ihlr-26084	518	64	sufficient	sufficient	ADJ
ihlr-26084	518	65	in	in	ADP
ihlr-26084	518	66	itself	itself	PRON
ihlr-26084	518	67	to	to	PART
ihlr-26084	518	68	find	find	VERB
ihlr-26084	518	69	anticompetitive	anticompetitive	ADJ
ihlr-26084	518	70	object	object	NOUN
ihlr-26084	518	71	.	.	PUNCT
ihlr-26084	519	1	third	third	ADJ
ihlr-26084	519	2	,	,	PUNCT
ihlr-26084	519	3	the	the	DET
ihlr-26084	519	4	general	general	ADJ
ihlr-26084	519	5	court	court	NOUN
ihlr-26084	519	6	recognized	recognize	VERB
ihlr-26084	519	7	that	that	SCONJ
ihlr-26084	519	8	the	the	DET
ihlr-26084	519	9	agreements	agreement	NOUN
ihlr-26084	519	10	must	must	AUX
ihlr-26084	519	11	be	be	AUX
ihlr-26084	519	12	viewed	view	VERB
ihlr-26084	519	13	in	in	ADP
ihlr-26084	519	14	light	light	NOUN
ihlr-26084	519	15	of	of	ADP
ihlr-26084	519	16	each	each	DET
ihlr-26084	519	17	other.145	other.145	ADJ
ihlr-26084	519	18	because	because	SCONJ
ihlr-26084	519	19	gsk	gsk	NOUN
ihlr-26084	519	20	concluded	conclude	VERB
ihlr-26084	519	21	those	those	DET
ihlr-26084	519	22	three	three	NUM
ihlr-26084	519	23	agreements	agreement	NOUN
ihlr-26084	519	24	,	,	PUNCT
ihlr-26084	519	25	it	it	PRON
ihlr-26084	519	26	could	could	AUX
ihlr-26084	519	27	maintain	maintain	VERB
ihlr-26084	519	28	its	its	PRON
ihlr-26084	519	29	dominant	dominant	ADJ
ihlr-26084	519	30	position	position	NOUN
ihlr-26084	519	31	:	:	PUNCT
ihlr-26084	519	32	together	together	ADV
ihlr-26084	519	33	,	,	PUNCT
ihlr-26084	519	34	they	they	PRON
ihlr-26084	519	35	formed	form	VERB
ihlr-26084	519	36	an	an	DET
ihlr-26084	519	37	overall	overall	ADJ
ihlr-26084	519	38	multilateral	multilateral	ADJ
ihlr-26084	519	39	reverse	reverse	ADJ
ihlr-26084	519	40	payment	payment	NOUN
ihlr-26084	519	41	strategy	strategy	NOUN
ihlr-26084	519	42	.	.	PUNCT
ihlr-26084	520	1	in	in	ADP
ihlr-26084	520	2	many	many	ADJ
ihlr-26084	520	3	respects	respect	NOUN
ihlr-26084	520	4	,	,	PUNCT
ihlr-26084	520	5	the	the	DET
ihlr-26084	520	6	general	general	ADJ
ihlr-26084	520	7	court	court	NOUN
ihlr-26084	520	8	went	go	VERB
ihlr-26084	520	9	further	far	ADV
ihlr-26084	520	10	than	than	ADP
ihlr-26084	520	11	the	the	DET
ihlr-26084	520	12	us	us	PROPN
ihlr-26084	520	13	supreme	supreme	PROPN
ihlr-26084	520	14	court	court	PROPN
ihlr-26084	520	15	and	and	CCONJ
ihlr-26084	520	16	the	the	DET
ihlr-26084	520	17	federal	federal	ADJ
ihlr-26084	520	18	circuit	circuit	NOUN
ihlr-26084	520	19	courts	court	NOUN
ihlr-26084	520	20	.	.	PUNCT
ihlr-26084	521	1	the	the	DET
ihlr-26084	521	2	general	general	ADJ
ihlr-26084	521	3	court	court	NOUN
ihlr-26084	521	4	presented	present	VERB
ihlr-26084	521	5	a	a	DET
ihlr-26084	521	6	“	"	PUNCT
ihlr-26084	521	7	no	no	DET
ihlr-26084	521	8	-	-	PUNCT
ihlr-26084	521	9	alternative	alternative	ADJ
ihlr-26084	521	10	140	140	NUM
ihlr-26084	521	11	.	.	PUNCT
ihlr-26084	522	1	i	i	PRON
ihlr-26084	522	2	d.	d.	PROPN
ihlr-26084	522	3	at	at	ADP
ihlr-26084	522	4	¶	¶	PROPN
ihlr-26084	522	5	21	21	NUM
ihlr-26084	522	6	.	.	PUNCT
ihlr-26084	523	1	141	141	NUM
ihlr-26084	523	2	.	.	PUNCT
ihlr-26084	524	1	i	i	PRON
ihlr-26084	524	2	d.	d.	PROPN
ihlr-26084	524	3	142	142	NUM
ihlr-26084	524	4	.	.	PUNCT
ihlr-26084	525	1	i	i	PRON
ihlr-26084	525	2	d.	d.	PROPN
ihlr-26084	525	3	143	143	NUM
ihlr-26084	525	4	.	.	PUNCT
ihlr-26084	526	1	i	i	PRON
ihlr-26084	526	2	d.	d.	PROPN
ihlr-26084	526	3	at	at	ADP
ihlr-26084	526	4	¶	¶	PROPN
ihlr-26084	526	5	52	52	NUM
ihlr-26084	526	6	.	.	PUNCT
ihlr-26084	527	1	144	144	NUM
ihlr-26084	527	2	.	.	PUNCT
ihlr-26084	528	1	i	i	PRON
ihlr-26084	528	2	d.	d.	PROPN
ihlr-26084	528	3	at	at	ADP
ihlr-26084	528	4	¶	¶	PROPN
ihlr-26084	528	5	122	122	NUM
ihlr-26084	528	6	.	.	PUNCT
ihlr-26084	528	7	145	145	NUM
ihlr-26084	528	8	.	.	PUNCT
ihlr-26084	529	1	i	i	PRON
ihlr-26084	529	2	d.	d.	PROPN
ihlr-26084	529	3	at	at	ADP
ihlr-26084	529	4	¶	¶	PROPN
ihlr-26084	529	5	155	155	NUM
ihlr-26084	529	6	-	-	SYM
ihlr-26084	529	7	57	57	NUM
ihlr-26084	529	8	(	(	PUNCT
ihlr-26084	529	9	“	"	PUNCT
ihlr-26084	529	10	[	[	X
ihlr-26084	529	11	t]he	t]he	ADV
ihlr-26084	529	12	set	set	NOUN
ihlr-26084	529	13	of	of	ADP
ihlr-26084	529	14	settlement	settlement	NOUN
ihlr-26084	529	15	agreements	agreement	NOUN
ihlr-26084	529	16	concluded	conclude	VERB
ihlr-26084	529	17	on	on	ADP
ihlr-26084	529	18	the	the	DET
ihlr-26084	529	19	initiative	initiative	NOUN
ihlr-26084	529	20	of	of	ADP
ihlr-26084	529	21	gsk	gsk	NOUN
ihlr-26084	529	22	were	be	AUX
ihlr-26084	529	23	part	part	NOUN
ihlr-26084	529	24	of	of	ADP
ihlr-26084	529	25	an	an	DET
ihlr-26084	529	26	overall	overall	ADJ
ihlr-26084	529	27	strategy	strategy	NOUN
ihlr-26084	529	28	on	on	ADP
ihlr-26084	529	29	the	the	DET
ihlr-26084	529	30	part	part	NOUN
ihlr-26084	529	31	of	of	ADP
ihlr-26084	529	32	that	that	DET
ihlr-26084	529	33	manufacturer	manufacturer	NOUN
ihlr-26084	529	34	of	of	ADP
ihlr-26084	529	35	originator	originator	NOUN
ihlr-26084	529	36	medicines	medicine	NOUN
ihlr-26084	529	37	and	and	CCONJ
ihlr-26084	529	38	had	have	VERB
ihlr-26084	529	39	,	,	PUNCT
ihlr-26084	529	40	if	if	SCONJ
ihlr-26084	529	41	not	not	PART
ihlr-26084	529	42	as	as	ADP
ihlr-26084	529	43	their	their	PRON
ihlr-26084	529	44	object	object	NOUN
ihlr-26084	529	45	,	,	PUNCT
ihlr-26084	529	46	at	at	ADP
ihlr-26084	529	47	least	least	ADJ
ihlr-26084	529	48	the	the	DET
ihlr-26084	529	49	effect	effect	NOUN
ihlr-26084	529	50	of	of	ADP
ihlr-26084	529	51	delaying	delay	VERB
ihlr-26084	529	52	the	the	DET
ihlr-26084	529	53	market	market	NOUN
ihlr-26084	529	54	entry	entry	NOUN
ihlr-26084	529	55	of	of	ADP
ihlr-26084	529	56	generic	generic	ADJ
ihlr-26084	529	57	medicines	medicine	NOUN
ihlr-26084	529	58	[	[	X
ihlr-26084	529	59	.	.	PUNCT
ihlr-26084	529	60	.	.	PUNCT
ihlr-26084	529	61	.	.	PUNCT
ihlr-26084	530	1	]	]	PUNCT
ihlr-26084	530	2	.	.	PUNCT
ihlr-26084	531	1	the	the	DET
ihlr-26084	531	2	anticompetitive	anticompetitive	ADJ
ihlr-26084	531	3	effects	effect	NOUN
ihlr-26084	531	4	of	of	ADP
ihlr-26084	531	5	such	such	DET
ihlr-26084	531	6	a	a	DET
ihlr-26084	531	7	contract	contract	NOUN
ihlr-26084	531	8	-	-	PUNCT
ihlr-26084	531	9	oriented	orient	VERB
ihlr-26084	531	10	strategy	strategy	NOUN
ihlr-26084	531	11	are	be	AUX
ihlr-26084	531	12	liable	liable	ADJ
ihlr-26084	531	13	to	to	PART
ihlr-26084	531	14	exceed	exceed	VERB
ihlr-26084	531	15	the	the	DET
ihlr-26084	531	16	anticompetitive	anticompetitive	ADJ
ihlr-26084	531	17	effects	effect	NOUN
ihlr-26084	531	18	inherent	inherent	ADJ
ihlr-26084	531	19	in	in	ADP
ihlr-26084	531	20	the	the	DET
ihlr-26084	531	21	conclusion	conclusion	NOUN
ihlr-26084	531	22	of	of	ADP
ihlr-26084	531	23	each	each	PRON
ihlr-26084	531	24	of	of	ADP
ihlr-26084	531	25	the	the	DET
ihlr-26084	531	26	agreements	agreement	NOUN
ihlr-26084	531	27	that	that	PRON
ihlr-26084	531	28	are	be	AUX
ihlr-26084	531	29	part	part	NOUN
ihlr-26084	531	30	of	of	ADP
ihlr-26084	531	31	it	it	PRON
ihlr-26084	531	32	.	.	PUNCT
ihlr-26084	531	33	”	"	PUNCT
ihlr-26084	531	34	)	)	PUNCT
ihlr-26084	531	35	.	.	PUNCT
ihlr-26084	532	1	2022	2022	NUM
ihlr-26084	532	2	]	]	PUNCT
ihlr-26084	532	3	reverse	reverse	ADJ
ihlr-26084	532	4	payment	payment	NOUN
ihlr-26084	532	5	:	:	PUNCT
ihlr-26084	532	6	a	a	DET
ihlr-26084	532	7	comparative	comparative	ADJ
ihlr-26084	532	8	study	study	NOUN
ihlr-26084	532	9	41	41	NUM
ihlr-26084	532	10	explanation	explanation	NOUN
ihlr-26084	532	11	”	"	PUNCT
ihlr-26084	532	12	test	test	NOUN
ihlr-26084	532	13	:	:	PUNCT
ihlr-26084	532	14	if	if	SCONJ
ihlr-26084	532	15	the	the	DET
ihlr-26084	532	16	agreement	agreement	NOUN
ihlr-26084	532	17	has	have	VERB
ihlr-26084	532	18	the	the	DET
ihlr-26084	532	19	object	object	NOUN
ihlr-26084	532	20	of	of	ADP
ihlr-26084	532	21	restricting	restrict	VERB
ihlr-26084	532	22	entry	entry	NOUN
ihlr-26084	532	23	,	,	PUNCT
ihlr-26084	532	24	then	then	ADV
ihlr-26084	532	25	it	it	PRON
ihlr-26084	532	26	is	be	AUX
ihlr-26084	532	27	anticompetitive	anticompetitive	ADJ
ihlr-26084	532	28	.	.	PUNCT
ihlr-26084	533	1	therefore	therefore	ADV
ihlr-26084	533	2	,	,	PUNCT
ihlr-26084	533	3	the	the	DET
ihlr-26084	533	4	court	court	NOUN
ihlr-26084	533	5	did	do	AUX
ihlr-26084	533	6	not	not	PART
ihlr-26084	533	7	require	require	VERB
ihlr-26084	533	8	looking	look	VERB
ihlr-26084	533	9	at	at	ADP
ihlr-26084	533	10	whether	whether	SCONJ
ihlr-26084	533	11	the	the	DET
ihlr-26084	533	12	agreement	agreement	NOUN
ihlr-26084	533	13	was	be	AUX
ihlr-26084	533	14	effective	effective	ADJ
ihlr-26084	533	15	at	at	ADP
ihlr-26084	533	16	decreasing	decrease	VERB
ihlr-26084	533	17	entry	entry	NOUN
ihlr-26084	533	18	.	.	PUNCT
ihlr-26084	534	1	however	however	ADV
ihlr-26084	534	2	,	,	PUNCT
ihlr-26084	534	3	if	if	SCONJ
ihlr-26084	534	4	the	the	DET
ihlr-26084	534	5	competition	competition	NOUN
ihlr-26084	534	6	authority	authority	NOUN
ihlr-26084	534	7	tries	try	VERB
ihlr-26084	534	8	to	to	PART
ihlr-26084	534	9	prove	prove	VERB
ihlr-26084	534	10	the	the	DET
ihlr-26084	534	11	agreement	agreement	NOUN
ihlr-26084	534	12	has	have	VERB
ihlr-26084	534	13	anticompetitive	anticompetitive	ADJ
ihlr-26084	534	14	effects	effect	NOUN
ihlr-26084	534	15	,	,	PUNCT
ihlr-26084	534	16	then	then	ADV
ihlr-26084	534	17	the	the	DET
ihlr-26084	534	18	competition	competition	NOUN
ihlr-26084	534	19	authority	authority	NOUN
ihlr-26084	534	20	can	can	AUX
ihlr-26084	534	21	not	not	PART
ihlr-26084	534	22	presume	presume	VERB
ihlr-26084	534	23	that	that	SCONJ
ihlr-26084	534	24	,	,	PUNCT
ihlr-26084	534	25	without	without	ADP
ihlr-26084	534	26	the	the	DET
ihlr-26084	534	27	agreement	agreement	NOUN
ihlr-26084	534	28	,	,	PUNCT
ihlr-26084	534	29	the	the	DET
ihlr-26084	534	30	patent	patent	NOUN
ihlr-26084	534	31	would	would	AUX
ihlr-26084	534	32	have	have	AUX
ihlr-26084	534	33	been	be	AUX
ihlr-26084	534	34	invalidated	invalidated	ADJ
ihlr-26084	534	35	or	or	CCONJ
ihlr-26084	534	36	the	the	DET
ihlr-26084	534	37	parties	party	NOUN
ihlr-26084	534	38	could	could	AUX
ihlr-26084	534	39	settle	settle	VERB
ihlr-26084	534	40	in	in	ADP
ihlr-26084	534	41	a	a	DET
ihlr-26084	534	42	less	less	ADV
ihlr-26084	534	43	restrictive	restrictive	ADJ
ihlr-26084	534	44	manner	manner	NOUN
ihlr-26084	534	45	.	.	PUNCT
ihlr-26084	535	1	the	the	DET
ihlr-26084	535	2	patent	patent	NOUN
ihlr-26084	535	3	holder	holder	NOUN
ihlr-26084	535	4	could	could	AUX
ihlr-26084	535	5	also	also	ADV
ihlr-26084	535	6	present	present	VERB
ihlr-26084	535	7	pro	pro	ADJ
ihlr-26084	535	8	-	-	ADJ
ihlr-26084	535	9	competitive	competitive	ADJ
ihlr-26084	535	10	evidence	evidence	NOUN
ihlr-26084	535	11	.	.	PUNCT
ihlr-26084	536	1	the	the	DET
ihlr-26084	536	2	next	next	ADJ
ihlr-26084	536	3	section	section	NOUN
ihlr-26084	536	4	discusses	discuss	VERB
ihlr-26084	536	5	what	what	PRON
ihlr-26084	536	6	can	can	AUX
ihlr-26084	536	7	be	be	AUX
ihlr-26084	536	8	done	do	VERB
ihlr-26084	536	9	to	to	PART
ihlr-26084	536	10	further	far	ADV
ihlr-26084	536	11	disincentivize	disincentivize	VERB
ihlr-26084	536	12	pay	pay	NOUN
ihlr-26084	536	13	-	-	PUNCT
ihlr-26084	536	14	fordelay	fordelay	NOUN
ihlr-26084	536	15	and	and	CCONJ
ihlr-26084	536	16	ease	ease	VERB
ihlr-26084	536	17	the	the	DET
ihlr-26084	536	18	entry	entry	NOUN
ihlr-26084	536	19	of	of	ADP
ihlr-26084	536	20	generics	generics	PROPN
ihlr-26084	536	21	.	.	PUNCT
ihlr-26084	537	1	iv	iv	X
ihlr-26084	537	2	.	.	PUNCT
ihlr-26084	538	1	recommendations	recommendation	NOUN
ihlr-26084	538	2	and	and	CCONJ
ihlr-26084	538	3	conclusion	conclusion	NOUN
ihlr-26084	538	4	pay	pay	NOUN
ihlr-26084	538	5	for	for	ADP
ihlr-26084	538	6	delays	delay	NOUN
ihlr-26084	538	7	are	be	AUX
ihlr-26084	538	8	hard	hard	ADJ
ihlr-26084	538	9	to	to	PART
ihlr-26084	538	10	identify	identify	VERB
ihlr-26084	538	11	and	and	CCONJ
ihlr-26084	538	12	even	even	ADV
ihlr-26084	538	13	harder	hard	ADJ
ihlr-26084	538	14	to	to	PART
ihlr-26084	538	15	prosecute	prosecute	VERB
ihlr-26084	538	16	.	.	PUNCT
ihlr-26084	539	1	this	this	DET
ihlr-26084	539	2	section	section	NOUN
ihlr-26084	539	3	attempts	attempt	VERB
ihlr-26084	539	4	to	to	PART
ihlr-26084	539	5	make	make	VERB
ihlr-26084	539	6	some	some	DET
ihlr-26084	539	7	recommendation	recommendation	NOUN
ihlr-26084	539	8	how	how	SCONJ
ihlr-26084	539	9	pay	pay	VERB
ihlr-26084	539	10	-	-	PUNCT
ihlr-26084	539	11	for	for	ADP
ihlr-26084	539	12	-	-	PUNCT
ihlr-26084	539	13	delay	delay	NOUN
ihlr-26084	539	14	can	can	AUX
ihlr-26084	539	15	be	be	AUX
ihlr-26084	539	16	disincentivized	disincentivize	VERB
ihlr-26084	539	17	or	or	CCONJ
ihlr-26084	539	18	illuminated	illuminate	VERB
ihlr-26084	539	19	.	.	PUNCT
ihlr-26084	540	1	a.	a.	NOUN
ihlr-26084	540	2	remedies	remedy	NOUN
ihlr-26084	540	3	against	against	ADP
ihlr-26084	540	4	abuse	abuse	NOUN
ihlr-26084	540	5	current	current	ADJ
ihlr-26084	540	6	remedies	remedy	NOUN
ihlr-26084	540	7	are	be	AUX
ihlr-26084	540	8	maladapted	maladapted	ADJ
ihlr-26084	540	9	for	for	ADP
ihlr-26084	540	10	pay	pay	NOUN
ihlr-26084	540	11	-	-	PUNCT
ihlr-26084	540	12	for	for	ADP
ihlr-26084	540	13	-	-	PUNCT
ihlr-26084	540	14	delay	delay	NOUN
ihlr-26084	540	15	suits	suit	NOUN
ihlr-26084	540	16	.	.	PUNCT
ihlr-26084	541	1	they	they	PRON
ihlr-26084	541	2	do	do	AUX
ihlr-26084	541	3	not	not	PART
ihlr-26084	541	4	optimally	optimally	ADV
ihlr-26084	541	5	compensate	compensate	VERB
ihlr-26084	541	6	the	the	DET
ihlr-26084	541	7	victims	victim	NOUN
ihlr-26084	541	8	of	of	ADP
ihlr-26084	541	9	cartels	cartel	NOUN
ihlr-26084	541	10	,	,	PUNCT
ihlr-26084	541	11	nor	nor	CCONJ
ihlr-26084	541	12	do	do	AUX
ihlr-26084	541	13	they	they	PRON
ihlr-26084	541	14	optimally	optimally	ADV
ihlr-26084	541	15	deter	deter	VERB
ihlr-26084	541	16	the	the	DET
ihlr-26084	541	17	cartel	cartel	NOUN
ihlr-26084	541	18	members	member	NOUN
ihlr-26084	541	19	.	.	PUNCT
ihlr-26084	542	1	in	in	ADP
ihlr-26084	542	2	private	private	ADJ
ihlr-26084	542	3	suits	suit	NOUN
ihlr-26084	542	4	,	,	PUNCT
ihlr-26084	542	5	damages	damage	NOUN
ihlr-26084	542	6	attempt	attempt	VERB
ihlr-26084	542	7	to	to	PART
ihlr-26084	542	8	make	make	VERB
ihlr-26084	542	9	the	the	DET
ihlr-26084	542	10	victims	victim	NOUN
ihlr-26084	542	11	whole	whole	ADJ
ihlr-26084	542	12	.	.	PUNCT
ihlr-26084	543	1	in	in	ADP
ihlr-26084	543	2	cartel	cartel	NOUN
ihlr-26084	543	3	suits	suit	NOUN
ihlr-26084	543	4	,	,	PUNCT
ihlr-26084	543	5	damages	damage	NOUN
ihlr-26084	543	6	should	should	AUX
ihlr-26084	543	7	compensate	compensate	VERB
ihlr-26084	543	8	the	the	DET
ihlr-26084	543	9	purchasers	purchaser	NOUN
ihlr-26084	543	10	of	of	ADP
ihlr-26084	543	11	the	the	DET
ihlr-26084	543	12	good	good	NOUN
ihlr-26084	543	13	for	for	ADP
ihlr-26084	543	14	the	the	DET
ihlr-26084	543	15	additional	additional	ADJ
ihlr-26084	543	16	costs	cost	NOUN
ihlr-26084	543	17	linked	link	VERB
ihlr-26084	543	18	to	to	ADP
ihlr-26084	543	19	the	the	DET
ihlr-26084	543	20	coordinated	coordinated	ADJ
ihlr-26084	543	21	behavior	behavior	NOUN
ihlr-26084	543	22	.	.	PUNCT
ihlr-26084	544	1	in	in	ADP
ihlr-26084	544	2	the	the	DET
ihlr-26084	544	3	us	us	PROPN
ihlr-26084	544	4	,	,	PUNCT
ihlr-26084	544	5	these	these	DET
ihlr-26084	544	6	damages	damage	NOUN
ihlr-26084	544	7	are	be	AUX
ihlr-26084	544	8	trebled	treble	VERB
ihlr-26084	544	9	to	to	PART
ihlr-26084	544	10	promote	promote	VERB
ihlr-26084	544	11	deterrence.146	deterrence.146	PRON
ihlr-26084	544	12	however	however	ADV
ihlr-26084	544	13	,	,	PUNCT
ihlr-26084	544	14	in	in	ADP
ihlr-26084	544	15	practice	practice	NOUN
ihlr-26084	544	16	most	most	ADJ
ihlr-26084	544	17	total	total	ADJ
ihlr-26084	544	18	damages	damage	NOUN
ihlr-26084	544	19	do	do	AUX
ihlr-26084	544	20	not	not	PART
ihlr-26084	544	21	even	even	ADV
ihlr-26084	544	22	fully	fully	ADV
ihlr-26084	544	23	compensate	compensate	VERB
ihlr-26084	544	24	consumers	consumer	NOUN
ihlr-26084	544	25	once.147	once.147	PROPN
ihlr-26084	544	26	even	even	ADV
ihlr-26084	544	27	if	if	SCONJ
ihlr-26084	544	28	they	they	PRON
ihlr-26084	544	29	compensate	compensate	VERB
ihlr-26084	544	30	for	for	ADP
ihlr-26084	544	31	the	the	DET
ihlr-26084	544	32	price	price	NOUN
ihlr-26084	544	33	difference	difference	NOUN
ihlr-26084	544	34	,	,	PUNCT
ihlr-26084	544	35	compensatory	compensatory	ADJ
ihlr-26084	544	36	damages	damage	NOUN
ihlr-26084	544	37	do	do	AUX
ihlr-26084	544	38	not	not	PART
ihlr-26084	544	39	cover	cover	VERB
ihlr-26084	544	40	the	the	DET
ihlr-26084	544	41	harm	harm	NOUN
ihlr-26084	544	42	created	create	VERB
ihlr-26084	544	43	by	by	ADP
ihlr-26084	544	44	pharmaceutical	pharmaceutical	NOUN
ihlr-26084	544	45	companies	company	NOUN
ihlr-26084	544	46	carrying	carry	VERB
ihlr-26084	544	47	out	out	ADP
ihlr-26084	544	48	pay	pay	NOUN
ihlr-26084	544	49	-	-	PUNCT
ihlr-26084	544	50	fordelay	fordelay	NOUN
ihlr-26084	544	51	.	.	PUNCT
ihlr-26084	545	1	victims	victim	NOUN
ihlr-26084	545	2	in	in	ADP
ihlr-26084	545	3	this	this	DET
ihlr-26084	545	4	case	case	NOUN
ihlr-26084	545	5	would	would	AUX
ihlr-26084	545	6	include	include	VERB
ihlr-26084	545	7	both	both	CCONJ
ihlr-26084	545	8	the	the	DET
ihlr-26084	545	9	drug	drug	NOUN
ihlr-26084	545	10	purchasers	purchaser	NOUN
ihlr-26084	545	11	and	and	CCONJ
ihlr-26084	545	12	the	the	DET
ihlr-26084	545	13	individuals	individual	NOUN
ihlr-26084	545	14	who	who	PRON
ihlr-26084	545	15	had	have	AUX
ihlr-26084	545	16	not	not	PART
ihlr-26084	545	17	been	be	AUX
ihlr-26084	545	18	able	able	ADJ
ihlr-26084	545	19	to	to	PART
ihlr-26084	545	20	purchase	purchase	VERB
ihlr-26084	545	21	the	the	DET
ihlr-26084	545	22	drug	drug	NOUN
ihlr-26084	545	23	because	because	SCONJ
ihlr-26084	545	24	of	of	ADP
ihlr-26084	545	25	the	the	DET
ihlr-26084	545	26	cartel	cartel	NOUN
ihlr-26084	545	27	surcharge.148	surcharge.148	VERB
ihlr-26084	545	28	the	the	DET
ihlr-26084	545	29	latter	latter	ADJ
ihlr-26084	545	30	victims	victim	NOUN
ihlr-26084	545	31	can	can	AUX
ihlr-26084	545	32	not	not	PART
ihlr-26084	545	33	recover	recover	VERB
ihlr-26084	545	34	from	from	ADP
ihlr-26084	545	35	the	the	DET
ihlr-26084	545	36	pain	pain	NOUN
ihlr-26084	545	37	and	and	CCONJ
ihlr-26084	545	38	suffering	suffering	NOUN
ihlr-26084	545	39	that	that	PRON
ihlr-26084	545	40	would	would	AUX
ihlr-26084	545	41	have	have	AUX
ihlr-26084	545	42	been	be	AUX
ihlr-26084	545	43	avoided	avoid	VERB
ihlr-26084	545	44	had	have	AUX
ihlr-26084	545	45	they	they	PRON
ihlr-26084	545	46	had	have	VERB
ihlr-26084	545	47	access	access	NOUN
ihlr-26084	545	48	to	to	ADP
ihlr-26084	545	49	these	these	DET
ihlr-26084	545	50	medications	medication	NOUN
ihlr-26084	545	51	.	.	PUNCT
ihlr-26084	546	1	since	since	SCONJ
ihlr-26084	546	2	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	546	3	companies	company	NOUN
ihlr-26084	546	4	do	do	AUX
ihlr-26084	546	5	not	not	PART
ihlr-26084	546	6	internalize	internalize	VERB
ihlr-26084	546	7	these	these	DET
ihlr-26084	546	8	costs	cost	NOUN
ihlr-26084	546	9	,	,	PUNCT
ihlr-26084	546	10	they	they	PRON
ihlr-26084	546	11	are	be	AUX
ihlr-26084	546	12	not	not	PART
ihlr-26084	546	13	optimally	optimally	ADV
ihlr-26084	546	14	deterred	deter	VERB
ihlr-26084	546	15	.	.	PUNCT
ihlr-26084	547	1	in	in	ADP
ihlr-26084	547	2	public	public	ADJ
ihlr-26084	547	3	suits	suit	NOUN
ihlr-26084	547	4	,	,	PUNCT
ihlr-26084	547	5	fines	fine	NOUN
ihlr-26084	547	6	and	and	CCONJ
ihlr-26084	547	7	declaratory	declaratory	ADJ
ihlr-26084	547	8	judgements	judgement	NOUN
ihlr-26084	547	9	are	be	AUX
ihlr-26084	547	10	also	also	ADV
ihlr-26084	547	11	maladapted	maladapted	ADJ
ihlr-26084	547	12	to	to	ADP
ihlr-26084	547	13	deterring	deter	VERB
ihlr-26084	547	14	pay	pay	NOUN
ihlr-26084	547	15	-	-	PUNCT
ihlr-26084	547	16	for	for	ADP
ihlr-26084	547	17	-	-	PUNCT
ihlr-26084	547	18	delay	delay	NOUN
ihlr-26084	547	19	cases	case	NOUN
ihlr-26084	547	20	for	for	ADP
ihlr-26084	547	21	similar	similar	ADJ
ihlr-26084	547	22	reasons	reason	NOUN
ihlr-26084	547	23	.	.	PUNCT
ihlr-26084	548	1	fines	fine	NOUN
ihlr-26084	548	2	attempt	attempt	VERB
ihlr-26084	548	3	to	to	PART
ihlr-26084	548	4	make	make	VERB
ihlr-26084	548	5	the	the	DET
ihlr-26084	548	6	cartel	cartel	NOUN
ihlr-26084	548	7	members	member	NOUN
ihlr-26084	548	8	internalize	internalize	VERB
ihlr-26084	548	9	the	the	DET
ihlr-26084	548	10	cost	cost	NOUN
ihlr-26084	548	11	of	of	ADP
ihlr-26084	548	12	their	their	PRON
ihlr-26084	548	13	past	past	ADJ
ihlr-26084	548	14	activities	activity	NOUN
ihlr-26084	548	15	.	.	PUNCT
ihlr-26084	549	1	declaratory	declaratory	ADJ
ihlr-26084	549	2	judgments	judgment	NOUN
ihlr-26084	549	3	invalidate	invalidate	VERB
ihlr-26084	549	4	agreements	agreement	NOUN
ihlr-26084	549	5	to	to	PART
ihlr-26084	549	6	stop	stop	VERB
ihlr-26084	549	7	the	the	DET
ihlr-26084	549	8	cartel	cartel	NOUN
ihlr-26084	549	9	from	from	ADP
ihlr-26084	549	10	operating	operate	VERB
ihlr-26084	549	11	.	.	PUNCT
ihlr-26084	550	1	however	however	ADV
ihlr-26084	550	2	,	,	PUNCT
ihlr-26084	550	3	these	these	DET
ihlr-26084	550	4	two	two	NUM
ihlr-26084	550	5	remedies	remedy	NOUN
ihlr-26084	550	6	do	do	AUX
ihlr-26084	550	7	not	not	PART
ihlr-26084	550	8	address	address	VERB
ihlr-26084	550	9	the	the	DET
ihlr-26084	550	10	issues	issue	NOUN
ihlr-26084	550	11	of	of	ADP
ihlr-26084	550	12	future	future	ADJ
ihlr-26084	550	13	activities	activity	NOUN
ihlr-26084	550	14	.	.	PUNCT
ihlr-26084	551	1	in	in	ADP
ihlr-26084	551	2	the	the	DET
ihlr-26084	551	3	case	case	NOUN
ihlr-26084	551	4	of	of	ADP
ihlr-26084	551	5	pay	pay	NOUN
ihlr-26084	551	6	-	-	PUNCT
ihlr-26084	551	7	fordelay	fordelay	NOUN
ihlr-26084	551	8	,	,	PUNCT
ihlr-26084	551	9	the	the	DET
ihlr-26084	551	10	patents	patent	NOUN
ihlr-26084	551	11	used	use	VERB
ihlr-26084	551	12	to	to	PART
ihlr-26084	551	13	leverage	leverage	VERB
ihlr-26084	551	14	a	a	DET
ihlr-26084	551	15	settlement	settlement	NOUN
ihlr-26084	551	16	remain	remain	VERB
ihlr-26084	551	17	in	in	ADP
ihlr-26084	551	18	play	play	NOUN
ihlr-26084	551	19	.	.	PUNCT
ihlr-26084	552	1	after	after	SCONJ
ihlr-26084	552	2	the	the	DET
ihlr-26084	552	3	agreements	agreement	NOUN
ihlr-26084	552	4	are	be	AUX
ihlr-26084	552	5	invalidated	invalidated	ADJ
ihlr-26084	552	6	and	and	CCONJ
ihlr-26084	552	7	the	the	DET
ihlr-26084	552	8	fines	fine	NOUN
ihlr-26084	552	9	are	be	AUX
ihlr-26084	552	10	paid	pay	VERB
ihlr-26084	552	11	,	,	PUNCT
ihlr-26084	552	12	the	the	DET
ihlr-26084	552	13	branded	brand	VERB
ihlr-26084	552	14	companies	company	NOUN
ihlr-26084	552	15	would	would	AUX
ihlr-26084	552	16	146	146	NUM
ihlr-26084	552	17	.	.	NOUN
ihlr-26084	552	18	15	15	NUM
ihlr-26084	552	19	u.s.c	u.s.c	NOUN
ihlr-26084	552	20	.	.	PUNCT
ihlr-26084	553	1	§	§	PROPN
ihlr-26084	553	2	15(a	15(a	NUM
ihlr-26084	553	3	)	)	PUNCT
ihlr-26084	553	4	.	.	PUNCT
ihlr-26084	554	1	147	147	NUM
ihlr-26084	554	2	.	.	PUNCT
ihlr-26084	555	1	see	see	VERB
ihlr-26084	555	2	john	john	PROPN
ihlr-26084	555	3	m.	m.	PROPN
ihlr-26084	555	4	connor	connor	PROPN
ihlr-26084	555	5	&	&	CCONJ
ihlr-26084	555	6	robert	robert	PROPN
ihlr-26084	555	7	h.	h.	PROPN
ihlr-26084	555	8	lande	lande	PROPN
ihlr-26084	555	9	,	,	PUNCT
ihlr-26084	555	10	not	not	PART
ihlr-26084	555	11	treble	treble	ADJ
ihlr-26084	555	12	damages	damage	NOUN
ihlr-26084	555	13	:	:	PUNCT
ihlr-26084	555	14	cartel	cartel	NOUN
ihlr-26084	555	15	recoveries	recovery	NOUN
ihlr-26084	555	16	are	be	AUX
ihlr-26084	555	17	mostly	mostly	ADV
ihlr-26084	555	18	less	less	ADJ
ihlr-26084	555	19	than	than	ADP
ihlr-26084	555	20	single	single	ADJ
ihlr-26084	555	21	damages	damage	NOUN
ihlr-26084	555	22	,	,	PUNCT
ihlr-26084	555	23	100	100	NUM
ihlr-26084	555	24	iowa	iowa	PROPN
ihlr-26084	555	25	l.	l.	PROPN
ihlr-26084	555	26	rev	rev	PROPN
ihlr-26084	555	27	.	.	PROPN
ihlr-26084	555	28	1997	1997	NUM
ihlr-26084	555	29	(	(	PUNCT
ihlr-26084	555	30	2014	2014	NUM
ihlr-26084	555	31	)	)	PUNCT
ihlr-26084	555	32	.	.	PUNCT
ihlr-26084	556	1	148	148	NUM
ihlr-26084	556	2	.	.	PUNCT
ihlr-26084	557	1	see	see	VERB
ihlr-26084	557	2	e.g.	e.g.	ADV
ihlr-26084	557	3	,	,	PUNCT
ihlr-26084	557	4	blue	blue	ADJ
ihlr-26084	557	5	shield	shield	NOUN
ihlr-26084	557	6	of	of	ADP
ihlr-26084	557	7	virginia	virginia	PROPN
ihlr-26084	557	8	v.	v.	PROPN
ihlr-26084	557	9	mccready	mccready	PROPN
ihlr-26084	557	10	,	,	PUNCT
ihlr-26084	557	11	457	457	NUM
ihlr-26084	557	12	u.s	u.s	PROPN
ihlr-26084	557	13	.	.	PROPN
ihlr-26084	557	14	465	465	NUM
ihlr-26084	557	15	(	(	PUNCT
ihlr-26084	557	16	1982	1982	NUM
ihlr-26084	557	17	)	)	PUNCT
ihlr-26084	557	18	(	(	PUNCT
ihlr-26084	557	19	holding	hold	VERB
ihlr-26084	557	20	purchasers	purchaser	NOUN
ihlr-26084	557	21	of	of	ADP
ihlr-26084	557	22	alternative	alternative	ADJ
ihlr-26084	557	23	treatment	treatment	NOUN
ihlr-26084	557	24	had	have	AUX
ihlr-26084	557	25	standing	stand	VERB
ihlr-26084	557	26	to	to	PART
ihlr-26084	557	27	recover	recover	VERB
ihlr-26084	557	28	damages	damage	NOUN
ihlr-26084	557	29	)	)	PUNCT
ihlr-26084	557	30	.	.	PUNCT
ihlr-26084	558	1	42	42	NUM
ihlr-26084	558	2	indiana	indiana	PROPN
ihlr-26084	558	3	health	health	PROPN
ihlr-26084	558	4	law	law	PROPN
ihlr-26084	558	5	review	review	NOUN
ihlr-26084	558	6	[	[	X
ihlr-26084	558	7	vol	vol	NOUN
ihlr-26084	558	8	.	.	PUNCT
ihlr-26084	559	1	19:21	19:21	NUM
ihlr-26084	559	2	still	still	ADV
ihlr-26084	559	3	return	return	VERB
ihlr-26084	559	4	to	to	ADP
ihlr-26084	559	5	a	a	DET
ihlr-26084	559	6	monopoly	monopoly	NOUN
ihlr-26084	559	7	position	position	NOUN
ihlr-26084	559	8	.	.	PUNCT
ihlr-26084	560	1	the	the	DET
ihlr-26084	560	2	period	period	NOUN
ihlr-26084	560	3	until	until	ADP
ihlr-26084	560	4	which	which	PRON
ihlr-26084	560	5	generics	generic	NOUN
ihlr-26084	560	6	may	may	AUX
ihlr-26084	560	7	enter	enter	VERB
ihlr-26084	560	8	still	still	ADV
ihlr-26084	560	9	leads	lead	VERB
ihlr-26084	560	10	to	to	ADP
ihlr-26084	560	11	more	more	ADJ
ihlr-26084	560	12	monopoly	monopoly	NOUN
ihlr-26084	560	13	deadweight	deadweight	NOUN
ihlr-26084	560	14	loss	loss	NOUN
ihlr-26084	560	15	.	.	PUNCT
ihlr-26084	561	1	to	to	PART
ihlr-26084	561	2	address	address	VERB
ihlr-26084	561	3	the	the	DET
ihlr-26084	561	4	issue	issue	NOUN
ihlr-26084	561	5	of	of	ADP
ihlr-26084	561	6	future	future	ADJ
ihlr-26084	561	7	activities	activity	NOUN
ihlr-26084	561	8	,	,	PUNCT
ihlr-26084	561	9	courts	court	NOUN
ihlr-26084	561	10	and	and	CCONJ
ihlr-26084	561	11	policymakers	policymaker	NOUN
ihlr-26084	561	12	should	should	AUX
ihlr-26084	561	13	impose	impose	VERB
ihlr-26084	561	14	three	three	NUM
ihlr-26084	561	15	remedies	remedy	NOUN
ihlr-26084	561	16	.	.	PUNCT
ihlr-26084	562	1	first	first	ADV
ihlr-26084	562	2	,	,	PUNCT
ihlr-26084	562	3	courts	court	NOUN
ihlr-26084	562	4	should	should	AUX
ihlr-26084	562	5	create	create	VERB
ihlr-26084	562	6	a	a	DET
ihlr-26084	562	7	compulsory	compulsory	ADJ
ihlr-26084	562	8	licensing	licensing	NOUN
ihlr-26084	562	9	scheme	scheme	NOUN
ihlr-26084	562	10	.	.	PUNCT
ihlr-26084	563	1	if	if	SCONJ
ihlr-26084	563	2	a	a	DET
ihlr-26084	563	3	patent	patent	NOUN
ihlr-26084	563	4	holder	holder	NOUN
ihlr-26084	563	5	has	have	AUX
ihlr-26084	563	6	been	be	AUX
ihlr-26084	563	7	found	find	VERB
ihlr-26084	563	8	to	to	PART
ihlr-26084	563	9	engage	engage	VERB
ihlr-26084	563	10	in	in	ADP
ihlr-26084	563	11	an	an	DET
ihlr-26084	563	12	anticompetitive	anticompetitive	ADJ
ihlr-26084	563	13	payfor	payfor	NOUN
ihlr-26084	563	14	-	-	PUNCT
ihlr-26084	563	15	delay	delay	NOUN
ihlr-26084	563	16	,	,	PUNCT
ihlr-26084	563	17	then	then	ADV
ihlr-26084	563	18	any	any	DET
ihlr-26084	563	19	generic	generic	ADJ
ihlr-26084	563	20	manufacturer	manufacturer	NOUN
ihlr-26084	563	21	should	should	AUX
ihlr-26084	563	22	be	be	AUX
ihlr-26084	563	23	able	able	ADJ
ihlr-26084	563	24	to	to	PART
ihlr-26084	563	25	enter	enter	VERB
ihlr-26084	563	26	the	the	DET
ihlr-26084	563	27	market	market	NOUN
ihlr-26084	563	28	.	.	PUNCT
ihlr-26084	564	1	most	most	ADJ
ihlr-26084	564	2	countries	country	NOUN
ihlr-26084	564	3	–	–	PUNCT
ihlr-26084	564	4	including	include	VERB
ihlr-26084	564	5	france	france	PROPN
ihlr-26084	564	6	,	,	PUNCT
ihlr-26084	564	7	the	the	DET
ihlr-26084	564	8	uk	uk	PROPN
ihlr-26084	564	9	,	,	PUNCT
ihlr-26084	564	10	and	and	CCONJ
ihlr-26084	564	11	the	the	DET
ihlr-26084	564	12	us	us	PROPN
ihlr-26084	564	13	–	–	PUNCT
ihlr-26084	564	14	have	have	VERB
ihlr-26084	564	15	compulsory	compulsory	ADJ
ihlr-26084	564	16	licenses.149	licenses.149	PRON
ihlr-26084	564	17	compulsory	compulsory	ADJ
ihlr-26084	564	18	licenses	license	NOUN
ihlr-26084	564	19	are	be	AUX
ihlr-26084	564	20	rare	rare	ADJ
ihlr-26084	564	21	occurrences	occurrence	NOUN
ihlr-26084	564	22	because	because	SCONJ
ihlr-26084	564	23	some	some	PRON
ihlr-26084	564	24	argue	argue	VERB
ihlr-26084	564	25	that	that	SCONJ
ihlr-26084	564	26	it	it	PRON
ihlr-26084	564	27	would	would	AUX
ihlr-26084	564	28	deter	deter	VERB
ihlr-26084	564	29	future	future	ADJ
ihlr-26084	564	30	innovations	innovation	NOUN
ihlr-26084	564	31	;	;	PUNCT
ihlr-26084	564	32	however	however	ADV
ihlr-26084	564	33	,	,	PUNCT
ihlr-26084	564	34	the	the	DET
ihlr-26084	564	35	evidence	evidence	NOUN
ihlr-26084	564	36	tends	tend	VERB
ihlr-26084	564	37	to	to	PART
ihlr-26084	564	38	contradict	contradict	VERB
ihlr-26084	564	39	this	this	DET
ihlr-26084	564	40	argument.150	argument.150	PROPN
ihlr-26084	564	41	under	under	ADP
ihlr-26084	564	42	the	the	DET
ihlr-26084	564	43	agreement	agreement	NOUN
ihlr-26084	564	44	on	on	ADP
ihlr-26084	564	45	trade	trade	NOUN
ihlr-26084	564	46	-	-	PUNCT
ihlr-26084	564	47	related	relate	VERB
ihlr-26084	564	48	aspects	aspect	NOUN
ihlr-26084	564	49	of	of	ADP
ihlr-26084	564	50	intellectual	intellectual	ADJ
ihlr-26084	564	51	property	property	NOUN
ihlr-26084	564	52	rights	right	NOUN
ihlr-26084	564	53	(	(	PUNCT
ihlr-26084	564	54	“	"	PUNCT
ihlr-26084	564	55	trips”),151	trips”),151	PROPN
ihlr-26084	564	56	a	a	DET
ihlr-26084	564	57	government	government	NOUN
ihlr-26084	564	58	can	can	AUX
ihlr-26084	564	59	create	create	VERB
ihlr-26084	564	60	compulsory	compulsory	ADJ
ihlr-26084	564	61	licenses	license	NOUN
ihlr-26084	564	62	for	for	ADP
ihlr-26084	564	63	medications	medication	NOUN
ihlr-26084	564	64	if	if	SCONJ
ihlr-26084	564	65	the	the	DET
ihlr-26084	564	66	country	country	NOUN
ihlr-26084	564	67	faces	face	VERB
ihlr-26084	564	68	a	a	DET
ihlr-26084	564	69	public	public	ADJ
ihlr-26084	564	70	health	health	NOUN
ihlr-26084	564	71	emergency.152	emergency.152	PROPN
ihlr-26084	564	72	the	the	DET
ihlr-26084	564	73	trips	trip	NOUN
ihlr-26084	564	74	agreements	agreement	NOUN
ihlr-26084	564	75	also	also	ADV
ihlr-26084	564	76	permit	permit	VERB
ihlr-26084	564	77	these	these	DET
ihlr-26084	564	78	licenses	license	NOUN
ihlr-26084	564	79	to	to	PART
ihlr-26084	564	80	address	address	VERB
ihlr-26084	564	81	“	"	PUNCT
ihlr-26084	564	82	the	the	DET
ihlr-26084	564	83	abuse	abuse	NOUN
ihlr-26084	564	84	of	of	ADP
ihlr-26084	564	85	intellectual	intellectual	ADJ
ihlr-26084	564	86	property	property	NOUN
ihlr-26084	564	87	rights	right	NOUN
ihlr-26084	564	88	by	by	ADP
ihlr-26084	564	89	right	right	ADJ
ihlr-26084	564	90	holders	holder	NOUN
ihlr-26084	564	91	or	or	CCONJ
ihlr-26084	564	92	the	the	DET
ihlr-26084	564	93	resort	resort	NOUN
ihlr-26084	564	94	to	to	ADP
ihlr-26084	564	95	practices	practice	NOUN
ihlr-26084	564	96	which	which	PRON
ihlr-26084	564	97	unreasonably	unreasonably	ADV
ihlr-26084	564	98	restrain	restrain	VERB
ihlr-26084	564	99	trade	trade	NOUN
ihlr-26084	564	100	.	.	PUNCT
ihlr-26084	565	1	”153	”153	NOUN
ihlr-26084	565	2	the	the	DET
ihlr-26084	565	3	trips	trip	NOUN
ihlr-26084	565	4	authors	author	NOUN
ihlr-26084	565	5	may	may	AUX
ihlr-26084	565	6	not	not	PART
ihlr-26084	565	7	have	have	AUX
ihlr-26084	565	8	contemplated	contemplate	VERB
ihlr-26084	565	9	pay	pay	NOUN
ihlr-26084	565	10	-	-	PUNCT
ihlr-26084	565	11	for	for	ADP
ihlr-26084	565	12	-	-	PUNCT
ihlr-26084	565	13	delay	delay	NOUN
ihlr-26084	565	14	when	when	SCONJ
ihlr-26084	565	15	drafting	draft	VERB
ihlr-26084	565	16	this	this	DET
ihlr-26084	565	17	article	article	NOUN
ihlr-26084	565	18	;	;	PUNCT
ihlr-26084	565	19	but	but	CCONJ
ihlr-26084	565	20	pay	pay	NOUN
ihlr-26084	565	21	-	-	PUNCT
ihlr-26084	565	22	for	for	ADP
ihlr-26084	565	23	-	-	PUNCT
ihlr-26084	565	24	delay	delay	NOUN
ihlr-26084	565	25	is	be	AUX
ihlr-26084	565	26	an	an	DET
ihlr-26084	565	27	unreasonable	unreasonable	ADJ
ihlr-26084	565	28	restraint	restraint	NOUN
ihlr-26084	565	29	of	of	ADP
ihlr-26084	565	30	trade	trade	NOUN
ihlr-26084	565	31	.	.	PUNCT
ihlr-26084	566	1	compulsory	compulsory	ADJ
ihlr-26084	566	2	licensing	licensing	NOUN
ihlr-26084	566	3	as	as	ADP
ihlr-26084	566	4	a	a	DET
ihlr-26084	566	5	remedy	remedy	NOUN
ihlr-26084	566	6	for	for	ADP
ihlr-26084	566	7	pay	pay	NOUN
ihlr-26084	566	8	-	-	PUNCT
ihlr-26084	566	9	for	for	ADP
ihlr-26084	566	10	-	-	PUNCT
ihlr-26084	566	11	delay	delay	NOUN
ihlr-26084	566	12	would	would	AUX
ihlr-26084	566	13	provide	provide	VERB
ihlr-26084	566	14	an	an	DET
ihlr-26084	566	15	additional	additional	ADJ
ihlr-26084	566	16	deterrent	deterrent	NOUN
ihlr-26084	566	17	.	.	PUNCT
ihlr-26084	567	1	courts	court	NOUN
ihlr-26084	567	2	may	may	AUX
ihlr-26084	567	3	disfavor	disfavor	VERB
ihlr-26084	567	4	this	this	DET
ihlr-26084	567	5	remedy	remedy	NOUN
ihlr-26084	567	6	because	because	SCONJ
ihlr-26084	567	7	it	it	PRON
ihlr-26084	567	8	requires	require	VERB
ihlr-26084	567	9	ongoing	ongoing	ADJ
ihlr-26084	567	10	monitoring	monitoring	NOUN
ihlr-26084	567	11	to	to	PART
ihlr-26084	567	12	ensure	ensure	VERB
ihlr-26084	567	13	the	the	DET
ihlr-26084	567	14	compulsory	compulsory	ADJ
ihlr-26084	567	15	licensing	licensing	NOUN
ihlr-26084	567	16	fee	fee	NOUN
ihlr-26084	567	17	is	be	AUX
ihlr-26084	567	18	properly	properly	ADV
ihlr-26084	567	19	set	set	VERB
ihlr-26084	567	20	and	and	CCONJ
ihlr-26084	567	21	paid	pay	VERB
ihlr-26084	567	22	.	.	PUNCT
ihlr-26084	568	1	however	however	ADV
ihlr-26084	568	2	,	,	PUNCT
ihlr-26084	568	3	this	this	DET
ihlr-26084	568	4	remedy	remedy	NOUN
ihlr-26084	568	5	would	would	AUX
ihlr-26084	568	6	address	address	VERB
ihlr-26084	568	7	future	future	ADJ
ihlr-26084	568	8	sales	sale	NOUN
ihlr-26084	568	9	from	from	ADP
ihlr-26084	568	10	the	the	DET
ihlr-26084	568	11	patent	patent	NOUN
ihlr-26084	568	12	holder	holder	NOUN
ihlr-26084	568	13	.	.	PUNCT
ihlr-26084	569	1	second	second	ADJ
ihlr-26084	569	2	,	,	PUNCT
ihlr-26084	569	3	since	since	SCONJ
ihlr-26084	569	4	most	most	ADJ
ihlr-26084	569	5	courts	court	NOUN
ihlr-26084	569	6	do	do	AUX
ihlr-26084	569	7	not	not	PART
ihlr-26084	569	8	like	like	VERB
ihlr-26084	569	9	constant	constant	ADJ
ihlr-26084	569	10	supervision	supervision	NOUN
ihlr-26084	569	11	,	,	PUNCT
ihlr-26084	569	12	courts	court	NOUN
ihlr-26084	569	13	may	may	AUX
ihlr-26084	569	14	delegate	delegate	VERB
ihlr-26084	569	15	that	that	PRON
ihlr-26084	569	16	regulatory	regulatory	NOUN
ihlr-26084	569	17	duty.154	duty.154	VERB
ihlr-26084	569	18	in	in	ADP
ihlr-26084	569	19	most	most	ADJ
ihlr-26084	569	20	countries	country	NOUN
ihlr-26084	569	21	,	,	PUNCT
ihlr-26084	570	1	governmental	governmental	ADJ
ihlr-26084	570	2	agencies	agency	NOUN
ihlr-26084	570	3	(	(	PUNCT
ihlr-26084	570	4	e.g.	e.g.	ADV
ihlr-26084	570	5	,	,	PUNCT
ihlr-26084	570	6	nice	nice	ADJ
ihlr-26084	570	7	in	in	ADP
ihlr-26084	570	8	the	the	DET
ihlr-26084	570	9	uk	uk	PROPN
ihlr-26084	570	10	and	and	CCONJ
ihlr-26084	570	11	ceps	cep	NOUN
ihlr-26084	570	12	in	in	ADP
ihlr-26084	570	13	france	france	PROPN
ihlr-26084	570	14	)	)	PUNCT
ihlr-26084	570	15	regulate	regulate	VERB
ihlr-26084	570	16	medication	medication	NOUN
ihlr-26084	570	17	prices	price	NOUN
ihlr-26084	570	18	.	.	PUNCT
ihlr-26084	571	1	these	these	DET
ihlr-26084	571	2	regulating	regulate	VERB
ihlr-26084	571	3	entities	entity	NOUN
ihlr-26084	571	4	could	could	AUX
ihlr-26084	571	5	oversee	oversee	VERB
ihlr-26084	571	6	compulsory	compulsory	ADJ
ihlr-26084	571	7	licensing	licensing	NOUN
ihlr-26084	571	8	.	.	PUNCT
ihlr-26084	572	1	these	these	DET
ihlr-26084	572	2	regulating	regulate	VERB
ihlr-26084	572	3	entities	entity	NOUN
ihlr-26084	572	4	(	(	PUNCT
ihlr-26084	572	5	e.g.	e.g.	ADJ
ihlr-26084	572	6	,	,	PUNCT
ihlr-26084	572	7	france	france	PROPN
ihlr-26084	572	8	)	)	PUNCT
ihlr-26084	572	9	benchmark	benchmark	NOUN
ihlr-26084	572	10	the	the	DET
ihlr-26084	572	11	price	price	NOUN
ihlr-26084	572	12	of	of	ADP
ihlr-26084	572	13	the	the	DET
ihlr-26084	572	14	generic	generic	NOUN
ihlr-26084	572	15	against	against	ADP
ihlr-26084	572	16	the	the	DET
ihlr-26084	572	17	branded	brand	VERB
ihlr-26084	572	18	drug	drug	NOUN
ihlr-26084	572	19	and	and	CCONJ
ihlr-26084	572	20	vice	vice	NOUN
ihlr-26084	572	21	-	-	ADJ
ihlr-26084	572	22	versa	versa	ADJ
ihlr-26084	572	23	benchmark	benchmark	NOUN
ihlr-26084	572	24	:	:	PUNCT
ihlr-26084	572	25	when	when	SCONJ
ihlr-26084	572	26	a	a	DET
ihlr-26084	572	27	generic	generic	ADJ
ihlr-26084	572	28	enters	enter	NOUN
ihlr-26084	572	29	,	,	PUNCT
ihlr-26084	572	30	the	the	DET
ihlr-26084	572	31	price	price	NOUN
ihlr-26084	572	32	of	of	ADP
ihlr-26084	572	33	the	the	DET
ihlr-26084	572	34	generic	generic	ADJ
ihlr-26084	572	35	is	be	AUX
ihlr-26084	572	36	fixed	fix	VERB
ihlr-26084	572	37	at	at	ADP
ihlr-26084	572	38	60	60	NUM
ihlr-26084	572	39	%	%	NOUN
ihlr-26084	572	40	of	of	ADP
ihlr-26084	572	41	the	the	DET
ihlr-26084	572	42	branded	brand	VERB
ihlr-26084	572	43	drug	drug	NOUN
ihlr-26084	572	44	price.155	price.155	ADP
ihlr-26084	572	45	such	such	DET
ihlr-26084	572	46	an	an	DET
ihlr-26084	572	47	entity	entity	NOUN
ihlr-26084	572	48	could	could	AUX
ihlr-26084	572	49	combine	combine	VERB
ihlr-26084	572	50	the	the	DET
ihlr-26084	572	51	compulsory	compulsory	ADJ
ihlr-26084	572	52	licensing	licensing	NOUN
ihlr-26084	572	53	with	with	ADP
ihlr-26084	572	54	an	an	DET
ihlr-26084	572	55	automatic	automatic	ADJ
ihlr-26084	572	56	price	price	NOUN
ihlr-26084	572	57	drop	drop	NOUN
ihlr-26084	572	58	as	as	ADV
ihlr-26084	572	59	soon	soon	ADV
ihlr-26084	572	60	as	as	SCONJ
ihlr-26084	572	61	a	a	DET
ihlr-26084	572	62	court	court	NOUN
ihlr-26084	572	63	holds	hold	VERB
ihlr-26084	572	64	that	that	SCONJ
ihlr-26084	572	65	a	a	DET
ihlr-26084	572	66	patent	patent	NOUN
ihlr-26084	572	67	holder	holder	NOUN
ihlr-26084	572	68	engaged	engage	VERB
ihlr-26084	572	69	in	in	ADP
ihlr-26084	572	70	a	a	DET
ihlr-26084	572	71	pay	pay	VERB
ihlr-26084	572	72	-	-	PUNCT
ihlr-26084	572	73	for	for	ADP
ihlr-26084	572	74	-	-	PUNCT
ihlr-26084	572	75	delay	delay	NOUN
ihlr-26084	572	76	agreement	agreement	NOUN
ihlr-26084	572	77	:	:	PUNCT
ihlr-26084	572	78	i.e.	i.e.	X
ihlr-26084	572	79	,	,	PUNCT
ihlr-26084	572	80	the	the	DET
ihlr-26084	572	81	branded	brand	VERB
ihlr-26084	572	82	drug	drug	NOUN
ihlr-26084	572	83	would	would	AUX
ihlr-26084	572	84	be	be	AUX
ihlr-26084	572	85	set	set	VERB
ihlr-26084	572	86	at	at	ADP
ihlr-26084	572	87	60	60	NUM
ihlr-26084	572	88	%	%	NOUN
ihlr-26084	572	89	of	of	ADP
ihlr-26084	572	90	its	its	PRON
ihlr-26084	572	91	originally	originally	ADV
ihlr-26084	572	92	negotiated	negotiate	VERB
ihlr-26084	572	93	price	price	NOUN
ihlr-26084	572	94	.	.	PUNCT
ihlr-26084	573	1	in	in	ADP
ihlr-26084	573	2	doing	do	VERB
ihlr-26084	573	3	so	so	ADV
ihlr-26084	573	4	,	,	PUNCT
ihlr-26084	573	5	the	the	DET
ihlr-26084	573	6	branded	brand	VERB
ihlr-26084	573	7	drug	drug	NOUN
ihlr-26084	573	8	would	would	AUX
ihlr-26084	573	9	not	not	PART
ihlr-26084	573	10	enjoy	enjoy	VERB
ihlr-26084	573	11	the	the	DET
ihlr-26084	573	12	remainder	remainder	NOUN
ihlr-26084	573	13	of	of	ADP
ihlr-26084	573	14	the	the	DET
ihlr-26084	573	15	patent	patent	NOUN
ihlr-26084	573	16	.	.	PUNCT
ihlr-26084	574	1	finally	finally	ADV
ihlr-26084	574	2	,	,	PUNCT
ihlr-26084	574	3	the	the	DET
ihlr-26084	574	4	courts	court	NOUN
ihlr-26084	574	5	and	and	CCONJ
ihlr-26084	574	6	regulatory	regulatory	ADJ
ihlr-26084	574	7	entity	entity	NOUN
ihlr-26084	574	8	could	could	AUX
ihlr-26084	574	9	avoid	avoid	VERB
ihlr-26084	574	10	oversight	oversight	NOUN
ihlr-26084	574	11	issues	issue	NOUN
ihlr-26084	574	12	149	149	NUM
ihlr-26084	574	13	.	.	PUNCT
ihlr-26084	575	1	see	see	VERB
ihlr-26084	575	2	colleen	colleen	PROPN
ihlr-26084	575	3	chien	chien	PROPN
ihlr-26084	575	4	,	,	PUNCT
ihlr-26084	575	5	cheap	cheap	ADJ
ihlr-26084	575	6	drugs	drug	NOUN
ihlr-26084	575	7	at	at	ADP
ihlr-26084	575	8	what	what	DET
ihlr-26084	575	9	price	price	NOUN
ihlr-26084	575	10	to	to	ADP
ihlr-26084	575	11	innovation	innovation	NOUN
ihlr-26084	575	12	:	:	PUNCT
ihlr-26084	575	13	does	do	AUX
ihlr-26084	575	14	the	the	DET
ihlr-26084	575	15	compulsory	compulsory	ADJ
ihlr-26084	575	16	licensing	licensing	NOUN
ihlr-26084	575	17	of	of	ADP
ihlr-26084	575	18	pharmaceuticals	pharmaceutical	NOUN
ihlr-26084	575	19	hurt	hurt	NOUN
ihlr-26084	575	20	innovation	innovation	NOUN
ihlr-26084	575	21	,	,	PUNCT
ihlr-26084	575	22	18	18	NUM
ihlr-26084	575	23	berkeley	berkeley	PROPN
ihlr-26084	575	24	tech	tech	NOUN
ihlr-26084	575	25	.	.	PUNCT
ihlr-26084	576	1	l.j	l.j	AUX
ihlr-26084	576	2	.	.	PROPN
ihlr-26084	576	3	853	853	NUM
ihlr-26084	576	4	(	(	PUNCT
ihlr-26084	576	5	2003	2003	NUM
ihlr-26084	576	6	)	)	PUNCT
ihlr-26084	576	7	(	(	PUNCT
ihlr-26084	576	8	discussing	discuss	VERB
ihlr-26084	576	9	compulsory	compulsory	ADJ
ihlr-26084	576	10	licensing	licensing	NOUN
ihlr-26084	576	11	in	in	ADP
ihlr-26084	576	12	the	the	DET
ihlr-26084	576	13	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	576	14	industry	industry	NOUN
ihlr-26084	576	15	in	in	ADP
ihlr-26084	576	16	the	the	DET
ihlr-26084	576	17	united	united	PROPN
ihlr-26084	576	18	states	states	PROPN
ihlr-26084	576	19	)	)	PUNCT
ihlr-26084	576	20	.	.	PUNCT
ihlr-26084	577	1	150	150	NUM
ihlr-26084	577	2	.	.	PUNCT
ihlr-26084	577	3	see	see	VERB
ihlr-26084	577	4	i	i	PROPN
ihlr-26084	577	5	d.	d.	PROPN
ihlr-26084	577	6	;	;	PUNCT
ihlr-26084	577	7	petra	petra	PROPN
ihlr-26084	577	8	moser	moser	PROPN
ihlr-26084	577	9	&	&	CCONJ
ihlr-26084	577	10	alessandra	alessandra	PROPN
ihlr-26084	577	11	voena	voena	PROPN
ihlr-26084	577	12	,	,	PUNCT
ihlr-26084	577	13	compulsory	compulsory	ADJ
ihlr-26084	577	14	licensing	licensing	NOUN
ihlr-26084	577	15	:	:	PUNCT
ihlr-26084	577	16	evidence	evidence	NOUN
ihlr-26084	577	17	from	from	ADP
ihlr-26084	577	18	the	the	DET
ihlr-26084	577	19	trading	trading	NOUN
ihlr-26084	577	20	with	with	ADP
ihlr-26084	577	21	the	the	DET
ihlr-26084	577	22	enemy	enemy	NOUN
ihlr-26084	577	23	act	act	PROPN
ihlr-26084	577	24	,	,	PUNCT
ihlr-26084	577	25	102	102	NUM
ihlr-26084	577	26	am	am	NOUN
ihlr-26084	577	27	.	.	PUNCT
ihlr-26084	578	1	econ	econ	PROPN
ihlr-26084	578	2	.	.	PUNCT
ihlr-26084	579	1	rev	rev	PROPN
ihlr-26084	579	2	.	.	PROPN
ihlr-26084	579	3	396	396	NUM
ihlr-26084	579	4	(	(	PUNCT
ihlr-26084	579	5	2012	2012	NUM
ihlr-26084	579	6	)	)	PUNCT
ihlr-26084	579	7	(	(	PUNCT
ihlr-26084	579	8	finding	find	VERB
ihlr-26084	579	9	compulsory	compulsory	ADJ
ihlr-26084	579	10	licenses	license	NOUN
ihlr-26084	579	11	boosted	boost	VERB
ihlr-26084	579	12	domestic	domestic	ADJ
ihlr-26084	579	13	inventions	invention	NOUN
ihlr-26084	579	14	)	)	PUNCT
ihlr-26084	579	15	.	.	PUNCT
ihlr-26084	580	1	151	151	NUM
ihlr-26084	580	2	.	.	PUNCT
ihlr-26084	581	1	see	see	VERB
ihlr-26084	581	2	agreement	agreement	NOUN
ihlr-26084	581	3	on	on	ADP
ihlr-26084	581	4	trade	trade	NOUN
ihlr-26084	581	5	-	-	PUNCT
ihlr-26084	581	6	related	relate	VERB
ihlr-26084	581	7	aspects	aspect	NOUN
ihlr-26084	581	8	of	of	ADP
ihlr-26084	581	9	intellectual	intellectual	ADJ
ihlr-26084	581	10	property	property	NOUN
ihlr-26084	581	11	rights	right	NOUN
ihlr-26084	581	12	,	,	PUNCT
ihlr-26084	581	13	apr	apr	PROPN
ihlr-26084	581	14	.	.	PROPN
ihlr-26084	581	15	15	15	NUM
ihlr-26084	581	16	,	,	PUNCT
ihlr-26084	581	17	1994	1994	NUM
ihlr-26084	581	18	,	,	PUNCT
ihlr-26084	581	19	marrakesh	marrakesh	NOUN
ihlr-26084	581	20	agreement	agreement	NOUN
ihlr-26084	581	21	establishing	establish	VERB
ihlr-26084	581	22	the	the	DET
ihlr-26084	581	23	world	world	NOUN
ihlr-26084	581	24	trade	trade	NOUN
ihlr-26084	581	25	organization	organization	NOUN
ihlr-26084	581	26	.	.	PUNCT
ihlr-26084	582	1	152	152	NUM
ihlr-26084	582	2	.	.	PUNCT
ihlr-26084	583	1	i	i	PRON
ihlr-26084	583	2	d.	d.	PROPN
ihlr-26084	583	3	at	at	ADP
ihlr-26084	583	4	art	art	NOUN
ihlr-26084	583	5	.	.	PUNCT
ihlr-26084	584	1	8	8	NUM
ihlr-26084	584	2	.	.	X
ihlr-26084	584	3	153	153	NUM
ihlr-26084	584	4	.	.	PUNCT
ihlr-26084	585	1	i	i	PRON
ihlr-26084	585	2	d.	d.	PROPN
ihlr-26084	585	3	154	154	NUM
ihlr-26084	585	4	.	.	PUNCT
ihlr-26084	586	1	see	see	VERB
ihlr-26084	586	2	paul	paul	PROPN
ihlr-26084	586	3	l.	l.	PROPN
ihlr-26084	586	4	joskow	joskow	PROPN
ihlr-26084	586	5	,	,	PUNCT
ihlr-26084	586	6	transaction	transaction	NOUN
ihlr-26084	586	7	cost	cost	NOUN
ihlr-26084	586	8	economics	economic	NOUN
ihlr-26084	586	9	,	,	PUNCT
ihlr-26084	586	10	antitrust	antitrust	ADJ
ihlr-26084	586	11	rules	rule	NOUN
ihlr-26084	586	12	,	,	PUNCT
ihlr-26084	586	13	and	and	CCONJ
ihlr-26084	586	14	remedies	remedy	NOUN
ihlr-26084	586	15	,	,	PUNCT
ihlr-26084	586	16	18	18	NUM
ihlr-26084	586	17	j.	j.	PROPN
ihlr-26084	586	18	law	law	PROPN
ihlr-26084	586	19	,	,	PUNCT
ihlr-26084	586	20	econ	econ	PROPN
ihlr-26084	586	21	.	.	PROPN
ihlr-26084	586	22	&	&	CCONJ
ihlr-26084	586	23	org	org	PROPN
ihlr-26084	586	24	.	.	PUNCT
ihlr-26084	586	25	95	95	NUM
ihlr-26084	586	26	(	(	PUNCT
ihlr-26084	586	27	2002	2002	NUM
ihlr-26084	586	28	)	)	PUNCT
ihlr-26084	586	29	(	(	PUNCT
ihlr-26084	586	30	discussing	discuss	VERB
ihlr-26084	586	31	why	why	SCONJ
ihlr-26084	586	32	courts	court	NOUN
ihlr-26084	586	33	favor	favor	VERB
ihlr-26084	586	34	certain	certain	ADJ
ihlr-26084	586	35	remedies	remedy	NOUN
ihlr-26084	586	36	)	)	PUNCT
ihlr-26084	586	37	.	.	PUNCT
ihlr-26084	587	1	155	155	NUM
ihlr-26084	587	2	.	.	PUNCT
ihlr-26084	587	3	rémond	rémond	ADJ
ihlr-26084	587	4	,	,	PUNCT
ihlr-26084	587	5	supra	supra	PROPN
ihlr-26084	587	6	note	note	NOUN
ihlr-26084	587	7	89	89	NUM
ihlr-26084	587	8	.	.	PUNCT
ihlr-26084	587	9	2022	2022	NUM
ihlr-26084	587	10	]	]	PUNCT
ihlr-26084	587	11	reverse	reverse	ADJ
ihlr-26084	587	12	payment	payment	NOUN
ihlr-26084	587	13	:	:	PUNCT
ihlr-26084	587	14	a	a	DET
ihlr-26084	587	15	comparative	comparative	ADJ
ihlr-26084	587	16	study	study	NOUN
ihlr-26084	587	17	43	43	NUM
ihlr-26084	587	18	altogether	altogether	ADV
ihlr-26084	587	19	by	by	ADP
ihlr-26084	587	20	rendering	render	VERB
ihlr-26084	587	21	the	the	DET
ihlr-26084	587	22	patent(s	patent(s	NOUN
ihlr-26084	587	23	)	)	PUNCT
ihlr-26084	587	24	used	use	VERB
ihlr-26084	587	25	to	to	PART
ihlr-26084	587	26	protect	protect	VERB
ihlr-26084	587	27	the	the	DET
ihlr-26084	587	28	branded	brand	VERB
ihlr-26084	587	29	drug	drug	NOUN
ihlr-26084	587	30	unenforceable	unenforceable	ADJ
ihlr-26084	587	31	.	.	PUNCT
ihlr-26084	588	1	this	this	DET
ihlr-26084	588	2	unenforceability	unenforceability	NOUN
ihlr-26084	588	3	would	would	AUX
ihlr-26084	588	4	extend	extend	VERB
ihlr-26084	588	5	to	to	ADP
ihlr-26084	588	6	any	any	DET
ihlr-26084	588	7	compound	compound	NOUN
ihlr-26084	588	8	that	that	PRON
ihlr-26084	588	9	serves	serve	VERB
ihlr-26084	588	10	the	the	DET
ihlr-26084	588	11	same	same	ADJ
ihlr-26084	588	12	therapeutic	therapeutic	ADJ
ihlr-26084	588	13	treatment	treatment	NOUN
ihlr-26084	588	14	or	or	CCONJ
ihlr-26084	588	15	any	any	DET
ihlr-26084	588	16	patents	patent	NOUN
ihlr-26084	588	17	that	that	PRON
ihlr-26084	588	18	cover	cover	VERB
ihlr-26084	588	19	the	the	DET
ihlr-26084	588	20	manufacturing	manufacturing	NOUN
ihlr-26084	588	21	process	process	NOUN
ihlr-26084	588	22	.	.	PUNCT
ihlr-26084	589	1	patents	patent	NOUN
ihlr-26084	589	2	obtained	obtain	VERB
ihlr-26084	589	3	through	through	ADP
ihlr-26084	589	4	fraud	fraud	NOUN
ihlr-26084	589	5	can	can	AUX
ihlr-26084	589	6	violate	violate	VERB
ihlr-26084	589	7	antitrust	antitrust	ADJ
ihlr-26084	589	8	laws.156	laws.156	PROPN
ihlr-26084	589	9	the	the	DET
ihlr-26084	589	10	u.s	u.s	PROPN
ihlr-26084	589	11	.	.	PROPN
ihlr-26084	589	12	supreme	supreme	PROPN
ihlr-26084	589	13	court	court	PROPN
ihlr-26084	589	14	has	have	AUX
ihlr-26084	589	15	expressed	express	VERB
ihlr-26084	589	16	that	that	SCONJ
ihlr-26084	589	17	patents	patent	NOUN
ihlr-26084	589	18	are	be	AUX
ihlr-26084	589	19	like	like	ADP
ihlr-26084	589	20	a	a	DET
ihlr-26084	589	21	“	"	PUNCT
ihlr-26084	589	22	public	public	ADJ
ihlr-26084	589	23	franchise	franchise	NOUN
ihlr-26084	589	24	.	.	PUNCT
ihlr-26084	589	25	”157	”157	NOUN
ihlr-26084	590	1	an	an	DET
ihlr-26084	590	2	unlawful	unlawful	ADJ
ihlr-26084	590	3	pay	pay	NOUN
ihlr-26084	590	4	-	-	PUNCT
ihlr-26084	590	5	for	for	ADP
ihlr-26084	590	6	-	-	PUNCT
ihlr-26084	590	7	delay	delay	NOUN
ihlr-26084	590	8	amounts	amount	VERB
ihlr-26084	590	9	to	to	ADP
ihlr-26084	590	10	an	an	DET
ihlr-26084	590	11	illegal	illegal	ADJ
ihlr-26084	590	12	extension	extension	NOUN
ihlr-26084	590	13	of	of	ADP
ihlr-26084	590	14	the	the	DET
ihlr-26084	590	15	public	public	ADJ
ihlr-26084	590	16	franchise	franchise	NOUN
ihlr-26084	590	17	that	that	PRON
ihlr-26084	590	18	defrauds	defraud	VERB
ihlr-26084	590	19	the	the	DET
ihlr-26084	590	20	public	public	NOUN
ihlr-26084	590	21	.	.	PUNCT
ihlr-26084	591	1	policymakers	policymaker	NOUN
ihlr-26084	591	2	should	should	AUX
ihlr-26084	591	3	investigate	investigate	VERB
ihlr-26084	591	4	how	how	SCONJ
ihlr-26084	591	5	to	to	PART
ihlr-26084	591	6	make	make	VERB
ihlr-26084	591	7	unenforceable	unenforceable	ADJ
ihlr-26084	591	8	any	any	DET
ihlr-26084	591	9	patent	patent	NOUN
ihlr-26084	591	10	maintained	maintain	VERB
ihlr-26084	591	11	through	through	ADP
ihlr-26084	591	12	anticompetitive	anticompetitive	ADJ
ihlr-26084	591	13	behavior	behavior	NOUN
ihlr-26084	591	14	.	.	PUNCT
ihlr-26084	592	1	b.	b.	PROPN
ihlr-26084	592	2	beyond	beyond	ADP
ihlr-26084	592	3	regulated	regulated	ADJ
ihlr-26084	592	4	prices	price	NOUN
ihlr-26084	592	5	countries	country	NOUN
ihlr-26084	592	6	like	like	ADP
ihlr-26084	592	7	france	france	PROPN
ihlr-26084	592	8	benchmark	benchmark	VERB
ihlr-26084	592	9	the	the	DET
ihlr-26084	592	10	pricing	pricing	NOUN
ihlr-26084	592	11	of	of	ADP
ihlr-26084	592	12	generics	generic	NOUN
ihlr-26084	592	13	against	against	ADP
ihlr-26084	592	14	the	the	DET
ihlr-26084	592	15	branded	brand	VERB
ihlr-26084	592	16	drug	drug	NOUN
ihlr-26084	592	17	manufacturer	manufacturer	NOUN
ihlr-26084	592	18	.	.	PUNCT
ihlr-26084	593	1	while	while	SCONJ
ihlr-26084	593	2	the	the	DET
ihlr-26084	593	3	benefits	benefit	NOUN
ihlr-26084	593	4	of	of	ADP
ihlr-26084	593	5	those	those	DET
ihlr-26084	593	6	settlements	settlement	NOUN
ihlr-26084	593	7	are	be	AUX
ihlr-26084	593	8	smaller	small	ADJ
ihlr-26084	593	9	than	than	ADP
ihlr-26084	593	10	in	in	ADP
ihlr-26084	593	11	other	other	ADJ
ihlr-26084	593	12	jurisdictions	jurisdiction	NOUN
ihlr-26084	593	13	(	(	PUNCT
ihlr-26084	593	14	e.g.	e.g.	ADV
ihlr-26084	593	15	,	,	PUNCT
ihlr-26084	593	16	the	the	DET
ihlr-26084	593	17	us	us	PROPN
ihlr-26084	593	18	)	)	PUNCT
ihlr-26084	593	19	,	,	PUNCT
ihlr-26084	593	20	this	this	DET
ihlr-26084	593	21	approach	approach	NOUN
ihlr-26084	593	22	still	still	ADV
ihlr-26084	593	23	incentivizes	incentivize	VERB
ihlr-26084	593	24	pay	pay	NOUN
ihlr-26084	593	25	-	-	PUNCT
ihlr-26084	593	26	for	for	ADP
ihlr-26084	593	27	-	-	PUNCT
ihlr-26084	593	28	delay	delay	NOUN
ihlr-26084	593	29	settlements	settlement	NOUN
ihlr-26084	593	30	.	.	PUNCT
ihlr-26084	594	1	regulators	regulator	NOUN
ihlr-26084	594	2	can	can	AUX
ihlr-26084	594	3	deter	deter	VERB
ihlr-26084	594	4	many	many	ADJ
ihlr-26084	594	5	practices	practice	NOUN
ihlr-26084	594	6	by	by	ADP
ihlr-26084	594	7	regulating	regulate	VERB
ihlr-26084	594	8	the	the	DET
ihlr-26084	594	9	period	period	NOUN
ihlr-26084	594	10	of	of	ADP
ihlr-26084	594	11	exclusivity	exclusivity	NOUN
ihlr-26084	594	12	and	and	CCONJ
ihlr-26084	594	13	attaching	attach	VERB
ihlr-26084	594	14	generic	generic	ADJ
ihlr-26084	594	15	market	market	NOUN
ihlr-26084	594	16	entry	entry	NOUN
ihlr-26084	594	17	to	to	ADP
ihlr-26084	594	18	the	the	DET
ihlr-26084	594	19	branded	brand	VERB
ihlr-26084	594	20	market	market	NOUN
ihlr-26084	594	21	authorization	authorization	NOUN
ihlr-26084	594	22	instead	instead	ADV
ihlr-26084	594	23	of	of	ADP
ihlr-26084	594	24	the	the	DET
ihlr-26084	594	25	patent	patent	NOUN
ihlr-26084	594	26	protection	protection	NOUN
ihlr-26084	594	27	.	.	PUNCT
ihlr-26084	595	1	regulators	regulator	NOUN
ihlr-26084	595	2	already	already	ADV
ihlr-26084	595	3	ignore	ignore	VERB
ihlr-26084	595	4	patent	patent	NOUN
ihlr-26084	595	5	validity	validity	NOUN
ihlr-26084	595	6	when	when	SCONJ
ihlr-26084	595	7	they	they	PRON
ihlr-26084	595	8	guarantee	guarantee	VERB
ihlr-26084	595	9	years	year	NOUN
ihlr-26084	595	10	of	of	ADP
ihlr-26084	595	11	exclusivity.158	exclusivity.158	NOUN
ihlr-26084	595	12	while	while	SCONJ
ihlr-26084	595	13	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	595	14	companies	company	NOUN
ihlr-26084	595	15	could	could	AUX
ihlr-26084	595	16	use	use	VERB
ihlr-26084	595	17	patents	patent	NOUN
ihlr-26084	595	18	to	to	PART
ihlr-26084	595	19	protect	protect	VERB
ihlr-26084	595	20	their	their	PRON
ihlr-26084	595	21	innovation	innovation	NOUN
ihlr-26084	595	22	during	during	ADP
ihlr-26084	595	23	their	their	PRON
ihlr-26084	595	24	research	research	NOUN
ihlr-26084	595	25	and	and	CCONJ
ihlr-26084	595	26	development	development	NOUN
ihlr-26084	595	27	,	,	PUNCT
ihlr-26084	595	28	the	the	DET
ihlr-26084	595	29	market	market	NOUN
ihlr-26084	595	30	exclusivity	exclusivity	NOUN
ihlr-26084	595	31	of	of	ADP
ihlr-26084	595	32	a	a	DET
ihlr-26084	595	33	drug	drug	NOUN
ihlr-26084	595	34	period	period	NOUN
ihlr-26084	595	35	should	should	AUX
ihlr-26084	595	36	not	not	PART
ihlr-26084	595	37	be	be	AUX
ihlr-26084	595	38	linked	link	VERB
ihlr-26084	595	39	to	to	ADP
ihlr-26084	595	40	patents	patent	NOUN
ihlr-26084	595	41	.	.	PUNCT
ihlr-26084	596	1	first	first	ADV
ihlr-26084	596	2	,	,	PUNCT
ihlr-26084	596	3	such	such	DET
ihlr-26084	596	4	an	an	DET
ihlr-26084	596	5	approach	approach	NOUN
ihlr-26084	596	6	could	could	AUX
ihlr-26084	596	7	streamline	streamline	VERB
ihlr-26084	596	8	market	market	NOUN
ihlr-26084	596	9	entry	entry	NOUN
ihlr-26084	596	10	because	because	SCONJ
ihlr-26084	596	11	generic	generic	ADJ
ihlr-26084	596	12	manufacturers	manufacturer	NOUN
ihlr-26084	596	13	would	would	AUX
ihlr-26084	596	14	no	no	ADV
ihlr-26084	596	15	longer	long	ADV
ihlr-26084	596	16	have	have	VERB
ihlr-26084	596	17	to	to	PART
ihlr-26084	596	18	carry	carry	VERB
ihlr-26084	596	19	out	out	ADP
ihlr-26084	596	20	a	a	DET
ihlr-26084	596	21	patent	patent	NOUN
ihlr-26084	596	22	clearance	clearance	NOUN
ihlr-26084	596	23	studies	study	NOUN
ihlr-26084	596	24	.	.	PUNCT
ihlr-26084	597	1	instead	instead	ADV
ihlr-26084	597	2	,	,	PUNCT
ihlr-26084	597	3	they	they	PRON
ihlr-26084	597	4	could	could	AUX
ihlr-26084	597	5	safely	safely	ADV
ihlr-26084	597	6	enter	enter	VERB
ihlr-26084	597	7	a	a	DET
ihlr-26084	597	8	market	market	NOUN
ihlr-26084	597	9	knowing	know	VERB
ihlr-26084	597	10	that	that	SCONJ
ihlr-26084	597	11	the	the	DET
ihlr-26084	597	12	statutory	statutory	ADJ
ihlr-26084	597	13	period	period	NOUN
ihlr-26084	597	14	has	have	AUX
ihlr-26084	597	15	expired	expire	VERB
ihlr-26084	597	16	.	.	PUNCT
ihlr-26084	598	1	alleviating	alleviate	VERB
ihlr-26084	598	2	some	some	DET
ihlr-26084	598	3	patent	patent	NOUN
ihlr-26084	598	4	uncertainties	uncertainty	NOUN
ihlr-26084	598	5	would	would	AUX
ihlr-26084	598	6	promote	promote	VERB
ihlr-26084	598	7	generic	generic	ADJ
ihlr-26084	598	8	entry	entry	NOUN
ihlr-26084	598	9	.	.	PUNCT
ihlr-26084	599	1	regulatory	regulatory	ADJ
ihlr-26084	599	2	agencies	agency	NOUN
ihlr-26084	599	3	should	should	AUX
ihlr-26084	599	4	investigate	investigate	VERB
ihlr-26084	599	5	what	what	PRON
ihlr-26084	599	6	should	should	AUX
ihlr-26084	599	7	be	be	AUX
ihlr-26084	599	8	the	the	DET
ihlr-26084	599	9	optimal	optimal	ADJ
ihlr-26084	599	10	statutory	statutory	ADJ
ihlr-26084	599	11	period	period	NOUN
ihlr-26084	599	12	.	.	PUNCT
ihlr-26084	600	1	currently	currently	ADV
ihlr-26084	600	2	,	,	PUNCT
ihlr-26084	600	3	patent	patent	NOUN
ihlr-26084	600	4	protection	protection	NOUN
ihlr-26084	600	5	duration	duration	NOUN
ihlr-26084	600	6	varies	vary	VERB
ihlr-26084	600	7	from	from	ADP
ihlr-26084	600	8	drug	drug	NOUN
ihlr-26084	600	9	to	to	ADP
ihlr-26084	600	10	drug	drug	NOUN
ihlr-26084	600	11	because	because	SCONJ
ihlr-26084	600	12	some	some	DET
ihlr-26084	600	13	manufacturers	manufacturer	NOUN
ihlr-26084	600	14	extend	extend	VERB
ihlr-26084	600	15	their	their	PRON
ihlr-26084	600	16	protection	protection	NOUN
ihlr-26084	600	17	through	through	ADP
ihlr-26084	600	18	process	process	NOUN
ihlr-26084	600	19	patent	patent	NOUN
ihlr-26084	600	20	protection	protection	NOUN
ihlr-26084	600	21	or	or	CCONJ
ihlr-26084	600	22	compound	compound	NOUN
ihlr-26084	600	23	protection	protection	NOUN
ihlr-26084	600	24	.	.	PUNCT
ihlr-26084	601	1	drug	drug	NOUN
ihlr-26084	601	2	manufacturers	manufacturer	NOUN
ihlr-26084	601	3	complain	complain	VERB
ihlr-26084	601	4	that	that	SCONJ
ihlr-26084	601	5	patent	patent	NOUN
ihlr-26084	601	6	protection	protection	NOUN
ihlr-26084	601	7	is	be	AUX
ihlr-26084	601	8	necessary	necessary	ADJ
ihlr-26084	601	9	because	because	SCONJ
ihlr-26084	601	10	research	research	NOUN
ihlr-26084	601	11	and	and	CCONJ
ihlr-26084	601	12	development	development	NOUN
ihlr-26084	601	13	for	for	ADP
ihlr-26084	601	14	drugs	drug	NOUN
ihlr-26084	601	15	are	be	AUX
ihlr-26084	601	16	expensive	expensive	ADJ
ihlr-26084	601	17	and	and	CCONJ
ihlr-26084	601	18	that	that	SCONJ
ihlr-26084	601	19	only	only	ADV
ihlr-26084	601	20	a	a	DET
ihlr-26084	601	21	few	few	ADJ
ihlr-26084	601	22	drugs	drug	NOUN
ihlr-26084	601	23	pan	pan	VERB
ihlr-26084	601	24	out.159	out.159	PROPN
ihlr-26084	601	25	however	however	ADV
ihlr-26084	601	26	,	,	PUNCT
ihlr-26084	601	27	much	much	ADJ
ihlr-26084	601	28	of	of	ADP
ihlr-26084	601	29	this	this	DET
ihlr-26084	601	30	complaint	complaint	NOUN
ihlr-26084	601	31	seems	seem	VERB
ihlr-26084	601	32	156	156	NUM
ihlr-26084	601	33	.	.	PUNCT
ihlr-26084	602	1	see	see	VERB
ihlr-26084	602	2	e.g.	e.g.	ADV
ihlr-26084	602	3	,	,	PUNCT
ihlr-26084	602	4	walker	walker	NOUN
ihlr-26084	602	5	process	process	NOUN
ihlr-26084	602	6	equipment	equipment	PROPN
ihlr-26084	602	7	,	,	PUNCT
ihlr-26084	602	8	inc	inc	PROPN
ihlr-26084	602	9	.	.	PROPN
ihlr-26084	603	1	v.	v.	ADP
ihlr-26084	603	2	food	food	PROPN
ihlr-26084	603	3	machinery	machinery	PROPN
ihlr-26084	603	4	&	&	CCONJ
ihlr-26084	603	5	chemical	chemical	PROPN
ihlr-26084	603	6	corp	corp	PROPN
ihlr-26084	603	7	.	.	PROPN
ihlr-26084	603	8	,	,	PUNCT
ihlr-26084	603	9	382	382	NUM
ihlr-26084	603	10	u.s	u.s	PROPN
ihlr-26084	603	11	.	.	PROPN
ihlr-26084	603	12	172	172	NUM
ihlr-26084	603	13	(	(	PUNCT
ihlr-26084	603	14	1965	1965	NUM
ihlr-26084	603	15	)	)	PUNCT
ihlr-26084	603	16	(	(	PUNCT
ihlr-26084	603	17	holding	hold	VERB
ihlr-26084	603	18	enforcing	enforce	VERB
ihlr-26084	603	19	a	a	DET
ihlr-26084	603	20	patent	patent	NOUN
ihlr-26084	603	21	obtained	obtain	VERB
ihlr-26084	603	22	through	through	ADP
ihlr-26084	603	23	fraud	fraud	NOUN
ihlr-26084	603	24	on	on	ADP
ihlr-26084	603	25	the	the	DET
ihlr-26084	603	26	patent	patent	NOUN
ihlr-26084	603	27	office	office	NOUN
ihlr-26084	603	28	may	may	AUX
ihlr-26084	603	29	be	be	AUX
ihlr-26084	603	30	violative	violative	ADJ
ihlr-26084	603	31	of	of	ADP
ihlr-26084	603	32	the	the	DET
ihlr-26084	603	33	sherman	sherman	PROPN
ihlr-26084	603	34	act	act	PROPN
ihlr-26084	603	35	)	)	PUNCT
ihlr-26084	603	36	;	;	PUNCT
ihlr-26084	604	1	therasense	therasense	PROPN
ihlr-26084	604	2	inc	inc	PROPN
ihlr-26084	604	3	.	.	PROPN
ihlr-26084	604	4	v.	v.	ADP
ihlr-26084	604	5	becton	becton	PROPN
ihlr-26084	604	6	dickinson	dickinson	PROPN
ihlr-26084	604	7	and	and	CCONJ
ihlr-26084	604	8	co.	co.	PROPN
ihlr-26084	604	9	,	,	PUNCT
ihlr-26084	604	10	649	649	NUM
ihlr-26084	604	11	f.3d	f.3d	NUM
ihlr-26084	604	12	1276	1276	NUM
ihlr-26084	604	13	,	,	PUNCT
ihlr-26084	604	14	1288	1288	NUM
ihlr-26084	604	15	(	(	PUNCT
ihlr-26084	604	16	fed	fed	PROPN
ihlr-26084	604	17	.	.	PUNCT
ihlr-26084	604	18	cir	cir	PROPN
ihlr-26084	604	19	.	.	PROPN
ihlr-26084	604	20	2011	2011	NUM
ihlr-26084	604	21	)	)	PUNCT
ihlr-26084	604	22	(	(	PUNCT
ihlr-26084	604	23	“	"	PUNCT
ihlr-26084	604	24	[	[	X
ihlr-26084	604	25	i]nequitable	i]nequitable	ADJ
ihlr-26084	604	26	conduct	conduct	NOUN
ihlr-26084	604	27	regarding	regard	VERB
ihlr-26084	604	28	any	any	DET
ihlr-26084	604	29	single	single	ADJ
ihlr-26084	604	30	claim	claim	NOUN
ihlr-26084	604	31	renders	render	VERB
ihlr-26084	604	32	the	the	DET
ihlr-26084	604	33	entire	entire	ADJ
ihlr-26084	604	34	patent	patent	NOUN
ihlr-26084	604	35	unenforceable	unenforceable	ADJ
ihlr-26084	604	36	,	,	PUNCT
ihlr-26084	604	37	”	"	PUNCT
ihlr-26084	604	38	“	"	PUNCT
ihlr-26084	604	39	can	can	AUX
ihlr-26084	604	40	not	not	PART
ihlr-26084	604	41	be	be	AUX
ihlr-26084	604	42	cured	cure	VERB
ihlr-26084	604	43	by	by	ADP
ihlr-26084	604	44	reissue	reissue	NOUN
ihlr-26084	604	45	,	,	PUNCT
ihlr-26084	604	46	”	"	PUNCT
ihlr-26084	604	47	and	and	CCONJ
ihlr-26084	604	48	“	"	PUNCT
ihlr-26084	604	49	can	can	AUX
ihlr-26084	604	50	spread	spread	VERB
ihlr-26084	604	51	from	from	ADP
ihlr-26084	604	52	a	a	DET
ihlr-26084	604	53	single	single	ADJ
ihlr-26084	604	54	patent	patent	NOUN
ihlr-26084	604	55	to	to	PART
ihlr-26084	604	56	render	render	VERB
ihlr-26084	604	57	unenforceable	unenforceable	ADJ
ihlr-26084	604	58	other	other	ADJ
ihlr-26084	604	59	related	related	ADJ
ihlr-26084	604	60	patents	patent	NOUN
ihlr-26084	604	61	and	and	CCONJ
ihlr-26084	604	62	applications	application	NOUN
ihlr-26084	604	63	in	in	ADP
ihlr-26084	604	64	the	the	DET
ihlr-26084	604	65	same	same	ADJ
ihlr-26084	604	66	technology	technology	NOUN
ihlr-26084	604	67	family	family	NOUN
ihlr-26084	604	68	.	.	PUNCT
ihlr-26084	604	69	”	"	PUNCT
ihlr-26084	604	70	)	)	PUNCT
ihlr-26084	604	71	.	.	PUNCT
ihlr-26084	605	1	157	157	NUM
ihlr-26084	605	2	.	.	PUNCT
ihlr-26084	606	1	oil	oil	NOUN
ihlr-26084	606	2	states	states	PROPN
ihlr-26084	606	3	energy	energy	NOUN
ihlr-26084	606	4	v.	v.	ADP
ihlr-26084	606	5	greene	greene	PROPN
ihlr-26084	606	6	's	's	PART
ihlr-26084	606	7	energy	energy	NOUN
ihlr-26084	606	8	group	group	NOUN
ihlr-26084	606	9	,	,	PUNCT
ihlr-26084	606	10	138	138	NUM
ihlr-26084	606	11	s.	s.	PROPN
ihlr-26084	606	12	ct	ct	PROPN
ihlr-26084	606	13	.	.	PROPN
ihlr-26084	606	14	1365	1365	NUM
ihlr-26084	606	15	(	(	PUNCT
ihlr-26084	606	16	2018	2018	NUM
ihlr-26084	606	17	)	)	PUNCT
ihlr-26084	606	18	.	.	PUNCT
ihlr-26084	607	1	the	the	DET
ihlr-26084	607	2	us	us	PROPN
ihlr-26084	607	3	supreme	supreme	PROPN
ihlr-26084	607	4	court	court	PROPN
ihlr-26084	607	5	has	have	AUX
ihlr-26084	607	6	referred	refer	VERB
ihlr-26084	607	7	to	to	ADP
ihlr-26084	607	8	patent	patent	NOUN
ihlr-26084	607	9	as	as	ADP
ihlr-26084	607	10	“	"	PUNCT
ihlr-26084	607	11	public	public	ADJ
ihlr-26084	607	12	franchise	franchise	NOUN
ihlr-26084	607	13	”	"	PUNCT
ihlr-26084	607	14	instead	instead	ADV
ihlr-26084	607	15	of	of	ADP
ihlr-26084	607	16	a	a	DET
ihlr-26084	607	17	right	right	ADJ
ihlr-26084	607	18	akin	akin	ADJ
ihlr-26084	607	19	to	to	ADP
ihlr-26084	607	20	property	property	NOUN
ihlr-26084	607	21	rights	right	NOUN
ihlr-26084	607	22	.	.	PUNCT
ihlr-26084	608	1	i	i	PRON
ihlr-26084	608	2	d.	d.	PROPN
ihlr-26084	608	3	137374	137374	NUM
ihlr-26084	608	4	.	.	PUNCT
ihlr-26084	609	1	so	so	ADV
ihlr-26084	609	2	,	,	PUNCT
ihlr-26084	609	3	patents	patent	NOUN
ihlr-26084	609	4	can	can	AUX
ihlr-26084	609	5	be	be	AUX
ihlr-26084	609	6	revoked	revoke	VERB
ihlr-26084	609	7	without	without	ADP
ihlr-26084	609	8	compensation	compensation	NOUN
ihlr-26084	609	9	or	or	CCONJ
ihlr-26084	609	10	a	a	DET
ihlr-26084	609	11	review	review	NOUN
ihlr-26084	609	12	from	from	ADP
ihlr-26084	609	13	article	article	NOUN
ihlr-26084	609	14	iii	iii	NUM
ihlr-26084	609	15	courts	court	NOUN
ihlr-26084	609	16	under	under	ADP
ihlr-26084	609	17	the	the	DET
ihlr-26084	609	18	seventh	seventh	ADJ
ihlr-26084	609	19	amendment	amendment	NOUN
ihlr-26084	609	20	.	.	PUNCT
ihlr-26084	610	1	158	158	X
ihlr-26084	610	2	.	.	PUNCT
ihlr-26084	611	1	valerie	valerie	PROPN
ihlr-26084	611	2	junod	junod	PROPN
ihlr-26084	611	3	,	,	PUNCT
ihlr-26084	611	4	drug	drug	NOUN
ihlr-26084	611	5	marketing	marketing	NOUN
ihlr-26084	611	6	exclusivity	exclusivity	NOUN
ihlr-26084	611	7	under	under	ADP
ihlr-26084	611	8	united	united	PROPN
ihlr-26084	611	9	states	states	PROPN
ihlr-26084	611	10	and	and	CCONJ
ihlr-26084	611	11	european	european	PROPN
ihlr-26084	611	12	union	union	PROPN
ihlr-26084	611	13	law	law	NOUN
ihlr-26084	611	14	,	,	PUNCT
ihlr-26084	611	15	59	59	NUM
ihlr-26084	611	16	food	food	NOUN
ihlr-26084	611	17	&	&	CCONJ
ihlr-26084	611	18	drug	drug	PROPN
ihlr-26084	611	19	l.j	l.j	PROPN
ihlr-26084	611	20	.	.	PROPN
ihlr-26084	611	21	479	479	NUM
ihlr-26084	611	22	(	(	PUNCT
ihlr-26084	611	23	2004	2004	NUM
ihlr-26084	611	24	)	)	PUNCT
ihlr-26084	611	25	.	.	PUNCT
ihlr-26084	612	1	159	159	NUM
ihlr-26084	612	2	.	.	PUNCT
ihlr-26084	613	1	melanie	melanie	PROPN
ihlr-26084	613	2	j.	j.	PROPN
ihlr-26084	613	3	brown	brown	PROPN
ihlr-26084	613	4	,	,	PUNCT
ihlr-26084	613	5	reverse	reverse	VERB
ihlr-26084	613	6	payment	payment	NOUN
ihlr-26084	613	7	settlements	settlement	NOUN
ihlr-26084	613	8	in	in	ADP
ihlr-26084	613	9	the	the	DET
ihlr-26084	613	10	european	european	PROPN
ihlr-26084	613	11	commission	commission	PROPN
ihlr-26084	613	12	's	's	PART
ihlr-26084	613	13	pharmaceutical	pharmaceutical	ADJ
ihlr-26084	613	14	sector	sector	NOUN
ihlr-26084	613	15	inquiry	inquiry	NOUN
ihlr-26084	613	16	report	report	NOUN
ihlr-26084	613	17	:	:	PUNCT
ihlr-26084	613	18	a	a	DET
ihlr-26084	613	19	missed	miss	VERB
ihlr-26084	613	20	opportunity	opportunity	NOUN
ihlr-26084	613	21	to	to	PART
ihlr-26084	613	22	benefit	benefit	VERB
ihlr-26084	613	23	from	from	ADP
ihlr-26084	613	24	u.s	u.s	PROPN
ihlr-26084	613	25	.	.	PROPN
ihlr-26084	613	26	experience	experience	NOUN
ihlr-26084	613	27	,	,	PUNCT
ihlr-26084	613	28	33	33	NUM
ihlr-26084	613	29	44	44	NUM
ihlr-26084	613	30	indiana	indiana	PROPN
ihlr-26084	613	31	health	health	PROPN
ihlr-26084	613	32	law	law	PROPN
ihlr-26084	613	33	review	review	NOUN
ihlr-26084	614	1	[	[	X
ihlr-26084	614	2	vol	vol	NOUN
ihlr-26084	614	3	.	.	PUNCT
ihlr-26084	615	1	19:21	19:21	NUM
ihlr-26084	615	2	exaggerated	exaggerate	VERB
ihlr-26084	615	3	.	.	PUNCT
ihlr-26084	616	1	first	first	ADV
ihlr-26084	616	2	,	,	PUNCT
ihlr-26084	616	3	most	most	ADJ
ihlr-26084	616	4	of	of	ADP
ihlr-26084	616	5	the	the	DET
ihlr-26084	616	6	manufacturers	manufacturer	NOUN
ihlr-26084	616	7	’	’	PART
ihlr-26084	616	8	cost	cost	NOUN
ihlr-26084	616	9	are	be	AUX
ihlr-26084	616	10	not	not	PART
ihlr-26084	616	11	linked	link	VERB
ihlr-26084	616	12	to	to	ADP
ihlr-26084	616	13	research	research	NOUN
ihlr-26084	616	14	.	.	PUNCT
ihlr-26084	617	1	in	in	ADP
ihlr-26084	617	2	a	a	DET
ihlr-26084	617	3	survey	survey	NOUN
ihlr-26084	617	4	,	,	PUNCT
ihlr-26084	617	5	the	the	DET
ihlr-26084	617	6	european	european	PROPN
ihlr-26084	617	7	commission	commission	PROPN
ihlr-26084	617	8	found	find	VERB
ihlr-26084	617	9	that	that	SCONJ
ihlr-26084	617	10	drug	drug	NOUN
ihlr-26084	617	11	manufacturers	manufacturer	NOUN
ihlr-26084	617	12	spent	spend	VERB
ihlr-26084	617	13	more	more	ADJ
ihlr-26084	617	14	on	on	ADP
ihlr-26084	617	15	marketing	marketing	NOUN
ihlr-26084	617	16	and	and	CCONJ
ihlr-26084	617	17	promotion	promotion	NOUN
ihlr-26084	617	18	than	than	ADP
ihlr-26084	617	19	on	on	ADP
ihlr-26084	617	20	research	research	NOUN
ihlr-26084	617	21	(	(	PUNCT
ihlr-26084	617	22	21	21	NUM
ihlr-26084	617	23	%	%	NOUN
ihlr-26084	617	24	versus	versus	ADP
ihlr-26084	617	25	18	18	NUM
ihlr-26084	617	26	%	%	NOUN
ihlr-26084	617	27	of	of	ADP
ihlr-26084	617	28	annual	annual	ADJ
ihlr-26084	617	29	costs	cost	NOUN
ihlr-26084	617	30	)	)	PUNCT
ihlr-26084	617	31	in	in	ADP
ihlr-26084	617	32	2007.160	2007.160	NUM
ihlr-26084	617	33	the	the	DET
ihlr-26084	617	34	scale	scale	NOUN
ihlr-26084	617	35	of	of	ADP
ihlr-26084	617	36	marketing	marketing	NOUN
ihlr-26084	617	37	costs	cost	NOUN
ihlr-26084	617	38	may	may	AUX
ihlr-26084	617	39	also	also	ADV
ihlr-26084	617	40	be	be	AUX
ihlr-26084	617	41	underestimated	underestimate	VERB
ihlr-26084	617	42	:	:	PUNCT
ihlr-26084	617	43	an	an	DET
ihlr-26084	617	44	industry	industry	NOUN
ihlr-26084	617	45	observer	observer	NOUN
ihlr-26084	617	46	noted	note	VERB
ihlr-26084	617	47	that	that	SCONJ
ihlr-26084	617	48	some	some	DET
ihlr-26084	617	49	marketing	marketing	NOUN
ihlr-26084	617	50	costs	cost	NOUN
ihlr-26084	617	51	are	be	AUX
ihlr-26084	617	52	classified	classify	VERB
ihlr-26084	617	53	as	as	ADP
ihlr-26084	617	54	research	research	NOUN
ihlr-26084	617	55	costs.161	costs.161	VERB
ihlr-26084	617	56	this	this	DET
ihlr-26084	617	57	observation	observation	NOUN
ihlr-26084	617	58	in	in	ADP
ihlr-26084	617	59	europe	europe	PROPN
ihlr-26084	617	60	is	be	AUX
ihlr-26084	617	61	surprising	surprising	ADJ
ihlr-26084	617	62	because	because	SCONJ
ihlr-26084	617	63	most	most	ADJ
ihlr-26084	617	64	european	european	ADJ
ihlr-26084	617	65	countries	country	NOUN
ihlr-26084	617	66	do	do	AUX
ihlr-26084	617	67	not	not	PART
ihlr-26084	617	68	allow	allow	VERB
ihlr-26084	617	69	most	most	ADJ
ihlr-26084	617	70	drugs	drug	NOUN
ihlr-26084	617	71	to	to	PART
ihlr-26084	617	72	be	be	AUX
ihlr-26084	617	73	advertised	advertise	VERB
ihlr-26084	617	74	to	to	AUX
ihlr-26084	617	75	consumers.162	consumers.162	PROPN
ihlr-26084	617	76	second	second	ADV
ihlr-26084	617	77	,	,	PUNCT
ihlr-26084	617	78	the	the	DET
ihlr-26084	617	79	cost	cost	NOUN
ihlr-26084	617	80	survey	survey	NOUN
ihlr-26084	617	81	did	do	AUX
ihlr-26084	617	82	not	not	PART
ihlr-26084	617	83	ask	ask	VERB
ihlr-26084	617	84	about	about	ADP
ihlr-26084	617	85	litigation	litigation	NOUN
ihlr-26084	617	86	costs	cost	NOUN
ihlr-26084	617	87	.	.	PUNCT
ihlr-26084	618	1	however	however	ADV
ihlr-26084	618	2	,	,	PUNCT
ihlr-26084	618	3	during	during	ADP
ihlr-26084	618	4	a	a	DET
ihlr-26084	618	5	hearing	hearing	NOUN
ihlr-26084	618	6	,	,	PUNCT
ihlr-26084	618	7	congresswoman	congresswoman	NOUN
ihlr-26084	618	8	katie	katie	PROPN
ihlr-26084	618	9	porter	porter	PROPN
ihlr-26084	618	10	pointed	point	VERB
ihlr-26084	618	11	out	out	ADP
ihlr-26084	618	12	that	that	SCONJ
ihlr-26084	618	13	abbvie	abbvie	PROPN
ihlr-26084	618	14	spent	spend	VERB
ihlr-26084	618	15	$	$	SYM
ihlr-26084	618	16	1.6	1.6	NUM
ihlr-26084	618	17	billion	billion	NUM
ihlr-26084	618	18	on	on	ADP
ihlr-26084	618	19	litigation	litigation	NOUN
ihlr-26084	618	20	and	and	CCONJ
ihlr-26084	618	21	settlements	settlement	NOUN
ihlr-26084	618	22	,	,	PUNCT
ihlr-26084	618	23	$	$	SYM
ihlr-26084	618	24	2.45	2.45	NUM
ihlr-26084	618	25	billion	billion	NUM
ihlr-26084	618	26	on	on	ADP
ihlr-26084	618	27	research	research	NOUN
ihlr-26084	618	28	and	and	CCONJ
ihlr-26084	618	29	development	development	NOUN
ihlr-26084	618	30	,	,	PUNCT
ihlr-26084	618	31	and	and	CCONJ
ihlr-26084	618	32	$	$	SYM
ihlr-26084	618	33	4.71	4.71	NUM
ihlr-26084	618	34	billion	billion	NUM
ihlr-26084	618	35	on	on	ADP
ihlr-26084	618	36	marketing	marketing	NOUN
ihlr-26084	618	37	between	between	ADP
ihlr-26084	618	38	2013	2013	NUM
ihlr-26084	618	39	and	and	CCONJ
ihlr-26084	618	40	2018.163	2018.163	NUM
ihlr-26084	618	41	in	in	ADP
ihlr-26084	618	42	total	total	ADJ
ihlr-26084	618	43	,	,	PUNCT
ihlr-26084	618	44	abbvie	abbvie	PROPN
ihlr-26084	618	45	’s	’s	PART
ihlr-26084	618	46	litigation	litigation	NOUN
ihlr-26084	618	47	and	and	CCONJ
ihlr-26084	618	48	settlements	settlement	NOUN
ihlr-26084	618	49	and	and	CCONJ
ihlr-26084	618	50	marketing	marketing	NOUN
ihlr-26084	618	51	budgets	budget	NOUN
ihlr-26084	618	52	were	be	AUX
ihlr-26084	618	53	more	more	ADV
ihlr-26084	618	54	than	than	ADP
ihlr-26084	618	55	double	double	VERB
ihlr-26084	618	56	its	its	PRON
ihlr-26084	618	57	research	research	NOUN
ihlr-26084	618	58	budget	budget	NOUN
ihlr-26084	618	59	.	.	PUNCT
ihlr-26084	619	1	incentivizing	incentivize	VERB
ihlr-26084	619	2	research	research	NOUN
ihlr-26084	619	3	and	and	CCONJ
ihlr-26084	619	4	bringing	bring	VERB
ihlr-26084	619	5	drugs	drug	NOUN
ihlr-26084	619	6	to	to	ADP
ihlr-26084	619	7	the	the	DET
ihlr-26084	619	8	market	market	NOUN
ihlr-26084	619	9	through	through	ADP
ihlr-26084	619	10	patent	patent	NOUN
ihlr-26084	619	11	protection	protection	NOUN
ihlr-26084	619	12	leads	lead	VERB
ihlr-26084	619	13	to	to	ADP
ihlr-26084	619	14	more	more	ADJ
ihlr-26084	619	15	expenditure	expenditure	NOUN
ihlr-26084	619	16	on	on	ADP
ihlr-26084	619	17	rent	rent	NOUN
ihlr-26084	619	18	-	-	PUNCT
ihlr-26084	619	19	seeking	seeking	NOUN
ihlr-26084	619	20	than	than	ADP
ihlr-26084	619	21	on	on	ADP
ihlr-26084	619	22	research	research	NOUN
ihlr-26084	619	23	.	.	PUNCT
ihlr-26084	620	1	abbvie	abbvie	PROPN
ihlr-26084	620	2	is	be	AUX
ihlr-26084	620	3	one	one	NUM
ihlr-26084	620	4	of	of	ADP
ihlr-26084	620	5	the	the	DET
ihlr-26084	620	6	companies	company	NOUN
ihlr-26084	620	7	most	most	ADV
ihlr-26084	620	8	involved	involved	ADJ
ihlr-26084	620	9	in	in	ADP
ihlr-26084	620	10	us	we	PRON
ihlr-26084	620	11	pay	pay	VERB
ihlr-26084	620	12	-	-	PUNCT
ihlr-26084	620	13	for	for	ADP
ihlr-26084	620	14	-	-	PUNCT
ihlr-26084	620	15	delay	delay	NOUN
ihlr-26084	620	16	cases.164	cases.164	NOUN
ihlr-26084	620	17	the	the	DET
ihlr-26084	620	18	abbvie	abbvie	PROPN
ihlr-26084	620	19	expenditures	expenditure	NOUN
ihlr-26084	620	20	show	show	VERB
ihlr-26084	620	21	that	that	SCONJ
ihlr-26084	620	22	the	the	DET
ihlr-26084	620	23	period	period	NOUN
ihlr-26084	620	24	of	of	ADP
ihlr-26084	620	25	exclusivity	exclusivity	NOUN
ihlr-26084	620	26	approach	approach	NOUN
ihlr-26084	620	27	would	would	AUX
ihlr-26084	620	28	reduce	reduce	VERB
ihlr-26084	620	29	the	the	DET
ihlr-26084	620	30	need	need	NOUN
ihlr-26084	620	31	for	for	ADP
ihlr-26084	620	32	these	these	DET
ihlr-26084	620	33	litigations	litigation	NOUN
ihlr-26084	620	34	and	and	CCONJ
ihlr-26084	620	35	settlements	settlement	NOUN
ihlr-26084	620	36	,	,	PUNCT
ihlr-26084	620	37	many	many	ADJ
ihlr-26084	620	38	of	of	ADP
ihlr-26084	620	39	which	which	PRON
ihlr-26084	620	40	have	have	AUX
ihlr-26084	620	41	been	be	AUX
ihlr-26084	620	42	linked	link	VERB
ihlr-26084	620	43	to	to	PART
ihlr-26084	620	44	pay	pay	VERB
ihlr-26084	620	45	-	-	PUNCT
ihlr-26084	620	46	for	for	ADP
ihlr-26084	620	47	-	-	PUNCT
ihlr-26084	620	48	delay	delay	NOUN
ihlr-26084	620	49	and	and	CCONJ
ihlr-26084	620	50	the	the	DET
ihlr-26084	620	51	litigations	litigation	NOUN
ihlr-26084	620	52	discussed	discuss	VERB
ihlr-26084	620	53	above	above	ADV
ihlr-26084	620	54	.	.	PUNCT
ihlr-26084	621	1	ignoring	ignore	VERB
ihlr-26084	621	2	marketing	marketing	NOUN
ihlr-26084	621	3	costs	cost	NOUN
ihlr-26084	621	4	in	in	ADP
ihlr-26084	621	5	the	the	DET
ihlr-26084	621	6	exclusivity	exclusivity	NOUN
ihlr-26084	621	7	calculation	calculation	NOUN
ihlr-26084	621	8	would	would	AUX
ihlr-26084	621	9	disincentivize	disincentivize	VERB
ihlr-26084	621	10	poor	poor	ADJ
ihlr-26084	621	11	practices	practice	NOUN
ihlr-26084	621	12	as	as	ADV
ihlr-26084	621	13	well	well	ADV
ihlr-26084	621	14	.	.	PUNCT
ihlr-26084	622	1	second	second	ADJ
ihlr-26084	622	2	,	,	PUNCT
ihlr-26084	622	3	regulatory	regulatory	ADJ
ihlr-26084	622	4	agencies	agency	NOUN
ihlr-26084	622	5	should	should	AUX
ihlr-26084	622	6	investigate	investigate	VERB
ihlr-26084	622	7	the	the	DET
ihlr-26084	622	8	optimal	optimal	ADJ
ihlr-26084	622	9	statutory	statutory	ADJ
ihlr-26084	622	10	protection	protection	NOUN
ihlr-26084	622	11	period	period	NOUN
ihlr-26084	622	12	.	.	PUNCT
ihlr-26084	623	1	these	these	DET
ihlr-26084	623	2	protection	protection	NOUN
ihlr-26084	623	3	period	period	NOUN
ihlr-26084	623	4	may	may	AUX
ihlr-26084	623	5	not	not	PART
ihlr-26084	623	6	need	need	VERB
ihlr-26084	623	7	to	to	PART
ihlr-26084	623	8	be	be	AUX
ihlr-26084	623	9	identical	identical	ADJ
ihlr-26084	623	10	.	.	PUNCT
ihlr-26084	624	1	instead	instead	ADV
ihlr-26084	624	2	,	,	PUNCT
ihlr-26084	624	3	colum	colum	NOUN
ihlr-26084	624	4	.	.	PUNCT
ihlr-26084	625	1	j.l	j.l	PROPN
ihlr-26084	625	2	.	.	PROPN
ihlr-26084	625	3	&	&	CCONJ
ihlr-26084	625	4	arts	arts	PROPN
ihlr-26084	625	5	377	377	NUM
ihlr-26084	625	6	,	,	PUNCT
ihlr-26084	625	7	378	378	NUM
ihlr-26084	625	8	-	-	SYM
ihlr-26084	625	9	79	79	NUM
ihlr-26084	625	10	(	(	PUNCT
ihlr-26084	625	11	2009	2009	NUM
ihlr-26084	625	12	)	)	PUNCT
ihlr-26084	625	13	.	.	PUNCT
ihlr-26084	626	1	160	160	NUM
ihlr-26084	626	2	.	.	PUNCT
ihlr-26084	627	1	ec	ec	PROPN
ihlr-26084	627	2	report	report	PROPN
ihlr-26084	627	3	,	,	PUNCT
ihlr-26084	627	4	supra	supra	PROPN
ihlr-26084	627	5	note	note	NOUN
ihlr-26084	627	6	4	4	NUM
ihlr-26084	627	7	,	,	PUNCT
ihlr-26084	627	8	table	table	NOUN
ihlr-26084	627	9	4	4	NUM
ihlr-26084	627	10	.	.	NOUN
ihlr-26084	627	11	161	161	NUM
ihlr-26084	627	12	.	.	PUNCT
ihlr-26084	628	1	i	i	PRON
ihlr-26084	628	2	d.	d.	VERB
ihlr-26084	628	3	at	at	ADP
ihlr-26084	628	4	fn	fn	PROPN
ihlr-26084	628	5	.	.	PROPN
ihlr-26084	629	1	51	51	NUM
ihlr-26084	629	2	.	.	NOUN
ihlr-26084	630	1	162	162	NUM
ihlr-26084	630	2	.	.	PUNCT
ihlr-26084	631	1	for	for	ADP
ihlr-26084	631	2	example	example	NOUN
ihlr-26084	631	3	,	,	PUNCT
ihlr-26084	631	4	in	in	ADP
ihlr-26084	631	5	france	france	PROPN
ihlr-26084	631	6	,	,	PUNCT
ihlr-26084	631	7	article	article	NOUN
ihlr-26084	631	8	l.	l.	PROPN
ihlr-26084	631	9	5122	5122	NUM
ihlr-26084	631	10	-	-	SYM
ihlr-26084	631	11	1	1	NUM
ihlr-26084	631	12	to	to	ADP
ihlr-26084	631	13	l.	l.	PROPN
ihlr-26084	631	14	5122	5122	NUM
ihlr-26084	631	15	-	-	SYM
ihlr-26084	631	16	16	16	NUM
ihlr-26084	631	17	code	code	NOUN
ihlr-26084	631	18	de	de	X
ihlr-26084	631	19	la	la	X
ihlr-26084	631	20	santé	santé	X
ihlr-26084	631	21	publique	publique	X
ihlr-26084	631	22	(	(	PUNCT
ihlr-26084	631	23	french	french	ADJ
ihlr-26084	631	24	public	public	ADJ
ihlr-26084	631	25	health	health	PROPN
ihlr-26084	631	26	code	code	PROPN
ihlr-26084	631	27	)	)	PUNCT
ihlr-26084	631	28	regulates	regulate	VERB
ihlr-26084	631	29	advertisement	advertisement	NOUN
ihlr-26084	631	30	to	to	ADP
ihlr-26084	631	31	the	the	DET
ihlr-26084	631	32	general	general	ADJ
ihlr-26084	631	33	public	public	ADJ
ihlr-26084	631	34	and	and	CCONJ
ihlr-26084	631	35	medical	medical	ADJ
ihlr-26084	631	36	professionals	professional	NOUN
ihlr-26084	631	37	.	.	PUNCT
ihlr-26084	632	1	article	article	PROPN
ihlr-26084	632	2	l.	l.	PROPN
ihlr-26084	632	3	5122	5122	NUM
ihlr-26084	632	4	-	-	SYM
ihlr-26084	632	5	6	6	NUM
ihlr-26084	632	6	prohibits	prohibit	VERB
ihlr-26084	632	7	the	the	DET
ihlr-26084	632	8	direct	direct	ADJ
ihlr-26084	632	9	advertisement	advertisement	NOUN
ihlr-26084	632	10	to	to	ADP
ihlr-26084	632	11	the	the	DET
ihlr-26084	632	12	general	general	ADJ
ihlr-26084	632	13	public	public	NOUN
ihlr-26084	632	14	of	of	ADP
ihlr-26084	632	15	prescription	prescription	NOUN
ihlr-26084	632	16	-	-	PUNCT
ihlr-26084	632	17	only	only	ADV
ihlr-26084	632	18	medicinal	medicinal	ADJ
ihlr-26084	632	19	products	product	NOUN
ihlr-26084	632	20	(	(	PUNCT
ihlr-26084	632	21	i.e.	i.e.	X
ihlr-26084	632	22	,	,	PUNCT
ihlr-26084	632	23	«	«	PUNCT
ihlr-26084	632	24	la	la	X
ihlr-26084	632	25	publicité	publicité	X
ihlr-26084	632	26	auprès	auprès	X
ihlr-26084	632	27	du	du	PROPN
ihlr-26084	632	28	public	public	PROPN
ihlr-26084	632	29	pour	pour	PROPN
ihlr-26084	632	30	un	un	PROPN
ihlr-26084	632	31	médicament	médicament	PROPN
ihlr-26084	632	32	n'est	n'est	PROPN
ihlr-26084	632	33	admise	admise	NOUN
ihlr-26084	632	34	qu'à	qu'à	AUX
ihlr-26084	632	35	la	la	PRON
ihlr-26084	632	36	condition	condition	NOUN
ihlr-26084	632	37	que	que	PROPN
ihlr-26084	632	38	ce	ce	PROPN
ihlr-26084	632	39	médicament	médicament	PROPN
ihlr-26084	632	40	ne	ne	PROPN
ihlr-26084	632	41	soit	soit	PROPN
ihlr-26084	632	42	pas	pas	PROPN
ihlr-26084	632	43	soumis	soumis	PROPN
ihlr-26084	632	44	à	à	X
ihlr-26084	632	45	prescription	prescription	NOUN
ihlr-26084	632	46	médicale	médicale	NOUN
ihlr-26084	632	47	»	»	PUNCT
ihlr-26084	632	48	which	which	PRON
ihlr-26084	632	49	translate	translate	VERB
ihlr-26084	632	50	to	to	ADP
ihlr-26084	632	51	advertising	advertise	VERB
ihlr-26084	632	52	the	the	DET
ihlr-26084	632	53	public	public	NOUN
ihlr-26084	632	54	for	for	ADP
ihlr-26084	632	55	any	any	DET
ihlr-26084	632	56	medication	medication	NOUN
ihlr-26084	632	57	is	be	AUX
ihlr-26084	632	58	only	only	ADV
ihlr-26084	632	59	possible	possible	ADJ
ihlr-26084	632	60	if	if	SCONJ
ihlr-26084	632	61	this	this	DET
ihlr-26084	632	62	medication	medication	NOUN
ihlr-26084	632	63	is	be	AUX
ihlr-26084	632	64	not	not	PART
ihlr-26084	632	65	subject	subject	ADJ
ihlr-26084	632	66	to	to	ADP
ihlr-26084	632	67	medical	medical	ADJ
ihlr-26084	632	68	prescription	prescription	NOUN
ihlr-26084	632	69	(	(	PUNCT
ihlr-26084	632	70	authors	author	NOUN
ihlr-26084	632	71	’	'	PUNCT
ihlr-26084	632	72	translation	translation	NOUN
ihlr-26084	632	73	)	)	PUNCT
ihlr-26084	632	74	)	)	PUNCT
ihlr-26084	632	75	.	.	PUNCT
ihlr-26084	633	1	163	163	NUM
ihlr-26084	633	2	.	.	PUNCT
ihlr-26084	634	1	tim	tim	PROPN
ihlr-26084	634	2	dickinson	dickinson	PROPN
ihlr-26084	634	3	,	,	PUNCT
ihlr-26084	634	4	katie	katie	PROPN
ihlr-26084	634	5	porter	porter	PROPN
ihlr-26084	634	6	delivers	deliver	VERB
ihlr-26084	634	7	another	another	DET
ihlr-26084	634	8	knockout	knockout	NOUN
ihlr-26084	634	9	punch	punch	NOUN
ihlr-26084	634	10	,	,	PUNCT
ihlr-26084	634	11	rolling	roll	VERB
ihlr-26084	634	12	stone	stone	NOUN
ihlr-26084	634	13	(	(	PUNCT
ihlr-26084	634	14	may	may	PROPN
ihlr-26084	634	15	19	19	NUM
ihlr-26084	634	16	,	,	PUNCT
ihlr-26084	634	17	2021	2021	NUM
ihlr-26084	634	18	,	,	PUNCT
ihlr-26084	634	19	3:51	3:51	NUM
ihlr-26084	634	20	pm	pm	NOUN
ihlr-26084	634	21	)	)	PUNCT
ihlr-26084	634	22	,	,	PUNCT
ihlr-26084	634	23	https://www.rollingstone.com/politics/politics-news/katie-porter-abbviegonzalez-big-pharma-knockout-punch-1171735/	https://www.rollingstone.com/politics/politics-news/katie-porter-abbviegonzalez-big-pharma-knockout-punch-1171735/	VERB
ihlr-26084	635	1	[	[	X
ihlr-26084	635	2	https://perma.cc/4als-xpj6	https://perma.cc/4als-xpj6	PROPN
ihlr-26084	635	3	]	]	PUNCT
ihlr-26084	635	4	.	.	PUNCT
ihlr-26084	636	1	164	164	NUM
ihlr-26084	636	2	.	.	PUNCT
ihlr-26084	637	1	abbvie	abbvie	PROPN
ihlr-26084	637	2	or	or	CCONJ
ihlr-26084	637	3	abbvie	abbvie	NOUN
ihlr-26084	637	4	subsidiaries	subsidiary	NOUN
ihlr-26084	637	5	have	have	AUX
ihlr-26084	637	6	been	be	AUX
ihlr-26084	637	7	involved	involve	VERB
ihlr-26084	637	8	in	in	ADP
ihlr-26084	637	9	at	at	ADV
ihlr-26084	637	10	least	least	ADV
ihlr-26084	637	11	ten	ten	NUM
ihlr-26084	637	12	federal	federal	ADJ
ihlr-26084	637	13	pay	pay	VERB
ihlr-26084	637	14	-	-	PUNCT
ihlr-26084	637	15	for	for	ADP
ihlr-26084	637	16	-	-	PUNCT
ihlr-26084	637	17	delay	delay	NOUN
ihlr-26084	637	18	antitrust	antitrust	ADJ
ihlr-26084	637	19	cases	case	NOUN
ihlr-26084	637	20	since	since	SCONJ
ihlr-26084	637	21	2003	2003	NUM
ihlr-26084	637	22	:	:	PUNCT
ihlr-26084	637	23	andrx	andrx	NOUN
ihlr-26084	637	24	pharms	pharm	NOUN
ihlr-26084	637	25	.	.	PUNCT
ihlr-26084	637	26	,	,	PUNCT
ihlr-26084	637	27	inc	inc	PROPN
ihlr-26084	637	28	.	.	PROPN
ihlr-26084	637	29	v.	v.	PROPN
ihlr-26084	637	30	biovail	biovail	PROPN
ihlr-26084	637	31	corp	corp	PROPN
ihlr-26084	637	32	.	.	PROPN
ihlr-26084	637	33	,	,	PUNCT
ihlr-26084	637	34	int’l	int’l	NUM
ihlr-26084	637	35	,	,	PUNCT
ihlr-26084	637	36	256	256	NUM
ihlr-26084	637	37	f.3d	f.3d	NUM
ihlr-26084	637	38	799	799	NUM
ihlr-26084	637	39	(	(	PUNCT
ihlr-26084	637	40	d.c	d.c	PROPN
ihlr-26084	637	41	.	.	PUNCT
ihlr-26084	637	42	circ	circ	PROPN
ihlr-26084	637	43	.	.	PUNCT
ihlr-26084	638	1	2001	2001	NUM
ihlr-26084	638	2	)	)	PUNCT
ihlr-26084	638	3	;	;	PUNCT
ihlr-26084	638	4	in	in	ADP
ihlr-26084	638	5	re	re	PROPN
ihlr-26084	638	6	cardizem	cardizem	PROPN
ihlr-26084	638	7	cd	cd	PROPN
ihlr-26084	638	8	antitrust	antitrust	ADJ
ihlr-26084	638	9	litig	litig	NOUN
ihlr-26084	638	10	.	.	PUNCT
ihlr-26084	639	1	,	,	PUNCT
ihlr-26084	639	2	332	332	NUM
ihlr-26084	639	3	f.3d	f.3d	NUM
ihlr-26084	639	4	896	896	NUM
ihlr-26084	639	5	(	(	PUNCT
ihlr-26084	639	6	6th	6th	ADJ
ihlr-26084	639	7	cir	cir	NOUN
ihlr-26084	639	8	.	.	PROPN
ihlr-26084	639	9	2003	2003	NUM
ihlr-26084	639	10	)	)	PUNCT
ihlr-26084	639	11	;	;	PUNCT
ihlr-26084	639	12	arkansas	arkansas	PROPN
ihlr-26084	639	13	carpenters	carpenters	PROPN
ihlr-26084	639	14	health	health	PROPN
ihlr-26084	639	15	&	&	CCONJ
ihlr-26084	639	16	welfare	welfare	PROPN
ihlr-26084	639	17	fund	fund	PROPN
ihlr-26084	639	18	v.	v.	PROPN
ihlr-26084	639	19	bayer	bayer	PROPN
ihlr-26084	639	20	ag	ag	PROPN
ihlr-26084	639	21	,	,	PUNCT
ihlr-26084	639	22	604	604	NUM
ihlr-26084	639	23	f.3d	f.3d	NUM
ihlr-26084	639	24	98	98	NUM
ihlr-26084	639	25	(	(	PUNCT
ihlr-26084	639	26	2d	2d	NUM
ihlr-26084	639	27	cir	cir	NOUN
ihlr-26084	639	28	.	.	PUNCT
ihlr-26084	639	29	2010	2010	NUM
ihlr-26084	639	30	)	)	PUNCT
ihlr-26084	639	31	;	;	PUNCT
ihlr-26084	639	32	ark	ark	PROPN
ihlr-26084	639	33	.	.	PUNCT
ihlr-26084	640	1	carpenters	carpenters	PROPN
ihlr-26084	640	2	health	health	PROPN
ihlr-26084	640	3	&	&	CCONJ
ihlr-26084	640	4	welfare	welfare	PROPN
ihlr-26084	640	5	fund	fund	PROPN
ihlr-26084	640	6	v.	v.	ADP
ihlr-26084	640	7	bayer	bayer	PROPN
ihlr-26084	640	8	ag	ag	PROPN
ihlr-26084	640	9	(	(	PUNCT
ihlr-26084	640	10	in	in	ADP
ihlr-26084	640	11	re	re	ADP
ihlr-26084	640	12	ciprofloxacin	ciprofloxacin	NOUN
ihlr-26084	640	13	hydrochloride	hydrochloride	ADJ
ihlr-26084	640	14	antitrust	antitrust	ADJ
ihlr-26084	640	15	litig	litig	NOUN
ihlr-26084	640	16	.	.	PUNCT
ihlr-26084	640	17	)	)	PUNCT
ihlr-26084	641	1	,	,	PUNCT
ihlr-26084	641	2	544	544	NUM
ihlr-26084	641	3	f.3d	f.3d	NUM
ihlr-26084	641	4	1323	1323	NUM
ihlr-26084	641	5	(	(	PUNCT
ihlr-26084	641	6	fed	fed	PROPN
ihlr-26084	641	7	.	.	PUNCT
ihlr-26084	641	8	cir	cir	PROPN
ihlr-26084	641	9	.	.	PROPN
ihlr-26084	641	10	2008	2008	NUM
ihlr-26084	641	11	)	)	PUNCT
ihlr-26084	641	12	;	;	PUNCT
ihlr-26084	641	13	ftc	ftc	PROPN
ihlr-26084	641	14	v.	v.	PROPN
ihlr-26084	641	15	watson	watson	PROPN
ihlr-26084	641	16	pharms	pharms	PROPN
ihlr-26084	641	17	.	.	PUNCT
ihlr-26084	641	18	,	,	PUNCT
ihlr-26084	641	19	inc	inc	PROPN
ihlr-26084	641	20	.	.	PROPN
ihlr-26084	641	21	,	,	PUNCT
ihlr-26084	641	22	677	677	NUM
ihlr-26084	641	23	f.3d	f.3d	NUM
ihlr-26084	641	24	1298	1298	NUM
ihlr-26084	641	25	(	(	PUNCT
ihlr-26084	641	26	11th	11th	ADJ
ihlr-26084	641	27	cir	cir	NOUN
ihlr-26084	641	28	.	.	PROPN
ihlr-26084	641	29	2012	2012	NUM
ihlr-26084	641	30	)	)	PUNCT
ihlr-26084	641	31	;	;	PUNCT
ihlr-26084	641	32	ftc	ftc	PROPN
ihlr-26084	641	33	v.	v.	ADP
ihlr-26084	641	34	actavis	actavis	PROPN
ihlr-26084	641	35	,	,	PUNCT
ihlr-26084	641	36	inc	inc	PROPN
ihlr-26084	641	37	.	.	PROPN
ihlr-26084	641	38	,	,	PUNCT
ihlr-26084	641	39	570	570	NUM
ihlr-26084	641	40	u.s	u.s	PROPN
ihlr-26084	641	41	.	.	PROPN
ihlr-26084	641	42	136	136	NUM
ihlr-26084	641	43	(	(	PUNCT
ihlr-26084	641	44	2013	2013	NUM
ihlr-26084	641	45	)	)	PUNCT
ihlr-26084	641	46	;	;	PUNCT
ihlr-26084	641	47	in	in	ADP
ihlr-26084	641	48	re	re	ADP
ihlr-26084	641	49	loestrin	loestrin	PROPN
ihlr-26084	641	50	antitrust	antitrust	ADJ
ihlr-26084	641	51	litigation	litigation	NOUN
ihlr-26084	641	52	,	,	PUNCT
ihlr-26084	641	53	nos	nos	PROPN
ihlr-26084	641	54	.	.	PROPN
ihlr-26084	641	55	14	14	NUM
ihlr-26084	641	56	-	-	SYM
ihlr-26084	641	57	2071	2071	NUM
ihlr-26084	641	58	,	,	PUNCT
ihlr-26084	641	59	15	15	NUM
ihlr-26084	641	60	-	-	SYM
ihlr-26084	641	61	1250	1250	NUM
ihlr-26084	641	62	,	,	PUNCT
ihlr-26084	641	63	2016	2016	NUM
ihlr-26084	641	64	wl	wl	NOUN
ihlr-26084	641	65	698077	698077	NUM
ihlr-26084	641	66	(	(	PUNCT
ihlr-26084	641	67	1st	1st	ADJ
ihlr-26084	641	68	cir	cir	NOUN
ihlr-26084	641	69	.	.	PROPN
ihlr-26084	641	70	2016	2016	NUM
ihlr-26084	641	71	)	)	PUNCT
ihlr-26084	641	72	;	;	PUNCT
ihlr-26084	641	73	in	in	ADP
ihlr-26084	641	74	re	re	NOUN
ihlr-26084	641	75	wellbutrin	wellbutrin	NOUN
ihlr-26084	641	76	xl	xl	PROPN
ihlr-26084	641	77	antitrust	antitrust	ADJ
ihlr-26084	641	78	litigation	litigation	NOUN
ihlr-26084	641	79	,	,	PUNCT
ihlr-26084	641	80	868	868	NUM
ihlr-26084	641	81	f.3d	f.3d	NUM
ihlr-26084	641	82	132	132	NUM
ihlr-26084	641	83	,	,	PUNCT
ihlr-26084	641	84	141	141	NUM
ihlr-26084	641	85	(	(	PUNCT
ihlr-26084	641	86	3d	3d	NUM
ihlr-26084	641	87	cir	cir	NOUN
ihlr-26084	641	88	.	.	PROPN
ihlr-26084	641	89	2017	2017	NUM
ihlr-26084	641	90	)	)	PUNCT
ihlr-26084	641	91	;	;	PUNCT
ihlr-26084	641	92	in	in	ADP
ihlr-26084	641	93	re	re	ADP
ihlr-26084	641	94	actos	actos	PROPN
ihlr-26084	641	95	direct	direct	ADJ
ihlr-26084	641	96	purchaser	purchaser	NOUN
ihlr-26084	641	97	antitrust	antitrust	ADJ
ihlr-26084	641	98	litig	litig	NOUN
ihlr-26084	641	99	.	.	PUNCT
ihlr-26084	642	1	,	,	PUNCT
ihlr-26084	642	2	414	414	NUM
ihlr-26084	642	3	f.	f.	PROPN
ihlr-26084	642	4	supp	supp	PROPN
ihlr-26084	642	5	.	.	PUNCT
ihlr-26084	643	1	3d	3d	NUM
ihlr-26084	643	2	635	635	NUM
ihlr-26084	643	3	,	,	PUNCT
ihlr-26084	643	4	640	640	NUM
ihlr-26084	643	5	(	(	PUNCT
ihlr-26084	643	6	s.d.n.y	s.d.n.y	PROPN
ihlr-26084	643	7	.	.	PROPN
ihlr-26084	643	8	2019	2019	NUM
ihlr-26084	643	9	)	)	PUNCT
ihlr-26084	643	10	;	;	PUNCT
ihlr-26084	643	11	ftc	ftc	PROPN
ihlr-26084	643	12	v.	v.	PROPN
ihlr-26084	643	13	abbvie	abbvie	PROPN
ihlr-26084	643	14	inc	inc	PROPN
ihlr-26084	643	15	.	.	PROPN
ihlr-26084	643	16	,	,	PUNCT
ihlr-26084	643	17	976	976	NUM
ihlr-26084	643	18	f.3d	f.3d	NUM
ihlr-26084	643	19	327	327	NUM
ihlr-26084	643	20	(	(	PUNCT
ihlr-26084	643	21	3d	3d	PROPN
ihlr-26084	643	22	cir	cir	NOUN
ihlr-26084	643	23	.	.	PUNCT
ihlr-26084	643	24	2020	2020	NUM
ihlr-26084	643	25	)	)	PUNCT
ihlr-26084	643	26	.	.	PUNCT
ihlr-26084	644	1	2022	2022	NUM
ihlr-26084	644	2	]	]	PUNCT
ihlr-26084	644	3	reverse	reverse	ADJ
ihlr-26084	644	4	payment	payment	NOUN
ihlr-26084	644	5	:	:	PUNCT
ihlr-26084	644	6	a	a	DET
ihlr-26084	644	7	comparative	comparative	ADJ
ihlr-26084	644	8	study	study	NOUN
ihlr-26084	644	9	45	45	NUM
ihlr-26084	644	10	the	the	DET
ihlr-26084	644	11	regulatory	regulatory	ADJ
ihlr-26084	644	12	agency	agency	NOUN
ihlr-26084	644	13	could	could	AUX
ihlr-26084	644	14	change	change	VERB
ihlr-26084	644	15	the	the	DET
ihlr-26084	644	16	statutory	statutory	ADJ
ihlr-26084	644	17	protection	protection	NOUN
ihlr-26084	644	18	based	base	VERB
ihlr-26084	644	19	on	on	ADP
ihlr-26084	644	20	the	the	DET
ihlr-26084	644	21	type	type	NOUN
ihlr-26084	644	22	of	of	ADP
ihlr-26084	644	23	diseases	disease	NOUN
ihlr-26084	644	24	and/or	and/or	CCONJ
ihlr-26084	644	25	the	the	DET
ihlr-26084	644	26	existing	exist	VERB
ihlr-26084	644	27	therapeutical	therapeutical	ADJ
ihlr-26084	644	28	treatment	treatment	NOUN
ihlr-26084	644	29	.	.	PUNCT
ihlr-26084	645	1	these	these	DET
ihlr-26084	645	2	governmental	governmental	NOUN
ihlr-26084	645	3	already	already	ADV
ihlr-26084	645	4	do	do	VERB
ihlr-26084	645	5	a	a	DET
ihlr-26084	645	6	cost	cost	NOUN
ihlr-26084	645	7	-	-	PUNCT
ihlr-26084	645	8	efficiency	efficiency	NOUN
ihlr-26084	645	9	analysis	analysis	NOUN
ihlr-26084	645	10	to	to	ADP
ihlr-26084	645	11	award	award	NOUN
ihlr-26084	645	12	prices	price	NOUN
ihlr-26084	645	13	:	:	PUNCT
ihlr-26084	645	14	they	they	PRON
ihlr-26084	645	15	could	could	AUX
ihlr-26084	645	16	do	do	VERB
ihlr-26084	645	17	the	the	DET
ihlr-26084	645	18	same	same	ADJ
ihlr-26084	645	19	to	to	PART
ihlr-26084	645	20	award	award	VERB
ihlr-26084	645	21	protection	protection	NOUN
ihlr-26084	645	22	.	.	PUNCT
ihlr-26084	646	1	the	the	DET
ihlr-26084	646	2	period	period	NOUN
ihlr-26084	646	3	should	should	AUX
ihlr-26084	646	4	also	also	ADV
ihlr-26084	646	5	depend	depend	VERB
ihlr-26084	646	6	on	on	ADP
ihlr-26084	646	7	whether	whether	SCONJ
ihlr-26084	646	8	the	the	DET
ihlr-26084	646	9	drug	drug	NOUN
ihlr-26084	646	10	gained	gain	VERB
ihlr-26084	646	11	its	its	PRON
ihlr-26084	646	12	first	first	ADJ
ihlr-26084	646	13	market	market	NOUN
ihlr-26084	646	14	authorization	authorization	NOUN
ihlr-26084	646	15	,	,	PUNCT
ihlr-26084	646	16	or	or	CCONJ
ihlr-26084	646	17	the	the	DET
ihlr-26084	646	18	drug	drug	NOUN
ihlr-26084	646	19	uses	use	VERB
ihlr-26084	646	20	molecules	molecule	NOUN
ihlr-26084	646	21	that	that	PRON
ihlr-26084	646	22	were	be	AUX
ihlr-26084	646	23	already	already	ADV
ihlr-26084	646	24	approved	approve	VERB
ihlr-26084	646	25	for	for	ADP
ihlr-26084	646	26	a	a	DET
ihlr-26084	646	27	different	different	ADJ
ihlr-26084	646	28	therapeutic	therapeutic	ADJ
ihlr-26084	646	29	treatment	treatment	NOUN
ihlr-26084	646	30	.	.	PUNCT
ihlr-26084	647	1	an	an	DET
ihlr-26084	647	2	additional	additional	ADJ
ihlr-26084	647	3	therapeutic	therapeutic	ADJ
ihlr-26084	647	4	application	application	NOUN
ihlr-26084	647	5	does	do	AUX
ihlr-26084	647	6	not	not	PART
ihlr-26084	647	7	involve	involve	VERB
ihlr-26084	647	8	the	the	DET
ihlr-26084	647	9	same	same	ADJ
ihlr-26084	647	10	cost	cost	NOUN
ihlr-26084	647	11	of	of	ADP
ihlr-26084	647	12	development	development	NOUN
ihlr-26084	647	13	as	as	ADP
ihlr-26084	647	14	a	a	DET
ihlr-26084	647	15	novel	novel	ADJ
ihlr-26084	647	16	application	application	NOUN
ihlr-26084	647	17	and	and	CCONJ
ihlr-26084	647	18	hence	hence	ADV
ihlr-26084	647	19	should	should	AUX
ihlr-26084	647	20	not	not	PART
ihlr-26084	647	21	be	be	AUX
ihlr-26084	647	22	rewarded	reward	VERB
ihlr-26084	647	23	with	with	ADP
ihlr-26084	647	24	the	the	DET
ihlr-26084	647	25	same	same	ADJ
ihlr-26084	647	26	exclusivity	exclusivity	NOUN
ihlr-26084	647	27	period	period	NOUN
ihlr-26084	647	28	.	.	PUNCT
ihlr-26084	648	1	in	in	ADP
ihlr-26084	648	2	other	other	ADJ
ihlr-26084	648	3	words	word	NOUN
ihlr-26084	648	4	,	,	PUNCT
ihlr-26084	648	5	the	the	DET
ihlr-26084	648	6	period	period	NOUN
ihlr-26084	648	7	could	could	AUX
ihlr-26084	648	8	depend	depend	VERB
ihlr-26084	648	9	on	on	ADP
ihlr-26084	648	10	the	the	DET
ihlr-26084	648	11	marginal	marginal	ADJ
ihlr-26084	648	12	benefit	benefit	NOUN
ihlr-26084	648	13	of	of	ADP
ihlr-26084	648	14	the	the	DET
ihlr-26084	648	15	drug	drug	NOUN
ihlr-26084	648	16	.	.	PUNCT
ihlr-26084	649	1	more	more	ADV
ihlr-26084	649	2	importantly	importantly	ADV
ihlr-26084	649	3	,	,	PUNCT
ihlr-26084	649	4	such	such	DET
ihlr-26084	649	5	an	an	DET
ihlr-26084	649	6	approach	approach	NOUN
ihlr-26084	649	7	would	would	AUX
ihlr-26084	649	8	avoid	avoid	VERB
ihlr-26084	649	9	pay	pay	VERB
ihlr-26084	649	10	-	-	PUNCT
ihlr-26084	649	11	for	for	ADP
ihlr-26084	649	12	-	-	PUNCT
ihlr-26084	649	13	delay	delay	NOUN
ihlr-26084	649	14	.	.	PUNCT
ihlr-26084	650	1	patent	patent	NOUN
ihlr-26084	650	2	validity	validity	NOUN
ihlr-26084	650	3	would	would	AUX
ihlr-26084	650	4	become	become	VERB
ihlr-26084	650	5	irrelevant	irrelevant	ADJ
ihlr-26084	650	6	,	,	PUNCT
ihlr-26084	650	7	and	and	CCONJ
ihlr-26084	650	8	the	the	DET
ihlr-26084	650	9	generics	generic	NOUN
ihlr-26084	650	10	could	could	AUX
ihlr-26084	650	11	enter	enter	VERB
ihlr-26084	650	12	as	as	ADV
ihlr-26084	650	13	soon	soon	ADV
ihlr-26084	650	14	as	as	SCONJ
ihlr-26084	650	15	the	the	DET
ihlr-26084	650	16	statutory	statutory	ADJ
ihlr-26084	650	17	period	period	NOUN
ihlr-26084	650	18	is	be	AUX
ihlr-26084	650	19	over	over	ADV
ihlr-26084	650	20	.	.	PUNCT
ihlr-26084	651	1	furthermore	furthermore	ADV
ihlr-26084	651	2	,	,	PUNCT
ihlr-26084	651	3	the	the	DET
ihlr-26084	651	4	agency	agency	NOUN
ihlr-26084	651	5	could	could	AUX
ihlr-26084	651	6	also	also	ADV
ihlr-26084	651	7	terminate	terminate	VERB
ihlr-26084	651	8	the	the	DET
ihlr-26084	651	9	statutory	statutory	ADJ
ihlr-26084	651	10	protection	protection	NOUN
ihlr-26084	651	11	if	if	SCONJ
ihlr-26084	651	12	the	the	DET
ihlr-26084	651	13	brand	brand	NOUN
ihlr-26084	651	14	manufacturer	manufacturer	NOUN
ihlr-26084	651	15	were	be	AUX
ihlr-26084	651	16	found	find	VERB
ihlr-26084	651	17	to	to	PART
ihlr-26084	651	18	be	be	AUX
ihlr-26084	651	19	acting	act	VERB
ihlr-26084	651	20	anticompetitively	anticompetitively	ADV
ihlr-26084	651	21	.	.	PUNCT
ihlr-26084	652	1	while	while	SCONJ
ihlr-26084	652	2	such	such	ADJ
ihlr-26084	652	3	widescale	widescale	ADJ
ihlr-26084	652	4	reform	reform	NOUN
ihlr-26084	652	5	is	be	AUX
ihlr-26084	652	6	unlikely	unlikely	ADJ
ihlr-26084	652	7	because	because	SCONJ
ihlr-26084	652	8	of	of	ADP
ihlr-26084	652	9	vested	vested	ADJ
ihlr-26084	652	10	interest	interest	NOUN
ihlr-26084	652	11	,	,	PUNCT
ihlr-26084	652	12	if	if	SCONJ
ihlr-26084	652	13	nothing	nothing	PRON
ihlr-26084	652	14	,	,	PUNCT
ihlr-26084	652	15	the	the	DET
ihlr-26084	652	16	coronavirus	coronavirus	NOUN
ihlr-26084	652	17	pandemic	pandemic	ADJ
ihlr-26084	652	18	has	have	AUX
ihlr-26084	652	19	reinforced	reinforce	VERB
ihlr-26084	652	20	to	to	ADP
ihlr-26084	652	21	many	many	ADJ
ihlr-26084	652	22	that	that	SCONJ
ihlr-26084	652	23	the	the	DET
ihlr-26084	652	24	current	current	ADJ
ihlr-26084	652	25	healthcare	healthcare	NOUN
ihlr-26084	652	26	system	system	NOUN
ihlr-26084	652	27	–	–	PUNCT
ihlr-26084	652	28	including	include	VERB
ihlr-26084	652	29	drug	drug	NOUN
ihlr-26084	652	30	treatment	treatment	NOUN
ihlr-26084	652	31	–	–	PUNCT
ihlr-26084	652	32	needs	need	VERB
ihlr-26084	652	33	to	to	PART
ihlr-26084	652	34	be	be	AUX
ihlr-26084	652	35	revisited	revisit	VERB
ihlr-26084	652	36	.	.	PUNCT
ihlr-26084	653	1	it	it	PRON
ihlr-26084	653	2	is	be	AUX
ihlr-26084	653	3	a	a	DET
ihlr-26084	653	4	unique	unique	ADJ
ihlr-26084	653	5	market	market	NOUN
ihlr-26084	653	6	where	where	SCONJ
ihlr-26084	653	7	the	the	DET
ihlr-26084	653	8	market	market	NOUN
ihlr-26084	653	9	participants	participant	NOUN
ihlr-26084	653	10	have	have	AUX
ihlr-26084	653	11	always	always	ADV
ihlr-26084	653	12	found	find	VERB
ihlr-26084	653	13	new	new	ADJ
ihlr-26084	653	14	ways	way	NOUN
ihlr-26084	653	15	to	to	PART
ihlr-26084	653	16	profit	profit	VERB
ihlr-26084	653	17	at	at	ADP
ihlr-26084	653	18	the	the	DET
ihlr-26084	653	19	consumers	consumer	NOUN
ihlr-26084	653	20	’	'	PUNCT
ihlr-26084	653	21	expense	expense	NOUN
ihlr-26084	653	22	.	.	PUNCT